
<html lang="en"     class="pb-page"  data-request-id="4ae587aa-3b7f-49e5-b885-0aec444f1395"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-1;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.0c01698;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2" /></meta><meta name="dc.Creator" content="Chunjian  Liu" /></meta><meta name="dc.Creator" content="James  Lin" /></meta><meta name="dc.Creator" content="Charles  Langevine" /></meta><meta name="dc.Creator" content="Daniel  Smith" /></meta><meta name="dc.Creator" content="Jianqing  Li" /></meta><meta name="dc.Creator" content="John S.  Tokarski" /></meta><meta name="dc.Creator" content="Javed  Khan" /></meta><meta name="dc.Creator" content="Max  Ruzanov" /></meta><meta name="dc.Creator" content="Joann  Strnad" /></meta><meta name="dc.Creator" content="Adriana  Zupa-Fernandez" /></meta><meta name="dc.Creator" content="Lihong  Cheng" /></meta><meta name="dc.Creator" content="Kathleen M.  Gillooly" /></meta><meta name="dc.Creator" content="David  Shuster" /></meta><meta name="dc.Creator" content="Yifan  Zhang" /></meta><meta name="dc.Creator" content="Anil  Thankappan" /></meta><meta name="dc.Creator" content="Kim W.  McIntyre" /></meta><meta name="dc.Creator" content="Charu  Chaudhry" /></meta><meta name="dc.Creator" content="Paul A.  Elzinga" /></meta><meta name="dc.Creator" content="Manoj  Chiney" /></meta><meta name="dc.Creator" content="Anjaneya  Chimalakonda" /></meta><meta name="dc.Creator" content="Louis J.  Lombardo" /></meta><meta name="dc.Creator" content="John E.  Macor" /></meta><meta name="dc.Creator" content="Percy H.  Carter" /></meta><meta name="dc.Creator" content="James R.  Burke" /></meta><meta name="dc.Creator" content="David S.  Weinstein" /></meta><meta name="dc.Description" content="A search for structurally diversified Tyk2 JH2 ligands from 6 (BMS-986165), a pyridazine carboxamide-derived Tyk2 JH2 ligand as a clinical Tyk2 inhibitor currently in late development for the treat..." /></meta><meta name="Description" content="A search for structurally diversified Tyk2 JH2 ligands from 6 (BMS-986165), a pyridazine carboxamide-derived Tyk2 JH2 ligand as a clinical Tyk2 inhibitor currently in late development for the treat..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 28, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01698" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01698" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01698" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01698" /></link>
        
    
    

<title>Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2 | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01698" /></meta><meta property="og:title" content="Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0022.jpeg" /></meta><meta property="og:description" content="A search for structurally diversified Tyk2 JH2 ligands from 6 (BMS-986165), a pyridazine carboxamide-derived Tyk2 JH2 ligand as a clinical Tyk2 inhibitor currently in late development for the treatment of psoriasis, began with a survey of six-membered heteroaryl groups in place of the N-methyl triazolyl moiety in 6. The X-ray co-crystal structure of an early lead (12) revealed a potential new binding pocket. Exploration of the new pocket resulted in two frontrunners for a clinical candidate. The potential hydrogen bonding interaction with Thr599 in the pocket was achieved with a tertiary amide moiety, confirmed by the X-ray co-crystal structure of 29. When the diversity search was extended to nicotinamides, a single fluorine atom addition was found to significantly enhance the permeability, which directly led to the discovery of 7 (BMS-986202) as a clinical Tyk2 inhibitor that binds to Tyk2 JH2. The preclinical studies of 7, including efficacy studies in mouse models of IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus, will also be presented." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="A search for structurally diversified Tyk2 JH2 ligands from 6 (BMS-986165), a pyridazine carboxamide-derived Tyk2 JH2 ligand as a clinical Tyk2 inhibitor currently in late development for the treatment of psoriasis, began with a survey of six-membered heteroaryl groups in place of the N-methyl triazolyl moiety in 6. The X-ray co-crystal structure of an early lead (12) revealed a potential new binding pocket. Exploration of the new pocket resulted in two frontrunners for a clinical candidate. The potential hydrogen bonding interaction with Thr599 in the pocket was achieved with a tertiary amide moiety, confirmed by the X-ray co-crystal structure of 29. When the diversity search was extended to nicotinamides, a single fluorine atom addition was found to significantly enhance the permeability, which directly led to the discovery of 7 (BMS-986202) as a clinical Tyk2 inhibitor that binds to Tyk2 JH2. The preclinical studies of 7, including efficacy studies in mouse models of IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus, will also be presented." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0022.jpeg" /></meta><meta name="twitter:title" content="Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01698"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01698">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01698&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01698&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01698&amp;href=/doi/10.1021/acs.jmedchem.0c01698" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 1</span><span class="cit-fg-pageRange">, 677-694</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/1" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01671" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01705" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Chunjian Liu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chunjian Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#b5d6ddc0dbdfdcd4db9bd9dcc0f5d7d8d49bd6dad8"><span class="__cf_email__" data-cfemail="35565d405b5f5c545b1b595c40755758541b565a58">[emailÂ protected]</span></a>. Tel: +1 609 252 6067.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chunjian++Liu">Chunjian Liu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3708-2372" title="Orcid link">http://orcid.org/0000-0003-3708-2372</a></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">James Lin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James Lin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James++Lin">James Lin</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Charles Langevine</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Charles Langevine</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Charles++Langevine">Charles Langevine</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Daniel Smith</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daniel Smith</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Discovery Synthesis, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daniel++Smith">Daniel Smith</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Jianqing Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jianqing Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Discovery Synthesis, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jianqing++Li">Jianqing Li</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8445-9796" title="Orcid link">http://orcid.org/0000-0002-8445-9796</a></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">John S. Tokarski</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John S. Tokarski</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Structure and Design, Molecular Discovery Technologies, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John+S.++Tokarski">John S. Tokarski</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Javed Khan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Javed Khan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Structure and Design, Molecular Discovery Technologies, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Javed++Khan">Javed Khan</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Max Ruzanov</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Max Ruzanov</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Structure and Design, Molecular Discovery Technologies, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Max++Ruzanov">Max Ruzanov</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Joann Strnad</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Joann Strnad</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Joann++Strnad">Joann Strnad</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Adriana Zupa-Fernandez</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Adriana Zupa-Fernandez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Adriana++Zupa-Fernandez">Adriana Zupa-Fernandez</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Lihong Cheng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lihong Cheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lihong++Cheng">Lihong Cheng</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Kathleen M. Gillooly</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kathleen M. Gillooly</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kathleen+M.++Gillooly">Kathleen M. Gillooly</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">David Shuster</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David Shuster</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David++Shuster">David Shuster</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Yifan Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yifan Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yifan++Zhang">Yifan Zhang</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Anil Thankappan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anil Thankappan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anil++Thankappan">Anil Thankappan</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Kim W. McIntyre</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kim W. McIntyre</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kim+W.++McIntyre">Kim W. McIntyre</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Charu Chaudhry</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Charu Chaudhry</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Leads Discovery and Optimization, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Charu++Chaudhry">Charu Chaudhry</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Paul A. Elzinga</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul A. Elzinga</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Metabolism and Pharmacokinetic Department, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul+A.++Elzinga">Paul A. Elzinga</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Manoj Chiney</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Manoj Chiney</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Metabolism and Pharmacokinetic Department, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Manoj++Chiney">Manoj Chiney</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Anjaneya Chimalakonda</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anjaneya Chimalakonda</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Metabolism and Pharmacokinetic Department, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anjaneya++Chimalakonda">Anjaneya Chimalakonda</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Louis J. Lombardo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Louis J. Lombardo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Louis+J.++Lombardo">Louis J. Lombardo</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3335-6460" title="Orcid link">http://orcid.org/0000-0003-3335-6460</a></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">John E. Macor</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John E. Macor</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John+E.++Macor">John E. Macor</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Percy H. Carter</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Percy H. Carter</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Percy+H.++Carter">Percy H. Carter</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">James R. Burke</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James R. Burke</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James+R.++Burke">James R. Burke</a></span></div></div></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor">David S. Weinstein</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David S. Weinstein</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+S.++Weinstein">David S. Weinstein</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01698&amp;href=/doi/10.1021%2Facs.jmedchem.0c01698" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 1</span><span class="cit-pageRange">, 677â694</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 28, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>28 September 2020</li><li><span class="item_label"><b>Published</b> online</span>28 December 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 January 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01698" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01698</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D677%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DChunjian%2BLiu%252C%2BJames%2BLin%252C%2BCharles%2BLangevine%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D1%26contentID%3Dacs.jmedchem.0c01698%26title%3DDiscovery%2Bof%2BBMS-986202%253A%2BA%2BClinical%2BTyk2%2BInhibitor%2Bthat%2BBinds%2Bto%2BTyk2%2BJH2%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D694%26publicationDate%3DJanuary%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01698"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2959</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01698" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Chunjian&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;Lin&quot;},{&quot;first_name&quot;:&quot;Charles&quot;,&quot;last_name&quot;:&quot;Langevine&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;Smith&quot;},{&quot;first_name&quot;:&quot;Jianqing&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;S. Tokarski&quot;},{&quot;first_name&quot;:&quot;Javed&quot;,&quot;last_name&quot;:&quot;Khan&quot;},{&quot;first_name&quot;:&quot;Max&quot;,&quot;last_name&quot;:&quot;Ruzanov&quot;},{&quot;first_name&quot;:&quot;Joann&quot;,&quot;last_name&quot;:&quot;Strnad&quot;},{&quot;first_name&quot;:&quot;Adriana&quot;,&quot;last_name&quot;:&quot;Zupa-Fernandez&quot;},{&quot;first_name&quot;:&quot;Lihong&quot;,&quot;last_name&quot;:&quot;Cheng&quot;},{&quot;first_name&quot;:&quot;Kathleen&quot;,&quot;last_name&quot;:&quot;M. Gillooly&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Shuster&quot;},{&quot;first_name&quot;:&quot;Yifan&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Anil&quot;,&quot;last_name&quot;:&quot;Thankappan&quot;},{&quot;first_name&quot;:&quot;Kim&quot;,&quot;last_name&quot;:&quot;W. McIntyre&quot;},{&quot;first_name&quot;:&quot;Charu&quot;,&quot;last_name&quot;:&quot;Chaudhry&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;A. Elzinga&quot;},{&quot;first_name&quot;:&quot;Manoj&quot;,&quot;last_name&quot;:&quot;Chiney&quot;},{&quot;first_name&quot;:&quot;Anjaneya&quot;,&quot;last_name&quot;:&quot;Chimalakonda&quot;},{&quot;first_name&quot;:&quot;Louis&quot;,&quot;last_name&quot;:&quot;J. Lombardo&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;E. Macor&quot;},{&quot;first_name&quot;:&quot;Percy&quot;,&quot;last_name&quot;:&quot;H. Carter&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;R. Burke&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;S. Weinstein&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;28&quot;,&quot;issue&quot;:&quot;1&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;677-694&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01698&quot;},&quot;abstract&quot;:&quot;A search for structurally diversified Tyk2 JH2 ligands from 6 (BMS-986165), a pyridazine carboxamide-derived Tyk2 JH2 ligand as a clinical Tyk2 inhibitor currently in late development for the treatment of psoriasis, began with a survey of six-membered heteroaryl groups in place of the N-methyl triazolyl moiety in 6. The X-ray co-crystal structure of an early lead (12) revealed a potential new binding pocket. Exploration of the new pocket resulted in two frontrunners for a clinical candidate. The potential hydrogen bonding interaction with Thr599 in the pocket was achieved with a tertiary amide moiety, confirmed by the X-ray co-crystal structure of 29. When the diversity search was extended to nicotinamides, a single fluorine atom addition was found to significantly enhance the permeability, which directly led to the discovery of 7 (BMS-986202) as a clinical Tyk2 inhibitor that binds to Tyk2 JH2. The preclinical studies of 7, including efficacy studies in mouse models of IL-23-driven acanthosis, anti-CD40-indu&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01698&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01698" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01698&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01698" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01698&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01698" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01698&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01698&amp;href=/doi/10.1021/acs.jmedchem.0c01698" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01698" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01698" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01698%26sid%3Dliteratum%253Aachs%26pmid%3D33370104%26genre%3Darticle%26aulast%3DLiu%26date%3D2021%26atitle%3DDiscovery%2Bof%2BBMS-986202%253A%2BA%2BClinical%2BTyk2%2BInhibitor%2Bthat%2BBinds%2Bto%2BTyk2%2BJH2%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D1%26spage%3D677%26epage%3D694%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292017" title="Solvents">Solvents</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/1" title="Go to Volume 64, Issue 1"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/jmcmar.2021.64.issue-1/20210114/jmcmar.2021.64.issue-1.largecover.jpg" alt="Go to Volume 64, Issue 1"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0022.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01698&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A search for structurally diversified Tyk2 JH2 ligands from <b>6</b> (BMS-986165), a pyridazine carboxamide-derived Tyk2 JH2 ligand as a clinical Tyk2 inhibitor currently in late development for the treatment of psoriasis, began with a survey of six-membered heteroaryl groups in place of the <i>N</i>-methyl triazolyl moiety in <b>6</b>. The X-ray co-crystal structure of an early lead (<b>12</b>) revealed a potential new binding pocket. Exploration of the new pocket resulted in two frontrunners for a clinical candidate. The potential hydrogen bonding interaction with Thr599 in the pocket was achieved with a tertiary amide moiety, confirmed by the X-ray co-crystal structure of <b>29</b>. When the diversity search was extended to nicotinamides, a single fluorine atom addition was found to significantly enhance the permeability, which directly led to the discovery of <b>7</b> (BMS-986202) as a clinical Tyk2 inhibitor that binds to Tyk2 JH2. The preclinical studies of <b>7</b>, including efficacy studies in mouse models of IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus, will also be presented.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73541" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73541" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Tyrosine kinase 2 (Tyk2) is a non-receptor tyrosine kinase belonging to the Janus kinase (Jak) family that also includes Jak1, Jak2, and Jak3. Jak family members regulate immunomodulatory cytokine-initiated signaling by phosphorylating their receptors, which in turn leads to recruitment and phosphorylation of signal transducer and activation of transcription (STAT) proteins to affect the Jak-STAT-dependent transcription and functional responses.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4 ref5">(1â5)</a> These cytokine signaling pathways play key roles in the pathogenesis of autoimmune and inflammatory disorders. The pursuit of Jak inhibitors as therapeutic agents has so far resulted in five FDA-approved drugs. They are pan-Jak inhibitor tofacitinib,<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> Jak1/2 dual inhibitors ruxolitinib<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> and baricitinib,<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a> moderately selective Jak1 inhibitor upadacitinib,<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> and moderately selective Jak2 inhibitor fedratinib.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> For the Tyk2 specific Tyk2-STAT signaling, the involved cytokines include the p40-containing IL-12 and IL-23 as well as Type I interferon IFNÎ±, which are implicated in diseases such as psoriasis,<a onclick="showRef(event, 'ref16 ref17 ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18 ref19 ref20">(16â20)</a> systemic lupus erythematosus (SLE),<a onclick="showRef(event, 'ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23">(21â23)</a> and inflammatory bowel disease (IBD).<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> Intervening in the Tyk2-STAT signaling pathway by targeting these cytokines with biologics has been proved to be a feasible therapeutic solution to autoimmune and inflammatory diseases. For example, ustekinumab, a human IL-12/23 monoclonal antibody, was approved by FDA for the treatment of psoriasis,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Crohnâs diseases,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> and ulcerative colitis.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Anifrolumab, a human monoclonal antibody that binds to and blocks Type I interferons, was shown to be efficacious in the treatment of SLE in phase III clinical trials recently.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Meanwhile, genetic studies have shown that Tyk2-deficient mice were resistant to collagen-induced arthritis (CIA) and experimental autoimmune encephalomyelitis (EAE),<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30,31)</a> while deactivating mutations in the Tyk2 gene could provide protection from multiple autoimmune disorders including psoriasis, rheumatoid arthritis (RA), and SLE.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> As a result, Tyk2, a key regulator of the Tyk2-STAT cascade, is rationalized to be a promising small molecule target for developing orally active therapeutic agents for autoimmune and inflammatory disorders.<a onclick="showRef(event, 'ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref33 ref34 ref35">(33â35)</a></div><div class="NLM_p">A characteristic feature of Tyk2 and other Jak family members is that they possess a canonical catalytic kinase domain and a pseudokinase domain proximal to each other.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a> The catalytic kinase and pseudokinase domains are also called Jak homology 1 (JH1) and Jak homology 2 (JH2), respectively. The catalytic domains of all the Jak family members have a high degree of homology, and as a result, identification of highly selective JH1 inhibitors has proven to be challenging. This is evident by the fact that the five aforementioned FDA-approved Jak inhibitor drugs, all being Jak JH1 inhibitors, consist of one pan-Jak inhibitor, two Jak1/2 dual inhibitors, one moderately selective Jak1 inhibitor, and one moderately selective Jak2 inhibitor. Severe side effects observed during clinical studies prevented the FDA from approving more efficacious higher doses for tofacitinib<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and baricitinib<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> for the treatment of rheumatoid arthritis (RA). Also, baricitinib<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and upadacitinib<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> each carry a boxed warning, the most serious warning the FDA issues, for risks of serious infection, malignancy, and thrombosis. The adverse effects of these drugs may be linked to the lack of specificity or selectivity. Tyk2 JH1 inhibitors such as <b>1</b>,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a><b>2</b>,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a><b>3</b> (PF-06700841),<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40,41)</a> and <b>4</b> (PF-06826647)<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) have been reported, with <b>3</b> and <b>4</b> in clinical trial phases II and I, respectively. Like the JH1 inhibitors of other Jak family members, these inhibitors are only modestly selective as they also show significant activities against other Jak family members. Our strategy to selectively target the Tyk2-STAT signaling pathway takes advantage of Tyk2 JH2. Overall, Tyk2 JH2 closely resembles Tyk2 JH1, but there are some unique differences in the binding pockets between the two domains,<a onclick="showRef(event, 'ref37 ref43'); return false;" href="javascript:void(0);" class="ref ref37 ref43">(37,43)</a> which may be sufficient for identification of Tyk2 JH2 selective inhibitors. A good indication is that Tyk2 JH2 only binds adenosine triphosphate (ATP) very weakly with a <i>K</i><sub>d</sub> of 24 Î¼M.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Comparison of the crystal structures of Tyk2 JH2,<a onclick="showRef(event, 'ref37 ref44'); return false;" href="javascript:void(0);" class="ref ref37 ref44">(37,44)</a> Jak1 JH2,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> and Jak2 JH2<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> also reveals unique differences in the binding pockets among these pseudokinase domains. The weak ATP binding of Tyk2 JH2 did not demonstrate any catalytic activity. However, it has been shown by mutation studies that Tyk2 JH2 plays an important regulatory role in Tyk2 function,<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> suggesting that Tyk2 JH2 can be a druggable target.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Literature Tyk2 JH1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01698&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We previously reported Tyk2 JH2 ligands that were remarkably selective and effective in blocking the activation of Tyk2 JH1.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Then, with compound <b>5</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), an imidazopyridazine derivative, we demonstrated the proof of concept for the idea that a small molecule Tyk2 JH2 ligand could serve as an orally active therapeutic agent for autoimmune and inflammatory diseases.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Most recently, we disclosed pyridazine carboxamide-based Tyk2 JH2 ligand <b>6</b> (BMS-986165) as a Tyk2 inhibitor that is currently in phase III clinical development for the treatment of psoriasis.<a onclick="showRef(event, 'ref50 ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref50 ref51 ref52">(50â52)</a> Now, we present the identification and preclinical studies of a nicotinamide-derived clinical Tyk2 JH2 binding Tyk2 inhibitor <b>7</b> (BMS-986202).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Tyk2 JH2 ligands as Tyk2 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01698&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76174" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76174" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> StructureâActivity Relationship (SAR) Studies, Lead Optimization, and X-ray Co-crystal Structures</h3><div class="NLM_p">To search for structurally differentiated Tyk2 JH2 ligands, we first investigated if the <i>N</i>-methyl triazolyl group in <b>6</b> could be replaced with a six-membered heteroaryl group. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, the use of 2-pyridyl in place of the <i>N</i>-methyl triazinyl group in <b>6</b> resulted in analog <b>8</b>, which turned out to be 8-fold less active than <b>6</b> against the Tyk2 pseudokinase. The compound was also less potent in the IFNÎ± stimulated luciferase reporter assay<a onclick="showRef(event, 'ref49 ref53'); return false;" href="javascript:void(0);" class="ref ref49 ref53">(49,53)</a> in Kit225 T cells and in the IFNÎ± stimulated STAT5 phosphorylation human whole blood (hWB) assay<a onclick="showRef(event, 'ref49 ref53'); return false;" href="javascript:void(0);" class="ref ref49 ref53">(49,53)</a> by 8- and 24-fold, respectively. Compounds <b>9â12</b> are isomeric analogs derived from the replacement of <i>N</i>-methyl triazinyl in <b>6</b> with pyridazinyl, pyrimidinyl, and pyrazinyl groups. They displayed comparable activities to one another in the Tyk2 JH2 enzymatic, cellular, and hWB assays. Compared to <b>8</b>, their hWB activities were shown to be 2- to 8-fold more potent, though their enzymatic and cellular activities were about the same or only 2- to 3-fold better. <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> also contains the liver microsomal (LM) stability data for <b>8â12</b>. Clearly, <b>12</b> was the early standout from this six-membered heteroaryl group survey as it was not only the most potent analog but also the only one that was found to be stable in liver microsomes. As a result, <b>12</b> was chosen for further SAR studies. On the other hand, two issues were identified for <b>12</b>. First, though it showed an encouraging pharmacokinetic profile, improvement was needed. Second, <b>12</b> was associated with poor aqueous solubility (<1 Î¼g/mL at pH 6.5).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR Observed for Ar with <b>8â12</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0014.gif" alt="" id="gr13" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0015.gif" alt="" id="gr14" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Mean values are determined from at least three experiments unless otherwise noted.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Mean values determined from two experiments.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Value determined from one experiment.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Percentage remaining after 10 min of incubation in microsomes.</p></div></div><div></div></div><div class="NLM_p">We were able to quickly obtain an X-ray co-crystal structure of <b>12</b> with the Tyk2 JH2 protein.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> As indicated in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>a, the key binding interactions between <b>12</b> and Tyk2 JH2 include (1) hydrogen bonds between the cyclopropane carboxamide NH and the carbonyl groups of Val690 as well as between a N atom of the pyridazine core and the NH group of Val690 at the hinge region, (2) a hydrogen bond between the pyridazine carboxamide NH and the carbonyl groups of Glu688, (3) a hydrogen bonding network involving the pyridazine carboxamide carbonyl group, the methoxy oxygen group, and Lys642, (4) a hydrogen bond between a N atom of pyrimidine and a NH group of Arg738, and (5) a unique hydrophobic interaction of the methoxy group with a shallow hydrophobic pocket (shown with a gray surface representation). In addition to the key binding interactions, the co-crystal structure also revealed a large empty pocket at the end of pyrimidine ring of <b>12</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>b). It was also noticed that, on the pocket surface, Thr599 with OH and NH groups available for potential hydrogen bond formation is within an accessible distance (â¼5 Ã).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray co-crystal structure of <b>12</b> bound to Tyk2 JH2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K7O">7K7O</a>). (a) Binding interaction highlights. (b) Surface representation of the Tyk2 JH2 protein showing a pocket available at the top of the pyrimidine ring.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01698&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We decided to explore the potential of the new pocket. As expected, small substitutions such as Me, F, and OMe at the 5â³-position (<b>13â15</b>) were tolerated (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>), but they provided no advantages over <b>12</b>. Compared to the 5â³-substitutions, the 4â³-substitutions (<b>16</b> and <b>17</b>) were less tolerated or detrimental. We next explored some bulkier, more hydrophilic functionalities such as tertiary carbinol (<b>18</b>) and amide (<b>19</b>) moieties to take advantage of the new pocket and address the poor aqueous solubility observed for <b>12</b>, with the hope of also making interactions with Thr599. Analogs <b>18</b> and <b>19</b> turned out to be highly potent against Tyk2 JH2 enzymatic, cellular, and hWB assays. Also, <b>18</b> did show a significantly improved aqueous solubility of 14 Î¼g/mL at pH 6.5, while the aqueous solubility for <b>19</b> was not determined. However, unfortunately, both <b>18</b> and <b>19</b> displayed very poor Caco-2 permeability of 24 nm/s. Attempts to improve the permeability by using more hydrophobic carbinol (<b>20</b>) or amide (<b>21</b>) moieties were unsuccessful. We also introduced a F substituent on the aniline phenyl in <b>18</b> and <b>19</b>, but the resulting analogs <b>22</b> and <b>23</b> did not show any improvement in permeability.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR Observed for R and X with <b>12â23</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0016.gif" alt="" id="gr15" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0017.gif" alt="" id="gr16" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Mean values are determined from at least three experiments unless otherwise noted.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Mean values determined from two experiments.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">Value determined from one experiment.</p></div></div><div></div></div><div class="NLM_p">Continuing to search for ways to improve the permeability for <b>18</b> and <b>19</b>, we prepared analogs <b>24</b> and <b>25</b>, where a pyrazine ring was employed in place of the pyrimidine ring (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). We rationalized that pyrazine analogs <b>24</b> and <b>25</b> should be less polar and more permeable than pyrimidine analogs <b>18</b> and <b>19</b>. To our satisfaction, <b>24</b> and <b>25</b> displayed much improved Caco-2 values of 146 and 98 nm/s, respectively. What is more, in sharp contrast to early pyrazine analog <b>11</b>, compounds <b>24</b> and <b>25</b> were found to be stable in liver microsomes. For example, after 10 min of incubation of <b>24</b> in human, rat, and mouse liver microsomes, the parent <b>24</b> was detected to be 95%, 90%, and 99%, respectively. These data may suggest that the 5â³-position of the pyrazinyl in <b>11</b> be a metabolic soft spot. With respect to activity, <b>24</b> appeared slightly less potent than <b>18</b>, while <b>25</b> slightly more potent than <b>19</b> in the hWB assay. Replacement of the pyrimidine ring in <b>18</b> and <b>19</b> with a pyridine ring led to <b>26</b> and <b>27</b>, which showed moderately improved permeability. The pyridazine analogs <b>28</b> and <b>29</b> were also synthesized, but they did not provide much improvement in permeability. It should be pointed out that, compared to the unsubstituted pyridinyl (<b>8</b>), pyridazinyl (<b>9</b>), and pyrazinyl (<b>11</b>) compounds (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), the corresponding tertiary amide moiety containing analogs <b>27</b>, <b>29</b>, and <b>25</b> (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>) consistently showed improved activities in all the three assays. We were able to obtain an X-ray co-crystal structure of <b>29</b> bound to the Tyk2 JH2 protein (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), which confirmed a hydrogen bond interaction between the tertiary amide carbonyl O in <b>29</b> and the Thr599 hydroxyl H.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray co-crystal structure of <b>29</b> bound to Tyk2 JH2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K7Q">7K7Q</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01698&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SAR Observed for Ar with <b>24â29</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0018.gif" alt="" id="gr17" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0019.gif" alt="" id="gr18" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Mean values are determined from at least three experiments.</p></div></div><div></div></div><div class="NLM_p">For further structural diversity away from <b>6</b>, we also examined nicotinamide analogs and found that nicotinamide <b>30</b> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>) was at least as potent as its pyridazine carboxamide counterpart <b>12</b>. Subsequent profiling showed that <b>30</b> had an aqueous solubility of 32 Î¼g/mL, significantly better than that (<1 Î¼g/mL) for <b>12</b>. However, <b>30</b> was much less permeable compared to <b>12</b> as it displayed a Caco-2 value of 42 nm/s versus 339 nm/s for <b>12</b>. To improve the permeability for <b>30</b>, we tried the same strategy that successfully addressed the issue for pyridazine carboxamides <b>18</b> and <b>19</b>, namely, replacing the pyrimidine ring in <b>30</b> with a pyrazine ring. However, in this case, the resulting analogs <b>31</b> and <b>32</b> displayed reduced activities in the cellular and hWB assays, though compound <b>32</b> did show a significantly enhanced permeability of 187 nm/s. Fortunately, it was later found that the permeability of <b>30</b> could sufficiently be improved by introducing a single F atom to the molecule. The fluoro group could be added to the 5â³-position of the pyrimidine ring or to the 5â²-position of the aniline phenyl group. The resulting analogs <b>7</b> and <b>33</b> displayed a Caco-2 permeability of 96 and 113 nm/s, respectively, while largely maintaining the Tyk2 JH2 enzymatic, cellular, and hWB activities observed for <b>30</b>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. SAR Observed for Ar and X with <b>30â33</b> and <b>7</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0020.gif" alt="" id="gr19" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0021.gif" alt="" id="gr20" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Mean values are determined from at least three experiments.</p></div></div><div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Pharmacokinetic (PK) Studies</h3><div class="NLM_p">In the course of SAR explorations, a number of analogs were advanced to full PK studies in mouse based on activities and other profiling data. The results from <b>12</b>, <b>24</b>, <b>25</b>, and <b>7</b> are arranged in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>. As mentioned earlier, <b>12</b>, the early pyridazine carboxamide lead directly identified from the SAR survey of six-membered heteroaryl groups in place of the <i>N</i>-methyl triazole ring in <b>6</b> displayed an encouraging PK profile with its oral exposure (AUC<sub>0-24h</sub>) of 15 Î¼MÂ·h (when dosed at 10 mpk) and bioavailability (F%) of 31%, but improvements were desired. Compounds <b>24</b> and <b>25</b> were obtained from the exploration of the new binding pocket, and both showed moderately improved PK profiles, compared to <b>12</b>. However, more significant improvements were achieved with nicotinamide <b>7</b> as it increased the oral exposure by 4 times and doubled the bioavailability, compared to <b>12</b>. As a result, <b>7</b> was further studied for its PK properties in rat, cyno, and dog (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>), and its exposure and bioavailability were further improved in these species, with the bioavailability reaching to 100% in cyno and dog. Across the board, the compound was shown to be of low clearance rate and low volume of distribution.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Mouse PK Profiles for <b>12</b>, <b>24</b>, <b>25</b>, and <b>7</b><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t5fn2" aria-label="b">b</a><sup>,</sup><a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center"><b>12</b></th><th class="colsep0 rowsep0" align="center"><b>24</b></th><th class="colsep0 rowsep0" align="center"><b>25</b></th><th class="colsep0 rowsep0" align="center"><b>7</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PO dose (mg/kg)</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cmax (Î¼M)</td><td class="colsep0 rowsep0" align="left">5.4</td><td class="colsep0 rowsep0" align="left">6.1</td><td class="colsep0 rowsep0" align="left">7.8</td><td class="colsep0 rowsep0" align="left">13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0-24Â h</sub> (Î¼MÂ·h)</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">26</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">65</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (mL/min/kg)</td><td class="colsep0 rowsep0" align="left">7.9</td><td class="colsep0 rowsep0" align="left">5.3</td><td class="colsep0 rowsep0" align="left">7.6</td><td class="colsep0 rowsep0" align="left">3.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Vss (L/kg)</td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left">3.4</td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" align="left">1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">F (%)</td><td class="colsep0 rowsep0" align="left">31</td><td class="colsep0 rowsep0" align="left">41</td><td class="colsep0 rowsep0" align="left">43</td><td class="colsep0 rowsep0" align="left">62</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">IV dose: 1 mpk.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">IV vehicle: 20% water:80% PEG 400.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">PO vehicle: 5:5:90 TPGS:EtOH:PEG300.</p></div></div></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. PK Profiles for <b>7</b> in Rat, Cyno, and Dog<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t6fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center">rat</th><th class="colsep0 rowsep0" align="center">cyno</th><th class="colsep0 rowsep0" align="center">dog</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PO dose (mg/kg)</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cmax (Î¼M)</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0-24Â h</sub> (Î¼MÂ·h)</td><td class="colsep0 rowsep0" align="left">77</td><td class="colsep0 rowsep0" align="left">130</td><td class="colsep0 rowsep0" align="left">126</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (mL/min/kg)</td><td class="colsep0 rowsep0" align="left">3.6</td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left">1.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Vss (L/kg)</td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left">1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">F (%)</td><td class="colsep0 rowsep0" align="left">72</td><td class="colsep0 rowsep0" align="left">â¼100</td><td class="colsep0 rowsep0" align="left">â¼100</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">IV dose: 1 mpk for rat, 2 mpk for cyno and dog.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">IV vehicle: 20% water:80% PEG 400.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">PO vehicle: 5:5:90 TPGS:EtOH:PEG300.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Pharmacodynamic (PD) and Efficacious Studies of <b>7</b></h3><div class="NLM_p">To evaluate its PD responses, inhibitor <b>7</b> was tested for its ability to inhibit IL-12/IL-18-induced IFNÎ³ production in mice. The compound was first orally dosed to mice. One and 2 h later, the animals were challenged with IL-12 and IL-18, respectively. Five hours after drug administration, plasma samples were collected and analyzed for IFNÎ³ levels. As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, compound <b>7</b> dose-dependently inhibited IFNÎ³ production by 46% and 80% at doses of 2 and 10 mpk, respectively.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Inhibitor <b>7</b> in a mouse PD model of IL-12/IL-18-induced IFNÎ³ production (vehicle: 5:5:90 EtOH:TPGS:PEG300).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01698&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">For efficacy evaluations in disease models, <b>7</b> was studied in a mouse skin inflammation (psoriasis-like) model of IL-23-driven acanthosis. In this study, IL-23 was injected to mice every other day during a period of 12 days to induce acanthosis. Inhibitor <b>7</b> was orally dosed to mice once a day for the same period, with the first dose approximately 2 h prior to the first injection of IL-23. The mouse ear thickness was measured periodically and calculated for the percent change in thickness from the baseline measurement taken before the initial IL-23 injection. Ustekinumab, a human anti-IL-23 antibody was used as a positive control in the study. As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, <b>7</b> inhibited ear swelling in a dose-responsive manner, with a dose of 30 mpk (QD) showing at least equivalent efficacy to ustekinumab.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Inhibitor <b>7</b> in a mouse model of IL-23-driven acanthosis (QD dosing; vehicle: 5:5:90 TPGS:EtOH:PEG300).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01698&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Inhibitor <b>7</b> was also studied in the SCID mouse model of anti-CD40-induced colitis. The compound was orally dosed to SCID mice once a day for 6 days. Immediately after the first dose, the mice were challenged with a single injection of an anti-CD40 antibody to induce colitis. On day 6, all animals were euthanized for histological evaluations. An anti-p40-antibody was used as a positive control in this study. The colon histology score indicated that <b>7</b> was effective in inhibiting colitis in a dose-dependent manner, with doses of 25 and 60 mpk showing equivalent efficacy to the anti-p40 antibody (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Inhibitor <b>7</b> in the SCID mouse model of anti-CD40-induced colitis (QD dosing; vehicle: aqueous suspension containing 0.5% Methocel and 0.1% Tween-80).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01698&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Lastly, <b>7</b> was evaluated in a 12 week, spontaneous lupus model in NZB/W mice. NZB/W mice are a type of New Zealand black and white hybrid mice. These mice will spontaneously develop an autoimmune syndrome similar to that of lupus patients, characterized by high levels of antinuclear antibodies and proteinuria, and therefore can be used as a lupus model without needing any challenges.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Compound <b>7</b> was orally dosed to NZB/W mice at the age of 23 weeks or so, when no severe proteinuria was detected, once a day for 12 weeks. The anti-dsDNA titers and proteinuria were measured periodically. In this study, mouse anti-interferon receptor antibody MAR1-5A3 was used as a positive control. As shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>, Tyk2 JH2 ligand <b>7</b> dose-dependently suppressed the level of anti-dsDNA titers and prevented proteinuria development.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Inhibitor <b>7</b> in a spontaneous lupus model in NZB/W mice (QD dosing; vehicle: 5:5:90 EtOH:TPGS:PEG300).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01698&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Additional Profiling Data of <b>7</b></h3><div class="NLM_p">Extensive profiling was completed for <b>7</b>, and some of the data are arranged in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>. As shown earlier, <b>7</b> and many other analogs were extremely active against our Tyk2 JH2 enzymatic assay, and we believed that the enzymatic assay might be beyond its capability to determine the true IC<sub>50</sub> values for those compounds. As a result, for important analogs, we also obtained their Ki values by Morrison titration.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> For <b>7</b>, the Tyk2 JH2 IC<sub>50</sub> was measured to be 0.19 nM, but its Ki was determined to be 0.02 nM. In addition to the IFNÎ± stimulated luciferase reporter assay<a onclick="showRef(event, 'ref49 ref53'); return false;" href="javascript:void(0);" class="ref ref49 ref53">(49,53)</a> in Kit225 T cells, we also had an IL-23 stimulated reporter assay (in Kit225 T cells).<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> against which the cellular activity (IL-23 IC<sub>50</sub>) of <b>7</b> was determined to be 12 nM, almost identical to what was obtained from the INFÎ± stimulated cellular assay. In addition to the hWB assay, <b>7</b> was also evaluated in a mWB assay.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> It was found that <b>7</b> was 8-fold less potent in the mWB assay than in the hWB assay. Given the efficacy observed in multiple mouse disease models, this human/mouse WB potency discrepancy only made us feel more confident about the prospects for the compound in patients. The 8-fold discrepancy between the hWB and mWB potency is also consistent with what was observed for <b>6</b> (BMS-986165). Inhibitor <b>7</b> is stable in liver microsomes, with half lives of greater than 120 min in mouse, rat, monkey, and humans and 89 min in dog. The serum protein binding for <b>7</b> in these species ranges from 89.3% to 96.0%, leaving a good range of free fraction of drug available. Compound <b>7</b> did not inhibit cytochrome P450 isozymes 1A2, 3A4, 2B6, 2C9, 2C19, and 2D6 with IC<sub>50</sub> values less than 40 Î¼M, but it was a weak inhibitor of 2C19 with an IC<sub>50</sub> of 14 Î¼M. The compound proved to be exquisitely selective over other kinases, displaying >10,000-fold selectivity for Tyk2 JH2 over a diverse panel of 273 kinases and pseudokinases that include Jak family members. Compound <b>7</b> did bind Jak1 JH2 with an IC<sub>50</sub> of 7.8 nM, but this enzymatic binding did not lead to any functional activities as <b>7</b> displayed an activity (IC<sub>50</sub>) of greater than 12.5 Î¼M in the IL-2 stimulated Jak1/3-dependent cellular assay. The compound was also shown to display an activity (IC<sub>50</sub>) of greater than 10 Î¼M in the EPO-stimulated Jak2-dependent TF-1 cell assay. In short, the profiling studies did not reveal liabilities for <b>7</b>, and the compound ultimately passed the preclinical toxicity studies to advance to clinical studies.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. <i>In vitro</i> Profile of <b>7</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">assays</th><th class="colsep0 rowsep0" align="center">results</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tyk2 JH2 IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">0.19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tyk2 JH2 Ki (nM)</td><td class="colsep0 rowsep0" align="left">0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IFNÎ± IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-23 IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hWB IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">58</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mWB IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">481</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">liverÂ microsomalÂ half-lifeÂ (min)</td><td class="colsep0 rowsep0" align="left">>120 in mouse, rat, monkey, and humans; 89 in dog</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Caco-2 A to B (nm/s)</td><td class="colsep0 rowsep0" align="left">96</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SerumÂ proteinÂ bindingÂ (%)</td><td class="colsep0 rowsep0" align="left">92.4 (h), 96.0 (r), 93.3 (m), 94.1 (c), 89.3 (d)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">P450 IC<sub>50</sub> (Î¼M)</td><td class="colsep0 rowsep0" align="left">>40 for 1A2, 3A4, 2B6, 2C9, 2D6; 14 for 2C19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">kinase selectivity</td><td class="colsep0 rowsep0" align="left">>10,000-fold over 273 kinases and pseudokinases, JAK1 JH2 IC<sub>50</sub> = 7.8 nM, IL-2 IC<sub>50</sub> (Jak1/3-dependent cellular activity): >12.5 Î¼M, EPO IC<sub>50</sub> (Jak2-dependent cellular activity): >10 Î¼M</td></tr></tbody></table></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Chemistry</h3><div class="NLM_p">The syntheses of pyridazine carboxamides <b>8â20</b>, <b>24â27</b>, and <b>29</b> are outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Reaction of 3-bromo-2-methoxyaniline (<b>34</b>) with 4,4,4â²,4â²,5,5,5â²,5â²-octamethyl-2,2â²-bi(1,3,2-dioxaborolane) in the presence of [1,1â²-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (PdCl<sub>2</sub>(dppf)-CH<sub>2</sub>Cl<sub>2</sub>) supplied dioxaborolane <b>35</b>. Suzuki coupling reaction of <b>35</b> and heteroaryl halide (ArCl), commercially available or readily prepared using literature procedures, gave rise to aniline <b>36aâr</b>. Treatment of <b>36aâr</b> with 4,6-dichloro-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>37</b>), a previously reported key intermediate,<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> and lithium bis(trimethylsilyl)amide regioselectively provided precursor <b>38aâr</b>. Buchwald coupling reaction of <b>38aâr</b> and cyclopropanecarboxamide, effected by tris(dibenzylideneacetone)dipalladium(0) (Pd<sub>2</sub>(dba)<sub>3</sub>) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (XantPhos), afforded analogs <b>8â20</b>, <b>24â27</b>, and <b>29</b>.</div><figure id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>8â20</b>, <b>24â27</b>, and <b>29</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01698&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4,4,4â²,4â²,5,5,5â²,5â²-octamethyl-2,2â²-bi(1,3,2-dioxaborolane), PdCl<sub>2</sub>(dppf)-CH<sub>2</sub>Cl<sub>2</sub>, KOAc, 1,4-dioxane, 110 Â°C, 20 h, 60%; (b) ArCl, PdCl<sub>2</sub>(dppf)-CH<sub>2</sub>Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, 110 Â°C, 31â82%; (c) <b>37</b>, LiN(SiMe<sub>3</sub>)<sub>2</sub>, THF, rt, 7â92%; (d) cyclopropanecarboxamide, Pd<sub>2</sub>(dba)<sub>3,</sub> XantPhos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 145 Â°C, 6â56%.</p></p></figure><div class="NLM_p">The syntheses of <b>21</b> and <b>23</b> are shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Suzuki reaction of <b>35</b> and ethyl 2-chloropyrimidine-5-carboxylate provided aniline <b>41a</b>. To avoid significant hydrolysis of the ester functionality, it was important to run the reaction at a relatively low temperature (75 Â°C) and within a relatively short period of time (4 h). In the same manner, <b>41b</b> was obtained from <b>40</b>, which was prepared from 3-bromo-5-fluoro-2-methoxyaniline (<b>39</b>). Treatment of <b>41a</b> and <b>41b</b> with 4,6-dichloro-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>37</b>)<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> in the presence of lithium bis(trimethylsilyl)amide resulted in chloropyridazine carboxamides <b>42a</b> and <b>42b</b>, which were then converted to <b>43a</b> and <b>43b</b> by Buchwald reaction. Hydrolysis of <b>43a</b> and <b>43b</b> with lithium hydroxide, followed by an amide formation coupling reaction, furnished analogs <b>21</b> and <b>23</b>.</div><figure id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>21</b> and <b>23</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01698&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) ethyl 2-chloropyrimidine-5-carboxylate, PdCl<sub>2</sub>(dppf)-CH<sub>2</sub>Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, 75 Â°C, 74%; (b) 4,4,4â²,4â²,5,5,5â²,5â²-octamethyl-2,2â²-bi(1,3,2-dioxaborolane), PdCl<sub>2</sub>(dppf)-CH<sub>2</sub>Cl<sub>2</sub>, K<sub>2</sub>OAc, 1,4-dioxane, 105 Â°C, 61%; (c) ethyl 2-chloropyrimidine-5-carboxylate, PdCl<sub>2</sub>(dppf)-CH<sub>2</sub>Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, 75 Â°C, 79%; (d) <b>37</b>, LiN(SiMe<sub>3</sub>)<sub>2</sub>, THF, rt, 32% and 43% for <b>42a</b> and <b>42b</b>, respectively; (e) cyclopropanecarboxamide, Pd<sub>2</sub>(dba)<sub>3,</sub> XantPhos, Cs<sub>2</sub>CO<sub>3,</sub> 1,4-dioxane, 150 Â°C, microwave, 72% and 50% for <b>43a</b> and <b>43b</b>, respectively; (f) i. LiOHÂ·H<sub>2</sub>O, MeOH/THF, rt; ii. Et<sub>2</sub>NH or Me<sub>2</sub>NH, BOP, (<i>i</i>-Pr)<sub>2</sub>NEt, THF, 50 Â°C, 12% and 42% over two steps for <b>21</b> and <b>23</b>, respectively.</p></p></figure><div class="NLM_p">Analogs <b>22</b> and <b>28</b> were synthesized according to <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Bromopyrimidine <b>44</b> was obtained from <b>40</b>, via Suzuki reaction, and transformed to vinyl ether <b>45a</b> with tributyl(1-ethoxyvinyl)stannane and Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>. Meanwhile, vinyl ether <b>45b</b> was prepared from <b>35</b> and commercially available 3-chloro-6-(1-ethoxyvinyl)pyridazine. Reaction of <b>45a</b> and <b>45b</b> with 4,6-dichloro-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>37</b>)<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> and lithium bis(trimethylsilyl)amide led to the formation of <b>46a</b> and <b>46b</b>, which were then reacted with cyclopropanecarboxamide in the presence of Pd<sub>2</sub>(dba)<sub>3</sub> and XantPhos to yield <b>47a</b> and <b>47b</b>. Vinyl ether <b>47a</b> and <b>47b</b> were converted to methyl ketone <b>48a</b> and <b>48b</b> with 1 N hydrochloric acid. Treatment of <b>48a</b> and <b>48b</b> with methylmagnesium bromide provided targets <b>22</b> and <b>28</b>.</div><figure id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <b>22</b> and <b>28</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01698&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 2,5-dibromopyrimidine, PdCl<sub>2</sub>(dppf)-CH<sub>2</sub>Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, 90 Â°C, 43%; (b) tributyl(1-ethoxyvinyl)stannane, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N, DMF, 100 Â°C, 75%; (c) 3-chloro-6-(1-ethoxyvinyl)pyridazine, PdCl<sub>2</sub>(dppf)-CH<sub>2</sub>Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, 105 Â°C, 1,4-dioxane, 100%; (d) <b>37</b>, LiN(SiMe<sub>3</sub>)<sub>2</sub>, THF, rt, 75% and 52 for <b>46a</b> and <b>46b</b>, respectively; (e) cyclopropanecarboxamide, Pd<sub>2</sub>(dba)<sub>3,</sub> XantPhos, Cs<sub>2</sub>CO<sub>3,</sub> 1,4-dioxane, 150 Â°C, microwave, 71% for <b>47a</b>; (f) 1 N HCl, THF, rt, 76% for <b>48a</b> and 52% (over 2 steps) for <b>48b</b>; (g) MeMgBr, THF, 0 Â°C, 29% and 38% for <b>22</b> and <b>28</b>, respectively.</p></p></figure><div class="NLM_p">Nicotinamides <b>7</b> and <b>30â33</b> were synthesized (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>) in a similar manner as pyridazine carboxamides <b>8â20</b>, <b>24â27</b>, and <b>29</b> were (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>), except that now 4,6-dichloro-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)nicotinamide (<b>49</b>)<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> was employed in place of 4,6-dichloro-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>37</b>). Dichloronicotinamide <b>49</b> displayed the same desired regioselectivity as dichloropyridazine carboxamide <b>37</b> when reacting with anilines <b>36e</b>, <b>36g</b>, and <b>36sâu</b> in the presence of lithium bis(trimethylsilyl)amide. Also, the resulting chloronicotinamide <b>50aâe</b> behaved very similarly to their chloropyridazine carboxamide counterparts when subjected to Buchwald conditions to afford <b>7</b> and <b>30â33</b>.</div><figure id="sch4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of <b>7</b> and <b>30â33</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01698&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) ArCl, PdCl<sub>2</sub>(dppf)-CH<sub>2</sub>Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, 110 Â°C, 29â81%; (b) <b>49</b>, LiN(SiMe<sub>3</sub>)<sub>2</sub>, THF, rt, 63â77%; (c) cyclopropanecarboxamide, Pd<sub>2</sub>(dba)<sub>3,</sub> XantPhos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 145 Â°C, 45â65%.</p></p></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14307" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14307" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">To search for structurally diversified Tyk2 inhibitors that bind to Tyk2 JH2, a SAR survey of six-membered heteroaryl groups in place of the <i>N</i>-methyl triazolyl group in <b>6</b> was conducted. Interestingly, the X-ray co-crystal structure of an early lead (<b>12</b>) from this survey revealed a potential new binding pocket. Exploration of this potential pocket resulted in compounds with improved potency, properties, and PK profiles, compared to the early analogs. The X-ray co-crystal structure of such an analog (<b>29</b>) showed an additional hydrogen bonding interaction with Thr599 in the pocket. In the nicotinamide series, a series that is much more polar and less permeable than the pyridazine carboxamides, it was found that introduction of a single F atom to a molecule could significantly improve the permeability. This finding directly led to the identification of <b>7</b> (BMS-986202). Tyk2 JH2 ligand <b>7</b> proved to be remarkably selective over other kinases including Jak family members. The compound dose-dependently inhibited IL-12/IL-18-induced IFNÎ³ production in a pharmacodynamic model. It was further demonstrated that <b>7</b> was highly efficacious in three disease models: IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07581" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07581" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Chemistry</h3><div class="NLM_p last">All reagents were purchased from commercial sources and used without further purification unless otherwise noted. All reactions involving air- or moisture-sensitive reagents were performed under an inert atmosphere. Proton and carbon magnetic resonance (<sup>1</sup>H and <sup>13</sup>C NMR) spectra were recorded either on a Bruker Avance 400 or a JEOL Eclipse 500 spectrometer and are reported in ppm relative to the reference solvent of the sample in which they were run. HPLC and LCMS analyses were conducted using a Shimadzu LC-10AS liquid chromatograph and a SPDUV-vis detector at 220 or 254 nm with the MS detection performed with a Micromass Platform LC spectrometer. HPLC analyses were performed using the following conditions: Ballistic YMC S5 ODS 4.6 mm Ã 50 mm column with a binary solvent system where solvent A = 10% methanol and 90% water with 0.2% phosphoric acid and solvent B = 90% methanol and 10% water with 0.2% phosphoric acid, flow rate = 4 mL/min, linear gradient time = 4 min. All final compounds had HPLC purity of 95% or better unless specifically mentioned. LCMS analyses were performed using the following conditions: Phenomenex 5 Î¼m C184.6 mm Ã 50 mm column with a binary solvent system where solvent A = 10% methanol and 90% water with 0.1% trifluoroacetic acid and solvent B = 90% methanol and 10% water with 0.1% trifluoroacetic acid, flow rate = 4 mL/min, linear gradient time = 2 min. Preparative reversed-phase HPLC purifications were performed using one of the following two conditions: (1) Ballistic YMC S5 ODS 20 mm Ã 100 mm column with a binary solvent system where solvent A = 10% methanol and 90% water with 0.1% trifluoroacetic acid and solvent B = 90% methanol and 10% water with and 0.1% trifluoroacetic acid, flow rate = 20 mL/min, linear gradient time = 10 min; (2) Waters XBridge C18, 19 Ã 200 mm column with a binary solvent system where solvent A = 5% acetonitrile and 95% water with 10 mM ammonium acetate and solvent B = 95% acetonitrile and 5% water with 10 mM ammonium acetate, flow rate = 20 mL/min, linear gradient time = 20 min.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 2-Methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (<b>35</b>)</h3><div class="NLM_p last">A mixture of 3-bromo-2-methoxyaniline (<b>34</b>) (3.00 g, 14.85 mmol), 4,4,4â²,4â²,5,5,5â²,5â²-octamethyl-2,2â²-bi(1,3,2-dioxaborolane) (5.66 g, 22.27 mmol), PdCl<sub>2</sub>(dppf)-CH<sub>2</sub>Cl<sub>2</sub> adduct (0.728 g, 0.891 mmol), and potassium acetate (4.37 g, 44.5 mmol) in 1,4-dioxane (60 mL) was heated in a pressure bottle at 110 Â°C for 20 h. Upon cooling to rt, the mixture was diluted with ethyl acetate (60 mL) and filtered through Celite. The filtrate was concentrated under vacuum, and the residue was subjected to flash chromatography (330 g ISCO column, 0â40% ethyl acetate/hexane) to provide the title compound (2.31 g, 9.27 mmol, 62% yield) as a white solid. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>20</sub>BNO<sub>3</sub> (M + H)<sup>+</sup>: 250.2, found: 250.3. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 6.79â6.77 (m, 2H), 6.76â6.72 (m, 1H), 4.77 (s, 2H), 3.63 (s, 3H), 1.27 (s, 12H).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> General Procedure for the Preparation of <b>36aâu</b>, Exemplified by 2-(5-(3-Amino-2-methoxyphenyl)pyrazin-2-yl)propan-2-ol (<b>36n</b>)</h3><div class="NLM_p">A mixture of 2-(5-chloropyrazin-2-yl)propan-2-ol<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> (0.1907 g, 1.105 mmol), 2-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (<b>35</b>) (0.2842 g, 1.015 mmol), 2 M K<sub>3</sub>PO<sub>4</sub> solution (1.523 mL, 3.05 mmol), and PdCl<sub>2</sub>(dppf)-CH<sub>2</sub>Cl<sub>2</sub> adduct (0.050 g, 0.061 mmol) in 1,4-dioxane (7 mL) in a sealed pressure vial was degassed and heated at 105 Â°C for 20 h. After cooling to room temperature, the solution was diluted with ethyl acetate (25 mL) and filtered through Celite. The filtrate was washed with water (10 mL). The aqueous layer was extracted with ethyl acetate (2 x 25 mL). The combined organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. The residue was subjected to flash chromatography (24 g ISCO column, 0â100% ethyl acetate/hexane) to give the title compound (0.221 g, 0.834 mmol, 82% yield) as a yellow oil. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>17</sub>N<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 260.1, found: 260.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.95 (d, <i>J</i> = 1.5 Hz, 1H), 8.90 (d, <i>J</i> = 1.6 Hz, 1H), 6.98â6.92 (m, 1H), 6.90â6.85 (m, 1H), 6.81 (dd, <i>J</i> = 7.8, 1.8 Hz, 1H), 5.45 (s, 1H), 5.10 (s, 2H), 3.47 (s, 3H), 1.51 (s, 6H).</div><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 2-Methoxy-3-(pyridin-2-yl)aniline (<b>36a</b>)</h4><div class="NLM_p last">Yield: 44%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>12</sub>N<sub>2</sub>O (M + H)<sup>+</sup>: 201.1, found: 201.3. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.68â8.62 (m, 1H), 7.87â7.81 (m, 1H), 7.80â7.76 (m, 1H), 7.33 (ddd, <i>J</i> = 7.2, 4.8, 1.4 Hz, 1H), 6.94â6.88 (m, 1H), 6.87â6.82 (m, 1H), 6.76 (dd, <i>J</i> = 7.6, 1.8 Hz, 1H), 5.00 (s, 2H), 3.42 (s, 3H).</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 2-Methoxy-3-(pyridazin-3-yl)aniline (<b>36b</b>)</h4><div class="NLM_p last">Yield: 59%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>11</sub>N<sub>3</sub>O (M + H)<sup>+</sup>: 202.1, found: 202.1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.20 (dd, <i>J</i> = 4.8, 1.8 Hz, 1H), 7.97 (dd, <i>J</i> = 8.6, 1.5 Hz, 1H), 7.73 (dd, <i>J</i> = 8.6, 4.8 Hz, 1H), 7.04â6.94 (m, 1H), 6.87 (ddd, <i>J</i> = 9.9, 7.9, 1.8 Hz, 2H), 5.12 (s, 2H), 3.42 (s, 3H).</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 2-Methoxy-3-(pyrimidin-4-yl)aniline (<b>36c</b>)</h4><div class="NLM_p last">Yield: 59%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>11</sub>N<sub>3</sub>O (M + H)<sup>+</sup>: 202.1, found: 202.2.</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 2-Methoxy-3-(pyrazin-2-yl)aniline (<b>36d</b>)</h4><div class="NLM_p last">Yield: 67%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>11</sub>N<sub>3</sub>O (M + H)<sup>+</sup>: 202.1, found: 202.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.01 (d, <i>J</i> = 1.5 Hz, 1H), 8.73 (dd, <i>J</i> = 2.6, 1.6 Hz, 1H), 8.58 (d, <i>J</i> = 2.6 Hz, 1H), 7.00â6.94 (m, 1H), 6.90â6.86 (m, 1H), 6.83 (dd, <i>J</i> = 7.8, 1.8 Hz, 1H), 5.12 (s, 2H), 3.46 (s, 3H).</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 2-Methoxy-3-(pyrimidin-2-yl)aniline (<b>36e</b>)</h4><div class="NLM_p last">Yield: 81%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>11</sub>N<sub>3</sub>O (M + H)<sup>+</sup>: 202.1, found: 202.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.89 (d, <i>J</i> = 5.1 Hz, 2H), 7.44 (t, <i>J</i> = 4.8 Hz, 1H), 6.96â6.88 (m, 1H), 6.86â6.80 (m, 2H), 5.00 (s, 2H), 3.63 (s, 3H).</div></div><div id="sec4_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 2-Methoxy-3-(5-methylpyrimidin-2-yl)aniline (<b>36f</b>)</h4><div class="NLM_p last">Yield: 31%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>13</sub>N<sub>3</sub>O (M + H)<sup>+</sup>: 216.1, found: 216.1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.73 (s, 2H), 6.94â6.86 (m, 1H), 6.83â6.77 (m, 2H), 4.97 (br s, 2H), 3.61 (s, 3H), 2.32 (s, 3H).</div></div><div id="sec4_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 3-(5-Fluoropyrimidin-2-yl)-2-methoxyaniline (<b>36g</b>)</h4><div class="NLM_p last">Yield: 82%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>10</sub>FN<sub>3</sub>O (M + H)<sup>+</sup>: 220.1, found: 220.4. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.98 (d, <i>J</i> = 0.7 Hz, 2H), 6.96â6.88 (m, 1H), 6.86â6.79 (m, 2H), 5.03 (s, 2H), 3.62 (s, 3H).</div></div><div id="sec4_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 2-Methoxy-3-(5-methoxypyrimidin-2-yl)aniline (<b>36h</b>)</h4><div class="NLM_p last">Yield: 54%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>13</sub>N<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 232.1, found: 232.2.</div></div><div id="sec4_3_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 2-Methoxy-3-(4-methylpyrimidin-2-yl)aniline (<b>36i</b>)</h4><div class="NLM_p last">Yield: 50%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>13</sub>N<sub>3</sub>O (M + H)<sup>+</sup>: 216.1, found: 216.2.</div></div><div id="sec4_3_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 2-Methoxy-3-(4-methoxypyrimidin-2-yl)aniline (<b>36j</b>)</h4><div class="NLM_p last">Yield: 40%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>13</sub>N<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 232.1, found: 232.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.59 (d, <i>J</i> = 5.9 Hz, 1H), 6.91â6.85 (m, 3H), 6.84â6.80 (m, 1H), 5.00 (s, 2H), 3.97 (s, 3H), 3.68 (s, 3H).</div></div><div id="sec4_3_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 2-(2-(3-Amino-2-methoxyphenyl)pyrimidin-5-yl)propan-2-ol (<b>36k</b>)</h4><div class="NLM_p last">Yield: 54%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>17</sub>N<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 260.1, found: 260.1.</div></div><div id="sec4_3_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 2-(3-Amino-2-methoxyphenyl)-<i>N</i>,<i>N</i>-dimethylpyrimidine-5-carboxamide (<b>36l</b>)</h4><div class="NLM_p last">Yield: 46%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>16</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 273.1, found: 273.2. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ 8.88 (s, 2H), 7.22â7.15 (m, 1H), 6.97 (t, <i>J</i> = 7.8 Hz, 1H), 6.83 (dd, <i>J</i> = 7.8, 1.6 Hz, 1H), 3.90 (br s, 2H), 3.63 (s, 3H), 3.10 (br s, 3H), 3.05 (br s, 3H).</div></div><div id="sec4_3_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 2-(2-(3-Amino-2-methoxyphenyl)pyrimidin-5-yl)-1,1,1-trifluoropropan-2-ol (<b>36m</b>)</h4><div class="NLM_p last">Yield: 47%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>14</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 314.1, found: 314.4.</div></div><div id="sec4_3_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 5-(3-Amino-2-methoxyphenyl)-<i>N</i>,<i>N</i>-dimethylpyrazine-2-carboxamide (<b>36o</b>)</h4><div class="NLM_p last">Yield: 71%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>16</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 273.1, found: 273.1.</div></div><div id="sec4_3_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 2-(6-(3-Amino-2-methoxyphenyl)pyridin-3-yl)propan-2-ol (<b>36p</b>)</h4><div class="NLM_p last">Yield: 35%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 259.1, found: 259.2.</div></div><div id="sec4_3_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 6-(3-Amino-2-methoxyphenyl)-<i>N</i>,<i>N</i>-dimethylnicotinamide (<b>36q</b>)</h4><div class="NLM_p last">Yield: 51%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>17</sub>N<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 272.1, found: 272.1. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) Î´ 8.80 (dd, <i>J</i> = 2.3, 0.9 Hz, 1H), 7.94 (dd, <i>J</i> = 8.2, 0.8 Hz, 1H), 7.85 (dd, <i>J</i> = 8.1, 2.3 Hz, 1H), 7.15 (dd, <i>J</i> = 7.8, 1.7 Hz, 1H), 7.06 (t, <i>J</i> = 7.8 Hz, 1H), 6.86 (dd, <i>J</i> = 7.8, 1.7 Hz, 1H), 4.19â3.74 (br s, 2H), 3.53 (s, 3H), 3.19 (br s, 3H), 3.12 (br s, 3H).</div></div><div id="sec4_3_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 6-(3-Amino-2-methoxyphenyl)-<i>N</i>,<i>N</i>-dimethylpyridazine-3-carboxamide (<b>36r</b>)</h4><div class="NLM_p last">Yield: 72%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>16</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 273.1, found: 273.1.</div></div><div id="sec4_3_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 2-Methoxy-3-(5-methylpyrazin-2-yl)aniline (<b>36s</b>)</h4><div class="NLM_p last">Yield: 59%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>13</sub>N<sub>3</sub>O (M + H)<sup>+</sup>: 216.1, found: 216.2.</div></div><div id="sec4_3_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 2-Methoxy-3-(5-methoxypyrazin-2-yl)aniline (<b>36t</b>)</h4><div class="NLM_p last">Yield: 29%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>13</sub>N<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 232.1, found: 232.1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.59 (d, <i>J</i> = 1.3 Hz, 1H), 8.38 (d, <i>J</i> = 1.3 Hz, 1H), 6.96â6.88 (m, 1H), 6.87â6.81 (m, 1H), 6.76 (dd, <i>J</i> = 7.7, 1.8 Hz, 1H), 5.04 (s, 2H), 3.96 (s, 3H), 3.45 (s, 3H).</div></div><div id="sec4_3_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 5-Fluoro-2-methoxy-3-(pyrimidin-2-yl)aniline (<b>36u</b>)</h4><div class="NLM_p last">Yield: 73%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>10</sub>FN<sub>3</sub>O (M + H)<sup>+</sup>: 220.1, found: 220.1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.89 (d, <i>J</i> = 4.8 Hz, 2H), 7.46 (t, <i>J</i> = 5.0 Hz, 1H), 6.56 (ddd, <i>J</i> = 13.5, 10.1, 3.1 Hz, 2H), 5.36 (s, 2H), 3.60 (s, 3H).</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> General Procedure for the Preparation of <b>38aâr</b>, Exemplified by 6-Chloro-4-((3-(5-(2-hydroxypropan-2-yl)pyrazin-2-yl)-2-methoxyphenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>38n</b>)</h3><div class="NLM_p">To a solution of 2-(5-(3-amino-2-methoxyphenyl)pyrazin-2-yl)propan-2-ol (<b>36n</b>) (0.219 g, 0.843 mmol) and 4,6-dichloro-<i>N</i>-trideuteromethylpyridazine-3-carboxamide (<b>37</b>)<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> (0.168 g, 0.803 mmol) in THF (8 mL) at rt was added 1 M lithium bis(trimethylsilyl)amide/THF (3.21 mL, 3.21 mmol) over 1 min. The mixture was stirred at rt for 1 h before it was quenched with water (5 mL). The resulting mixture was adjusted with 1 N HCl solution to pH 9â10, diluted with ethyl acetate (125 mL), and washed with water (20 mL) and brine (20 mL) successively. The organic layer was dried over anhydrous MgSO<sub>4</sub> solution. The desired product (0.208 g, 0.482 mmol, 60% yield), was isolated as an off-white solid by flash chromatography (24 g ISCO column, 0â100% ethyl acetate/hexane). LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>18</sub>D<sub>3</sub>ClN<sub>6</sub>O<sub>3</sub> (M + H)<sup>+</sup>: 432.2, found: 432.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.14 (s, 1H), 9.39 (s, 1H), 9.02 (d, <i>J</i> = 1.5 Hz, 1H), 8.98 (d, <i>J</i> = 1.6 Hz, 1H), 7.72â7.61 (m, 2H), 7.38 (t, <i>J</i> = 7.9 Hz, 1H), 7.26 (s, 1H), 5.52 (s, 1H), 3.56 (s, 3H), 1.53 (s, 6H).</div><div id="sec4_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 6-Chloro-4-((2-methoxy-3-(pyridin-2-yl)phenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>38a</b>)</h4><div class="NLM_p last">Yield: 74%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>13</sub>D<sub>3</sub>ClN<sub>5</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 373.1, found: 373.3.</div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 6-Chloro-4-((2-methoxy-3-(pyridazin-3-yl)phenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>38b</b>)</h4><div class="NLM_p last">Yield: 92%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>12</sub>D<sub>3</sub>ClN<sub>6</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 374.1, found: 374.2.</div></div><div id="sec4_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 6-Chloro-4-((2-methoxy-3-(pyrimidin-4-yl)phenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>38c</b>)</h4><div class="NLM_p last">Yield: 66%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>12</sub>D<sub>3</sub>ClN<sub>6</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 374.1, found: 374.2.</div></div><div id="sec4_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 6-Chloro-4-((2-methoxy-3-(pyrazins-2-yl)phenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>38d</b>)</h4><div class="NLM_p last">Yield: 78%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>12</sub>D<sub>3</sub>ClN<sub>6</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 374.1, found: 374.2.</div></div><div id="sec4_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 6-Chloro-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>38e</b>)</h4><div class="NLM_p last">Yield: 58%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>12</sub>D<sub>3</sub>ClN<sub>6</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 374.1, found: 374.2.</div></div><div id="sec4_4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 6-Chloro-4-((2-methoxy-3-(5-methylpyrimidin-2-yl)phenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>38f</b>)</h4><div class="NLM_p last">Yield: 40%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>14</sub>D<sub>3</sub>ClN<sub>6</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 388.1, found: 388.1.</div></div><div id="sec4_4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 6-Chloro-4-((3-(5-fluoropyrimidin-2-yl)-2-methoxyphenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>38g</b>)</h4><div class="NLM_p last">Yield: 67%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>11</sub>D<sub>3</sub>ClFN<sub>6</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 392.1, found: 392.3. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.09 (s, 1H), 9.36 (s, 1H), 9.04 (s, 2H), 7.67 (dd, <i>J</i> = 7.9, 1.5 Hz, 1H), 7.58 (dd, <i>J</i> = 7.7, 1.5 Hz, 1H), 7.33 (t, <i>J</i> = 7.8 Hz, 1H), 7.18 (s, 1H), 3.65 (s, 3H).</div></div><div id="sec4_4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 6-Chloro-4-((2-methoxy-3-(5-methoxypyrimidin-2-yl)phenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>38h</b>)</h4><div class="NLM_p last">Yield: 55%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>14</sub>D<sub>3</sub>ClN<sub>6</sub>O<sub>3</sub> (M + H)<sup>+</sup>: 404.1, found: 404.4.</div></div><div id="sec4_4_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 6-Chloro-4-((2-methoxy-3-(4-methylpyrimidin-2-yl)phenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>38i</b>)</h4><div class="NLM_p last">Yield: 65%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>14</sub>D<sub>3</sub>ClN<sub>6</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 388.1, found: 388.3.</div></div><div id="sec4_4_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 6-Chloro-4-((2-methoxy-3-(4-methoxypyrimidin-2-yl)phenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>38j</b>)</h4><div class="NLM_p last">Yield: 47%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>14</sub>D<sub>3</sub>ClN<sub>6</sub>O<sub>3</sub> (M + H)<sup>+</sup>: 404.1, found: 404.2.</div></div><div id="sec4_4_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 6-Chloro-4-((3-(5-(2-hydroxypropan-2-yl)pyrimidin-2-yl)-2-methoxyphenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>38k</b>)</h4><div class="NLM_p last">Yield: 23%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>18</sub>D<sub>3</sub>ClN<sub>6</sub>O<sub>3</sub> (M + H)<sup>+</sup>: 432.2, found: 432.2.</div></div><div id="sec4_4_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 6-Chloro-4-((3-(5-(dimethylcarbamoyl)pyrimidin-2-yl)-2-methoxyphenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>38l</b>)</h4><div class="NLM_p last">Yield: 7%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>17</sub>D<sub>3</sub>ClN<sub>7</sub>O<sub>3</sub> (M + H)<sup>+</sup>: 445.2, found: 445.5.</div></div><div id="sec4_4_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 6-Chloro-4-((2-methoxy-3-(5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)pyrimidin-2-yl)phenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>38m</b>)</h4><div class="NLM_p last">Yield: 83%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>15</sub>D<sub>3</sub>ClF<sub>3</sub>N<sub>6</sub>O<sub>3</sub> (M + H)<sup>+</sup>: 486.1, found: 486.5. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.10 (s, 1H), 9.37 (s, 1H), 9.14 (s, 2H), 7.70 (dd, <i>J</i> = 7.9, 1.5 Hz, 1H), 7.65 (dd, <i>J</i> = 7.8, 1.6 Hz, 1H), 7.35 (t, <i>J</i> = 7.9 Hz, 1H), 7.19 (s, 1H), 7.13 (s, 1H), 3.70 (s, 3H), 1.83 (s, 3H).</div></div><div id="sec4_4_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 6-Chloro-4-((3-(5-(dimethylcarbamoyl)pyrazin-2-yl)-2-methoxyphenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>38o</b>)</h4><div class="NLM_p last">Yield: 89%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>17</sub>D<sub>3</sub>ClN<sub>7</sub>O<sub>3</sub> (M + H)<sup>+</sup>: 445.2, found: 445.1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.17 (s, 1H), 9.40 (s, 1H), 9.09 (d, <i>J</i> = 1.5 Hz, 1H), 8.97 (d, <i>J</i> = 1.5 Hz, 1H), 7.71 (td, <i>J</i> = 7.8, 1.6 Hz, 2H), 7.41 (t, <i>J</i> = 7.9 Hz, 1H), 7.28 (s, 1H), 3.58 (s, 3H), 3.08 (s, 3H), 3.07 (s, 3H).</div></div><div id="sec4_4_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 6-Chloro-4-((3-(5-(2-hydroxypropan-2-yl)pyridin-2-yl)-2-methoxyphenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>38p</b>)</h4><div class="NLM_p last">Yield: 49%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>19</sub>D<sub>3</sub>ClN<sub>5</sub>O<sub>3</sub> (M + H)<sup>+</sup>: 431.2, found: 431.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.15 (s, 1H), 9.38 (s, 1H), 8.82 (dd, <i>J</i> = 2.3, 0.7 Hz, 1H), 7.96 (dd, <i>J</i> = 8.3, 2.4 Hz, 1H), 7.85â7.77 (m, 1H), 7.65â7.56 (m, 2H), 7.32 (t, <i>J</i> = 7.8 Hz, 1H), 7.26 (s, 1H), 5.33â5.21 (br s, 1H), 3.51 (s, 3H), 1.52 (s, 6H).</div></div><div id="sec4_4_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 6-Chloro-4-((3-(5-(dimethylcarbamoyl)pyridin-2-yl)-2-methoxyphenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>38q</b>)</h4><div class="NLM_p last">Yield: 70%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>17</sub>D<sub>3</sub>ClN<sub>7</sub>O<sub>3</sub> (M + H)<sup>+</sup>: 444.2, found: 444.2.</div></div><div id="sec4_4_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 6-Chloro-4-((3-(6-(dimethylcarbamoyl)pyridazin-3-yl)-2-methoxyphenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>38r</b>)</h4><div class="NLM_p last">Yield: 81%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>17</sub>D<sub>3</sub>ClN<sub>7</sub>O<sub>3</sub> (M + H)<sup>+</sup>: 445.2, found: 445.1.</div></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> General Procedure for the Preparation of <b>8â20</b>, <b>24â27</b>, and <b>29</b>, Exemplified by 6-(Cyclopropanecarboxamido)-4-((3-(5-(2-hydroxypropan-2-yl)pyrazin-2-yl)-2-methoxyphenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>24</b>)</h3><div class="NLM_p">A mixture of 6-chloro-4-((3-(5-(2-hydroxypropan-2-yl)pyrazin-2-yl)-2-methoxyphenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>38n</b>) (0.102 g, 0.236 mmol), cyclopropanecarboxamide (0.040 g, 0.473 mmol), XantPhos (0.021 g, 0.035 mmol), cesium carbonate (0.169 g, 0.520 mmol), and Pd<sub>2</sub>(dba)<sub>3</sub> (0.032 g, 0.035 mmol) in 1,4-dioxane (5.4 mL) and <i>N</i>-methyl-2-pyrrolidinone (0.54 mL) was heated at 145 Â°C under microwave conditions for 1 h. Upon cooling to rt, the mixture was diluted with ethyl acetate (10 mL) and filtered through Celite. The filtrate was concentrated under vacuum, and the residue was subjected to preparative HPLC. The correct fractions were combined, basified with solid NaHCO<sub>3,</sub> concentrated under vacuum, and extracted with dichloromethane (3 x 30 mL). The combined extract was dried over Na<sub>2</sub>SO<sub>4</sub>. Removal of the solvent under vacuum provided the title compound (0.0342 g, 0.071 mmol, 30% yield) as a light yellow solid. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>24</sub>D<sub>3</sub>N<sub>7</sub>O<sub>4</sub> (M + H)<sup>+</sup>: 481.2, found: 481.5. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.32 (s, 1H), 10.97 (s, 1H), 9.14 (s, 1H), 9.01 (d, <i>J</i> = 1.5 Hz, 1H), 8.96 (d, <i>J</i> = 1.5 Hz, 1H), 8.16 (s, 1H), 7.60â7.52 (m, 2H), 7.39â7.29 (m, 1H), 5.49 (s, 1H), 3.53 (s, 3H), 2.14â2.03 (m, 1H), 1.52 (s, 6H), 0.86â0.78 (m, 4H).</div><div id="sec4_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 6-(Cyclopropanecarboxamido)-4-((2-methoxy-3-(pyridin-2-yl)phenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>8</b>)</h4><div class="NLM_p last">Yield: 28%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>19</sub>D<sub>3</sub>N<sub>6</sub>O<sub>3</sub> (M + H)<sup>+</sup>: 422.2, found: 422.4. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.31 (s, 1H), 10.98 (s, 1H), 9.12 (s, 1H), 8.76â8.67 (m, 1H), 8.18 (s, 1H), 7.92â7.87 (m, 1H), 7.87â7.83 (m, 1H), 7.52 (td, <i>J</i> = 8.0, 1.6 Hz, 2H), 7.40 (ddd, <i>J</i> = 7.2, 4.9, 1.3 Hz, 1H), 7.31 (t, <i>J</i> = 7.9 Hz, 1H), 3.48 (s, 3H), 2.09 (quin, <i>J</i> = 6.1 Hz, 1H), 0.84 (d, <i>J</i> = 6.1 Hz, 1H).</div></div><div id="sec4_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 6-(Cyclopropanecarboxamido)-4-((2-methoxy-3-(pyridazin-3-yl)phenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>9</b>)</h4><div class="NLM_p last">Yield: 17%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>18</sub>D<sub>3</sub>N<sub>7</sub>O<sub>3</sub> (M + H)<sup>+</sup>: 423.2, found: 423.4. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.32 (s, 1H), 10.98 (s, 1H), 9.25 (dd, <i>J</i> = 5.0, 1.7 Hz, 1H), 9.13 (s, 1H), 8.16 (s, 1H), 8.04 (dd, <i>J</i> = 8.6, 1.5 Hz, 1H), 7.79 (dd, <i>J</i> = 8.6, 5.1 Hz, 1H), 7.58 (ddd, <i>J</i> = 11.5, 7.9, 1.5 Hz, 2H), 7.41â7.33 (m, 1H), 3.47 (s, 3H), 2.08 (quin, <i>J</i> = 6.2 Hz, 1H), 0.83 (d, <i>J</i> = 6.2 Hz, 4H).</div></div><div id="sec4_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 6-(Cyclopropanecarboxamido)-4-((2-methoxy-3-(pyrimidin-4-yl)phenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>10</b>)</h4><div class="NLM_p last">Yield: 46%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>18</sub>D<sub>3</sub>N<sub>7</sub>O<sub>3</sub> (M + H)<sup>+</sup>: 423.2, found: 423.3. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.34 (s, 1H), 11.00 (s, 1H), 9.32 (d, <i>J</i> = 1.2 Hz, 1H), 9.16 (s, 1H), 8.89 (d, <i>J</i> = 5.4 Hz, 1H), 8.16 (s, 1H), 8.00 (dd, <i>J</i> = 5.3, 1.4 Hz, 1H), 7.69 (dd, <i>J</i> = 7.8, 1.5 Hz, 1H), 7.62 (dd, <i>J</i> = 7.9, 1.5 Hz, 1H), 7.38 (t, <i>J</i> = 7.9 Hz, 1H), 3.56 (s, 3H), 2.09 (quin, <i>J</i> = 6.2 Hz, 1H), 0.86â0.81 (m, 4H).</div></div><div id="sec4_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 6-(Cyclopropanecarboxamido)-4-((2-methoxy-3-(pyrazin-2-yl)phenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>11</b>)</h4><div class="NLM_p last">Yield: 34%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>18</sub>D<sub>3</sub>N<sub>7</sub>O<sub>3</sub> (M + H)<sup>+</sup>: 423.2, found: 423.3. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.34 (s, 1H), 10.99 (s, 1H), 9.15 (s, 1H), 9.08 (d, <i>J</i> = 1.5 Hz, 1H), 8.80 (dd, <i>J</i> = 2.6, 1.6 Hz, 1H), 8.66 (d, <i>J</i> = 2.6 Hz, 1H), 8.17 (s, 1H), 7.58 (ddd, <i>J</i> = 7.9, 6.8, 1.5 Hz, 2H), 7.43â7.30 (m, 1H), 3.52 (s, 3H), 2.18â2.03 (m, 1H), 0.89â0.78 (m, 4H).</div></div><div id="sec4_5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 6-(Cyclopropanecarboxamido)-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>12</b>)</h4><div class="NLM_p last">Yield: 36%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>18</sub>D<sub>3</sub>N<sub>7</sub>O<sub>3</sub> (M + H)<sup>+</sup>: 423.2, found: 423.5. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.30 (s, 1H), 10.93 (s, 1H), 9.11 (s, 1H), 8.94 (d, <i>J</i> = 4.8 Hz, 2H), 8.14 (s, 1H), 7.57 (dd, <i>J</i> = 7.9, 1.5 Hz, 1H), 7.54â7.49 (m, 2H), 7.30 (t, <i>J</i> = 7.9 Hz, 1H), 3.67 (s, 3H), 2.07 (quin, <i>J</i> = 6.1 Hz, 1H), 0.85â0.78 (m, 4H).</div></div><div id="sec4_5_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 6-(Cyclopropanecarboxamido)-4-((2-methoxy-3-(5-methylpyrimidin-2-yl)phenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>13</b>)</h4><div class="NLM_p last">Yield: 31%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>20</sub>D<sub>3</sub>N<sub>7</sub>O<sub>3</sub> (M + H)<sup>+</sup>: 437.2, found: 437.0. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.33 (s, 1H), 10.94 (s, 1H), 9.14 (s, 1H), 8.79 (s, 2H), 8.16 (s, 1H), 7.56 (d, <i>J</i> = 8.1 Hz, 1H), 7.50 (d, <i>J</i> = 7.1 Hz, 1H), 7.30 (t, <i>J</i> = 7.9 Hz, 1H), 3.66 (s, 3H), 2.35 (s, 3H), 2.08 (quin, <i>J</i> = 6.1 Hz, 1H), 0.86â0.80 (m, 4H).</div></div><div id="sec4_5_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> 6-(Cyclopropanecarboxamido)-4-((3-(5-fluoropyrimidin-2-yl)-2-methoxyphenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>14</b>)</h4><div class="NLM_p last">Yield: 36%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>17</sub>D<sub>3</sub>FN<sub>7</sub>O<sub>3</sub> (M + H)<sup>+</sup>: 441.2, found: 441.4. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.32 (s, 1H), 10.95 (s, 1H), 9.13 (s, 1H), 9.04 (s, 2H), 8.15 (s, 1H), 7.59 (dd, <i>J</i> = 7.9, 1.2 Hz, 1H), 7.53 (dd, <i>J</i> = 7.8, 1.5 Hz, 1H), 7.32 (t, <i>J</i> = 7.9 Hz, 1H), 3.68 (s, 3H), 2.15â2.05 (m, 1H), 0.87â0.80 (m, 4H).</div></div><div id="sec4_5_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> 6-(Cyclopropanecarboxamido)-4-((2-methoxy-3-(5-methoxypyrimidin-2-yl)phenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>15</b>)</h4><div class="NLM_p last">Yield: 36%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>20</sub>D<sub>3</sub>N<sub>7</sub>O<sub>4</sub> (M + H)<sup>+</sup>: 453.2, found: 453.4. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.31 (s, 1H), 10.90 (s, 1H), 9.11 (s, 1H), 8.67 (s, 2H), 8.13 (s, 1H), 7.53 (br d, <i>J</i> = 8.1 Hz, 1H), 7.49 (d, <i>J</i> = 7.7 Hz, 1H), 7.28 (t, <i>J</i> = 7.7 Hz, 1H), 3.97 (s, 3H), 3.64 (s, 3H), 2.12â1.99 (m, 1H), 0.88â0.77 (m, 4H).</div></div><div id="sec4_5_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> 6-(Cyclopropanecarboxamido)-4-((2-methoxy-3-(4-methylpyrimidin-2-yl)phenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>16</b>)</h4><div class="NLM_p last">Yield: 31%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>20</sub>D<sub>3</sub>N<sub>7</sub>O<sub>3</sub> (M + H)<sup>+</sup>: 437.2, found: 437.4. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.32 (s, 1H), 10.93 (s, 1H), 9.13 (s, 1H), 8.78 (d, <i>J</i> = 5.1 Hz, 1H), 8.15 (s, 1H), 7.57 (dd, <i>J</i> = 7.9, 1.5 Hz, 1H), 7.51 (dd, <i>J</i> = 7.8, 1.5 Hz, 1H), 7.39 (d, <i>J</i> = 5.1 Hz, 1H), 7.33â7.27 (m, 1H), 3.70 (s, 3H), 2.55 (s, 3H), 2.09 (quin, <i>J</i> = 6.1 Hz, 1H), 0.83 (d, <i>J</i> = 5.9 Hz, 4H).</div></div><div id="sec4_5_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> 6-(Cyclopropanecarboxamido)-4-((2-methoxy-3-(4-methoxypyrimidin-2-yl)phenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>17</b>)</h4><div class="NLM_p last">Yield: 33%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>20</sub>D<sub>3</sub>N<sub>7</sub>O<sub>4</sub> (M + H)<sup>+</sup>: 453.2, found: 453.3. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.34 (s, 1H), 10.95 (s, 1H), 9.15 (s, 1H), 8.65 (d, <i>J</i> = 5.7 Hz, 1H), 8.15 (s, 1H), 7.58 (d, <i>J</i> = 7.7 Hz, 2H), 7.31 (t, <i>J</i> = 7.9 Hz, 1H), 6.94 (d, <i>J</i> = 5.7 Hz, 1H), 3.99 (s, 3H), 3.72 (s, 3H), 2.17â2.02 (m, 1H), 0.89â0.76 (m, 4H).</div></div><div id="sec4_5_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 6-(Cyclopropanecarboxamido)-4-((3-(5-(2-hydroxypropan-2-yl)pyrimidin-2-yl)-2-methoxyphenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>18</b>)</h4><div class="NLM_p last">Yield: 56%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>24</sub>D<sub>3</sub>N<sub>7</sub>O<sub>4</sub> (M + H)<sup>+</sup>: 481.2, found: 481.1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.32 (s, 1H), 10.94 (s, 1H), 9.14 (s, 1H), 9.01 (s, 2H), 8.16 (s, 1H), 7.55 (ddd, <i>J</i> = 17.5, 7.9, 1.6 Hz, 2H), 7.39â7.24 (m, 1H), 5.45 (s, 1H), 3.70 (s, 3H), 2.15â2.03 (m, 1H), 1.55 (s, 6H), 0.90â0.77 (m, 4H).</div></div><div id="sec4_5_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> 6-(Cyclopropanecarboxamido)-4-((3-(5-(dimethylcarbamoyl)pyrimidin-2-yl)-2-methoxyphenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>19</b>)</h4><div class="NLM_p last">Yield: 6%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>23</sub>D<sub>3</sub>N<sub>8</sub>O<sub>4</sub> (M + H)<sup>+</sup>: 494.2, found: 494.6. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.33 (s, 1H), 10.97 (s, 1H), 9.14 (s, 1H), 9.04 (s, 2H), 8.16 (s, 1H), 7.68â7.56 (m, 2H), 7.41â7.27 (m, 1H), 3.71 (s, 3H), 3.06 (s, 6H), 2.16â2.03 (m, 1H), 0.90â0.78 (m, 4H).</div></div><div id="sec4_5_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> 6-(Cyclopropanecarboxamido)-4-((2-methoxy-3-(5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)pyrimidin-2-yl)phenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>20</b>)</h4><div class="NLM_p last">Yield: 22%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>21</sub>D<sub>3</sub>F<sub>3</sub>N<sub>7</sub>O<sub>4</sub> (M + H)<sup>+</sup>: 535.2, found: 535.5. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.32 (s, 1H), 10.95 (s, 1H), 9.18â9.10 (m, 3H), 8.15 (s, 1H), 7.59 (ddd, <i>J</i> = 9.8, 8.0, 1.5 Hz, 2H), 7.33 (t, <i>J</i> = 7.9 Hz, 1H), 7.12 (s, 1H), 3.71 (s, 3H), 2.16â2.01 (m, 1H), 1.83 (s, 3H), 0.88â0.78 (m, 4H).</div></div><div id="sec4_5_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> 6-(Cyclopropanecarboxamido)-4-((3-(5-(dimethylcarbamoyl)pyrazin-2-yl)-2-methoxyphenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>25</b>)</h4><div class="NLM_p last">Yield: 49%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>23</sub>D<sub>3</sub>N<sub>8</sub>O<sub>4</sub> (M + H)<sup>+</sup>: 494.2, found: 494.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.35 (s, 1H), 11.01 (s, 1H), 9.16 (s, 1H), 9.08 (d, <i>J</i> = 1.6 Hz, 1H), 8.96 (d, <i>J</i> = 1.5 Hz, 1H), 8.17 (s, 1H), 7.63 (ddd, <i>J</i> = 7.9, 6.4, 1.5 Hz, 2H), 7.46â7.33 (m, 1H), 3.56 (s, 3H), 3.08 (s, 3H), 3.07 (s, 3H), 2.16â2.05 (m, 1H), 0.89â0.80 (m, 4H).</div></div><div id="sec4_5_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> 6-(Cyclopropanecarboxamido)-4-((3-(5-(2-hydroxypropan-2-yl)pyridin-2-yl)-2-methoxyphenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>26</b>)</h4><div class="NLM_p last">Yield: 24%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>25</sub>D<sub>3</sub>N<sub>6</sub>O<sub>4</sub> (M + H)<sup>+</sup>: 480.2, found: 480.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.32 (s, 1H), 10.98 (s, 1H), 9.14 (s, 1H), 8.81 (dd, <i>J</i> = 2.3, 0.6 Hz, 1H), 8.18 (s, 1H), 7.94 (dd, <i>J</i> = 8.2, 2.3 Hz, 1H), 7.81 (d, <i>J</i> = 8.3 Hz, 1H), 7.55 (dd, <i>J</i> = 7.8, 1.6 Hz, 1H), 7.50 (dd, <i>J</i> = 7.9, 1.5 Hz, 1H), 7.33â7.27 (m, 1H), 5.26 (br s, 1H), 3.49 (s, 3H), 2.13â2.06 (m, 1H), 1.51 (s, 6H), 0.83 (d, <i>J</i> = 5.9 Hz, 4H).</div></div><div id="sec4_5_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> 6-(Cyclopropanecarboxamido)-4-((3-(5-(dimethylcarbamoyl)pyridin-2-yl)-2-methoxyphenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>27</b>)</h4><div class="NLM_p last">Yield: 43%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>24</sub>D<sub>3</sub>N<sub>7</sub>O<sub>4</sub> (M + H)<sup>+</sup>: 493.2, found: 493.2. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.35 (s, 1H), 11.00 (s, 1H), 9.15 (s, 1H), 8.75 (s, 1H), 8.18 (s, 1H), 8.01â7.90 (m, 2H), 7.66â7.48 (m, 2H), 7.34 (t, <i>J</i> = 7.7 Hz, 1H), 3.51 (s, 3H), 3.04 (br s, 3H), 3.01 (br s, 3H), 2.14â2.02 (m, 1H), 0.87â0.81 (m, 4H).</div></div><div id="sec4_5_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> 6-(Cyclopropanecarboxamido)-4-((3-(6-(dimethylcarbamoyl)pyridazin-3-yl)-2-methoxyphenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>29</b>)</h4><div class="NLM_p last">Yield: 16%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>23</sub>D<sub>3</sub>N<sub>8</sub>O<sub>4</sub> (M + H)<sup>+</sup>: 494.2, found: 494.2. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.36 (s, 1H), 11.00 (s, 1H), 9.16 (s, 1H), 8.25â8.14 (m, 2H), 7.95 (d, <i>J</i> = 8.8 Hz, 1H), 7.64 (dd, <i>J</i> = 6.7, 5.4 Hz, 2H), 7.40 (t, <i>J</i> = 7.9 Hz, 1H), 3.50 (s, 3H), 3.11 (s, 3H), 3.05 (s, 3H), 2.09 (quin, <i>J</i> = 6.1 Hz, 1H), 0.90â0.79 (m, 4H).</div></div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> 5-Fluoro-2-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (<b>40</b>)</h3><div class="NLM_p last">A mixture of 3-bromo-5-fluoro-2-methoxyaniline (<b>39</b>) (0.304 g, 1.382 mmol), 4,4,4â²,4â²,5,5,5â²,5â²-octamethyl-2,2â²-bi(1,3,2-dioxaborolane) (0.526 g, 2.072 mmol), PdCl<sub>2</sub>(dppf)-CH<sub>2</sub>Cl<sub>2</sub> adduct (0.068 g, 0.083 mmol), and potassium acetate (0.407 g, 4.14 mmol) in 1,4-dioxane (7 mL) was heated in a pressure bottle at 105 Â°C for 18 h. The mixture was diluted with ethyl acetate (10 mL) and filtered through Celite. The filtrate was concentrated under vacuum, and the residue was submitted to flash chromatography (40 g ISCO column, solid loading, 0â60% diethyl ether/hexane) to afford the title compound (0.225 g, 0.842 mmol, 61% yield) as a white solid. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>19</sub>BFNO<sub>3</sub> (M + H)<sup>+</sup>: 268.1, found: 268.2. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ 6.74 (dd, <i>J</i> = 8.7, 3.0 Hz, 1H), 6.53 (dd, <i>J</i> = 9.6, 3.1 Hz, 1H), 3.91 (br s, 2H), 3.77 (s, 3H), 1.35 (s, 12H).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> Ethyl 2-(3-Amino-2-methoxyphenyl)pyrimidine-5-carboxylate (<b>41a</b>)</h3><div class="NLM_p last">A solution of 2-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (<b>35</b>) (1.508 g, 6.06 mmol), ethyl 2-chloropyrimidine-5-carboxylate (1.244 g, 6.67 mmol), PdCl<sub>2</sub>(dppf)-CH<sub>2</sub>Cl<sub>2</sub> adduct (0.260 g, 0.319 mmol), and 2 M K<sub>3</sub>PO<sub>4</sub> solution (9.0 mL, 18.0 mmol) in 1,4-ioxane (40 mL) in a sealed vial was heated at 75 Â°C for 4 h. Upon cooling to rt, the mixture was diluted with ethyl acetate (150 mL) and filtered through Celite. The filtrate was washed with brine (40 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. The residue was subjected to flash chromatography (80 g ISCO column, solid loading, 0â75% ethyl acetate/hexane) to afford the title compound (1.288 g, 4.48 mmol, 74% yield) as a slightly yellow oil. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>15</sub>N<sub>3</sub>O<sub>3</sub> (M + H)<sup>+</sup>: 274.1, found: 274.3. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.31 (s, 2H), 6.98â6.93 (m, 2H), 6.91â6.85 (m, 1H), 5.08 (s, 2H), 4.41 (q, <i>J</i> = 7.1 Hz, 2H), 3.65 (s, 3H), 1.37 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> Ethyl 2-(3-Amino-5-fluoro-2-methoxyphenyl)pyrimidine-5-carboxylate (<b>41b</b>)</h3><div class="NLM_p last">This compound was prepared from <b>40</b> in the same manner as <b>41a</b> from <b>35</b>. Yield: 79%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>14</sub>FN<sub>3</sub>O<sub>3</sub> (M + H)<sup>+</sup>: 292.1, found: 292.4. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.32 (s, 2H), 6.73â6.61 (m, 2H), 5.46 (s, 2H), 4.41 (q, <i>J</i> = 7.1 Hz, 2H), 3.64 (s, 3H), 1.37 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> Ethyl 2-(3-((6-Chloro-3-((methyl-<i>d</i><sub>3</sub>)carbamoyl)pyridazin-4-yl)amino)-2-methoxyphenyl)pyrimidine-5-carboxylate (<b>42a</b>)</h3><div class="NLM_p last">To a solution of ethyl 2-(3-amino-2-methoxyphenyl)pyrimidine-5-carboxylate (<b>41a</b>) (0.710 g, 2.60 mmol) and 4,6-dichloro-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>37</b>)<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> (0.552 g, 2.64 mmol) in THF (24 mL) at rt was added 1 M lithium bis(trimethylsilyl)amide/THF (8.0 mL, 8.00 mmol) over 3 min. The mixture was stirred at rt for 1.25 h before it was quenched with acetic acid (0.51 mL, 8.91 mmol), diluted with ethyl acetate (150 mL), washed with brine (30 mL), and dried over anhydrous MgSO<sub>4</sub>. The desired product (0.366 g, 0.820 mmol, 32% yield) was isolated as a white solid by flash chromatography (40 g ISCO column, 0â50% ethyl acetate/hexane). LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>16</sub>D<sub>3</sub>ClN<sub>6</sub>O<sub>4</sub> (M + H)<sup>+</sup>: 446.2, found: 446.6. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.13 (s, 1H), 9.38 (s, 3H), 7.79â7.67 (m, 2H), 7.37 (t, <i>J</i> = 7.9 Hz, 1H), 7.22 (s, 1H), 4.42 (q, <i>J</i> = 7.1 Hz, 2H), 3.70 (s, 3H), 1.38 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> Ethyl 2-(3-((6-Chloro-3-((methyl-<i>d</i><sub>3</sub>)carbamoyl)pyridazin-4-yl)amino)-5-fluoro-2-methoxyphenyl)pyrimidine-5-carboxylate (<b>42b</b>)</h3><div class="NLM_p last">This compound was prepared from <b>41b</b> in the same manner as <b>42a</b> from <b>41a</b>. Yield: 43%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>15</sub>D<sub>3</sub>ClFN<sub>6</sub>O<sub>4</sub> (M + H)<sup>+</sup>: 464.1, found: 464.5. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.27 (s, 1H), 9.44â9.36 (m, 3H), 7.77â7.68 (m, 1H), 7.52â7.43 (m, 2H), 4.42 (q, <i>J</i> = 7.2 Hz, 2H), 3.71 (s, 3H), 1.38 (t, <i>J</i> = 7.0 Hz, 3H).</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> Ethyl 2-(3-((6-(Cyclopropanecarboxamido)-3-((methyl-<i>d</i><sub>3</sub>)carbamoyl)pyridazin-4-yl)amino)-2-methoxyphenyl)pyrimidine-5-carboxylate (<b>43a</b>)</h3><div class="NLM_p last">A mixture of ethyl 2-(3-((6-chloro-3-((methyl-<i>d</i><sub>3</sub>)carbamoyl)pyridazin-4-yl)amino)-2-methoxyphenyl)pyrimidine-5-carboxylate (<b>42a</b>) (0.344 g, 0.772 mmol) and cyclopropanecarboxamide (0.131 g, 1.543 mmol), XantPhos (0.067 g, 0.116 mmol), Cs<sub>2</sub>CO<sub>3</sub> (0.553 g, 1.697 mmol), and Pd<sub>2</sub>(dba)<sub>3</sub> (0.085 g, 0.093 mmol) in 1,4-dioxane (10 mL) was degassed and heated at 150 Â°C under microwave conditions for 2.5 h. Upon cooling to rt, the mixture was diluted with ethyl acetate (20 mL) and filtered through Celite. To the filtrate was added silica gel (1.7 g), and the mixture was concentrated under vacuum. The residue was subjected to flash chromatography (24 g ISCO column, 25â100% ethyl acetate/hexane) to provide the title compound (0.293 g, 0.556 mmol, 72% yield) as a yellow solid. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>22</sub>D<sub>3</sub>N<sub>7</sub>O<sub>5</sub> (M + H)<sup>+</sup>: 495.2, found: 495.6. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.33 (s, 1H), 10.98 (s, 1H), 9.40â9.35 (m, 2H), 9.14 (s, 1H), 8.16 (s, 1H), 7.68â7.61 (m, 2H), 7.35 (t, <i>J</i> = 7.9 Hz, 1H), 4.42 (q, <i>J</i> = 7.1 Hz, 2H), 3.71 (s, 3H), 2.09 (quin, <i>J</i> = 6.2 Hz, 1H), 1.38 (t, <i>J</i> = 7.1 Hz, 3H), 0.85â0.81 (m, 4H).</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> Ethyl 2-(3-((6-(Cyclopropanecarboxamido)-3-((methyl-<i>d</i><sub>3</sub>)carbamoyl)pyridazin-4-yl)amino)-5-fluoro-2-methoxyphenyl)pyrimidine-5-carboxylate (<b>43b</b>)</h3><div class="NLM_p last">This compound was prepared from <b>42b</b> in the same manner as <b>43a</b> from <b>42a</b>. Yield: 50%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>21</sub>D<sub>3</sub>FN<sub>7</sub>O<sub>5</sub> (M + H)<sup>+</sup>: 513.2, found: 513.4. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.40 (s, 1H), 11.18 (s, 1H), 9.39 (s, 2H), 9.18 (s, 1H), 8.27 (s, 1H), 7.58 (dd, <i>J</i> = 9.6, 3.2 Hz, 1H), 7.42 (dd, <i>J</i> = 9.0, 3.3 Hz, 1H), 4.42 (q, <i>J</i> = 7.0 Hz, 2H), 3.72 (s, 3H), 2.17â2.06 (m, 1H), 1.38 (t, <i>J</i> = 7.2 Hz, 3H), 0.91â0.81 (m, 4H).</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> 6-(Cyclopropanecarboxamido)-4-((3-(5-(diethylcarbamoyl)pyrimidin-2-yl)-2-methoxyphenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>21</b>)</h3><div class="NLM_p">To a solution of ethyl 2-(3-((6-(cyclopropanecarboxamido)-3-((methyl-<i>d</i><sub>3</sub>)carbamoyl)pyridazin-4-yl)amino)-2-methoxyphenyl)pyrimidine-5-carboxylate (<b>43a</b>) (0.274 g, 0.554 mmol) in methanol (2 mL) and THF (4 mL) at rt was added lithium hydroxide monohydrate (0.122 g, 2.90 mmol) in water (1.5 mL) over 1 min. The mixture was stirred at rt for 1 h and then concentrated under vacuum to a volume of approximately 1.5 mL. The residue was acidified with 1 N hydrochloric acid to pH 4â5. The precipitate was collected by suction filtration and further purified by trituration with ethyl acetate to provide 2-(3-((6-(cyclopropanecarboxamido)-3-((methyl-<i>d</i><sub>3</sub>)carbamoyl)pyridazin-4-yl)amino)-2-methoxyphenyl)pyrimidine-5-carboxylic acid (0.170 g, 0.321 mmol, 58% yield). LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>18</sub>D<sub>3</sub>N<sub>7</sub>O<sub>5</sub> (M + H)<sup>+</sup>: 467.2, found: 467.6.</div><div class="NLM_p last">A mixture of 2-(3-((6-(cyclopropanecarboxamido)-3-((methyl-<i>d</i><sub>3</sub>)carbamoyl)pyridazin-4-yl)amino)-2-methoxyphenyl)pyrimidine-5-carboxylic acid (0.033 g, 0.070 mmol), diethylamine (0.024 mL, 0.232 mmol), benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP) (0.0534 g, 0.121 mmol), and diisopropyldiethylamin (0.06 mL, 0.344 mmol) in THF (1.5 mL) was heated at 50 Â°C in a sealed vial for 16 h. The mixture was diluted with methanol and injected preparative HPLC. The correct fractions were combined, concentrated under vacuum, basified with saturated NaHCO<sub>3</sub> solution, and extracted with dichloromethane (3 x 30 mL). The combined extract was dried over anhydrous MgSO<sub>4</sub>. Removal of the solvent under vacuum afforded the title compound (0.0073 g, 0.014 mmol, 20% yield) as a white solid. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>27</sub>D<sub>3</sub>N<sub>8</sub>O<sub>4</sub> (M + H)<sup>+</sup>: 522.3, found: 522.7. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.32 (s, 1H), 10.97 (s, 1H), 9.14 (s, 1H), 9.00 (s, 2H), 8.15 (s, 1H), 7.66â7.56 (m, 2H), 7.34 (t, <i>J</i> = 7.9 Hz, 1H), 3.70 (s, 3H), 3.33â3.29 (m, 4H), 2.15â2.03 (m, 1H), 1.22â1.13 (m, 6H), 0.86â0.81 (m, 4H).</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> 6-(Cyclopropanecarboxamido)-4-((3-(5-(dimethylcarbamoyl)pyrimidin-2-yl)-5-fluoro-2-methoxyphenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>23</b>)</h3><div class="NLM_p last">This compound was prepared from <b>43b</b> in the same manner as <b>21</b> from <b>43a</b>. Yield over two steps: 42%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>22</sub>D<sub>3</sub>FN<sub>8</sub>O<sub>4</sub> (M + H)<sup>+</sup>: 512.2, found: 512.5. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.42 (s, 1H), 11.17 (s, 1H), 9.20 (br s, 1H), 9.06 (s, 2H), 8.27 (s, 1H), 7.55 (br d, <i>J</i> = 7.0 Hz, 1H), 7.39 (dd, <i>J</i> = 9.0, 2.7 Hz, 1H), 3.72 (s, 3H), 3.05 (br s, 3H), 3.04 (br s, 3H), 2.16â2.05 (m, 1H), 0.86 (br d, <i>J</i> = 6.1 Hz, 4H).</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> 3-(5-Bromopyrimidin-2-yl)-5-fluoro-2-methoxyaniline (<b>44</b>)</h3><div class="NLM_p last">A mixture of 5-fluoro-2-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (<b>40</b>) (0.785 g, 2.94 mmol), 2,5-dibromopyrimidine (0.734 g, 3.09 mmol), PdCl<sub>2</sub>(dppf)-CH<sub>2</sub>Cl<sub>2</sub> adduct (0.144 g, 0.176 mmol), and 2 M K<sub>3</sub>PO<sub>4</sub> solution (4.41 mL, 8.82 mmol) in 1,4-dioxane (22 mL) was heated at 90 Â°C for 3 h. The mixture was diluted with ethyl acetate (30 mL) and filtered through Celite. The filtrate was concentrated under vacuum to dryness. The residue was diluted with water (20 mL) and extracted with dichloromethane (4 x 40 mL). The combined extract was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. The desired product (0.376 g, 1.261 mmol, 43% yield) was isolated as a pale yellow solid by flash chromatography (80 g ISCO column, 20â50% ethyl acetate/hexane). LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>9</sub>BrFN<sub>3</sub>O (M + H)<sup>+</sup>: 298.0, found: 298.0. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.09 (s, 2H), 6.60 (m, 2H), 5.42 (s, 2H), 3.61 (s, 3H).</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> 3-(5-(1-Ethoxyvinyl)pyrimidin-2-yl)-5-fluoro-2-methoxyaniline (<b>45a</b>)</h3><div class="NLM_p last">A mixture of 3-(5-bromopyrimidin-2-yl)-5-fluoro-2-methoxyaniline (<b>44</b>) (376 mg, 1.261 mmol), tributyl(1-ethoxyvinyl)stannane (0.457 mL, 1.387 mmol), bis(triphenylphosphine)palladium(II) chloride (26.6 mg, 0.038 mmol), and triethylamine (0.211 mL, 1.514 mmol) in DMF (8 mL) was heated at 100 Â°C for 16 h. Upon cooling to rt, the mixture was diluted with ethyl acetate (15 mL) and filtered through Celite. The filtrate was further diluted with ethyl acetate (150 mL), washed with water (3 x 35 mL) and brine (35 mL), and dried over anhydrous MgSO<sub>4</sub>. Removal of solvent under vacuum provided the title compound (275 mg, 0.950 mmol, 75% yield). This product was used in the next step without further purification. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>16</sub>FN<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 290.1, found: 290.1.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> 3-(6-(1-Ethoxyvinyl)pyridazin-3-yl)-2-methoxyaniline (<b>45b</b>)</h3><div class="NLM_p last">A mixture of 2-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (<b>35</b>) (650 mg, 2.61 mmol), 3-chloro-6-(1-ethoxyvinyl)pyridazine (506 mg, 2.74 mmol), PdCl<sub>2</sub>(dppf)-CH<sub>2</sub>Cl<sub>2</sub> adduct (128 mg, 0.157 mmol), and 2 M K<sub>3</sub>PO<sub>4</sub> solution (3.91 mL, 7.83 mmol) in 1,4-dioxane (16 mL) was heated at 105 Â°C for 16 h. The mixture was diluted with ethyl acetate (20 mL) and filtered through Celite. The filtrate was concentrated under vacuum to dryness. The residue was diluted with water (20 mL) and extracted with dichloromethane (4 x 40 mL). The combined extract was dried over anhydrous MgSO<sub>4</sub> and concentrated under vacuum. The residue was subjected to flash chromatography (80 g ISCO column, 30â70% ethyl acetate/hexane) to provide the title compound (722 mg, 2.66 mmol, 100% yield) as a slightly yellow oil. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>17</sub>N<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 272.1, found: 272.1.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> 6-Chloro-4-((3-(5-(1-ethoxyvinyl)pyrimidin-2-yl)-5-fluoro-2-methoxyphenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>46a</b>)</h3><div class="NLM_p last">To a solution of 4,6-dichloro-<i>N</i>-trideuteromethylpyridazine-3-carboxamide (<b>37</b>)<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> (210 mg, 1.00 mmol) and 3-(5-(1-ethoxyvinyl)pyrimidin-2-yl)-5-fluoro-2-methoxyaniline (<b>45a</b>) (275 mg, 0.951 mmol) in THF (10 mL) at rt was added lithium bis(trimethylsilyl)amide in THF (2.57 mL, 2.57 mmol) over 1 min. The mixture was stirred at rt for 1 h before it was quenched with water (3 mL). The resulting mixture was adjusted with 1 N HCl solution to pH 9â10, diluted with ethyl acetate (150 mL), washed with water (2 x 30 mL) and brine (30 mL) successively, and dried over anhydrous MgSO4. After the solvent was removed under vacuum, the residue was subjected to flash chromatography (40 g ISCO column, solid loading, 25â50% ethyl acetate/dichloromethane) to provide the title compound (329 mg, 0.712 mmol, 75% yield) as a white solid. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>17</sub>D<sub>3</sub>ClFN<sub>6</sub>O<sub>3</sub> (M + H)<sup>+</sup>: 462.2, found: 462.1.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> 6-Chloro-4-((3-(6-(1-ethoxyvinyl)pyridazin-3-yl)-2-methoxyphenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>46b</b>)</h3><div class="NLM_p last">This compound was prepared from <b>45b</b> in the same manner as <b>45a</b> from <b>44a</b>. Yield: 52%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>18</sub>D<sub>3</sub>ClN<sub>6</sub>O<sub>3</sub> (M + H)<sup>+</sup>: 444.2, found: 444.2.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> 6-(Cyclopropanecarboxamido)-4-((3-(5-(1-ethoxyvinyl)pyrimidin-2-yl)-5-fluoro-2-methoxyphenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>47a</b>)</h3><div class="NLM_p last">A mixture of 6-chloro-4-((3-(5-(1-ethoxyvinyl)pyrimidin-2-yl)-5-fluoro-2-methoxyphenyl)amino)-N-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>46a</b>) (0.329 g, 0.712 mmol), cyclopropanecarboxamide (0.121 g, 1.425 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (0.098 g, 0.107 mmol), XantPhos (0.062 g, 0.107 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (0.511 g, 1.567 mmol) in 1,4-dioxane (6 mL) was heated at 150 Â°C under microwave for 1 h. Upon cooling to rt, the mixture was diluted with ethyl acetate (10 mL) and filtered through Celite. The filtrate was concentrated under vacuum. The residue was subjected to flash chromatography (40 g ISCO column, solid loading, 40â80% ethyl acetate/dichloromethane) to afford the title compound, (0.258 g, 0.505 mmol, 71% yield) as a white solid. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>23</sub>D<sub>3</sub>FN<sub>7</sub>O<sub>4</sub> (M + H)<sup>+</sup>: 511.2, found: 511.2.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> 6-(Cyclopropanecarboxamido)-4-((3-(6-(1-ethoxyvinyl)pyridazin-3-yl)-2-methoxyphenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>47b</b>)</h3><div class="NLM_p last">This compound was prepared from <b>46b</b> in the same manner as <b>47a</b> from <b>46a</b>. The yield for this step was not calculated because the isolated product was contaminated with 1-methylpyrrolidin-2-one (NMP) (see <b>48b</b> for a total yield for two steps). LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>24</sub>D<sub>3</sub>N<sub>7</sub>O<sub>4</sub> (M + H)<sup>+</sup>: 493.2, found: 493.2.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> 4-((3-(5-Acetylpyrimidin-2-yl)-5-fluoro-2-methoxyphenyl)amino)-6-(cyclopropanecarboxamido)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>48a</b>)</h3><div class="NLM_p last">To a suspension of 6-(cyclopropanecarboxamido)-4-((3-(5-(1-ethoxyvinyl)pyrimidin-2-yl)-5-fluoro-2-methoxyphenyl)amino)-<i>N</i>-trideuteromethylpyridazine-3-carboxamide (<b>47a</b>) (0.258 g, 0.505 mmol) in THF (20 mL) at rt was added 1 N hydrochloric acid (10 mL, 10.0 mmol). The resulting solution was stirred at rt for 16 h and then concentrated under vacuum to a volume of approximately 10 mL. The residue was basified with 1 N NaOH solution to pH 10. The resulting suspension was allowed to stand at 0 Â°C for 1 h. The desired product (0.185 g, 0.383 mmol, 76% yield) was collected as a yellow solid by suction filtration and dried at 60 Â°C under vacuum. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>19</sub>D<sub>3</sub>FN<sub>7</sub>O<sub>4</sub> (M + H)<sup>+</sup>: 483.2, found: 483.2.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i98" class="anchor-spacer"></div><h3 class="article-section__title" id="_i98"> 4-((3-(6-Acetylpyridazin-3-yl)-2-methoxyphenyl)amino)-6-(cyclopropanecarboxamido)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>48b</b>)</h3><div class="NLM_p last">This compound was prepared from <b>47b</b> in the same manner as <b>48a</b> from <b>47a</b>. Yield: 52% for two steps. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>20</sub>D<sub>3</sub>N<sub>7</sub>O<sub>4</sub> (M + H)<sup>+</sup>: 465.2, found: 465.3. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.35 (s, 1H), 11.01 (s, 1H), 9.16 (s, 1H), 8.32â8.25 (m, 1H), 8.24â8.15 (m, 2H), 7.67 (td, <i>J</i> = 7.7, 1.5 Hz, 2H), 7.42 (t, <i>J</i> = 7.9 Hz, 1H), 3.51 (s, 3H), 2.84 (s, 3H), 2.14â2.05 (m, 1H), 0.84 (d, <i>J</i> = 6.1 Hz, 4H).</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i99" class="anchor-spacer"></div><h3 class="article-section__title" id="_i99"> 6-(Cyclopropanecarboxamido)-4-((5-fluoro-3-(5-(2-hydroxypropan-2-yl)pyrimidin-2-yl)-2-methoxyphenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>22</b>)</h3><div class="NLM_p last">To a solution of 4-((3-(5-acetylpyrimidin-2-yl)-5-fluoro-2-methoxyphenyl)amino)-6-(cyclopropanecarboxamido)-<i>N</i>-trideuteromethylpyridazine-3-carboxamide (<b>48a</b>) (85 mg, 0.176 mmol) in THF (10 mL) at 0 Â°C was dropwise added methylmagnesium bromide (0.352 mL, 1.057 mmol). The resulting mixture was stirred at 0 Â°C for 45 min before it was quenched with water (5 mL). The mixture was diluted with ethyl acetate (120 mL), washed with water (2 x 30 mL) and brine (30 mL) successively, and dried over anhydrous MgSO<sub>4</sub>. After the solvent was removed under vacuum, the residue was subjected to preparative HPLC. The correct fractions were combined, concentrated under vacuum, basified with 1.5 M K<sub>2</sub>HPO<sub>4</sub> solution to pH 10, and extracted with dichloromethane (3 x 30 mL). The combined extract was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. Removal of the solvent under vacuum provided the title compound (26.0 mg, 0.052 mmol, 29% yield) as a pale solid. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>23</sub>D<sub>3</sub>FN<sub>7</sub>O<sub>4</sub> (M + H)<sup>+</sup>: 499.2, found: 499.2. LCMS <i>m</i>/<i>z</i> = 499.2 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.40 (s, 1H), 11.13 (s, 1H), 9.18 (s, 1H), 9.03 (s, 2H), 8.26 (s, 1H), 7.50 (dd, <i>J</i> = 9.6, 3.1 Hz, 1H), 7.33 (dd, <i>J</i> = 9.1, 3.1 Hz, 1H), 5.48 (s, 1H), 3.71 (s, 3H), 2.20â2.01 (m, 1H), 1.55 (s, 6H), 0.93â0.80 (m, 4H).</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i100" class="anchor-spacer"></div><h3 class="article-section__title" id="_i100"> 6-(Cyclopropanecarboxamido)-4-((3-(6-(2-hydroxypropan-2-yl)pyridazin-3-yl)-2-methoxyphenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>28</b>)</h3><div class="NLM_p last">This compound was prepared from <b>48b</b> in the same manner as <b>22</b> from <b>48a</b>. Yield: 38%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>24</sub>D<sub>3</sub>N<sub>7</sub>O<sub>4</sub> (M + H)<sup>+</sup>: 481.2, found: 481.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.34 (s, 1H), 11.00 (s, 1H), 9.15 (s, 1H), 8.18 (s, 1H), 8.08â8.03 (m, 1H), 8.00â7.95 (m, 1H), 7.59 (d, <i>J</i> = 7.8 Hz, 2H), 7.41â7.34 (m, 1H), 5.53 (s, 1H), 3.49 (s, 3H), 2.10 (quin, <i>J</i> = 6.1 Hz, 1H), 1.60 (s, 6H), 0.84 (d, <i>J</i> = 6.1 Hz, 4H).</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i101" class="anchor-spacer"></div><h3 class="article-section__title" id="_i101"> General Procedure for the Preparation of <b>50aâe</b>, Exemplified by 6-Chloro-4-((3-(5-fluoropyrimidin-2-yl)-2-methoxyphenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)nicotinamide (<b>50b</b>)</h3><div class="NLM_p">To a solution of 3-(5-fluoropyrimidin-2-yl)-2-methoxyaniline (<b>36 g</b>) (6.67 g, 30.4 mmol) and 4,6-dichloro-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)nicotinamide (<b>49</b>)<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> (6.03 g, 29.0 mmol) in THF (150 mL) at rt was added 1 M lithium bis(trimethylsilyl)amide/THF (90 mL, 90 mmol) over 5 min. The mixture was stirred at rt for 1.5 h before it was quenched by slow addition of water (40 mL). The resulting mixture was adjusted with 1 N hydrochloric acid to pH 9â10 and diluted with ethyl acetate (300 mL). After the layers were separated, the organic layer was washed with water (75 mL) and brine (75 mL) successively, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum to dryness. The residue was triturated with ethyl acetate to provide the title compound 7.80 g, 19.96 mmol, 69% yield) as a white solid. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>12</sub>D<sub>3</sub>ClFN<sub>5</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 391.1, found: 391.4. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.59 (s, 1H), 9.04 (s, 2H), 8.79 (s, 1H), 8.52 (s, 1H), 7.60 (dd, <i>J</i> = 7.9, 1.5 Hz, 1H), 7.53 (dd, <i>J</i> = 7.7, 1.3 Hz, 1H), 7.35â7.28 (m, 1H), 6.96â6.91 (m, 1H), 3.66 (s, 3H).</div><div id="sec4_26_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> 6-Chloro-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)nicotinamide (<b>50a</b>)</h4><div class="NLM_p last">Yield: 65%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>13</sub>D<sub>3</sub>ClN<sub>5</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 373.1, found: 373.3.</div></div><div id="sec4_26_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> 6-Chloro-4-((2-methoxy-3-(5-methylpyrazin-2-yl)phenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)nicotinamide (<b>50c</b>)</h4><div class="NLM_p last">Yield: 64%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>15</sub>D<sub>3</sub>ClN<sub>5</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 387.1, found: 387.0.</div></div><div id="sec4_26_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> 6-Chloro-4-((2-methoxy-3-(5-methoxypyrazin-2-yl)phenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)nicotinamide (<b>50d</b>)</h4><div class="NLM_p last">Yield: 63%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>15</sub>D<sub>3</sub>ClN<sub>5</sub>O<sub>3</sub> (M + H)<sup>+</sup>: 403.1, found: 403.3.</div></div><div id="sec4_26_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> 6-Chloro-4-((5-fluoro-2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)nicotinamide (<b>50e</b>)</h4><div class="NLM_p last">Yield: 77%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>12</sub>D<sub>3</sub>ClFN<sub>5</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 391.1, found: 391.1.</div></div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i106" class="anchor-spacer"></div><h3 class="article-section__title" id="_i106"> General Procedure for the Preparation of <b>30â33</b>, Exemplified by 6-(Cyclopropanecarboxamido)-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)nicotinamide (<b>30</b>)</h3><div class="NLM_p">A mixture of 6-chloro-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)-<i>N</i>-trideuteromethylnicotinamide (<b>50a</b>) (65 mg, 0.174 mmol), cyclopropanecarboxamide (29.7 mg, 0.349 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (23.95 mg, 0.026 mmol), XantPhos (15.13 mg, 0.026 mmol), and cesium carbonate (125 mg, 0.384 mmol) in 1,4-dioxane (2.2 mL) was heated at 145 Â°C under microwave conditions for 1 h. The mixture was diluted with ethyl acetate (8 mL) and filtered through Celite. The filtrate was concentrated under vacuum, and the residue was subjected to preparative HPLC. The correct fractions were combined, concentrated under vacuum, basified with saturated NaHCO<sub>3</sub> solution to pH 9â10, and extracted with dichloromethane (3 x 35 mL). The combined extract was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. Removal of the solvent under vacuum provided the title compound (38 mg, 0.089 mmol, 51% yield) as a white solid. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>19</sub>D<sub>3</sub>N<sub>6</sub>O<sub>3</sub> (M + H)<sup>+</sup>: 422.2, found: 422.3. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.78 (br s, 1H), 10.66 (s, 1H), 8.95 (d, <i>J</i> = 4.9 Hz, 2H), 8.59 (s, 1H), 8.52 (s, 1H), 8.04 (br s, 1H), 7.56 (dd, <i>J</i> = 8.0, 1.5 Hz, 1H), 7.51 (t, <i>J</i> = 4.9 Hz, 1H), 7.44 (dd, <i>J</i> = 7.8, 1.5 Hz, 1H), 7.30â7.24 (m, 1H), 3.68 (s, 3H), 2.04â1.90 (m, 1H), 0.85â0.74 (m, 4H).</div><div id="sec4_27_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> 6-(Cyclopropanecarboxamido)-4-((2-methoxy-3-(5-methylpyrazin-2-yl)phenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)nicotinamide (<b>31</b>)</h4><div class="NLM_p last">Yield: 45%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>21</sub>D<sub>3</sub>N<sub>6</sub>O<sub>3</sub> (M + H)<sup>+</sup>: 436.2, found: 436.0. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.78 (s, 1H), 10.72 (s, 1H), 8.95 (d, <i>J</i> = 1.5 Hz, 1H), 8.70â8.65 (m, 1H), 8.61 (s, 1H), 8.54 (s, 1H), 8.07 (s, 1H), 7.53 (dd, <i>J</i> = 7.9, 1.5 Hz, 1H), 7.47 (dd, <i>J</i> = 7.8, 1.6 Hz, 1H), 7.34â7.28 (m, 1H), 3.52 (s, 3H), 2.57 (s, 3H), 2.05â1.95 (m, 1H), 0.84â0.75 (m, 4H).</div></div><div id="sec4_27_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> 6-(Cyclopropanecarboxamido)-4-((2-methoxy-3-(5-methoxypyrazin-2-yl)phenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)nicotinamide (<b>32</b>)</h4><div class="NLM_p last">Yield: 50%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>21</sub>D<sub>3</sub>N<sub>6</sub>O<sub>4</sub> (M + H)<sup>+</sup>: 452.2, found: 452.4. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.74 (s, 1H), 10.63 (s, 1H), 8.65 (s, 1H), 8.61 (s, 1H), 8.50 (s, 1H), 8.44 (s, 1H), 8.05 (s, 1H), 7.47 (br dd, <i>J</i> = 12.3, 7.9 Hz, 2H), 7.33â7.25 (m, 1H), 3.98 (s, 3H), 3.61 (s, 3H), 2.01â1.93 (m, 1H), 0.78 (br d, <i>J</i> = 5.7 Hz, 4H).</div></div><div id="sec4_27_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> 6-(Cyclopropanecarboxamido)-4-((5-fluoro-2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)nicotinamide (<b>33</b>)</h4><div class="NLM_p last">Yield: 52%. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>18</sub>D<sub>3</sub>FN<sub>6</sub>O<sub>3</sub> (M + H)<sup>+</sup>: 440.2, found: 440.3. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.86 (d, <i>J</i> = 6.0 Hz, 2H), 8.97 (d, <i>J</i> = 4.9 Hz, 2H), 8.63 (s, 1H), 8.56 (s, 1H), 8.17 (s, 1H), 7.55 (t, <i>J</i> = 4.9 Hz, 1H), 7.43 (dd, <i>J</i> = 10.0, 3.1 Hz, 1H), 7.22 (dd, <i>J</i> = 9.1, 3.1 Hz, 1H), 3.69 (s, 3H), 2.07â1.97 (m, 1H), 0.87â0.77 (m, 4H).</div></div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i110" class="anchor-spacer"></div><h3 class="article-section__title" id="_i110"> 6-(Cyclopropanecarboxamido)-4-((3-(5-fluoropyrimidin-2-yl)-2-methoxyphenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)nicotinamide (<b>7</b>)</h3><div class="NLM_p last">1,4-Dioxane (200 mL) was placed in a N<sub>2</sub>-flushed three-necked 2 L round-bottom flask and bubbled with N<sub>2</sub> for 5 min before Pd<sub>2</sub>(dba)<sub>3</sub> (2.12 g, 2.316 mmol) and XantPhos (2.68 g, 4.63 mmol) were added. The mixture was stirred with N<sub>2</sub> bubbling for 5 min before 6-chloro-4-((3-(5-fluoropyrimidin-2-yl)-2-methoxyphenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)nicotinamide (<b>50b</b>) (18.1 g, 46.3 mmol), cyclopropanecarboxamide (7.88 g, 93 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (37.7 g, 116 mmol) were successively added. The reaction mixture was heated at reflux for 4 h. Upon cooling to 50 Â°C, the reaction mixture was diluted with ethyl acetate (800 mL), and <i>N</i>-acetyl-<span class="smallcaps smallerCapital">l</span>-cysteine (15.12 g, 93 mmol) was added. The resulting mixture was stirred at 50 Â°C for 12 h and then washed with water (800 mL). The aqueous layer was extracted with ethyl acetate (2 x 500 mL). The combined organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. The residue was subjected to flash chromatography (750 g ISCO column, 0â10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>). The product thus obtained was dissolved in refluxing EtOH (200 mL) over 1 h. The solution was gradually cooled to â2 Â°C with an ice/isopropyl alcohol bath. The recrystallized title compound (13.3 g, 30.3 mmol, 65% yield) was collected as a white solid by suction filtration, rinsed with cold EtOH (â20 Â°C), and dried on a high house vacuum line for 12 h. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>18</sub>D<sub>3</sub>FN<sub>6</sub>O<sub>3</sub> (M + H)<sup>+</sup>: 440.2, found: 440.1. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>18</sub>D<sub>3</sub>FN<sub>6</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 440.18475. Found: 440.19182. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.77 (s, 1H), 10.67 (s, 1H), 9.04 (d, <i>J</i> = 0.9 Hz, 2H), 8.59 (s, 1H), 8.53 (s, 1H), 8.07 (s, 1H), 7.57 (dd, <i>J</i> = 7.9, 1.6 Hz, 1H), 7.43 (dd, <i>J</i> = 7.7, 1.6 Hz, 1H), 7.31â7.23 (m, 1H), 3.68 (s, 3H), 2.04â1.94 (m, 1H), 0.82â0.75 (m, 4H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 172.7, 167.8, 160.6 (d, <i>J</i> = 6.4 Hz, 1C), 156.3 (d, <i>J</i> = 263.4 Hz, 1C), 153.9, 151.8, 150.3, 148.5, 145.2 (d, <i>J</i> = 20.0 Hz, 2C), 133.3, 132.8, 126.0, 123.8, 123.0, 109.3, 94.8, 61.3, 14.2, 7.6 (s, 2C).</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i111" class="anchor-spacer"></div><h3 class="article-section__title" id="_i111"> Tyk2/Jak1 JH2 Homogeneous Time-Resolved Fluorescence (HTRF) Assays</h3><div class="NLM_p last">Tyk2 JH2 homogeneous time-resolved fluorescence (HTRF) assay was previously described.<a onclick="showRef(event, 'ref49 ref53'); return false;" href="javascript:void(0);" class="ref ref49 ref53">(49,53)</a> The Jak1 JH2 HTRF assay was run in exactly the same way as the Tyk2 JH2 HTRF assay except that the His-JAK1 JH2 concentration utilized was 1 nM and the fluorescein-labeled kinase tracer was adjusted to respective Kd for Jak1 JH2.</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i112" class="anchor-spacer"></div><h3 class="article-section__title" id="_i112"> Protein Production and X-ray Crystallography</h3><div class="NLM_p last">Protein production, purification, co-crystallization, and structure determination of Tyk2 JH2 domain (575â869) in complex with compounds <b>12</b> and <b>29</b> were carried out as previously reported.<a onclick="showRef(event, 'ref43 ref49 ref50 ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref43 ref49 ref50 ref52 ref53">(43,49,50,52,53)</a></div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i113" class="anchor-spacer"></div><h3 class="article-section__title" id="_i113"> IL-12/IL-18-Induced Serum IFNÎ³ Inhibition in Mice</h3><div class="NLM_p last">Compound <b>7</b> in 5:5:90 TPGS:EtOH:PEG300 was dosed orally to female C57BL/6 mice (from Charles River Laboratories, age 8â10 weeks) (<i>n</i> = 8/group). One hour later, 0.02 Î¼g of recombinant rat IL-12 was administered IV. Another hour later following IL-12 administration, 1 Î¼g of recombinant rat IL-18 was administered IV. Three hours later, blood was collected and serum was obtained by centrifugation for analysis of IFNÎ³ by ELISA.</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i114" class="anchor-spacer"></div><h3 class="article-section__title" id="_i114"> IL-23-Induced Acanthosis in Mice</h3><div class="NLM_p last">To induce acanthosis, recombinant, dual chain, human IL-23 was diluted in sterile phosphate-buffered saline and injected (5 Î¼g in 20 Î¼L) into the right ear of C57BL/6 female mice (9 to 11 weeks of age), every other day until the last injection on day 10. Each ear was injected intradermally using a 0.5 cc insulin syringe. A starting âbaselineâ measurement of the non-injected right ear of each mouse was made on day 0. Thereafter, ear thickness (in thousandths of an inch) was measured every other day, prior to the next ear injection, using a Mitutoyo dial caliper. Oral dosing with <b>7</b> (3, 10, and 30 mg/kg) began approximately 2 h before the first IL-23 injection and continued once daily until day 9, and the study ended on day 11. The compound was formulated as a solution in EtOH:TPGS:PEG300, 5:5:90 vehicle. The placebo/control group was dosed with blank EtOH:TPGS:PEG300, 5:5:90 vehicle. Stelara was administered SC at a dose of 5 mg/kg on day 0.</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i115" class="anchor-spacer"></div><h3 class="article-section__title" id="_i115"> Anti-CD40 Antibody-Induced Colitis in Mice</h3><div class="NLM_p last">The efficacy of <b>7</b> was compared with that of the anti-p40 antibody in a p40-dependent model of colitis using B6.CB17-Prkdc<scid>/SzJ mice. On day â1 and day 4, mice (<i>n</i> = 10/group) were injected with 10 mg/kg anti-p40 antibody, SC. Starting on day 0 and continuing daily through day 5, additional groups of mice (<i>n</i> = 10/group) were dosed with 0 (vehicle control), 10, 25, or 60 mg/kg PO QD <b>7</b> in an aqueous suspension vehicle containing 0.5% Methocel (A4M), 0.1% Tween-80 with a final particle size typically â¼200â300 nm (d50). Also on day 0, colitis was induced in all five groups with a single injection of 100 Î¼g of FGK4.5 anti-CD40 mAb in PBS, IP. On a daily basis, mice were weighed and monitored for signs of colitis-including body weight loss and the accompanying loose stools and diarrhea. On day 6, all animals were euthanized. Intestine sections were fixed in formalin or added to RNA later for histological evaluations or cytokine profiling via RT-PCR, respectively. Terminal blood was collected for measuring circulating cytokine levels.</div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i116" class="anchor-spacer"></div><h3 class="article-section__title" id="_i116"> Lupus in NZB/W Mice</h3><div class="NLM_p">Baseline body weight, proteinuria, and serum dsDNA titers were determined for female NZB/W mice, age 23 weeks (Jackson Laboratories) prior to their randomization into treatment groups, each with <i>n</i> = 12. Mice were dosed by oral gavage, QD, for 12 weeks and included the following treatment groups: compound <b>7</b> at 3 and 10 mg/kg in vehicle (EtOH:TPGS:PEG300, 5:5:90) or vehicle alone. Mouse anti-interferon receptor antibody MAR1-5A3 was dosed at 0.5 mg/mouse (<i>n</i> = 10), SC, twice a week for the duration of the study. Mice were routinely monitored for overall health, and body weight, proteinuria, and dsDNA titers were measured every 3 weeks, with the last measurement at week 11.</div><div class="NLM_p last">All studies involving animals were conducted in accordance with institutional guidelines as defined by the Institutional Animal Care and Use Committee for U.S. institutions and with the approval of the Bristol-Myers Squibb Animal Care and Use Committee.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i117"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01698" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40824" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40824" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01698?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01698</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">The Molecular formula strings list (CSV) is available free of charge on the ACS Publications website at DOI:</p><p class="last">Molecular formula strings list (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01698/suppl_file/jm0c01698_si_001.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01698/suppl_file/jm0c01698_si_001.csv">jm0c01698_si_001.csv (2.64 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates for the X-ray structures of compound <b>12</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K7O">7K7O</a>) and <b>29</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K7Q">7K7Q</a>) bound to TYK2 JH2 are available from the RCSB Protein Data Bank (<a href="http://www.rscb.org" class="extLink">www.rscb.org</a>). Authors will release the atomic coordinates upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.0c01698" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32742" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32742" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chunjian Liu</span> - <span class="hlFld-Affiliation affiliation">Immunosciences
Discovery Chemistry, Bristol-Myers Squibb
Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3708-2372" title="Orcid link">http://orcid.org/0000-0003-3708-2372</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#12717a677c787b737c3c7e7b6752707f733c717d7f"><span class="__cf_email__" data-cfemail="23404b564d494a424d0d4f4a5663414e420d404c4e">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James Lin</span> - <span class="hlFld-Affiliation affiliation">Immunosciences
Discovery Chemistry, Bristol-Myers Squibb
Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Charles Langevine</span> - <span class="hlFld-Affiliation affiliation">Immunosciences
Discovery Chemistry, Bristol-Myers Squibb
Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel Smith</span> - <span class="hlFld-Affiliation affiliation">Department
of Discovery Synthesis, Bristol-Myers Squibb
Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianqing Li</span> - <span class="hlFld-Affiliation affiliation">Department
of Discovery Synthesis, Bristol-Myers Squibb
Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8445-9796" title="Orcid link">http://orcid.org/0000-0002-8445-9796</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John S. Tokarski</span> - <span class="hlFld-Affiliation affiliation">Molecular
Structure and Design, Molecular Discovery Technologies, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Javed Khan</span> - <span class="hlFld-Affiliation affiliation">Molecular
Structure and Design, Molecular Discovery Technologies, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Max Ruzanov</span> - <span class="hlFld-Affiliation affiliation">Molecular
Structure and Design, Molecular Discovery Technologies, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joann Strnad</span> - <span class="hlFld-Affiliation affiliation">Immunosciences
Discovery Biology, Bristol-Myers Squibb
Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Adriana Zupa-Fernandez</span> - <span class="hlFld-Affiliation affiliation">Immunosciences
Discovery Biology, Bristol-Myers Squibb
Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lihong Cheng</span> - <span class="hlFld-Affiliation affiliation">Immunosciences
Discovery Biology, Bristol-Myers Squibb
Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kathleen M. Gillooly</span> - <span class="hlFld-Affiliation affiliation">Immunosciences
Discovery Biology, Bristol-Myers Squibb
Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Shuster</span> - <span class="hlFld-Affiliation affiliation">Immunosciences
Discovery Biology, Bristol-Myers Squibb
Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yifan Zhang</span> - <span class="hlFld-Affiliation affiliation">Immunosciences
Discovery Biology, Bristol-Myers Squibb
Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anil Thankappan</span> - <span class="hlFld-Affiliation affiliation">Immunosciences
Discovery Biology, Bristol-Myers Squibb
Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kim W. McIntyre</span> - <span class="hlFld-Affiliation affiliation">Immunosciences
Discovery Biology, Bristol-Myers Squibb
Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Charu Chaudhry</span> - <span class="hlFld-Affiliation affiliation">Leads
Discovery and Optimization, Bristol-Myers
Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul A. Elzinga</span> - <span class="hlFld-Affiliation affiliation">Metabolism
and Pharmacokinetic Department, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Manoj Chiney</span> - <span class="hlFld-Affiliation affiliation">Metabolism
and Pharmacokinetic Department, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anjaneya Chimalakonda</span> - <span class="hlFld-Affiliation affiliation">Metabolism
and Pharmacokinetic Department, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Louis J. Lombardo</span> - <span class="hlFld-Affiliation affiliation">Immunosciences
Discovery Chemistry, Bristol-Myers Squibb
Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3335-6460" title="Orcid link">http://orcid.org/0000-0003-3335-6460</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John E. Macor</span> - <span class="hlFld-Affiliation affiliation">Immunosciences
Discovery Chemistry, Bristol-Myers Squibb
Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Percy H. Carter</span> - <span class="hlFld-Affiliation affiliation">Immunosciences
Discovery Chemistry, Bristol-Myers Squibb
Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James R. Burke</span> - <span class="hlFld-Affiliation affiliation">Immunosciences
Discovery Biology, Bristol-Myers Squibb
Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David S. Weinstein</span> - <span class="hlFld-Affiliation affiliation">Immunosciences
Discovery Chemistry, Bristol-Myers Squibb
Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i119">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20141" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20141" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors would like to acknowledge Richard Rampulla and the Department of Discovery Synthesis (DDS) at Biocon Bristol-Myers Squibb Research and Development Center (BBRC) for supplies of some intermediates.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">ABBREVIATIONS Used</td></tr><tr><td class="NLM_term">anti-dsDNA</td><td class="NLM_def"><p class="first last">anti-double stranded deoxyribonucleic acid</p></td></tr><tr><td class="NLM_term">Arg</td><td class="NLM_def"><p class="first last">arginine</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term">CD40</td><td class="NLM_def"><p class="first last">cluster of differentiation 40</p></td></tr><tr><td class="NLM_term">CIA</td><td class="NLM_def"><p class="first last">collagen-induced arthritis</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">EAE</td><td class="NLM_def"><p class="first last">experimental autoimmune encephalomyelitis</p></td></tr><tr><td class="NLM_term">Cmax</td><td class="NLM_def"><p class="first last">maximum concentration</p></td></tr><tr><td class="NLM_term">dba</td><td class="NLM_def"><p class="first last">dibenzylideneacetone</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">dppf</td><td class="NLM_def"><p class="first last">1,1â²-bis(dicyclohexylphosphino)ferrocene</p></td></tr><tr><td class="NLM_term">EPO</td><td class="NLM_def"><p class="first last">erythropoietin</p></td></tr><tr><td class="NLM_term">F</td><td class="NLM_def"><p class="first last">bioavailability</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">Glu</td><td class="NLM_def"><p class="first last">glutamic acid</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">HRMS</td><td class="NLM_def"><p class="first last">high-resolution mass spectrometry</p></td></tr><tr><td class="NLM_term">hWB</td><td class="NLM_def"><p class="first last">human whole blood</p></td></tr><tr><td class="NLM_term">Hz</td><td class="NLM_def"><p class="first last">hertz</p></td></tr><tr><td class="NLM_term">IBD</td><td class="NLM_def"><p class="first last">inflammatory bowel disease</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">half-maximal inhibitory concentration</p></td></tr><tr><td class="NLM_term">IFN</td><td class="NLM_def"><p class="first last">interferon</p></td></tr><tr><td class="NLM_term">IL</td><td class="NLM_def"><p class="first last">interleukin</p></td></tr><tr><td class="NLM_term">IV</td><td class="NLM_def"><p class="first last">intravenous administration</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term">JH1</td><td class="NLM_def"><p class="first last">Janus homology 1</p></td></tr><tr><td class="NLM_term">JH2</td><td class="NLM_def"><p class="first last">Janus homology 2</p></td></tr><tr><td class="NLM_term">LCMS</td><td class="NLM_def"><p class="first last">liquid chromatographyâmass spectrometry</p></td></tr><tr><td class="NLM_term">LLQ</td><td class="NLM_def"><p class="first last">lower limit of detection</p></td></tr><tr><td class="NLM_term">LM</td><td class="NLM_def"><p class="first last">liver microsomal</p></td></tr><tr><td class="NLM_term">Lys</td><td class="NLM_def"><p class="first last">lysine</p></td></tr><tr><td class="NLM_term">MHz</td><td class="NLM_def"><p class="first last">megahertz</p></td></tr><tr><td class="NLM_term">mpk</td><td class="NLM_def"><p class="first last">milligrams per kilogram</p></td></tr><tr><td class="NLM_term">mWB</td><td class="NLM_def"><p class="first last">mouse whole blood</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">PBMC</td><td class="NLM_def"><p class="first last">peripheral blood mononuclear cell</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamic</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">Protein Data Bank</p></td></tr><tr><td class="NLM_term">PEG</td><td class="NLM_def"><p class="first last">polyethylene glycol</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">PO</td><td class="NLM_def"><p class="first last">oral administration</p></td></tr><tr><td class="NLM_term">PTGS</td><td class="NLM_def"><p class="first last">tocopheryl polyethylene glycol</p></td></tr><tr><td class="NLM_term">QD</td><td class="NLM_def"><p class="first last">once-daily administration</p></td></tr><tr><td class="NLM_term">RA</td><td class="NLM_def"><p class="first last">rheumatoid arthritis</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structureâactivity relationships</p></td></tr><tr><td class="NLM_term">SCID</td><td class="NLM_def"><p class="first last">severe-combined immunodeficient</p></td></tr><tr><td class="NLM_term">SLE</td><td class="NLM_def"><p class="first last">systemic lupus erythematosus</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">Thr</td><td class="NLM_def"><p class="first last">threonine</p></td></tr><tr><td class="NLM_term">TYK2</td><td class="NLM_def"><p class="first last">tyrosine kinase 2</p></td></tr><tr><td class="NLM_term">Val</td><td class="NLM_def"><p class="first last">valine</p></td></tr><tr><td class="NLM_term">Vss</td><td class="NLM_def"><p class="first last">volume of distribution.</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i121">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11720" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11720" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 57 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Villarino, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâShea, J. J.</span></span> <span> </span><span class="NLM_article-title">Mechanisms and Consequences of Jak-STAT Signaling in the Immune System</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">374</span>â <span class="NLM_lpage">384</span>, <span class="refDoi">Â DOI: 10.1038/ni.3691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1038%2Fni.3691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=28323260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvFagu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=374-384&author=A.+V.+Villarinoauthor=Y.+Kannoauthor=J.+J.+O%E2%80%99Shea&title=Mechanisms+and+Consequences+of+Jak-STAT+Signaling+in+the+Immune+System&doi=10.1038%2Fni.3691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms and consequences of Jak-STAT signaling in the immune system</span></div><div class="casAuthors">Villarino, Alejandro V.; Kanno, Yuka; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">374-384</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinases of the Jak ('Janus kinase') family and transcription factors (TFs) of the STAT ('signal transducer and activator of transcription') family constitute a rapid membrane-to-nucleus signaling module that affects every aspect of the mammalian immune system.  Research on this paradigmatic pathway has experienced breakneck growth in the quarter century since its discovery and has yielded a stream of basic and clin. insights that have profoundly influenced modern understanding of human health and disease, exemplified by the bench-to-bedside success of Jak inhibitors ('jakinibs') and pathway-targeting drugs.  Here we review recent advances in Jak-STAT biol., focusing on immune cell function, disease etiol. and therapeutic intervention, as well as broader principles of gene regulation and signal-dependent TFs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrUlP3emd5BrVg90H21EOLACvtfcHk0liifk0T9D_xBw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvFagu7c%253D&md5=b50a88aee2b64fcb85c9a64d4ec1724e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fni.3691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.3691%26sid%3Dliteratum%253Aachs%26aulast%3DVillarino%26aufirst%3DA.%2BV.%26aulast%3DKanno%26aufirst%3DY.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DMechanisms%2520and%2520Consequences%2520of%2520Jak-STAT%2520Signaling%2520in%2520the%2520Immune%2520System%26jtitle%3DNat.%2520Immunol.%26date%3D2017%26volume%3D18%26spage%3D374%26epage%3D384%26doi%3D10.1038%2Fni.3691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sohn, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbema, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macleod, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulagowski, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewin-Koh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dengler, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L. C.</span></span> <span> </span><span class="NLM_article-title">A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective Inhibitors</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">2205</span>â <span class="NLM_lpage">2216</span>, <span class="refDoi">Â DOI: 10.4049/jimmunol.1202859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.4049%2Fjimmunol.1202859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=23894201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSgtL%252FP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=2205-2216&author=S.+J.+Sohnauthor=K.+Barrettauthor=A.+V.+Abbemaauthor=C.+Changauthor=P.+B.+Kohliauthor=H.+Kandaauthor=J.+Smithauthor=Y.+Laiauthor=A.+Zhouauthor=B.+Zhangauthor=W.+Yangauthor=K.+Williamsauthor=C.+Macleodauthor=C.+A.+Hurleyauthor=J.+J.+Kulagowskiauthor=N.+Lewin-Kohauthor=H.+S.+Denglerauthor=A.+R.+Johnsonauthor=N.+Ghilardiauthor=M.+Zakauthor=J.+Liangauthor=W.+S.+Blairauthor=S.+Magnusonauthor=L.+C.+Wu&title=A+Restricted+Role+for+TYK2+Catalytic+Activity+in+Human+Cytokine+Responses+Revealed+by+Novel+TYK2-Selective+Inhibitors&doi=10.4049%2Fjimmunol.1202859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective Inhibitors</span></div><div class="casAuthors">Sohn, Sue J.; Barrett, Kathy; Van Abbema, Anne; Chang, Christine; Kohli, Pawan Bir; Kanda, Hidenobu; Smith, Janice; Lai, Yingjie; Zhou, Aihe; Zhang, Birong; Yang, Wenqian; Williams, Karen; MacLeod, Calum; Hurley, Christopher A.; Kulagowski, Janusz J.; Lewin-Koh, Nicholas; Dengler, Hart S.; Johnson, Adam R.; Ghilardi, Nico; Zak, Mark; Liang, Jun; Blair, Wade S.; Magnuson, Steven; Wu, Lawren C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2205-2216</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">TYK2 is a JAK family protein tyrosine kinase activated in response to multiple cytokines, including type I IFNs, IL-6, IL-10, IL-12, and IL-23.  Extensive studies of mice that lack TYK2 expression indicate that the IFN-Î±, IL-12, and IL-23 pathways, but not the IL-6 or IL-10 pathways, are compromised.  In contrast, there have been few studies of the role of TYK2 in primary human cells.  A genetic mutation at the tyk2 locus that results in a lack of TYK2 protein in a single human patient has been linked to defects in the IFN-Î±, IL-6, IL-10, IL-12, and IL-23 pathways, suggesting a broad role for TYK2 protein in human cytokine responses.  In this article, we have used a panel of novel potent TYK2 small-mol. inhibitors with varying degrees of selectivity against other JAK kinases to address the requirement for TYK2 catalytic activity in cytokine pathways in primary human cells.  Our results indicate that the biol. processes that require TYK2 catalytic function in humans are restricted to the IL-12 and IL-23 pathways, and suggest that inhibition of TYK2 catalytic activity may be an efficacious approach for the treatment of select autoimmune diseases without broad immunosuppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgACYZYW8b07Vg90H21EOLACvtfcHk0liifk0T9D_xBw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSgtL%252FP&md5=527289e055e91fe2dfb15d3de7faa894</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1202859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1202859%26sid%3Dliteratum%253Aachs%26aulast%3DSohn%26aufirst%3DS.%2BJ.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DAbbema%26aufirst%3DA.%2BV.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DKanda%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DWilliams%26aufirst%3DK.%26aulast%3DMacleod%26aufirst%3DC.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26aulast%3DLewin-Koh%26aufirst%3DN.%26aulast%3DDengler%26aufirst%3DH.%2BS.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DZak%26aufirst%3DM.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DMagnuson%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DL.%2BC.%26atitle%3DA%2520Restricted%2520Role%2520for%2520TYK2%2520Catalytic%2520Activity%2520in%2520Human%2520Cytokine%2520Responses%2520Revealed%2520by%2520Novel%2520TYK2-Selective%2520Inhibitors%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26spage%3D2205%26epage%3D2216%26doi%3D10.4049%2Fjimmunol.1202859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghoreschi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâShea, J. J.</span></span> <span> </span><span class="NLM_article-title">Janus Kinases in Immune Cell Signaling</span>. <i>Immunol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>228</i></span>,  <span class="NLM_fpage">273</span>â <span class="NLM_lpage">287</span>, <span class="refDoi">Â DOI: 10.1111/j.1600-065X.2008.00754.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1111%2Fj.1600-065X.2008.00754.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=19290934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=273-287&author=K.+Ghoreschiauthor=A.+Laurenceauthor=J.+J.+O%E2%80%99Shea&title=Janus+Kinases+in+Immune+Cell+Signaling&doi=10.1111%2Fj.1600-065X.2008.00754.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinases in immune cell signaling</span></div><div class="casAuthors">Ghoreschi, Kamran; Laurence, Arian; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">273-287</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The Janus family kinases (Jaks), Jak1, Jak2, Jak3, and Tyk2, form one subgroup of the non-receptor protein tyrosine kinases.  They are involved in cell growth, survival, development, and differentiation of a variety of cells but are critically important for immune cells and hematopoietic cells.  Data from exptl. mice and clin. observations have unraveled multiple signaling events mediated by Jaks in innate and adaptive immunity.  Deficiency of Jak3 or Tyk2 results in defined clin. disorders, which are also evident in mouse models.  A striking phenotype assocd. with inactivating Jak3 mutations is severe combined immunodeficiency syndrome, whereas mutation of Tyk2 results in another primary immunodeficiency termed autosomal recessive hyperimmunoglobulin E syndrome.  By contrast, complete deletion of Jak1 or Jak2 in the mouse are not compatible with life and, unsurprisingly, do not have counterparts in human disease.  However, activating mutations of each of the Jaks are found in assocn. with malignant transformation, the most common being gain-of-function mutations of Jak2 in polycythemia vera and other myeloproliferative disorders.  Our existing knowledge on Jak signaling pathways and fundamental work on their biochem. structure and intracellular interactions allow us to develop new strategies for controlling autoimmune diseases or malignancies by developing selective Jak inhibitors, which are now coming into clin. use.  Despite the fact that Jaks were discovered only a little more than a decade ago, at the time of writing there are 20 clin. trials underway testing the safely and efficacy of Jak inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp23ncK0nYqpbVg90H21EOLACvtfcHk0lgrFLGvp9b3bw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ&md5=adc282a9ad381ee18abe57a82c921f65</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00754.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00754.x%26sid%3Dliteratum%253Aachs%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJanus%2520Kinases%2520in%2520Immune%2520Cell%2520Signaling%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D273%26epage%3D287%26doi%3D10.1111%2Fj.1600-065X.2008.00754.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murray, P. J.</span></span> <span> </span><span class="NLM_article-title">The JAK-STAT Signaling Pathway: Input and Output Integration</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">2623</span>â <span class="NLM_lpage">2629</span>, <span class="refDoi">Â DOI: 10.4049/jimmunol.178.5.2623</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.4049%2Fjimmunol.178.5.2623" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=17312100" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvFSju78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2007&pages=2623-2629&author=P.+J.+Murray&title=The+JAK-STAT+Signaling+Pathway%3A+Input+and+Output+Integration&doi=10.4049%2Fjimmunol.178.5.2623"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The JAK-STAT Signaling Pathway: Input and Output Integration</span></div><div class="casAuthors">Murray, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2623-2629</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">A review.  Universal and essential to cytokine receptor signaling, the JAK-STAT pathway is one of the best understood signal transduction cascades.  Almost 40 cytokine receptors signal through combinations of four JAK and seven STAT family members, suggesting commonality across the JAK-STAT signaling system.  Despite intense study, there remain substantial gaps in understanding how the cascades are activated and regulated.  Using the examples of the IL-6 and IL-10 receptors, the author discusses how diverse outcomes in gene expression result from regulatory events that effect the JAK1-STAT3 pathway, common to both receptors.  I also consider receptor preferences by different STATs and interpretive problems in the use of STAT-deficient cells and mice.  Finally, the author considers how the suppressor of cytokine signaling (SOCS) proteins regulate the quality and quantity of STAT signals from cytokine receptors.  New data suggests that SOCS proteins introduce addnl. diversity into the JAK-STAT pathway by adjusting the output of activated STATs that alters downstream gene activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcUsn_Apl_EbVg90H21EOLACvtfcHk0lgrFLGvp9b3bw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvFSju78%253D&md5=4f3eb8e58b729f4dab66ab7c1a2dcdab</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.178.5.2623&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.178.5.2623%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DP.%2BJ.%26atitle%3DThe%2520JAK-STAT%2520Signaling%2520Pathway%253A%2520Input%2520and%2520Output%2520Integration%26jtitle%3DJ.%2520Immunol.%26date%3D2007%26volume%3D178%26spage%3D2623%26epage%3D2629%26doi%3D10.4049%2Fjimmunol.178.5.2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, T.</span></span> <span> </span><span class="NLM_article-title">JAK-STAT Signaling: From Interferons to Cytokines</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>282</i></span>,  <span class="NLM_fpage">20059</span>â <span class="NLM_lpage">20063</span>, <span class="refDoi">Â DOI: 10.1074/jbc.R700016200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1074%2Fjbc.R700016200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=17502367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsFWntr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=20059-20063&author=C.+Schindlerauthor=D.+E.+Levyauthor=T.+Decker&title=JAK-STAT+Signaling%3A+From+Interferons+to+Cytokines&doi=10.1074%2Fjbc.R700016200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">JAK-STAT Signaling: From Interferons to Cytokines</span></div><div class="casAuthors">Schindler, Christian; Levy, David E.; Decker, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">20059-20063</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review.  The early availability of recombinant interferons (IFNs) afforded an opportunity to study how cytokines induce gene expression, culminating in the identification of JAK-STAT signaling paradigm.  Subsequent studies identified 7 STATs and 4 JAKs, providing an insight how IFNs and other members of the four-helix bundle cytokine family transduce their biol. responses.  Here, the authors briefly summarize this signaling paradigm and then focus on STAT-dependent transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx3j1nH6yBhbVg90H21EOLACvtfcHk0lgrFLGvp9b3bw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsFWntr8%253D&md5=9bbfc21b9afc22cd65dbd9a8605f7a03</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1074%2Fjbc.R700016200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.R700016200%26sid%3Dliteratum%253Aachs%26aulast%3DSchindler%26aufirst%3DC.%26aulast%3DLevy%26aufirst%3DD.%2BE.%26aulast%3DDecker%26aufirst%3DT.%26atitle%3DJAK-STAT%2520Signaling%253A%2520From%2520Interferons%2520to%2520Cytokines%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D20059%26epage%3D20063%26doi%3D10.1074%2Fjbc.R700016200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, K.</span></span> <span> </span><span class="NLM_article-title">FDA Approves Tofacitinib for Rheumatoid Arthritis</span>. <i>Am. J. Health Syst. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">2120</span>, <span class="refDoi">Â DOI: 10.2146/news120088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.2146%2Fnews120088" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=2120&author=K.+Traynor&title=FDA+Approves+Tofacitinib+for+Rheumatoid+Arthritis&doi=10.2146%2Fnews120088"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2146%2Fnews120088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2146%252Fnews120088%26sid%3Dliteratum%253Aachs%26aulast%3DTraynor%26aufirst%3DK.%26atitle%3DFDA%2520Approves%2520Tofacitinib%2520for%2520Rheumatoid%2520Arthritis%26jtitle%3DAm.%2520J.%2520Health%2520Syst.%2520Pharm.%26date%3D2012%26volume%3D69%26spage%3D2120%26doi%3D10.2146%2Fnews120088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenkopf, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brissette, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang-Poa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudlacz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lillie, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strelevitz, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanyam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whipple, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Changelian, P. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">8468</span>â <span class="NLM_lpage">8484</span>, <span class="refDoi">Â DOI: 10.1021/jm1004286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=C.+Shang-Poaauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hinesauthor=C.+Kentauthor=E.+M.+Kudlaczauthor=B.+M.+Lillieauthor=K.+S.+Magnusonauthor=S.+P.+McCurdyauthor=M.+J.+Munchhofauthor=B.+D.+Perryauthor=P.+S.+Sawyerauthor=T.+J.+Strelevitzauthor=C.+Subramanyamauthor=J.+Sunauthor=D.+A.+Whippleauthor=P.+S.+Changelian&title=Discovery+of+CP-690%2C550%3A+A+Potent+and+Selective+Janus+Kinase+%28JAK%29+Inhibitor+for+the+Treatment+of+Autoimmune+Diseases+and+Organ+Transplant+Rejection&doi=10.1021%2Fjm1004286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0lifcxfpvHX3wA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DKent%26aufirst%3DC.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520CP-690%252C550%253A%2520A%2520Potent%2520and%2520Selective%2520Janus%2520Kinase%2520%2528JAK%2529%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Autoimmune%2520Diseases%2520and%2520Organ%2520Transplant%2520Rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8468%26epage%3D8484%26doi%3D10.1021%2Fjm1004286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span> <i>FDA
Approves Jakafi (ruxolitinib)
to Treat Myelofibrosis</i>. . Nov 16, <span class="NLM_year">2011</span>. <a href="https://www.drugs.com/newdrugs/fda-approves-jakafi-myelofibrosis-2949.html" class="extLink">https://www.drugs.com/newdrugs/fda-approves-jakafi-myelofibrosis-2949.html</a> (accessed Nov 8, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+FDA%0AApproves+Jakafi+%28ruxolitinib%29%0Ato+Treat+Myelofibrosis.+.+Nov+16%2C+2011.+https%3A%2F%2Fwww.drugs.com%2Fnewdrugs%2Ffda-approves-jakafi-myelofibrosis-2949.html+%28accessed+Nov+8%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26jtitle%3DFDA%250AApproves%2520Jakafi%2520%2528ruxolitinib%2529%250Ato%2520Treat%2520Myelofibrosis%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campas-Moya, C.</span></span> <span> </span><span class="NLM_article-title">Ruxolitinib: Tyrosine-protein Kinase JAK1/2 Inhibitor: Treatment of Myelofibrosis: Treatment of Myeloproliferative Neoplasms: Treatment of Psoriasis</span>. <i>Drug Future</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">457</span>â <span class="NLM_lpage">465</span>, <span class="refDoi">Â DOI: 10.1358/dof.2010.035.06.1509764</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1358%2Fdof.2010.035.06.1509764" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=457-465&author=C.+Campas-Moya&title=Ruxolitinib%3A+Tyrosine-protein+Kinase+JAK1%2F2+Inhibitor%3A+Treatment+of+Myelofibrosis%3A+Treatment+of+Myeloproliferative+Neoplasms%3A+Treatment+of+Psoriasis&doi=10.1358%2Fdof.2010.035.06.1509764"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1358%2Fdof.2010.035.06.1509764&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2010.035.06.1509764%26sid%3Dliteratum%253Aachs%26aulast%3DCampas-Moya%26aufirst%3DC.%26atitle%3DRuxolitinib%253A%2520Tyrosine-protein%2520Kinase%2520JAK1%252F2%2520Inhibitor%253A%2520Treatment%2520of%2520Myelofibrosis%253A%2520Treatment%2520of%2520Myeloproliferative%2520Neoplasms%253A%2520Treatment%2520of%2520Psoriasis%26jtitle%3DDrug%2520Future%26date%3D2010%26volume%3D35%26spage%3D457%26epage%3D465%26doi%3D10.1358%2Fdof.2010.035.06.1509764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mogul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corsi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAuliffe, L.</span></span> <span> </span><span class="NLM_article-title">Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis</span>. <i>Ann. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">947</span>â <span class="NLM_lpage">953</span>, <span class="refDoi">Â DOI: 10.1177/1060028019839650</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1177%2F1060028019839650" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=30907116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVajsLjF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2019&pages=947-953&author=A.+Mogulauthor=K.+Corsiauthor=L.+McAuliffe&title=Baricitinib%3A+The+Second+FDA-Approved+JAK+Inhibitor+for+the+Treatment+of+Rheumatoid+Arthritis&doi=10.1177%2F1060028019839650"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis</span></div><div class="casAuthors">Mogul, Amanda; Corsi, Katherine; McAuliffe, Laura</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Pharmacotherapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">947-953</span>CODEN:
                <span class="NLM_cas:coden">APHRER</span>;
        ISSN:<span class="NLM_cas:issn">1542-6270</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Objective: To review the pharmacol., pharmacokinetics, safety, and efficacy of baricitinib, a recently approved selective Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA), and explore its potential role in therapy.  Data Sources: Articles were identified using a PubMed search from inception through Jan. 2019 using the terms rheumatoid arthritis, Olumiant, baricitinib, and LY3009104, its mol. name.  Study Selection and Data Extn.: Articles relating to randomized clin. trials, pharmacol., pharmacokinetics, efficacy, and safety of baricitinib were evaluated.  Data Synthesis: Baricitinib exerts its effects by inhibiting JAK1 and JAK2 enzymes, targeting cytokine and growth factor receptor stimulation, thus reducing downstream immune cell function.  Four trials have demonstrated the efficacy of baricitinib with or without methotrexate in patients naive to disease-modifying antirheumatic drugs (DMARDs) and those who had an inadequate response to or intolerance to both conventional and biol. DMARDs.  Furthermore, baricitinib was assocd. with delayed radiog. progression.  Despite baricitinib 4 mg often demonstrating greater efficacy compared with the 2 mg dose, only the 2 mg dose is Food and Drug Administration approved because of safety concerns with the 4 mg dose, primarily thromboembolism.  Relevance to Patient Care and Clin. Practice: Baricitinib provides an oral treatment option for patients failing tumor necrosis factor inhibitors (TNFis).  Safety, cost, and comparative effectiveness to tofacitinib should be considered prior to prescribing baricitinib.  Conclusion: Baricitinib is the second medication in its class and has been proven efficacious for the treatment of RA.  Given concerns for adverse effects assocd. with baricitinib, it should be reserved for patients who have failed one or more TNFis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0MPlLYo12drVg90H21EOLACvtfcHk0lhirdOl9z0H7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVajsLjF&md5=9f9a87369759bb6d5fd36356ebff3f27</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1177%2F1060028019839650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1060028019839650%26sid%3Dliteratum%253Aachs%26aulast%3DMogul%26aufirst%3DA.%26aulast%3DCorsi%26aufirst%3DK.%26aulast%3DMcAuliffe%26aufirst%3DL.%26atitle%3DBaricitinib%253A%2520The%2520Second%2520FDA-Approved%2520JAK%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Rheumatoid%2520Arthritis%26jtitle%3DAnn.%2520Pharmacother.%26date%3D2019%26volume%3D53%26spage%3D947%26epage%3D953%26doi%3D10.1177%2F1060028019839650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mayence, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eynde, J. J. V.</span></span> <span> </span><span class="NLM_article-title">Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases</span>. <i>Pharmaceuticals</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">37</span>, <span class="refDoi">Â DOI: 10.3390/ph12010037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.3390%2Fph12010037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFGlsrbJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=37&author=A.+Mayenceauthor=J.+J.+V.+Eynde&title=Baricitinib%3A+A+2018+Novel+FDA-Approved+Small+Molecule+Inhibiting+Janus+Kinases&doi=10.3390%2Fph12010037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Baricitinib: a 2018 novel FDA-approved small molecule inhibiting janus kinases</span></div><div class="casAuthors">Mayence, Annie; Vanden Eynde, Jean Jacques</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceuticals</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37</span>CODEN:
                <span class="NLM_cas:coden">PHARH2</span>;
        ISSN:<span class="NLM_cas:issn">1424-8247</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  In 2018, Baricitinib was approved by the Food and Drig Administration (FDA) for the treatment of rheumatoid arthritis.  Baricitinib exerts its action by targeting Janus kinases (JAK).  In this study, we describe the necessary steps for prepg. the drug using two alternative routes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW_aEEygkb07Vg90H21EOLACvtfcHk0lhirdOl9z0H7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFGlsrbJ&md5=879d0609660dccfd5a0c145bab708807</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.3390%2Fph12010037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fph12010037%26sid%3Dliteratum%253Aachs%26aulast%3DMayence%26aufirst%3DA.%26aulast%3DEynde%26aufirst%3DJ.%2BJ.%2BV.%26atitle%3DBaricitinib%253A%2520A%25202018%2520Novel%2520FDA-Approved%2520Small%2520Molecule%2520Inhibiting%2520Janus%2520Kinases%26jtitle%3DPharmaceuticals%26date%3D2019%26volume%3D12%26spage%3D37%26doi%3D10.3390%2Fph12010037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, C.</span></span> <i>FDA Approves Upadacitinib for Rheumatoid Arthritis</i>. <i>Rheumatology News</i>. Aug 16, <span class="NLM_year">2019</span>. <a href="https://www.mdedge.com/rheumatology/article/206593/rheumatoid-arthritis/fda-approves-upadacitinib-rheumatoid-arthritis" class="extLink">https://www.mdedge.com/rheumatology/article/206593/rheumatoid-arthritis/fda-approves-upadacitinib-rheumatoid-arthritis</a> (accessed Nov 8, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=C.+Palmer&title=FDA+Approves+Upadacitinib+for+Rheumatoid+Arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DPalmer%26aufirst%3DC.%26jtitle%3DFDA%2520Approves%2520Upadacitinib%2520for%2520Rheumatoid%2520Arthritis%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parmentier, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argiriadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padley, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosebraugh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, A. J.</span></span> <span> </span><span class="NLM_article-title">In Vitro and In Vivo Characterization of the JAK1 Selectivity of Upadacitinib (ABT-494)</span>. <i>BMC Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">23</span>, <span class="refDoi">Â DOI: 10.1186/s41927-018-0031-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1186%2Fs41927-018-0031-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=30886973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A280%3ADC%252BB3cbls1ymuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2018&pages=23&author=J.+M.+Parmentierauthor=J.+Vossauthor=C.+Graffauthor=A.+Schwartzauthor=M.+Argiriadiauthor=M.+Friedmanauthor=H.+S.+Campauthor=R.+J.+Padleyauthor=J.+S.+Georgeauthor=D.+Hylandauthor=M.+Rosebraughauthor=N.+Wishartauthor=L.+Olsonauthor=A.+J.+Long&title=In+Vitro+and+In+Vivo+Characterization+of+the+JAK1+Selectivity+of+Upadacitinib+%28ABT-494%29&doi=10.1186%2Fs41927-018-0031-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)</span></div><div class="casAuthors">Parmentier Julie M; Voss Jeff; Graff Candace; Schwartz Annette; Argiriadi Maria; Friedman Michael; George Jonathan S; Hyland Deborah; Wishart Neil; Olson Lisa; Long Andrew J; Camp Heidi S; Padley Robert J; Rosebraugh Matthew</div><div class="citationInfo"><span class="NLM_cas:title">BMC rheumatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Anti-cytokine therapies such as adalimumab, tocilizumab, and the small molecule JAK inhibitor tofacitinib have proven that cytokines and their subsequent downstream signaling processes are important in the pathogenesis of rheumatoid arthritis.  Tofacitinib, a pan-JAK inhibitor, is the first approved JAK inhibitor for the treatment of RA and has been shown to be effective in managing disease.  However, in phase 2 dose-ranging studies tofacitinib was associated with dose-limiting tolerability and safety issues such as anemia.  Upadacitinib (ABT-494) is a selective JAK1 inhibitor that was engineered to address the hypothesis that greater JAK1 selectivity over other JAK family members will translate into a more favorable benefit:risk profile.  Upadacitinib selectively targets JAK1 dependent disease drivers such as IL-6 and IFNÎ³, while reducing effects on reticulocytes and natural killer (NK) cells, which potentially contributed to the tolerability issues of tofacitinib.  Methods:  Structure-based hypotheses were used to design the JAK1 selective inhibitor upadacitinib.  JAK family selectivity was defined with in vitro assays including biochemical assessments, engineered cell lines, and cytokine stimulation.  In vivo selectivity was defined by the efficacy of upadacitinib and tofacitinib in a rat adjuvant induced arthritis model, activity on reticulocyte deployment, and effect on circulating NK cells.  The translation of the preclinical JAK1 selectivity was assessed in healthy volunteers using ex vivo stimulation with JAK-dependent cytokines.  Results:  Here, we show the structural basis for the JAK1 selectivity of upadacitinib, along with the in vitro JAK family selectivity profile and subsequent in vivo physiological consequences.  Upadacitinib is ~ 60 fold selective for JAK1 over JAK2, and > 100 fold selective over JAK3 in cellular assays.  While both upadacitinib and tofacitinib demonstrated efficacy in a rat model of arthritis, the increased selectivity of upadacitinib for JAK1 resulted in a reduced effect on reticulocyte deployment and NK cell depletion relative to efficacy.  Ex vivo pharmacodynamic data obtained from Phase I healthy volunteers confirmed the JAK1 selectivity of upadactinib in a clinical setting.  Conclusions:  The data presented here highlight the JAK1 selectivity of upadacinitinib and supports its use as an effective therapy for the treatment of RA with the potential for an improved benefit:risk profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTVFFxllNWaxfKb6ELK8t0fW6udTcc2eZKIkqSiQxf2Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbls1ymuw%253D%253D&md5=5ca2dcb18a98362567d2193e858cc800</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1186%2Fs41927-018-0031-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs41927-018-0031-x%26sid%3Dliteratum%253Aachs%26aulast%3DParmentier%26aufirst%3DJ.%2BM.%26aulast%3DVoss%26aufirst%3DJ.%26aulast%3DGraff%26aufirst%3DC.%26aulast%3DSchwartz%26aufirst%3DA.%26aulast%3DArgiriadi%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DM.%26aulast%3DCamp%26aufirst%3DH.%2BS.%26aulast%3DPadley%26aufirst%3DR.%2BJ.%26aulast%3DGeorge%26aufirst%3DJ.%2BS.%26aulast%3DHyland%26aufirst%3DD.%26aulast%3DRosebraugh%26aufirst%3DM.%26aulast%3DWishart%26aufirst%3DN.%26aulast%3DOlson%26aufirst%3DL.%26aulast%3DLong%26aufirst%3DA.%2BJ.%26atitle%3DIn%2520Vitro%2520and%2520In%2520Vivo%2520Characterization%2520of%2520the%2520JAK1%2520Selectivity%2520of%2520Upadacitinib%2520%2528ABT-494%2529%26jtitle%3DBMC%2520Rheumatol.%26date%3D2018%26volume%3D2%26spage%3D23%26doi%3D10.1186%2Fs41927-018-0031-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talpaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiladjian, J.-J.</span></span> <span> </span><span class="NLM_article-title">Fedratinib, a Newly Approved Treatment for Patients with Myeloproliferative Neoplasm-associated Myelofibrosis</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">17</span>, <span class="refDoi">Â DOI: 10.1038/s41375-020-0954-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1038%2Fs41375-020-0954-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=31776467" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&pages=1-17&author=M.+Talpazauthor=J.-J.+Kiladjian&title=Fedratinib%2C+a+Newly+Approved+Treatment+for+Patients+with+Myeloproliferative+Neoplasm-associated+Myelofibrosis&doi=10.1038%2Fs41375-020-0954-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fs41375-020-0954-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-020-0954-2%26sid%3Dliteratum%253Aachs%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DKiladjian%26aufirst%3DJ.-J.%26atitle%3DFedratinib%252C%2520a%2520Newly%2520Approved%2520Treatment%2520for%2520Patients%2520with%2520Myeloproliferative%2520Neoplasm-associated%2520Myelofibrosis%26jtitle%3DLeukemia%26date%3D2020%26spage%3D1%26epage%3D17%26doi%3D10.1038%2Fs41375-020-0954-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pardanani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasho, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noronha, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soll, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span> <span> </span><span class="NLM_article-title">TG101209, a Small Molecule JAK2-selective Kinase Inhibitor Potently Inhibits Myeloproliferative Disorder-associated <i>JAK</i>2V617F and <i>MPL</i>W515L/K Mutations</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1658</span>â <span class="NLM_lpage">1668</span>, <span class="refDoi">Â DOI: 10.1038/sj.leu.2404750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1038%2Fsj.leu.2404750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=17541402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnvVeltLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=1658-1668&author=A.+Pardananiauthor=J.+Hoodauthor=T.+Lashoauthor=R.+L.+Levineauthor=M.+B.+Martinauthor=G.+Noronhaauthor=C.+Finkeauthor=C.+C.+Makauthor=R.+Mesaauthor=H.+Zhuauthor=R.+Sollauthor=D.+G.+Gillilandauthor=A.+Tefferi&title=TG101209%2C+a+Small+Molecule+JAK2-selective+Kinase+Inhibitor+Potently+Inhibits+Myeloproliferative+Disorder-associated+JAK2V617F+and+MPLW515L%2FK+Mutations&doi=10.1038%2Fsj.leu.2404750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations</span></div><div class="casAuthors">Pardanani, A.; Hood, J.; Lasho, T.; Levine, R. L.; Martin, M. B.; Noronha, G.; Finke, C.; Mak, C. C.; Mesa, R.; Zhu, H.; Soll, R.; Gilliland, D. G.; Tefferi, A.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1658-1668</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">JAK2V617F and MPLW515L/K represent recently identified mutations in myeloproliferative disorders (MPD) that cause dysregulated JAK-STAT signaling, which is implicated in MPD pathogenesis.  The authors developed TG101209, an orally bioavailable small mol. that potently inhibits JAK2 (IC50 = 6 nM), FLT3 (IC50 = 25 nM) and RET (IC50 = 17 nM) kinases, with significantly less activity against other tyrosine kinases including JAK3 (IC50 = 169 nM).  TG101209 inhibited growth of Ba/F3 cells expressing JAK2V617F or MPLW515L mutations with an IC50 of â¼200 nM.  In a human JAK2V617F-expressing acute myeloid leukemia cell line, TG101209-induced cell cycle arrest and apoptosis, and inhibited phosphorylation of JAK2V617F, STAT5 and STAT3.  Therapeutic efficacy of TG101209 was demonstrated in a nude mouse model.  Furthermore, TG101209 suppressed growth of hematopoietic colonies from primary progenitor cells harboring JAK2V617F or MPL515 mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZFcz0joQsNbVg90H21EOLACvtfcHk0ljQrgroJcTpMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnvVeltLo%253D&md5=784ff4ff7d65097052d9d864c90e8138</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2404750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2404750%26sid%3Dliteratum%253Aachs%26aulast%3DPardanani%26aufirst%3DA.%26aulast%3DHood%26aufirst%3DJ.%26aulast%3DLasho%26aufirst%3DT.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DMartin%26aufirst%3DM.%2BB.%26aulast%3DNoronha%26aufirst%3DG.%26aulast%3DFinke%26aufirst%3DC.%26aulast%3DMak%26aufirst%3DC.%2BC.%26aulast%3DMesa%26aufirst%3DR.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DSoll%26aufirst%3DR.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DTG101209%252C%2520a%2520Small%2520Molecule%2520JAK2-selective%2520Kinase%2520Inhibitor%2520Potently%2520Inhibits%2520Myeloproliferative%2520Disorder-associated%2520JAK2V617F%2520and%2520MPLW515L%252FK%2520Mutations%26jtitle%3DLeukemia%26date%3D2007%26volume%3D21%26spage%3D1658%26epage%3D1668%26doi%3D10.1038%2Fsj.leu.2404750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piskin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sylva-Steenland, R. M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bos, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teunissen, M. B. M.</span></span> <span> </span><span class="NLM_article-title">In vitro and in situ Expression of IL-23 by Keratinocytes in Healthy Skin and Psoriasis lesions: Enhanced Expression in Psoriatic Skin</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">1908</span>â <span class="NLM_lpage">1915</span>, <span class="refDoi">Â DOI: 10.4049/jimmunol.176.3.1908</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.4049%2Fjimmunol.176.3.1908" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=16424222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BD28XlsFyktA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2006&pages=1908-1915&author=G.+Piskinauthor=R.+M.+R.+Sylva-Steenlandauthor=J.+D.+Bosauthor=M.+B.+M.+Teunissen&title=In+vitro+and+in+situ+Expression+of+IL-23+by+Keratinocytes+in+Healthy+Skin+and+Psoriasis+lesions%3A+Enhanced+Expression+in+Psoriatic+Skin&doi=10.4049%2Fjimmunol.176.3.1908"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro and In Situ Expression of IL-23 by Keratinocytes in Healthy Skin and Psoriasis Lesions: Enhanced Expression in Psoriatic Skin</span></div><div class="casAuthors">Piskin, Gamze; Sylva-Steenland, Regien M. R.; Bos, Jan D.; Teunissen, Marcel B. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1908-1915</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Keratinocytes contribute to cutaneous immune responses through the expression of cytokines.  The authors investigated whether human keratinocytes can express IL-23, a newly defined IFN-Î³-inducing cytokine composed of a unique p19 subunit and a p40 subunit shared with IL-12.  Cultured keratinocytes from normal and lesional psoriatic skin were found to express constitutively mRNA for both subunits of IL-23.  Low but significant levels of the heterodimeric IL-23 protein could be detected in cell lysates and supernatants from stimulated keratinocytes by immunoblotting and ELISA.  Functional anal. showed that these low levels of keratinocyte-derived IL-23 were sufficient to enhance the IFN-Î³ prodn. by memory T cells.  Immunostaining of skin sections confirmed expression of both subunits of IL-23 by keratinocytes in situ and also revealed expression of this cytokine in the dermal compartment.  IL-23 expression was significantly higher in psoriatic lesional skin, compared with normal and psoriatic nonlesional skin.  The immunostained prepns. of cultured cells and IL-23 levels in culture supernatants did not show any difference between normal and psoriatic keratinocytes indicating no intrinsic aberration of IL-23 expression in keratinocytes from psoriatic skin.  Double staining of cytospin prepns. demonstrated that IL-23 p19 is also expressed by epidermal Langerhans cells, dermal dendritic cells, and macrophages.  Psoriasis is a chronic inflammatory skin disease mediated by IFN-Î³-expressing type 1 memory T cells.  As IL-23 is important to activate memory T cells to produce IFN-Î³, its augmented expression of IL-23 by keratinocytes and cutaneous APC may contribute to the perpetuation of the inflammation process in this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEfsct9xM39rVg90H21EOLACvtfcHk0ljQrgroJcTpMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlsFyktA%253D%253D&md5=40142be77afa79fd8dc2f8a474502a2a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.176.3.1908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.176.3.1908%26sid%3Dliteratum%253Aachs%26aulast%3DPiskin%26aufirst%3DG.%26aulast%3DSylva-Steenland%26aufirst%3DR.%2BM.%2BR.%26aulast%3DBos%26aufirst%3DJ.%2BD.%26aulast%3DTeunissen%26aufirst%3DM.%2BB.%2BM.%26atitle%3DIn%2520vitro%2520and%2520in%2520situ%2520Expression%2520of%2520IL-23%2520by%2520Keratinocytes%2520in%2520Healthy%2520Skin%2520and%2520Psoriasis%2520lesions%253A%2520Enhanced%2520Expression%2520in%2520Psoriatic%2520Skin%26jtitle%3DJ.%2520Immunol.%26date%3D2006%26volume%3D176%26spage%3D1908%26epage%3D1915%26doi%3D10.4049%2Fjimmunol.176.3.1908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trepicchio, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oestreicher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhodapkar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, J. G.</span></span> <span> </span><span class="NLM_article-title">Increased Expression of Interleukin 23p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgris</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>199</i></span>,  <span class="NLM_fpage">125</span>â <span class="NLM_lpage">130</span>, <span class="refDoi">Â DOI: 10.1084/jem.20030451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1084%2Fjem.20030451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=14707118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvFWktw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=199&publication_year=2004&pages=125-130&author=E.+Leeauthor=W.+L.+Trepicchioauthor=J.+Oestreicherauthor=D.+Pittmanauthor=F.+Wangauthor=F.+Chamianauthor=M.+Dhodapkarauthor=J.+G.+Krueger&title=Increased+Expression+of+Interleukin+23p19+and+p40+in+Lesional+Skin+of+Patients+with+Psoriasis+Vulgris&doi=10.1084%2Fjem.20030451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris</span></div><div class="casAuthors">Lee, Edmund; Trepicchio, William L.; Oestreicher, Judith L.; Pittman, Debra; Wang, Frank; Chamian, Francesca; Dhodapkar, Madhav; Krueger, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">199</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">125-130</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Psoriasis is a type I-deviated disease characterized by the presence of interferon (IFN)-Î³ and multiple IFN-related inflammatory genes in lesions.  Because interleukin (IL)-23 is now recognized to play a role in the recruitment of inflammatory cells in a T helper cell (Th)1-mediated disease, we examd. psoriasis skin lesions for prodn. of this newly described cytokine.  IL-23 is composed of two subunits: a unique p19 subunit and a p40 subunit shared with IL-12.  We found a reliable increase in p19 mRNA by quant. reverse transcription polymerase chain reaction in lesional skin compared with nonlesional skin (22.3-fold increase; P = 0.001).  The p40 subunit, shared by IL-12 and IL-23, increased by 11.6-fold compared with nonlesional skin (P = 0.003), but the IL-12 p35 subunit was not increased in lesional skin.  IL-23 was expressed mainly by dermal cells and increased p40 immunoreactivity was visualized in large dermal cells in the lesions.  Cell isolation expts. from psoriatic tissue showed strong expression of p19 mRNA in cells expressing monocyte (CD14+ CD11c+ CD83-) and mature dendritic cell (DC) markers (CD14- CD11c+ CD83+), whereas in culture, the mRNAs for p40 and p19 were strongly up-regulated in stimulated monocytes and monocyte-derived DCs, persisting in the latter for much longer periods than IL-12.  Our data suggest that IL-23 is playing a more dominant role than IL-12 in psoriasis, a Th1 type of human inflammatory disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorJcxLmOKG_bVg90H21EOLACvtfcHk0liGIaXG-W2XtQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvFWktw%253D%253D&md5=b474156a73f56b9562f8074c00e4c711</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1084%2Fjem.20030451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20030451%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DE.%26aulast%3DTrepicchio%26aufirst%3DW.%2BL.%26aulast%3DOestreicher%26aufirst%3DJ.%26aulast%3DPittman%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DChamian%26aufirst%3DF.%26aulast%3DDhodapkar%26aufirst%3DM.%26aulast%3DKrueger%26aufirst%3DJ.%2BG.%26atitle%3DIncreased%2520Expression%2520of%2520Interleukin%252023p19%2520and%2520p40%2520in%2520Lesional%2520Skin%2520of%2520Patients%2520with%2520Psoriasis%2520Vulgris%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2004%26volume%3D199%26spage%3D125%26epage%3D130%26doi%3D10.1084%2Fjem.20030451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yawalkar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brand, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braathen, L. R.</span></span> <span> </span><span class="NLM_article-title">Expression of Interleukin-12 is Increased in Psoriatic Skin</span>. <i>J. Invest. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">1053</span>â <span class="NLM_lpage">1057</span>, <span class="refDoi">Â DOI: 10.1046/j.1523-1747.1998.00446.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1046%2Fj.1523-1747.1998.00446.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=9856816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADyaK1cXnvFyit78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=1998&pages=1053-1057&author=N.+Yawalkarauthor=S.+Karlenauthor=R.+Hungerauthor=C.+U.+Brandauthor=L.+R.+Braathen&title=Expression+of+Interleukin-12+is+Increased+in+Psoriatic+Skin&doi=10.1046%2Fj.1523-1747.1998.00446.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of interleukin-12 is increased in psoriatic skin</span></div><div class="casAuthors">Yawalkar, Nikhil; Karlen, Stephan; Hunger, Robert; Brand, Christoph U.; Braathen, Lasse R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Dermatology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1053-1057</span>CODEN:
                <span class="NLM_cas:coden">JIDEAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-202X</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science, Inc.</span>)
        </div><div class="casAbstract">Although the precise underlying pathomechanisms of psoriasis have not been fully elucidated, previous reports suggest that T helper 1-type cytokines are critically involved in the pathogenesis of this disease.  Interleukin-12 (IL-12), a heterodimeric cytokine, has been suggested to play a major role in the development of T helper 1 cell responses.  Here, the presence of IL-12 mRNA and protein was investigated in normal human skin as well as non-lesional and lesional psoriatic skin.  MRNA levels were detd. in biopsy specimens by a std. and a nested reverse transcriptase-polymerase chain reaction method.  Addnl., IL-12 protein expression was analyzed in situ by immunohistochem. using an antibody recognizing IL-12 p70.  Whereas specific transcripts for IL-12 p35 were reproducibly detected without any differences in all samples, enhanced IL-12 p40 mRNA signals were only found in lesional psoriatic skin as compared with normal and non-lesional psoriatic skin.  Furthermore, immunoreactivity for IL-12 p70 was markedly increased in the psoriatic skin lesions and was predominantly expressed on mononuclear cells in the dermis.  Thus, the authors' data suggest a crit. role for IL-12 in promoting and maintaining T cell activation and inducing T helper 1-type cytokines such as interferon-Î³ in psoriasis.  The authors speculate that IL-12 might be a key cytokine in the pathogenesis of psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAAbjfKV9NJ7Vg90H21EOLACvtfcHk0liGIaXG-W2XtQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnvFyit78%253D&md5=75640681f49caedafea2153151cf99f1</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1046%2Fj.1523-1747.1998.00446.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1523-1747.1998.00446.x%26sid%3Dliteratum%253Aachs%26aulast%3DYawalkar%26aufirst%3DN.%26aulast%3DKarlen%26aufirst%3DS.%26aulast%3DHunger%26aufirst%3DR.%26aulast%3DBrand%26aufirst%3DC.%2BU.%26aulast%3DBraathen%26aufirst%3DL.%2BR.%26atitle%3DExpression%2520of%2520Interleukin-12%2520is%2520Increased%2520in%2520Psoriatic%2520Skin%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D1998%26volume%3D111%26spage%3D1053%26epage%3D1057%26doi%3D10.1046%2Fj.1523-1747.1998.00446.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asahina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takekoshi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishimoto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komine, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamaki, K.</span></span> <span> </span><span class="NLM_article-title">Interleukin 12 Production by Monocytes from Patients with Psoriasis and its Inhibition by Ciclosporin A</span>. <i>Br. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">1180</span>â <span class="NLM_lpage">1183</span>, <span class="refDoi">Â DOI: 10.1111/j.1365-2133.2006.07180.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1111%2Fj.1365-2133.2006.07180.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=16704652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvVKkur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2006&pages=1180-1183&author=Y.+Tadaauthor=A.+Asahinaauthor=T.+Takekoshiauthor=E.+Kishimotoauthor=H.+Mitsuiauthor=H.+Saekiauthor=M.+Komineauthor=K.+Tamaki&title=Interleukin+12+Production+by+Monocytes+from+Patients+with+Psoriasis+and+its+Inhibition+by+Ciclosporin+A&doi=10.1111%2Fj.1365-2133.2006.07180.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Interleukin 12 production by monocytes from patients with psoriasis and its inhibition by ciclosporin A</span></div><div class="casAuthors">Tada, Y.; Asahina, A.; Takekoshi, T.; Kishimoto, E.; Mitsui, H.; Saeki, H.; Komine, M.; Tamaki, K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1180-1183</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Background: Psoriasis is a T-helper (Th)1 cytokine-mediated chronic skin disease and interleukin (IL)-12 has been shown to play a major role in the development of Th1 responses.  Objectives: To elucidate the role of IL-12 in the pathogenesis of psoriasis and to study the effect of ciclosporin A (CsA) on Th1 deviation of this disease.  Patients/Methods: We investigated IL-12 prodn. by stimulated monocytes from patients with psoriasis who were treated with or without CsA.  Monocytes were stimulated with interferon-Î³ plus lipopolysaccharide (LPS) or Staphylococcus aureus Cowan strain I (SAC).  The amt. of IL-12 p70 produced by stimulated monocytes was evaluated by ELISA.  Results: Compared with those from normal controls, LPS- but not SAC-stimulated monocytes from patients with psoriasis produced significantly higher amts. of IL-12.  Interestingly, LPS-stimulated monocytes from patients with psoriasis treated with CsA produced significantly decreased amts. of IL-12 compared with those patients not treated with CsA.  Conclusions: Our results suggest that IL-12 prodn. by monocytes may have a crit. role in the pathogenesis of psoriasis, and that the therapeutic effect of CsA on psoriasis may be achieved by correcting the deviation of the Th1/Th2 balance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo83AaDnVThWrVg90H21EOLACvtfcHk0lhlhUee-J7uXw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvVKkur8%253D&md5=9438f6f5abd41f6047f936a1f19c25f6</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2133.2006.07180.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2133.2006.07180.x%26sid%3Dliteratum%253Aachs%26aulast%3DTada%26aufirst%3DY.%26aulast%3DAsahina%26aufirst%3DA.%26aulast%3DTakekoshi%26aufirst%3DT.%26aulast%3DKishimoto%26aufirst%3DE.%26aulast%3DMitsui%26aufirst%3DH.%26aulast%3DSaeki%26aufirst%3DH.%26aulast%3DKomine%26aufirst%3DM.%26aulast%3DTamaki%26aufirst%3DK.%26atitle%3DInterleukin%252012%2520Production%2520by%2520Monocytes%2520from%2520Patients%2520with%2520Psoriasis%2520and%2520its%2520Inhibition%2520by%2520Ciclosporin%2520A%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2006%26volume%3D154%26spage%3D1180%26epage%3D1183%26doi%3D10.1111%2Fj.1365-2133.2006.07180.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piskin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tursen, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sylva-Steenland, R. M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bos, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teunissen, M. B. M.</span></span> <span> </span><span class="NLM_article-title">Clinical Improvement in Chronic Plaque-type Psoriasis Lesions after Narrow-band UVB Therapy is Accompanied by a Decrease in the Expression of IFN-Î³ Inducers - IL-12, IL-18 and IL-23</span>. <i>Exp. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">764</span>â <span class="NLM_lpage">772</span>, <span class="refDoi">Â DOI: 10.1111/j.0906-6705.2004.00246.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1111%2Fj.0906-6705.2004.00246.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=15560760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjt1yqug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2004&pages=764-772&author=G.+Piskinauthor=U.+Tursenauthor=R.+M.+R.+Sylva-Steenlandauthor=J.+D.+Bosauthor=M.+B.+M.+Teunissen&title=Clinical+Improvement+in+Chronic+Plaque-type+Psoriasis+Lesions+after+Narrow-band+UVB+Therapy+is+Accompanied+by+a+Decrease+in+the+Expression+of+IFN-%CE%B3+Inducers+-+IL-12%2C+IL-18+and+IL-23&doi=10.1111%2Fj.0906-6705.2004.00246.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical improvement in chronic plaque-type psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN-Î³ inducers - IL-12, IL-18 and IL-23</span></div><div class="casAuthors">Piskin, G.; Tursen, U.; Sylva-Steenland, R. M. R.; Bos, J. D.; Tennissen, M. B. M.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Dermatology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">764-772</span>CODEN:
                <span class="NLM_cas:coden">EXDEEY</span>;
        ISSN:<span class="NLM_cas:issn">0906-6705</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Type-1 cytokine-producing T cells are important in the pathogenesis of psoriasis vulgaris, for which efficient therapy is provided by means of narrow-band UV-B (NB-UVB).  The expression of the type-1 cytokine interferon-Î³ (IFN-Î³) is regulated by interleukin-12 (IL-12), IL-15, IL-18 and IL-23; however, not much is known about the effect of this therapy on the levels of these cytokines in lesional psoriatic skin in situ.  In this study, we investigated the effects of NB-UVB therapy on the expression of IFN-Î³-inducing cytokines.  Ten patients with chronic plaque-type psoriasis selected to be treated with NB-UVB therapy were recruited for these expts. and the expression of cytokines IL-12, IL-15, IL-18, IL-23 and IFN-Î³ in lesional psoriatic skin before, during and after therapy was detd. with the help of immunohistochem.  Double staining was performed in order to det. the cell types expressing these cytokines.  The decrease in the psoriasis area and severity index was accompanied by a significant decrease in the expression of IFN-Î³, and concomitantly, significant redn. of IFN-Î³-inducers IL-12, IL-18 and IL-23.  Thus, we concluded that the decrease of IFN-Î³ expression in psoriasis lesions after NB-UVB therapy could be a result of diminished expression of IL-12, IL-18 and IL-23 in lesional skin.  Therapies targeting these three cytokines should, therefore, be considered in the treatment of psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaPDkoT64eYLVg90H21EOLACvtfcHk0lhlhUee-J7uXw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjt1yqug%253D%253D&md5=4986e2e8d38599e548dde1732564ac09</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1111%2Fj.0906-6705.2004.00246.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.0906-6705.2004.00246.x%26sid%3Dliteratum%253Aachs%26aulast%3DPiskin%26aufirst%3DG.%26aulast%3DTursen%26aufirst%3DU.%26aulast%3DSylva-Steenland%26aufirst%3DR.%2BM.%2BR.%26aulast%3DBos%26aufirst%3DJ.%2BD.%26aulast%3DTeunissen%26aufirst%3DM.%2BB.%2BM.%26atitle%3DClinical%2520Improvement%2520in%2520Chronic%2520Plaque-type%2520Psoriasis%2520Lesions%2520after%2520Narrow-band%2520UVB%2520Therapy%2520is%2520Accompanied%2520by%2520a%2520Decrease%2520in%2520the%2520Expression%2520of%2520IFN-%25CE%25B3%2520Inducers%2520-%2520IL-12%252C%2520IL-18%2520and%2520IL-23%26jtitle%3DExp.%2520Dermatol.%26date%3D2004%26volume%3D13%26spage%3D764%26epage%3D772%26doi%3D10.1111%2Fj.0906-6705.2004.00246.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przepiera-BÄdzak, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawicki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walecka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brzosko, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brzosko, M.</span></span> <span> </span><span class="NLM_article-title">Serum Interleukin-23 in Polish Patients with Systemic Lupus Erythematosus: Association with Lupus Nephritis, Obesity, and Peripheral Vascular Disease</span>. <i>Mediators Inflammation</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_fpage">9401432</span>, <span class="refDoi">Â DOI: 10.1155/2017/9401432</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1155%2F2017%2F9401432" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=29430084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjsVOitbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=9401432&author=K.+Fischerauthor=H.+Przepiera-B%C4%99dzakauthor=M.+Sawickiauthor=A.+Waleckaauthor=I.+Brzoskoauthor=M.+Brzosko&title=Serum+Interleukin-23+in+Polish+Patients+with+Systemic+Lupus+Erythematosus%3A+Association+with+Lupus+Nephritis%2C+Obesity%2C+and+Peripheral+Vascular+Disease&doi=10.1155%2F2017%2F9401432"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Serum interleukin-23 in polish patients with systemic lupus erythematosus: association with lupus nephritis, obesity, and peripheral vascular disease</span></div><div class="casAuthors">Fischer, Katarzyna; Przepiera-Bedzak, Hanna; Sawicki, Marcin; Walecka, Anna; Brzosko, Iwona; Brzosko, Marek</div><div class="citationInfo"><span class="NLM_cas:title">Mediators of Inflammation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9401432/1-9401432/9</span>CODEN:
                <span class="NLM_cas:coden">MNFLEF</span>;
        ISSN:<span class="NLM_cas:issn">0962-9351</span>.
    
            (<span class="NLM_cas:orgname">Hindawi Publishing Corp.</span>)
        </div><div class="casAbstract">To analyze the correlation between the serum concn. of interleukin-(IL-) 23 and atherosclerotic changes, traditional atherosclerotic risk factors, the autoantibody profile, and involvement of selected organs in systemic lupus erythematosus (SLE) patients.  Patients and Methods.  We studied 94 SLE patients and 27 controls.  We analyzed the IL-23 serum concn., autoantibodies, carotid intima-media thickness and atherosclerotic plaque, the ankle-brachial index, atherosclerotic risk factors, and organ manifestations.  Concns. of IL-23 significantly differed between SLE patients and the controls (p = 0.0015).  On the basis of multivariate stepwise anal., we revealed that high levels of IL-23 were assocd. with atherosclerotic plaque in common femoral arteries (OR = 12.67; 95% CI: 1.41-113.84), lupus nephritis (OR = 3.69; 95% CI: 1.16-12.22), and obesity (OR = 4.21; 95% CI: 1.40-12.67).  Autoantibodies related to IL-23 were anti-phosphatidylethanolamine antibodies (OR = 11.06; 95% CI: 1.24-98.65) and anti-SS-B/La antibodies (OR = 15.43; 95% CI: 1.73-137.25).  IL-23 may be involved in lupus nephritis pathogenesis.  Through its assocn. with obesity and selected antiphospholipid antibodies, IL-23 might promote a hypercoagulable state contributing to atherothrombosis development in SLE patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsfvxe1P-17LVg90H21EOLACvtfcHk0lhaRDUyyswxZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjsVOitbk%253D&md5=6c3fb3ea15fdc8b0961b28290be39b35</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1155%2F2017%2F9401432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2017%252F9401432%26sid%3Dliteratum%253Aachs%26aulast%3DFischer%26aufirst%3DK.%26aulast%3DPrzepiera-B%25C4%2599dzak%26aufirst%3DH.%26aulast%3DSawicki%26aufirst%3DM.%26aulast%3DWalecka%26aufirst%3DA.%26aulast%3DBrzosko%26aufirst%3DI.%26aulast%3DBrzosko%26aufirst%3DM.%26atitle%3DSerum%2520Interleukin-23%2520in%2520Polish%2520Patients%2520with%2520Systemic%2520Lupus%2520Erythematosus%253A%2520Association%2520with%2520Lupus%2520Nephritis%252C%2520Obesity%252C%2520and%2520Peripheral%2520Vascular%2520Disease%26jtitle%3DMediators%2520Inflammation%26date%3D2017%26spage%3D9401432%26doi%3D10.1155%2F2017%2F9401432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niewold, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salloum, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poole, B. D.</span></span> <span> </span><span class="NLM_article-title">Interferon Alpha in Systemic Lupus Erythematosus</span>. <i>J. Biomed. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_fpage">948364</span>, <span class="refDoi">Â DOI: 10.1155/2010/948364</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1155%2F2010%2F948364" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=20652065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A280%3ADC%252BC3cnpsVyitA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&pages=948364&author=T.+B.+Niewoldauthor=D.+N.+Clarkauthor=R.+Salloumauthor=B.+D.+Poole&title=Interferon+Alpha+in+Systemic+Lupus+Erythematosus&doi=10.1155%2F2010%2F948364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Interferon alpha in systemic lupus erythematosus</span></div><div class="casAuthors">Niewold Timothy B; Clark Daniel N; Salloum Rafah; Poole Brian D</div><div class="citationInfo"><span class="NLM_cas:title">Journal of biomedicine & biotechnology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2010</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">948364</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The pleiotropic cytokine interferon alpha is involved in multiple aspects of lupus etiology and pathogenesis.  Interferon alpha is important under normal circumstances for antiviral responses and immune activation.  However, heightened levels of serum interferon alpha and expression of interferon response genes are common in lupus patients.  Lupus-associated autoantibodies can drive the production of interferon alpha and heightened levels of interferon interfere with immune regulation.  Several genes in the pathways leading to interferon production or signaling are associated with risk for lupus.  Clinical and cellular manifestations of excess interferon alpha in lupus combined with the genetic risk factors associated with interferon make this cytokine a rare bridge between genetic risk and phenotypic effects.  Interferon alpha influences the clinical picture of lupus and may represent a therapeutic target.  This paper provides an overview of the cellular, genetic, and clinical aspects of interferon alpha in lupus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSaY99d7aSGBINpW7w2tapOfW6udTcc2eYbZQknx9UH0rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cnpsVyitA%253D%253D&md5=2d0709a0539150a9b8d666107a4bca20</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1155%2F2010%2F948364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2010%252F948364%26sid%3Dliteratum%253Aachs%26aulast%3DNiewold%26aufirst%3DT.%2BB.%26aulast%3DClark%26aufirst%3DD.%2BN.%26aulast%3DSalloum%26aufirst%3DR.%26aulast%3DPoole%26aufirst%3DB.%2BD.%26atitle%3DInterferon%2520Alpha%2520in%2520Systemic%2520Lupus%2520Erythematosus%26jtitle%3DJ.%2520Biomed.%2520Biotechnol.%26date%3D2010%26spage%3D948364%26doi%3D10.1155%2F2010%2F948364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tucci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dammacco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvestris, F.</span></span> <span> </span><span class="NLM_article-title">Overexpression of Interleukin-12 and T Helper 1 Predominance in Lupus Nephritis</span>. <i>Clin. Exp. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">247</span>â <span class="NLM_lpage">254</span>, <span class="refDoi">Â DOI: 10.1111/j.1365-2249.2008.03758.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1111%2Fj.1365-2249.2008.03758.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=18795942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVSiur7N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2008&pages=247-254&author=M.+Tucciauthor=L.+Lombardiauthor=H.+B.+Richardsauthor=F.+Dammaccoauthor=F.+Silvestris&title=Overexpression+of+Interleukin-12+and+T+Helper+1+Predominance+in+Lupus+Nephritis&doi=10.1111%2Fj.1365-2249.2008.03758.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis</span></div><div class="casAuthors">Tucci, M.; Lombardi, L.; Richards, H. B.; Dammacco, F.; Silvestris, F.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">247-254</span>CODEN:
                <span class="NLM_cas:coden">CEXIAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-9104</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Imbalance of cytokine homeostasis is a prominent feature of both exptl. and human systemic lupus erythematosus (SLE).  Because interleukin (IL)-12 promotes interferon (IFN)-Î³ prodn. leading to polarization of peripheral cells toward a T helper (Th) 1 phenotype, we investigated its role in lupus nephritis (LN).  Sol. Th1 and Th2 cytokines were measured by ELISA in sera and urines of SLE patients and controls.  Th1/Th2 peripheral lymphocyte polarization was detd. by flow cytometry.  Glomerular accumulation of IL-12 was evaluated by immunohistochem., whereas urinary IL-12 was evaluated by ELISA.  Higher serum IL-12 levels in SLE were assocd. with LN, whereas IL-4 was unrelated to the renal damage.  Peripheral cells from LN patients showed a Th1 phenotype with a high IFN-Î³ expression that paralleled the severity of renal damage.  IL-12 was present within glomerular mononuclear cells in classes IV and V LN, and its accumulation was correlated strongly with urinary levels.  IL-12 overexpression in SLE may contribute to the development of LN.  Both serum and urinary IL-12 elevation reflect its glomerular prodn. and parallel Th1 polarization of peripheral T cells and high IFN-Î³ prodn.  In SLE patients, IL-12 measurement may thus be predictive of the development of LN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrirh1cpY_8dLVg90H21EOLACvtfcHk0li0sxI-LkIIGg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVSiur7N&md5=4a7f9fe503be792275d4b4f3ee3b1330</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2249.2008.03758.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2249.2008.03758.x%26sid%3Dliteratum%253Aachs%26aulast%3DTucci%26aufirst%3DM.%26aulast%3DLombardi%26aufirst%3DL.%26aulast%3DRichards%26aufirst%3DH.%2BB.%26aulast%3DDammacco%26aufirst%3DF.%26aulast%3DSilvestris%26aufirst%3DF.%26atitle%3DOverexpression%2520of%2520Interleukin-12%2520and%2520T%2520Helper%25201%2520Predominance%2520in%2520Lupus%2520Nephritis%26jtitle%3DClin.%2520Exp.%2520Immunol.%26date%3D2008%26volume%3D154%26spage%3D247%26epage%3D254%26doi%3D10.1111%2Fj.1365-2249.2008.03758.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moschen, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raine, T.</span></span> <span> </span><span class="NLM_article-title">IL-12, IL-23 and IL-17 in IBD: Immunobiology and Therapeutic Targeting</span>. <i>Nat. Rev. Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">185</span>â <span class="NLM_lpage">196</span>, <span class="refDoi">Â DOI: 10.1038/s41575-018-0084-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1038%2Fs41575-018-0084-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=30478416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlWnu7%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2019&pages=185-196&author=A.+R.+Moschenauthor=H.+Tilgauthor=T.+Raine&title=IL-12%2C+IL-23+and+IL-17+in+IBD%3A+Immunobiology+and+Therapeutic+Targeting&doi=10.1038%2Fs41575-018-0084-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting</span></div><div class="casAuthors">Moschen, Alexander R.; Tilg, Herbert; Raine, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Gastroenterology & Hepatology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">185-196</span>CODEN:
                <span class="NLM_cas:coden">NRGHA9</span>;
        ISSN:<span class="NLM_cas:issn">1759-5045</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  IL-12 and IL-23 are closely related cytokines with important roles in the regulation of tissue inflammation.  Converging evidence from studies in mice, human observational studies and population genetics supports the importance of these cytokines in the regulation of mucosal inflammation in the gut in particular.  Ustekinumab, a therapeutic antibody targeting both cytokines is now widely licensed for the treatment of Crohn's disease, including in Europe, the USA, Canada and Japan, while agents targeting IL-23 specifically are in late-phase clin. trials.  We review the emerging understanding of the biol. of IL-12 and IL-23, as well as that of their major downstream cytokines, including IL-17.  In particular, we discuss how their biol. has influenced the development of clin. trials and therapeutic strategies in IBD, as well as how findings from clin. trials, at times surprising, have in turn refocused our understanding of the underlying biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOpNxAUthv_rVg90H21EOLACvtfcHk0li0sxI-LkIIGg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlWnu7%252FE&md5=b1f23bb392012256b005f303341d8cc1</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fs41575-018-0084-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41575-018-0084-8%26sid%3Dliteratum%253Aachs%26aulast%3DMoschen%26aufirst%3DA.%2BR.%26aulast%3DTilg%26aufirst%3DH.%26aulast%3DRaine%26aufirst%3DT.%26atitle%3DIL-12%252C%2520IL-23%2520and%2520IL-17%2520in%2520IBD%253A%2520Immunobiology%2520and%2520Therapeutic%2520Targeting%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2019%26volume%3D16%26spage%3D185%26epage%3D196%26doi%3D10.1038%2Fs41575-018-0084-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andreou, N.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legaki, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazouli, M.</span></span> <span> </span><span class="NLM_article-title">Inflammatory Bowel Disease Pathobiology: the Role of the Interferon Signature</span>. <i>Ann. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">9</span>, <span class="refDoi">Â DOI: 10.20524/aog.2020.0457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.20524%2Faog.2020.0457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=31892791" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2020&pages=1-9&author=N.-P.+Andreouauthor=E.+Legakiauthor=M.+Gazouli&title=Inflammatory+Bowel+Disease+Pathobiology%3A+the+Role+of+the+Interferon+Signature&doi=10.20524%2Faog.2020.0457"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.20524%2Faog.2020.0457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.20524%252Faog.2020.0457%26sid%3Dliteratum%253Aachs%26aulast%3DAndreou%26aufirst%3DN.-P.%26aulast%3DLegaki%26aufirst%3DE.%26aulast%3DGazouli%26aufirst%3DM.%26atitle%3DInflammatory%2520Bowel%2520Disease%2520Pathobiology%253A%2520the%2520Role%2520of%2520the%2520Interferon%2520Signature%26jtitle%3DAnn.%2520Gastroenterol.%26date%3D2020%26volume%3D33%26spage%3D1%26epage%3D9%26doi%3D10.20524%2Faog.2020.0457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span> <i>FDA Approves Stelara
(ustekinumab) to Treat Psoriasis</i>. . Sept 25, <span class="NLM_year">2009</span>. <a href="https://www.drugs.com/newdrugs/fda-approves-stelara-ustekinumab-psoriasis-1667.html" class="extLink">https://www.drugs.com/newdrugs/fda-approves-stelara-ustekinumab-psoriasis-1667.html</a> (accessed Nov 8, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+FDA+Approves+Stelara%0A%28ustekinumab%29+to+Treat+Psoriasis.+.+Sept+25%2C+2009.+https%3A%2F%2Fwww.drugs.com%2Fnewdrugs%2Ffda-approves-stelara-ustekinumab-psoriasis-1667.html+%28accessed+Nov+8%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26jtitle%3DFDA%2520Approves%2520Stelara%250A%2528ustekinumab%2529%2520to%2520Treat%2520Psoriasis%26date%3D2009%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span> <i>FDA Approves Stelara
(ustekinumab) for the Treatment of Adults with Moderately to Severely
Active Crohnâs Diseases</i>. . Sept 26, <span class="NLM_year">2016</span>. <a href="https://www.drugs.com/newdrugs/fda-approves-stelara-ustekinumab-adults-moderately-severely-active-crohn-s-4436.html" class="extLink">https://www.drugs.com/newdrugs/fda-approves-stelara-ustekinumab-adults-moderately-severely-active-crohn-s-4436.html</a> (accessed Nov 8, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+FDA+Approves+Stelara%0A%28ustekinumab%29+for+the+Treatment+of+Adults+with+Moderately+to+Severely%0AActive+Crohn%E2%80%99s+Diseases.+.+Sept+26%2C+2016.+https%3A%2F%2Fwww.drugs.com%2Fnewdrugs%2Ffda-approves-stelara-ustekinumab-adults-moderately-severely-active-crohn-s-4436.html+%28accessed+Nov+8%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26jtitle%3DFDA%2520Approves%2520Stelara%250A%2528ustekinumab%2529%2520for%2520the%2520Treatment%2520of%2520Adults%2520with%2520Moderately%2520to%2520Severely%250AActive%2520Crohn%25E2%2580%2599s%2520Diseases%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boxler, D.</span></span> <i>Ustekinumab Gains FDA Approval as Ulcerative Colitis Treatment</i>. Drug Topics. Oct 23, <span class="NLM_year">2019</span>. <a href="https://www.drugtopics.com/view/ustekinumab-gains-fda-approval-ulcerative-colitis-treatment" class="extLink">https://www.drugtopics.com/view/ustekinumab-gains-fda-approval-ulcerative-colitis-treatment</a> (accessed Nov 8, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=D.+Boxler&title=Ustekinumab+Gains+FDA+Approval+as+Ulcerative+Colitis+Treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DBoxler%26aufirst%3DD.%26jtitle%3DUstekinumab%2520Gains%2520FDA%2520Approval%2520as%2520Ulcerative%2520Colitis%2520Treatment%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morand, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furie, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Askanase, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brohawn, P. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pineda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berglind, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummala, R.</span></span> <span> </span><span class="NLM_article-title">Trial of Anifrolumab in Active Systemic Lupus Erythematosus</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>382</i></span>,  <span class="NLM_fpage">211</span>â <span class="NLM_lpage">221</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1912196</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1056%2FNEJMoa1912196" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=31851795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1WjurY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2020&pages=211-221&author=E.+F.+Morandauthor=R.+Furieauthor=Y.+Tanakaauthor=I.+N.+Bruceauthor=A.+D.+Askanaseauthor=C.+Richezauthor=S.+C.+Baeauthor=P.+Z.+Brohawnauthor=L.+Pinedaauthor=A.+Berglindauthor=R.+Tummala&title=Trial+of+Anifrolumab+in+Active+Systemic+Lupus+Erythematosus&doi=10.1056%2FNEJMoa1912196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Trial of anifrolumab in active systemic lupus erythematosus</span></div><div class="casAuthors">Morand, E. F.; Furie, R.; Tanaka, Y.; Bruce, I. N.; Askanase, A. D.; Richez, C.; Bae, S.-C.; Brohawn, P. Z.; Pineda, L.; Berglind, A.; Tummala, R.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">211-221</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Anifrolumab, a human monoclonal antibody to type I interferon receptor subunit 1 investigated for the treatment of systemic lupus erythematosus (SLE), did not have a significant effect on the primary end point in a previous phase 3 trial.  The current phase 3 trial used a secondary end point from that trial as the primary end point. methods We randomly assigned patients in a 1:1 ratio to receive i.v. anifrolumab (300 mg) or placebo every 4 wk for 48 wk.  The primary end point of this trial was a response at week 52 defined with the use of the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA).  A BICLA response requires redn. in any moderate-to-severe baseline disease activity and no worsening in any of nine organ systems in the BILAG index, no worsening on the Systemic Lupus Erythematosus Disease Activity Index, no increase of 0.3 points or more in the score on the Physician Global Assessment of disease activity (on a scale from 0 [no disease activity] to 3 [severe disease]), no discontinuation of the trial intervention, and no use of medications restricted by the protocol.  Secondary end points included a BICLA response in patients with a high interferon gene signature at baseline; redns. in the glucocorticoid dose, in the severity of skin disease, and in counts of swollen and tender joints; and the annualized flare rate. results A total of 362 patients received the randomized intervention: 180 received anifrolumab and 182 received placebo.  The percentage of patients who had a BICLA response was 47.8% in the anifrolumab group and 31.5% in the placebo group (difference, 16.3 percentage points; 95% confidence interval, 6.3 to 26.3; P = 0.001).  Among patients with a high interferon gene signature, the percentage with a response was 48.0% in the anifrolumab group and 30.7% in the placebo group; among patients with a low interferon gene signature, the percentage was 46.7% and 35.5%, resp.  Secondary end points with respect to the glucocorticoid dose and the severity of skin disease, but not counts of swollen and tender joints and the annualized flare rate, also showed a significant benefit with anifrolumab.  Herpes zoster and bronchitis occurred in 7.2% and 12.2% of the patients, resp., who received anifrolumab.  There was one death from pneumonia in the anifrolumab group. conclusions Monthly administration of anifrolumab resulted in a higher percentage of patients with a response (as defined by a composite end point) at week 52 than did placebo, in contrast to the findings of a similar phase 3 trial involving patients with SLE that had a different primary end point.  The frequency of herpes zoster was higher with anifrolumab than with placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHmbZKnapYbLVg90H21EOLACvtfcHk0lgSMyWKogE6wg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1WjurY%253D&md5=a2c3436c34d4da2a93687426c442a1fa</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1912196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1912196%26sid%3Dliteratum%253Aachs%26aulast%3DMorand%26aufirst%3DE.%2BF.%26aulast%3DFurie%26aufirst%3DR.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DBruce%26aufirst%3DI.%2BN.%26aulast%3DAskanase%26aufirst%3DA.%2BD.%26aulast%3DRichez%26aufirst%3DC.%26aulast%3DBae%26aufirst%3DS.%2BC.%26aulast%3DBrohawn%26aufirst%3DP.%2BZ.%26aulast%3DPineda%26aufirst%3DL.%26aulast%3DBerglind%26aufirst%3DA.%26aulast%3DTummala%26aufirst%3DR.%26atitle%3DTrial%2520of%2520Anifrolumab%2520in%2520Active%2520Systemic%2520Lupus%2520Erythematosus%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D382%26spage%3D211%26epage%3D221%26doi%3D10.1056%2FNEJMoa1912196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ortmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeltz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shevach, E. M.</span></span> <span> </span><span class="NLM_article-title">A Heritable Defect in IL-12 Signaling in B10.Q/J Mice. I. <i>In vitro</i> Analysis</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>166</i></span>,  <span class="NLM_fpage">5712</span>â <span class="NLM_lpage">5719</span>, <span class="refDoi">Â DOI: 10.4049/jimmunol.166.9.5712</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.4049%2Fjimmunol.166.9.5712" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=11313413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjtFyqsr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2001&pages=5712-5719&author=R.+Ortmannauthor=R.+Smeltzauthor=G.+Yapauthor=A.+Sherauthor=E.+M.+Shevach&title=A+Heritable+Defect+in+IL-12+Signaling+in+B10.Q%2FJ+Mice.+I.+In+vitro+Analysis&doi=10.4049%2Fjimmunol.166.9.5712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A heritable defect in IL-12 signaling in B10.Q/J mice. I. In vitro analysis</span></div><div class="casAuthors">Ortmann, Robert; Smeltz, Ronald; Yap, George; Sher, Alan; Shevach, Ethan M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5712-5719</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">B10.Q mice are normally susceptible to the induction of collagen-induced arthritis.  The authors noted that one subline of B10.Q mice, B10.Q/J, was completely resistant to disease induction when immunized with collagen in CFA.  B10.Q/J mice have a global defect in the generation of Th1 responses, and antigen-specific T cells derived from this strain failed to produce IFN-Î³.  Because T cells from these mice could produce normal amts. of IFN-Î³ when activated by IL-12/IL-18-independent stimuli, the defect appeared to be a failure to respond to IL-12.  This defect extended to NK cells, which also failed to produce IFN-Î³ when stimulated by IL-12.  The capacity of NK cells, but not activated T cells, to produce IFN-Î³ in response to IL-12 could be partially restored by IL-18.  The expression of the IL-12R Î²1- and Î²2-chains on T cells and NK cells from B10.Q/J mice was normal.  However, activated T cells from B10.Q/J mice did not signal normally through the IL-12R and manifested a defect in their capacity to phosphorylate Stat4.  This defect was partial in that it could be overcome by increasing both the concn. of IL-12 and the incubation times in the Stat4 phosphorylation assays.  Because Stat4 function is apparently intact in B10.Q/J mice, the defect in IL-12 signaling can be localized between the IL-12R complex and Stat4.  This subtle abnormality in IL-12 responsiveness results in a profound defect in the generation of Th1 cells and the development of autoimmune disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnzWn-o1wME7Vg90H21EOLACvtfcHk0lgSMyWKogE6wg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjtFyqsr4%253D&md5=bf724d444e9db709a3a40fc251b73d40</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.166.9.5712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.166.9.5712%26sid%3Dliteratum%253Aachs%26aulast%3DOrtmann%26aufirst%3DR.%26aulast%3DSmeltz%26aufirst%3DR.%26aulast%3DYap%26aufirst%3DG.%26aulast%3DSher%26aufirst%3DA.%26aulast%3DShevach%26aufirst%3DE.%2BM.%26atitle%3DA%2520Heritable%2520Defect%2520in%2520IL-12%2520Signaling%2520in%2520B10.Q%252FJ%2520Mice.%2520I.%2520In%2520vitro%2520Analysis%26jtitle%3DJ.%2520Immunol.%26date%3D2001%26volume%3D166%26spage%3D5712%26epage%3D5719%26doi%3D10.4049%2Fjimmunol.166.9.5712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oyamada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikebe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itsumi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiwai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimoda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwakura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshikai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, H.</span></span> <span> </span><span class="NLM_article-title">Tyrosine Kinase 2 Plays Critical Roles in the Pathogenic CD4 T Cell Responses for the Development of Experimental Autoimmune Encephalomyelitis</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>183</i></span>,  <span class="NLM_fpage">7539</span>â <span class="NLM_lpage">7546</span>, <span class="refDoi">Â DOI: 10.4049/jimmunol.0902740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.4049%2Fjimmunol.0902740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=19917699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVehtrrE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2009&pages=7539-7546&author=A.+Oyamadaauthor=H.+Ikebeauthor=M.+Itsumiauthor=H.+Saiwaiauthor=S.+Okadaauthor=K.+Shimodaauthor=Y.+Iwakuraauthor=K.+I.+Nakayamaauthor=Y.+Iwamotoauthor=Y.+Yoshikaiauthor=H.+Yamada&title=Tyrosine+Kinase+2+Plays+Critical+Roles+in+the+Pathogenic+CD4+T+Cell+Responses+for+the+Development+of+Experimental+Autoimmune+Encephalomyelitis&doi=10.4049%2Fjimmunol.0902740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine Kinase 2 Plays Critical Roles in the Pathogenic CD4 T Cell Responses for the Development of Experimental Autoimmune Encephalomyelitis</span></div><div class="casAuthors">Oyamada, Akiko; Ikebe, Hiori; Itsumi, Momoe; Saiwai, Hirokazu; Okada, Seiji; Shimoda, Kazuya; Iwakura, Yoichiro; Nakayama, Keiichi I.; Iwamoto, Yukihide; Yoshikai, Yasunobu; Yamada, Hisakata</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7539-7546</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Tyrosine kinase 2 (Tyk2), a member of the JAK family, is involved in IL-12- and IL-23-mediated signaling.  In the present study, we examd. the roles of Tyk2 in the development of myelin oligodendrocyte glycoprotein (MOG)-induced exptl. autoimmune encephalomyelitis (EAE) by using Tyk2 knockout (KO) mice.  In vitro differentiation of Th1 but not Th17 cells was severely impaired in Tyk2 KO CD4 T cells, although Tyk2 KO Th17 cells did not respond to IL-23.  Tyk2 KO mice showed complete resistance against EAE with no infiltration of CD4 T cells in the spinal cord.  Surprisingly, the no. of MOG-specific Th17 cells in the periphery was comparable between KO and wild-type (WT) mice, whereas Th1 cells were greatly reduced in Tyk2 KO mice.  Adoptive transfer of MOG-primed WT T cells induced EAE in Tyk2 KO recipients, indicating that Tyk2 in the environment was dispensable for the infiltration of effector T cells into the spinal cord.  A reduced but significant no. of Tyk2 KO T cells were detected in the spinal cord of mice with EAE, which had been reconstituted with bone marrow cells of WT and KO mice.  Furthermore, MOG-immunized Tyk2 KO mice developed EAE after adoptive transfer of MOG-primed WT Th1 cells, which might trigger local inflammation that recruits Th17 cells.  Taken together, these results indicate that Tyk2 is critically involved in the pathogenic CD4 T cell responses and thus could be a target mol. for the treatment of autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0gM6rPFuApLVg90H21EOLACvtfcHk0lj7Zj53ZMo2jQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVehtrrE&md5=05bba19010fbdffbb10b751a1dda16fb</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0902740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0902740%26sid%3Dliteratum%253Aachs%26aulast%3DOyamada%26aufirst%3DA.%26aulast%3DIkebe%26aufirst%3DH.%26aulast%3DItsumi%26aufirst%3DM.%26aulast%3DSaiwai%26aufirst%3DH.%26aulast%3DOkada%26aufirst%3DS.%26aulast%3DShimoda%26aufirst%3DK.%26aulast%3DIwakura%26aufirst%3DY.%26aulast%3DNakayama%26aufirst%3DK.%2BI.%26aulast%3DIwamoto%26aufirst%3DY.%26aulast%3DYoshikai%26aufirst%3DY.%26aulast%3DYamada%26aufirst%3DH.%26atitle%3DTyrosine%2520Kinase%25202%2520Plays%2520Critical%2520Roles%2520in%2520the%2520Pathogenic%2520CD4%2520T%2520Cell%2520Responses%2520for%2520the%2520Development%2520of%2520Experimental%2520Autoimmune%2520Encephalomyelitis%26jtitle%3DJ.%2520Immunol.%26date%3D2009%26volume%3D183%26spage%3D7539%26epage%3D7546%26doi%3D10.4049%2Fjimmunol.0902740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dendrou, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attfield, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jostins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barber, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuttikkatte, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faergeman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheeseman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neville, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawcer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compston, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McVean, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fugger, L.</span></span> <span> </span><span class="NLM_article-title">Resolving TYK2 Locus Genotype-to-phenotype Differences in Autoimmunity</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">363ra149</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.aag1974</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1126%2Fscitranslmed.aag1974" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=27807284" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=363ra149&author=C.+A.+Dendrouauthor=A.+Cortesauthor=L.+Shipmanauthor=H.+G.+Evansauthor=K.+E.+Attfieldauthor=L.+Jostinsauthor=T.+Barberauthor=G.+Kaurauthor=S.+B.+Kuttikkatteauthor=O.+A.+Leachauthor=C.+Deselauthor=S.+L.+Faergemanauthor=J.+Cheesemanauthor=M.+J.+Nevilleauthor=S.+Sawcerauthor=A.+Compstonauthor=A.+R.+Johnsonauthor=C.+Everettauthor=J.+I.+Bellauthor=F.+Karpeauthor=M.+Ultschauthor=C.+Eigenbrotauthor=G.+McVeanauthor=L.+Fugger&title=Resolving+TYK2+Locus+Genotype-to-phenotype+Differences+in+Autoimmunity&doi=10.1126%2Fscitranslmed.aag1974"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aag1974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aag1974%26sid%3Dliteratum%253Aachs%26aulast%3DDendrou%26aufirst%3DC.%2BA.%26aulast%3DCortes%26aufirst%3DA.%26aulast%3DShipman%26aufirst%3DL.%26aulast%3DEvans%26aufirst%3DH.%2BG.%26aulast%3DAttfield%26aufirst%3DK.%2BE.%26aulast%3DJostins%26aufirst%3DL.%26aulast%3DBarber%26aufirst%3DT.%26aulast%3DKaur%26aufirst%3DG.%26aulast%3DKuttikkatte%26aufirst%3DS.%2BB.%26aulast%3DLeach%26aufirst%3DO.%2BA.%26aulast%3DDesel%26aufirst%3DC.%26aulast%3DFaergeman%26aufirst%3DS.%2BL.%26aulast%3DCheeseman%26aufirst%3DJ.%26aulast%3DNeville%26aufirst%3DM.%2BJ.%26aulast%3DSawcer%26aufirst%3DS.%26aulast%3DCompston%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DEverett%26aufirst%3DC.%26aulast%3DBell%26aufirst%3DJ.%2BI.%26aulast%3DKarpe%26aufirst%3DF.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DMcVean%26aufirst%3DG.%26aulast%3DFugger%26aufirst%3DL.%26atitle%3DResolving%2520TYK2%2520Locus%2520Genotype-to-phenotype%2520Differences%2520in%2520Autoimmunity%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2016%26volume%3D8%26spage%3D363ra149%26doi%3D10.1126%2Fscitranslmed.aag1974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, H.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, D.-Q.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Potential of Tyrosine Kinase 2 in Autoimmunity</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">571</span>â <span class="NLM_lpage">580</span>, <span class="refDoi">Â DOI: 10.1517/14728222.2014.892925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1517%2F14728222.2014.892925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=24654603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtFWksbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2014&pages=571-580&author=Y.+Liangauthor=Y.+Zhuauthor=Y.+Xiaauthor=H.+Pengauthor=X.-K.+Yangauthor=Y.-Y.+Liuauthor=W.-D.+Xuauthor=H.-F.+Panauthor=D.-Q.+Ye&title=Therapeutic+Potential+of+Tyrosine+Kinase+2+in+Autoimmunity&doi=10.1517%2F14728222.2014.892925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of tyrosine kinase 2 in autoimmunity</span></div><div class="casAuthors">Liang, Yan; Zhu, Yan; Xia, Yi; Peng, Hui; Yang, Xiao-Ke; Liu, Yan-Yan; Xu, Wang-Dong; Pan, Hai-Feng; Ye, Dong-Qing</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">571-580</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Tyrosine kinase 2 (Tyk2) is a Janus kinase family member that is crucial for signaling transduction in response to a wide variety of cytokines, including type I IFNs, IL-6, IL-10, IL-12 and IL-23.  An appropriate expression of Tyk2-mediated signaling might be essential for maintaining normal immune responses.  Areas covered: This review summarizes that Tyk2 is essential for the differentiation and function of a wide variety of immune cells, including natural killer cells, B cells, as well as T helper cells.  In addn., Tyk2-mediated signaling promoted the prodn. of autoimmune-assocd. components, which is implicated in the pathogenesis of autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis.  Aberrant expression of Tyk2 was obsd. in many autoimmune conditions.  Expert opinion: Until recently, no patent filings had claimed selective inhibitors of Tyk2.  Both CP-690,500 and CMP6 failed to be used in clin. treatment due to the difficulties of finding suitable selective leads or due to detrimental toxicities.  Although the result of Cmpd1 is promising, it remains to be seen how specific the Tyk2 inhibitor is and how they are working.  Currently, structure-based drug design (SBDD) technol. has provided us with a quite useful window for SBDD of Tyk2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0GDNGqruPWbVg90H21EOLACvtfcHk0lhL03tkq8jEXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtFWksbg%253D&md5=ed91081f06962424d5e2d1e62cc1a37f</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1517%2F14728222.2014.892925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.2014.892925%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DX.-K.%26aulast%3DLiu%26aufirst%3DY.-Y.%26aulast%3DXu%26aufirst%3DW.-D.%26aulast%3DPan%26aufirst%3DH.-F.%26aulast%3DYe%26aufirst%3DD.-Q.%26atitle%3DTherapeutic%2520Potential%2520of%2520Tyrosine%2520Kinase%25202%2520in%2520Autoimmunity%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2014%26volume%3D18%26spage%3D571%26epage%3D580%26doi%3D10.1517%2F14728222.2014.892925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, X.-Y.</span></span> <span> </span><span class="NLM_article-title">Selective Tyk2 Inhibitors as Potential Therapeutic Agents: a Patent Review (2015-2018)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">137</span>â <span class="NLM_lpage">149</span>, <span class="refDoi">Â DOI: 10.1080/13543776.2019.1567713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1080%2F13543776.2019.1567713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=30621465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsF2kuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=137-149&author=X.+Heauthor=X.+Chenauthor=H.+Zhangauthor=T.+Xieauthor=X.-Y.+Ye&title=Selective+Tyk2+Inhibitors+as+Potential+Therapeutic+Agents%3A+a+Patent+Review+%282015-2018%29&doi=10.1080%2F13543776.2019.1567713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018)</span></div><div class="casAuthors">He, Xingrui; Chen, Xiabin; Zhang, Hancheng; Xie, Tian; Ye, Xiang-Yang</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">137-149</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Tyrosine kinase 2 (Tyk2) is a non-receptor tyrosine-protein kinase, an enzyme that in humans is encoded by the TYK2 gene.  Tyk2, together with three other family subtypes, namely, Jak1, Jak2, and Jak3, belong to the JAK family.  Before 2014, far more publications and patents appeared in public domain attributing to the development of selective Jak2 and Jak3 inhibitors than those for selective Tyk2 and Jak1 inhibitors.  This review sought to give an overview of patents related to small mol. selective Tyk2 inhibitors published from 2015 to 2018.  The article also covers clin. activities of small mol. selective Tyk2 inhibitors in recent years.  As a key component of the JAK-STAT signaling pathway, Tyk2 regulates INFÎ±, IL12, and IL23.  Selective inhibition of Tyk2 can provide pharmacol. benefits in the treatment of many diseases such as psoriasis, systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), rheumatoid arthritis (RA), cancer, and diabetes.  The selectivity against other Jak family subtypes (such as Jak2) is crucial in order to minimize the potential side effects and to maximize the desired pharmacol. effects.  In this context, this review of recent selective Tyk2 inhibitor patents may prove valid, interesting, and promising within the therapeutic paradigm.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrer4xPnKRtvrVg90H21EOLACvtfcHk0lhL03tkq8jEXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsF2kuro%253D&md5=cf7fa5e5f7a92eb951886f7951f7da4b</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1080%2F13543776.2019.1567713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2019.1567713%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DT.%26aulast%3DYe%26aufirst%3DX.-Y.%26atitle%3DSelective%2520Tyk2%2520Inhibitors%2520as%2520Potential%2520Therapeutic%2520Agents%253A%2520a%2520Patent%2520Review%2520%25282015-2018%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2019%26volume%3D29%26spage%3D137%26epage%3D149%26doi%3D10.1080%2F13543776.2019.1567713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R. M.</span></span> <span> </span><span class="NLM_article-title">Advances in the Discovery and Development of Selective Tyrosine Kinase 2 (TYK2) Inhibitors</span>. <i>Med. Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">177</span>â <span class="NLM_lpage">200</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntlyjsb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2018&pages=177-200&author=D.+W.+Weinsteinauthor=R.+M.+Moslin&title=Advances+in+the+Discovery+and+Development+of+Selective+Tyrosine+Kinase+2+%28TYK2%29+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the discovery and development of selective tyrosine kinase 2 (TYK2) inhibitors</span></div><div class="casAuthors">Weinstein, David S.; Moslin, Ryan M.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">177-200</span>CODEN:
                <span class="NLM_cas:coden">MCREGD</span>;
        ISSN:<span class="NLM_cas:issn">2575-9175</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society, Division of Medicinal Chemistry</span>)
        </div><div class="casAbstract">A review discussing the advances in the discovery and development of selective tyrosine kinase 2 (TYK2) inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm_EO5ig1UTrVg90H21EOLACvtfcHk0lhL03tkq8jEXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntlyjsb8%253D&md5=1ae794f8190d9c312e67fcdd2e06b793</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeinstein%26aufirst%3DD.%2BW.%26aulast%3DMoslin%26aufirst%3DR.%2BM.%26atitle%3DAdvances%2520in%2520the%2520Discovery%2520and%2520Development%2520of%2520Selective%2520Tyrosine%2520Kinase%25202%2520%2528TYK2%2529%2520Inhibitors%26jtitle%3DMed.%2520Chem.%2520Rev.%26date%3D2018%26volume%3D53%26spage%3D177%26epage%3D200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toms, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshpande, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNally, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruner, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marto, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattler, M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Structure of a Pseudokinase Domain Switch that Controls Oncogenic Activation of Jak Kinases</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1221</span>â <span class="NLM_lpage">1223</span>, <span class="refDoi">Â DOI: 10.1038/nsmb.2673</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1038%2Fnsmb.2673" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=1221-1223&author=A.+V.+Tomsauthor=A.+Deshpandeauthor=R.+McNallyauthor=Y.+Jeongauthor=J.+M.+Rogersauthor=C.+U.+Kimauthor=S.+M.+Grunerauthor=S.+B.+Ficarroauthor=J.+A.+Martoauthor=M.+Sattler&title=Structure+of+a+Pseudokinase+Domain+Switch+that+Controls+Oncogenic+Activation+of+Jak+Kinases&doi=10.1038%2Fnsmb.2673"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2673%26sid%3Dliteratum%253Aachs%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DDeshpande%26aufirst%3DA.%26aulast%3DMcNally%26aufirst%3DR.%26aulast%3DJeong%26aufirst%3DY.%26aulast%3DRogers%26aufirst%3DJ.%2BM.%26aulast%3DKim%26aufirst%3DC.%2BU.%26aulast%3DGruner%26aufirst%3DS.%2BM.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DMarto%26aufirst%3DJ.%2BA.%26aulast%3DSattler%26aufirst%3DM.%26atitle%3DStructure%2520of%2520a%2520Pseudokinase%2520Domain%2520Switch%2520that%2520Controls%2520Oncogenic%2520Activation%2520of%2520Jak%2520Kinases%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2014%26volume%3D20%26spage%3D1221%26epage%3D1223%26doi%3D10.1038%2Fnsmb.2673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Min, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ungureanu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maxwell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HammarÃ©n, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thibault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillert, E.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenfield, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eksterowicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2)</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">27261</span>â <span class="NLM_lpage">27270</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M115.672048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1074%2Fjbc.M115.672048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=26359499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyrtrnO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=27261-27270&author=X.+Minauthor=D.+Ungureanuauthor=S.+Maxwellauthor=H.+Hammar%C3%A9nauthor=S.+Thibaultauthor=E.-K.+Hillertauthor=M.+Ayresauthor=B.+Greenfieldauthor=J.+Eksterowiczauthor=C.+Gabelauthor=N.+Walkerauthor=O.+Silvennoinenauthor=Z.+Wang&title=Structural+and+Functional+Characterization+of+the+JH2+Pseudokinase+Domain+of+JAK+Family+Tyrosine+Kinase+2+%28TYK2%29&doi=10.1074%2Fjbc.M115.672048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2)</span></div><div class="casAuthors">Min, Xiaoshan; Ungureanu, Daniela; Maxwell, Sarah; Hammaren, Henrik; Thibault, Steve; Hillert, Ellin-Kristina; Ayres, Merrill; Greenfield, Brad; Eksterowicz, John; Gabel, Chris; Walker, Nigel; Silvennoinen, Olli; Wang, Zhulun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">27261-27270</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">JAK (Janus family of cytoplasmic tyrosine kinases) family tyrosine kinase 2 (TYK2) participates in signaling through cytokine receptors involved in immune responses and inflammation.  JAKs are characterized by dual kinase domain: a tyrosine kinase domain (JH1) that is preceded by a pseudokinase domain (JH2).  The majority of disease-assocd. mutations in JAKs map to JH2, demonstrating its central regulatory function.  JH2s were considered catalytically inactive, but JAK2 JH2 was found to have low autoregulatory catalytic activity.  Whether the other JAK JH2s share ATP binding and enzymic activity has been unclear.  Here we report the crystal structure of TYK2 JH2 in complex with adenosine 5'-O-(thiotriphosphate) (ATP-Î³S) and characterize its nucleotide binding by biochem. and biophys. methods.  TYK2 JH2 did not show phosphotransfer activity, but it binds ATP and the nucleotide binding stabilizes the protein without inducing major conformational changes.  Mutation of the JH2 ATP-binding pocket increased basal TYK2 phosphorylation and downstream signaling.  The overall structural characteristics of TYK2 JH2 resemble JAK2 JH2, but distinct stabilizing mol. interactions around helix Î±AL in the activation loop provide a structural basis for differences in substrate access and catalytic activities among JAK family JH2s.  The structural and biochem. data suggest that ATP binding is functionally important for both TYK2 and JAK2 JH2s, whereas the regulatory phosphorylation appears to be a unique property of JAK2.  Finally, the co-crystal structure of TYK2 JH2 complexed with a small mol. inhibitor demonstrates that JH2 is accessible to ATP-competitive compds., which offers novel approaches for targeting cytokine signaling as well as potential therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4ZJIkM0pXXbVg90H21EOLACvtfcHk0lhaM283wDLFgA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyrtrnO&md5=2933fa07a5bdbea19f3d434591613070</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.672048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.672048%26sid%3Dliteratum%253Aachs%26aulast%3DMin%26aufirst%3DX.%26aulast%3DUngureanu%26aufirst%3DD.%26aulast%3DMaxwell%26aufirst%3DS.%26aulast%3DHammar%25C3%25A9n%26aufirst%3DH.%26aulast%3DThibault%26aufirst%3DS.%26aulast%3DHillert%26aufirst%3DE.-K.%26aulast%3DAyres%26aufirst%3DM.%26aulast%3DGreenfield%26aufirst%3DB.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DGabel%26aufirst%3DC.%26aulast%3DWalker%26aufirst%3DN.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DStructural%2520and%2520Functional%2520Characterization%2520of%2520the%2520JH2%2520Pseudokinase%2520Domain%2520of%2520JAK%2520Family%2520Tyrosine%2520Kinase%25202%2520%2528TYK2%2529%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D27261%26epage%3D27270%26doi%3D10.1074%2Fjbc.M115.672048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Abbema, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berezhkovsky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delarosa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVoss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halladay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyssikatos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menghrajani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambrone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, B.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, S.</span></span> <span> </span><span class="NLM_article-title">Lead Optimization of a 4-Aminopyridine Benzamide Scaffold To Identify Potent, Selective, and Orally Bioavailable TYK2 Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4521</span>â <span class="NLM_lpage">4536</span>, <span class="refDoi">Â DOI: 10.1021/jm400266t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400266t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsFakuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4521-4536&author=J.+Liangauthor=A.+van+Abbemaauthor=M.+Balazsauthor=K.+Barrettauthor=L.+Berezhkovskyauthor=W.+Blairauthor=C.+Changauthor=D.+Delarosaauthor=J.+DeVossauthor=J.+Driscollauthor=C.+Eigenbrotauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=J.+Halladayauthor=A.+Johnsonauthor=P.+B.+Kohliauthor=Y.+Laiauthor=Y.+Liuauthor=J.+Lyssikatosauthor=P.+Mantikauthor=K.+Menghrajaniauthor=J.+Murrayauthor=I.+Pengauthor=A.+Sambroneauthor=S.+Shiaauthor=Y.+Shinauthor=J.+Smithauthor=S.+Sohnauthor=V.+Tsuiauthor=M.+Ultschauthor=L.+C.+Wuauthor=Y.+Xiaoauthor=W.+Yangauthor=J.+Youngauthor=B.+Zhangauthor=B.-y.+Zhuauthor=S.+Magnuson&title=Lead+Optimization+of+a+4-Aminopyridine+Benzamide+Scaffold+To+Identify+Potent%2C+Selective%2C+and+Orally+Bioavailable+TYK2+Inhibitors&doi=10.1021%2Fjm400266t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Lead Optimization of a 4-Aminopyridine Benzamide Scaffold To Identify Potent, Selective, and Orally Bioavailable TYK2 Inhibitors</span></div><div class="casAuthors">Liang, Jun; van Abbema, Anne; Balazs, Mercedesz; Barrett, Kathy; Berezhkovsky, Leo; Blair, Wade; Chang, Christine; Delarosa, Donnie; DeVoss, Jason; Driscoll, Jim; Eigenbrot, Charles; Ghilardi, Nico; Gibbons, Paul; Halladay, Jason; Johnson, Adam; Kohli, Pawan Bir; Lai, Yingjie; Liu, Yanzhou; Lyssikatos, Joseph; Mantik, Priscilla; Menghrajani, Kapil; Murray, Jeremy; Peng, Ivan; Sambrone, Amy; Shia, Steven; Shin, Young; Smith, Jan; Sohn, Sue; Tsui, Vickie; Ultsch, Mark; Wu, Lawren C.; Xiao, Yisong; Yang, Wenqian; Young, Judy; Zhang, Birong; Zhu, Bing-yan; Magnuson, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4521-4536</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein the authors report the authors' lead optimization effort to identify potent, selective, and orally bioavailable TYK2 inhibitors, starting with lead mol. 2,6-dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide.  The authors used structure-based design to discover 2,6-dichloro-4-cyanophenyl and (1R,2R)-2-fluorocyclopropylamide modifications, each of which exhibited improved TYK2 potency and JAK1 and JAK2 selectivity relative to 2,6-dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide.  Further optimization eventually led to 2-Chloro-4-cyano-6-fluoro-N-(2-((1R,2R)-2-fluorocyclopropanecarboxamido)pyridin-4-yl)benzamide that showed good TYK2 enzyme and interleukin-12 (IL-12) cell potency, as well as acceptable cellular JAK1 and JAK2 selectivity and excellent oral exposure in mice.  When tested in a mouse IL-12 PK/PD model, 2-Chloro-4-cyano-6-fluoro-N-(2-((1R,2R)-2-ffluorocyclopropanecarboxamido)pyridin-4-yl)benzamide showed statistically significant knockdown of cytokine interferon-Î³ (IFNÎ³), suggesting that selective inhibition of TYK2 kinase activity might be sufficient to block the IL-12 pathway in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCinZ75WrtObVg90H21EOLACvtfcHk0lhUfCNk8da4jg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsFakuro%253D&md5=290ee5f1e3e093136ac5fbb418323421</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm400266t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400266t%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBerezhkovsky%26aufirst%3DL.%26aulast%3DBlair%26aufirst%3DW.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DDelarosa%26aufirst%3DD.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDriscoll%26aufirst%3DJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DHalladay%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLyssikatos%26aufirst%3DJ.%26aulast%3DMantik%26aufirst%3DP.%26aulast%3DMenghrajani%26aufirst%3DK.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DPeng%26aufirst%3DI.%26aulast%3DSambrone%26aufirst%3DA.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DSohn%26aufirst%3DS.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DL.%2BC.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DYoung%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DB.-y.%26aulast%3DMagnuson%26aufirst%3DS.%26atitle%3DLead%2520Optimization%2520of%2520a%25204-Aminopyridine%2520Benzamide%2520Scaffold%2520To%2520Identify%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Bioavailable%2520TYK2%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4521%26epage%3D4536%26doi%3D10.1021%2Fjm400266t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yogo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagamiya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih-Chung, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohba, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokunaga, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhim, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skene, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okabe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marui, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aso, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span> <span> </span><span class="NLM_article-title">Structure-based Design and Synthesis of 3-Amino-1,5-dihydro-4<i>H</i>-pyrazolopyridin-4-one Derivatives as Tyrosine Kinase 2 Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">733</span>â <span class="NLM_lpage">749</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01857</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01857" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVygsbrO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=733-749&author=T.+Yogoauthor=H.+Nagamiyaauthor=M.+Setoauthor=S.+Sasakiauthor=H.+Shih-Chungauthor=Y.+Ohbaauthor=N.+Tokunagaauthor=G.+N.+Leeauthor=C.+Y.+Rhimauthor=C.+H.+Yoonauthor=S.+Y.+Choauthor=R.+Skeneauthor=S.+Yamamotoauthor=Y.+Satouauthor=M.+Kunoauthor=T.+Miyazakiauthor=H.+Nakagawaauthor=A.+Okabeauthor=S.+Maruiauthor=K.+Asoauthor=M.+Yoshida&title=Structure-based+Design+and+Synthesis+of+3-Amino-1%2C5-dihydro-4H-pyrazolopyridin-4-one+Derivatives+as+Tyrosine+Kinase+2+Inhibitors&doi=10.1021%2Facs.jmedchem.5b01857"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design and Synthesis of 3-Amino-1,5-dihydro-4H-pyrazolopyridin-4-one Derivatives as Tyrosine Kinase 2 Inhibitors</span></div><div class="casAuthors">Yogo, Takatoshi; Nagamiya, Hiroyuki; Seto, Masaki; Sasaki, Satoshi; Shih-Chung, Huang; Ohba, Yusuke; Tokunaga, Norihito; Lee, Gil Nam; Rhim, Chul Yun; Yoon, Cheol Hwan; Cho, Suk Young; Skene, Robert; Yamamoto, Syunsuke; Satou, Yousuke; Kuno, Masako; Miyazaki, Takahiro; Nakagawa, Hideyuki; Okabe, Atsutoshi; Marui, Shogo; Aso, Kazuyoshi; Yoshida, Masato</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">733-749</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report herein the discovery and optimization of 3-amino-1,5-dihydro-4H-pyrazolopyridin-4-one TYK2 inhibitors.  High-throughput screening against TYK2 and JAK1-3 provided aminoindazole deriv. 1 (I) as a hit compd.  Scaffold hopping of the aminoindazole core led to the discovery of 3-amino-1,5-dihydro-4H-pyrazolopyridin-4-one deriv. 3 (III) as a novel chemotype of TYK2 inhibitors.  Interestingly, initial SAR study suggested that this scaffold could have a vertically flipped binding mode, which prompted us to introduce a substituent at the 7-position as a moiety directed toward the solvent-exposed region.  Introduction of a 1-methyl-3-pyrazolyl moiety at the 7-position resulted in a dramatic increase in TYK2 inhibitory activity, and further optimization led to the discovery of 20 (XX).  Compd. 20 inhibited IL-23-induced IL-22 prodn. in a rat PD assay, as well as inhibited IL-23 signaling in human PBMC.  Furthermore, 20 showed selectivity for IL-23 signaling inhibition against GM-CSF, demonstrating the unique cytokine selectivity of the novel TYK2 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFqjGKQbCdlbVg90H21EOLACvtfcHk0lhUfCNk8da4jg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVygsbrO&md5=05067e56ba1f96b58855f60eddc1a973</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01857%26sid%3Dliteratum%253Aachs%26aulast%3DYogo%26aufirst%3DT.%26aulast%3DNagamiya%26aufirst%3DH.%26aulast%3DSeto%26aufirst%3DM.%26aulast%3DSasaki%26aufirst%3DS.%26aulast%3DShih-Chung%26aufirst%3DH.%26aulast%3DOhba%26aufirst%3DY.%26aulast%3DTokunaga%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DG.%2BN.%26aulast%3DRhim%26aufirst%3DC.%2BY.%26aulast%3DYoon%26aufirst%3DC.%2BH.%26aulast%3DCho%26aufirst%3DS.%2BY.%26aulast%3DSkene%26aufirst%3DR.%26aulast%3DYamamoto%26aufirst%3DS.%26aulast%3DSatou%26aufirst%3DY.%26aulast%3DKuno%26aufirst%3DM.%26aulast%3DMiyazaki%26aufirst%3DT.%26aulast%3DNakagawa%26aufirst%3DH.%26aulast%3DOkabe%26aufirst%3DA.%26aulast%3DMarui%26aufirst%3DS.%26aulast%3DAso%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DM.%26atitle%3DStructure-based%2520Design%2520and%2520Synthesis%2520of%25203-Amino-1%252C5-dihydro-4H-pyrazolopyridin-4-one%2520Derivatives%2520as%2520Tyrosine%2520Kinase%25202%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D733%26epage%3D749%26doi%3D10.1021%2Facs.jmedchem.5b01857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrencik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efremov, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstenberger, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalsamy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingshead, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knafels, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limburg, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trujillo, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajdos, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Z.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((<i>S</i>)-2,2-Difluorocyclopropyl)((1R,5<i>S</i>)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)-pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8597</span>â <span class="NLM_lpage">8612</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b00917</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00917" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFWgtLfI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8597-8612&author=A.+Fensomeauthor=C.+M.+Amblerauthor=E.+Arnoldauthor=M.+E.+Bankerauthor=M.+F.+Brownauthor=J.+Chrencikauthor=J.+D.+Clarkauthor=M.+E.+Dowtyauthor=I.+V.+Efremovauthor=A.+Flickauthor=B.+S.+Gerstenbergerauthor=A.+Gopalsamyauthor=M.+M.+Haywardauthor=M.+Hegenauthor=B.+D.+Hollingsheadauthor=J.+Jussifauthor=J.+D.+Knafelsauthor=D.+C.+Limburgauthor=D.+Linauthor=T.+H.+Linauthor=B.+S.+Pierceauthor=E.+Saiahauthor=R.+Sharmaauthor=P.+T.+Symanowiczauthor=J.-B.+Telliezauthor=J.+I.+Trujilloauthor=F.+F.+Vajdosauthor=F.+Vincentauthor=Z.-K.+Wanauthor=L.+Xingauthor=X.+Yangauthor=X.+Yangauthor=L.+Zhang&title=Dual+Inhibition+of+TYK2+and+JAK1+for+the+Treatment+of+Autoimmune+Diseases%3A+Discovery+of+%28%28S%29-2%2C2-Difluorocyclopropyl%29%28%281R%2C5S%29-3-%282-%28%281-methyl-1H-pyrazol-4-yl%29amino%29-pyrimidin-4-yl%29-3%2C8-diazabicyclo%5B3.2.1%5Doctan-8-yl%29methanone+%28PF-06700841%29&doi=10.1021%2Facs.jmedchem.8b00917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)</span></div><div class="casAuthors">Fensome, Andrew; Ambler, Catherine M.; Arnold, Eric; Banker, Mary Ellen; Brown, Matthew F.; Chrencik, Jill; Clark, James D.; Dowty, Martin E.; Efremov, Ivan V.; Flick, Andrew; Gerstenberger, Brian S.; Gopalsamy, Ariamala; Hayward, Matthew M.; Hegen, Martin; Hollingshead, Brett D.; Jussif, Jason; Knafels, John D.; Limburg, David C.; Lin, David; Lin, Tsung H.; Pierce, Betsy S.; Saiah, Eddine; Sharma, Raman; Symanowicz, Peter T.; Telliez, Jean-Baptiste; Trujillo, John I.; Vajdos, Felix F.; Vincent, Fabien; Wan, Zhao-Kui; Xing, Li; Yang, Xiaojing; Yang, Xin; Zhang, Liying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8597-8612</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cytokine signaling is an important characteristic of autoimmune diseases.  Many pro-inflammatory cytokines signal through the Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) pathway.  JAK1 is important for the Î³-common chain cytokines, interleukin (IL)-6 and type-I interferon (IFN) family, while TYK2 in addn. to type-I IFN signaling also plays a role in IL-23 and IL-12 signaling.  Intervention with monoclonal antibodies (mAbs) or JAK1 inhibitors has demonstrated efficacy in Phase III psoriasis, psoriatic arthritis, inflammatory bowel disease and rheumatoid arthritis studies, leading to multiple drug approvals.  It is hypothesized that a dual JAK1/TYK2 inhibitor will provide addnl. efficacy, while managing risk by optimizing selectivity against JAK2 driven hematopoietic changes.  Our program began with a conformationally constrained piperazinyl-pyrimidine Type 1 ATP site inhibitor, subsequent work led to the discovery of PF-06700841 (compd. 23), which is in Phase II clin. development (NCT02969018, NCT02958865, NCT03395184, and NCT02974868).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWNhVkNWDMq7Vg90H21EOLACvtfcHk0lifwaOnzeoqOQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFWgtLfI&md5=c321512f524560cba445d070b9639e55</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00917%26sid%3Dliteratum%253Aachs%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DAmbler%26aufirst%3DC.%2BM.%26aulast%3DArnold%26aufirst%3DE.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DChrencik%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DEfremov%26aufirst%3DI.%2BV.%26aulast%3DFlick%26aufirst%3DA.%26aulast%3DGerstenberger%26aufirst%3DB.%2BS.%26aulast%3DGopalsamy%26aufirst%3DA.%26aulast%3DHayward%26aufirst%3DM.%2BM.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DHollingshead%26aufirst%3DB.%2BD.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DKnafels%26aufirst%3DJ.%2BD.%26aulast%3DLimburg%26aufirst%3DD.%2BC.%26aulast%3DLin%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DSaiah%26aufirst%3DE.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DTrujillo%26aufirst%3DJ.%2BI.%26aulast%3DVajdos%26aufirst%3DF.%2BF.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DWan%26aufirst%3DZ.-K.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DDual%2520Inhibition%2520of%2520TYK2%2520and%2520JAK1%2520for%2520the%2520Treatment%2520of%2520Autoimmune%2520Diseases%253A%2520Discovery%2520of%2520%2528%2528S%2529-2%252C2-Difluorocyclopropyl%2529%2528%25281R%252C5S%2529-3-%25282-%2528%25281-methyl-1H-pyrazol-4-yl%2529amino%2529-pyrimidin-4-yl%2529-3%252C8-diazabicyclo%255B3.2.1%255Doctan-8-yl%2529methanone%2520%2528PF-06700841%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D8597%26epage%3D8612%26doi%3D10.1021%2Facs.jmedchem.8b00917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banfield, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaramozza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieras, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goteti, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkle, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeva, E.</span></span> <span> </span><span class="NLM_article-title">The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients with Plaque Psoriasis</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">434</span>â <span class="NLM_lpage">447</span>, <span class="refDoi">Â DOI: 10.1002/jcph.1046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1002%2Fjcph.1046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=29266308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVKrurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2018&pages=434-447&author=C.+Banfieldauthor=M.+Scaramozzaauthor=W.+Zhangauthor=E.+Kierasauthor=K.+M.+Pageauthor=A.+Fensomeauthor=M.+Vincentauthor=M.+E.+Dowtyauthor=K.+Gotetiauthor=P.+J.+Winkleauthor=E.+Peeva&title=The+Safety%2C+Tolerability%2C+Pharmacokinetics%2C+and+Pharmacodynamics+of+a+TYK2%2FJAK1+Inhibitor+%28PF-06700841%29+in+Healthy+Subjects+and+Patients+with+Plaque+Psoriasis&doi=10.1002%2Fjcph.1046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis</span></div><div class="casAuthors">Banfield, Christopher; Scaramozza, Matthew; Zhang, Weidong; Kieras, Elizabeth; Page, Karen M.; Fensome, Andrew; Vincent, Michael; Dowty, Martin E.; Goteti, Kosalaram; Winkle, Peter J.; Peeva, Elena</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">434-447</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06700841 were assessed in a randomized, double-blind, placebo-controlled, single- and multiple-dose escalation, parallel-group study in healthy subjects and patients with plaque psoriasis.  The single ascending dose (1, 3, 10, 30, 100, or 200 mg) and multiple ascending dose (MAD; PF-06700841; up to 175 mg once daily or 50 mg twice daily for 10 days) periods included 54 healthy participants.  In addn., 30 patients with psoriasis received PF-06700841 30 or 100 mg or placebo once daily for 28 days.  Single PF-06700841 doses were rapidly absorbed, with peak plasma concns. â¤ 1 h, proportional exposure up to 100 mg, and mean half-life 3.8-7.5 h.  On day 10 of MAD, plasma concns. peaked at â¤1.5 h postdose (10-175 mg once daily).  Elimination half-life was 4.9-10.7 h; steady state was reached by day 8.  In psoriasis patients on day 28, peak plasma concns. occurred at 1-2 h.  Biomarkers IP-10 and high-sensitivity C-reactive protein were reduced and returned to near baseline levels after dosing.  Maximal mean percent change from baseline in the Psoriasis Area and Severity Index scores for PF-06700841 30 mg once daily and 100 mg once daily were -67.92% and -96.31%, resp., in week 4.  All adverse events were mild/moderate.  PF-06700841 was safe and well tolerated up to 200 mg once daily in healthy subjects and 100 mg once daily in patients with psoriasis, suggesting potential therapeutic utility in plaque psoriasis and other inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHMconrLwJf7Vg90H21EOLACvtfcHk0ljwLXJdq4xkpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVKrurw%253D&md5=a907c91ff2d50db9cba930c2249ed37b</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2Fjcph.1046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.1046%26sid%3Dliteratum%253Aachs%26aulast%3DBanfield%26aufirst%3DC.%26aulast%3DScaramozza%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DKieras%26aufirst%3DE.%26aulast%3DPage%26aufirst%3DK.%2BM.%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DVincent%26aufirst%3DM.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DGoteti%26aufirst%3DK.%26aulast%3DWinkle%26aufirst%3DP.%2BJ.%26aulast%3DPeeva%26aufirst%3DE.%26atitle%3DThe%2520Safety%252C%2520Tolerability%252C%2520Pharmacokinetics%252C%2520and%2520Pharmacodynamics%2520of%2520a%2520TYK2%252FJAK1%2520Inhibitor%2520%2528PF-06700841%2529%2520in%2520Healthy%2520Subjects%2520and%2520Patients%2520with%2520Plaque%2520Psoriasis%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2018%26volume%3D58%26spage%3D434%26epage%3D447%26doi%3D10.1002%2Fjcph.1046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerstenberger, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dermenci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fish, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingshead, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knafels, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajdos, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, S. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_fpage">13561</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.0c00948</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00948" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFeksL%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&pages=13561&author=B.+S.+Gerstenbergerauthor=C.+Amblerauthor=E.+P.+Arnoldauthor=M.-E.+Bankerauthor=M.+F.+Brownauthor=J.+D.+Clarkauthor=A.+Dermenciauthor=M.+E.+Dowtyauthor=A.+Fensomeauthor=S.+Fishauthor=M.+M.+Haywardauthor=M.+Hegenauthor=B.+D.+Hollingsheadauthor=J.+D.+Knafelsauthor=D.+W.+Linauthor=T.+H.+Linauthor=D.+R.+Owenauthor=E.+Saiahauthor=R.+Sharmaauthor=F.+F.+Vajdosauthor=L.+Xingauthor=X.+Yangauthor=X.+Yangauthor=S.+W.+Wright&title=Discovery+of+Tyrosine+Kinase+2+%28TYK2%29+Inhibitor+%28PF-06826647%29+for+the+Treatment+of+Autoimmune+Diseases&doi=10.1021%2Facs.jmedchem.0c00948"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases</span></div><div class="casAuthors">Gerstenberger, Brian S.; Ambler, Catherine; Arnold, Eric P.; Banker, Mary-Ellen; Brown, Matthew F.; Clark, James D.; Dermenci, Alpay; Dowty, Martin E.; Fensome, Andrew; Fish, Susan; Hayward, Matthew M.; Hegen, Martin; Hollingshead, Brett D.; Knafels, John D.; Lin, David W.; Lin, Tsung H.; Owen, Dafydd R.; Saiah, Eddine; Sharma, Raman; Vajdos, Felix F.; Xing, Li; Yang, Xiaojing; Yang, Xin; Wright, Stephen W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">13561-13577</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tyrosine kinase 2 (TYK2) is a member of the JAK kinase family that regulates signal transduction downstream of receptors for the IL-23/IL-12 pathways and type I interferon family, where it pairs with JAK2 or JAK1, resp.  On the basis of human genetic and emerging clin. data, a selective TYK2 inhibitor provides an opportunity to treat autoimmune diseases delivering a potentially differentiated clin. profile compared to currently approved JAK inhibitors.  The discovery of an ATP-competitive pyrazolopyrazinyl series of TYK2 inhibitors was accomplished through computational and structurally enabled design starting from a known kinase hinge binding motif.  With understanding of PK/PD relationships, a target profile balancing TYK2 potency and selectivity over off-target JAK2 was established.  Lead optimization involved modulating potency, selectivity, and ADME properties which led to the identification of the clin. candidate PF-06826647 (22).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDqYsbCoP1k7Vg90H21EOLACvtfcHk0ljwLXJdq4xkpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFeksL%252FE&md5=b096585420a37ce60c1be0b851570fb8</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00948%26sid%3Dliteratum%253Aachs%26aulast%3DGerstenberger%26aufirst%3DB.%2BS.%26aulast%3DAmbler%26aufirst%3DC.%26aulast%3DArnold%26aufirst%3DE.%2BP.%26aulast%3DBanker%26aufirst%3DM.-E.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DDermenci%26aufirst%3DA.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DFish%26aufirst%3DS.%26aulast%3DHayward%26aufirst%3DM.%2BM.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DHollingshead%26aufirst%3DB.%2BD.%26aulast%3DKnafels%26aufirst%3DJ.%2BD.%26aulast%3DLin%26aufirst%3DD.%2BW.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DOwen%26aufirst%3DD.%2BR.%26aulast%3DSaiah%26aufirst%3DE.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DVajdos%26aufirst%3DF.%2BF.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DWright%26aufirst%3DS.%2BW.%26atitle%3DDiscovery%2520of%2520Tyrosine%2520Kinase%25202%2520%2528TYK2%2529%2520Inhibitor%2520%2528PF-06826647%2529%2520for%2520the%2520Treatment%2520of%2520Autoimmune%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26spage%3D13561%26doi%3D10.1021%2Facs.jmedchem.0c00948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zupa-Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tredup, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedicord, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edavettal, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witmer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkin, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blat, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitts, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span> <span> </span><span class="NLM_article-title">Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes is Blocked by Pharmacological Stabilization of its Pseudokinase Domain</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">11061</span>â <span class="NLM_lpage">11074</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M114.619502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1074%2Fjbc.M114.619502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=25762719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFSqt70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=11061-11074&author=J.+S.+Tokarskiauthor=A.+Zupa-Fernandezauthor=J.+A.+Tredupauthor=K.+Pikeauthor=C.+Y.+Changauthor=D.+Xieauthor=L.+Chengauthor=D.+Pedicordauthor=J.+Muckelbauerauthor=S.+R.+Johnsonauthor=S.+Wuauthor=S.+C.+Edavettalauthor=Y.+Hongauthor=M.+R.+Witmerauthor=L.+L.+Elkinauthor=Y.+Blatauthor=W.+J.+Pittsauthor=D.+S.+Weinsteinauthor=J.+R.+Burke&title=Tyrosine+Kinase+2-mediated+Signal+Transduction+in+T+Lymphocytes+is+Blocked+by+Pharmacological+Stabilization+of+its+Pseudokinase+Domain&doi=10.1074%2Fjbc.M114.619502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase 2-mediated signal transduction in T lymphocytes is blocked by pharmacological stabilization of its pseudokinase domain</span></div><div class="casAuthors">Tokarski, John S.; Zupa-Fernandez, Adriana; Tredup, Jeffrey A.; Pike, Kristen; Chang, Chieh Ying; Xie, Dianlin; Cheng, Lihong; Pedicord, Donna; Muckelbauer, Jodi; Johnson, Stephen R.; Wu, Sophie; Edavettal, Suzanne C.; Hong, Yang; Witmer, Mark R.; Elkin, Lisa L.; Blat, Yuval; Pitts, William J.; Weinstein, David S.; Burke, James R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">11061-11074</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Inhibition of signal transduction downstream of the IL-23 receptor represents an intriguing approach to the treatment of autoimmunity.  Using a chemogenomics approach marrying kinome-wide inhibitory profiles of a compd. library with the cellular activity against an IL-23-stimulated transcriptional response in T lymphocytes, a class of inhibitors was identified that bind to and stabilize the pseudokinase domain of the Janus kinase tyrosine kinase 2 (Tyk2), resulting in blockade of receptor-mediated activation of the adjacent catalytic domain.  These Tyk2 pseudokinase domain stabilizers were also shown to inhibit Tyk2-dependent signaling through the Type I interferon receptor but not Tyk2-independent signaling and transcriptional cellular assays, including stimulation through the receptors for IL-2 (JAK1- and JAK3-dependent) and thrombopoietin (JAK2-dependent), demonstrating the high functional selectivity of this approach.  A crystal structure of the pseudokinase domain liganded with a representative example showed the compd. bound to a site analogous to the ATP-binding site in catalytic kinases with features consistent with high ligand selectivity.  The results support a model where the pseudokinase domain regulates activation of the catalytic domain by forming receptor-regulated inhibitory interactions.  Tyk2 pseudokinase stabilizers, therefore, represent a novel approach to the design of potent and selective agents for the treatment of autoimmunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwSl_Zer56d7Vg90H21EOLACvtfcHk0lhZ_5ooeLqCRw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFSqt70%253D&md5=49e10a7c3e430c8be198c119b26bb16b</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.619502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.619502%26sid%3Dliteratum%253Aachs%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DZupa-Fernandez%26aufirst%3DA.%26aulast%3DTredup%26aufirst%3DJ.%2BA.%26aulast%3DPike%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DPedicord%26aufirst%3DD.%26aulast%3DMuckelbauer%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DEdavettal%26aufirst%3DS.%2BC.%26aulast%3DHong%26aufirst%3DY.%26aulast%3DWitmer%26aufirst%3DM.%2BR.%26aulast%3DElkin%26aufirst%3DL.%2BL.%26aulast%3DBlat%26aufirst%3DY.%26aulast%3DPitts%26aufirst%3DW.%2BJ.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26atitle%3DTyrosine%2520Kinase%25202-mediated%2520Signal%2520Transduction%2520in%2520T%2520Lymphocytes%2520is%2520Blocked%2520by%2520Pharmacological%2520Stabilization%2520of%2520its%2520Pseudokinase%2520Domain%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D11061%26epage%3D11074%26doi%3D10.1074%2Fjbc.M114.619502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lupardus, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallweber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bir Kohli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span> <span> </span><span class="NLM_article-title">Structure of the Pseudokinase-Kinase Domains from Protein Kinase TYK2 Reveals a Mechanism for Janus Kinase (JAK) Autoinhibition</span>. <i>Proc. Natl. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">8025</span>â <span class="NLM_lpage">8030</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1401180111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1073%2Fpnas.1401180111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=24843152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A280%3ADC%252BC2cjktFyntg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=8025-8030&author=P.+J.+Lupardusauthor=M.+Ultschauthor=H.+Wallweberauthor=P.+Bir+Kohliauthor=A.+R.+Johnsonauthor=C.+Eigenbrot&title=Structure+of+the+Pseudokinase-Kinase+Domains+from+Protein+Kinase+TYK2+Reveals+a+Mechanism+for+Janus+Kinase+%28JAK%29+Autoinhibition&doi=10.1073%2Fpnas.1401180111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition</span></div><div class="casAuthors">Lupardus Patrick J; Ultsch Mark; Wallweber Heidi; Eigenbrot Charles; Bir Kohli Pawan; Johnson Adam R</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8025-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Janus kinases (JAKs) are receptor-associated multidomain tyrosine kinases that act downstream of many cytokines and interferons.  JAK kinase activity is regulated by the adjacent pseudokinase domain via an unknown mechanism.  Here, we report the 2.8-ÃA structure of the two-domain pseudokinase-kinase module from the JAK family member TYK2 in its autoinhibited form.  We find that the pseudokinase and kinase interact near the kinase active site and that most reported mutations in cancer-associated JAK alleles cluster in or near this interface.  Mutation of residues near the TYK2 interface that are analogous to those in cancer-associated JAK alleles, including the V617F and "exon 12" JAK2 mutations, results in increased kinase activity in vitro.  These data indicate that JAK pseudokinases are autoinhibitory domains that hold the kinase domain inactive until receptor dimerization stimulates transition to an active state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRsxgEXiV6j3TQLBVDQn4bCfW6udTcc2eZ4-sCVcT1DWbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjktFyntg%253D%253D&md5=47f1d528f736376c9e02add92839ac67</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1401180111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1401180111%26sid%3Dliteratum%253Aachs%26aulast%3DLupardus%26aufirst%3DP.%2BJ.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DWallweber%26aufirst%3DH.%26aulast%3DBir%2BKohli%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DEigenbrot%26aufirst%3DC.%26atitle%3DStructure%2520of%2520the%2520Pseudokinase-Kinase%2520Domains%2520from%2520Protein%2520Kinase%2520TYK2%2520Reveals%2520a%2520Mechanism%2520for%2520Janus%2520Kinase%2520%2528JAK%2529%2520Autoinhibition%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%26date%3D2014%26volume%3D111%26spage%3D8025%26epage%3D8030%26doi%3D10.1073%2Fpnas.1401180111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toms, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshpande, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNally, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruner, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marto, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Structure of a Pseudokinase Domain Switch that Controls Oncogenic Activation of Jak Kinases</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1221</span>â <span class="NLM_lpage">1223</span>, <span class="refDoi">Â DOI: 10.1038/nsmb.2673</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1038%2Fnsmb.2673" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=24013208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtl2ktrnO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1221-1223&author=A.+V.+Tomsauthor=A.+Deshpandeauthor=R.+McNallyauthor=Y.+Jeongauthor=J.+M.+Rogersauthor=C.+U.+Kimauthor=S.+M.+Grunerauthor=S.+B.+Ficarroauthor=J.+A.+Martoauthor=M.+Sattlerauthor=J.+D.+Griffinauthor=M.+J.+Eck&title=Structure+of+a+Pseudokinase+Domain+Switch+that+Controls+Oncogenic+Activation+of+Jak+Kinases&doi=10.1038%2Fnsmb.2673"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases</span></div><div class="casAuthors">Toms, Angela V.; Deshpande, Anagha; McNally, Randall; Jeong, Youngjee; Rogers, Julia M.; Kim, Chae Un; Gruner, Sol M.; Ficarro, Scott B.; Marto, Jarrod A.; Sattler, Martin; Griffin, James D.; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1221-1223</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The V617F mutation in the Jak2 pseudokinase domain causes myeloproliferative neoplasms, and the equiv. mutation in Jak1 (V658F) is found in T-cell leukemias.  Crystal structures of wild-type and V658F-mutant human Jak1 pseudokinase reveal a conformational switch that remodels a linker segment encoded by exon 12, which is also a site of mutations in Jak2.  This switch is required for V617F-mediated Jak2 activation and possibly for physiol. Jak activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH5DpUPWQk57Vg90H21EOLACvtfcHk0lhzXX52lbC3Pw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtl2ktrnO&md5=e38a60cb1460c113ba8460319902c493</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2673%26sid%3Dliteratum%253Aachs%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DDeshpande%26aufirst%3DA.%26aulast%3DMcNally%26aufirst%3DR.%26aulast%3DJeong%26aufirst%3DY.%26aulast%3DRogers%26aufirst%3DJ.%2BM.%26aulast%3DKim%26aufirst%3DC.%2BU.%26aulast%3DGruner%26aufirst%3DS.%2BM.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DMarto%26aufirst%3DJ.%2BA.%26aulast%3DSattler%26aufirst%3DM.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructure%2520of%2520a%2520Pseudokinase%2520Domain%2520Switch%2520that%2520Controls%2520Oncogenic%2520Activation%2520of%2520Jak%2520Kinases%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D1221%26epage%3D1223%26doi%3D10.1038%2Fnsmb.2673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bandaranayake, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ungureanu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, S. R.</span></span> <span> </span><span class="NLM_article-title">Crystal Structures of the JAK2 Pseudokinase Domain and the Pathogenic Mutant V617F</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">754</span>â <span class="NLM_lpage">759</span>, <span class="refDoi">Â DOI: 10.1038/nsmb.2348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1038%2Fnsmb.2348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=22820988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVKntLbM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=754-759&author=R.+M.+Bandaranayakeauthor=D.+Ungureanuauthor=Y.+Shanauthor=D.+E.+Shawauthor=O.+Silvennoinenauthor=S.+R.+Hubbard&title=Crystal+Structures+of+the+JAK2+Pseudokinase+Domain+and+the+Pathogenic+Mutant+V617F&doi=10.1038%2Fnsmb.2348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F</span></div><div class="casAuthors">Bandaranayake, Rajintha M.; Ungureanu, Daniela; Shan, Yibing; Shaw, David E.; Silvennoinen, Olli; Hubbard, Stevan R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">754-759</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The protein tyrosine kinase JAK2 mediates signaling through numerous cytokine receptors.  JAK2 possesses a pseudokinase domain (JH2) and a tyrosine kinase domain (JH1).  Through unknown mechanisms, JH2 regulates the catalytic activity of JH1, and hyperactivating mutations in the JH2 region of human JAK2 cause myeloproliferative neoplasms (MPNs).  We showed previously that JAK2 JH2 is, in fact, catalytically active.  Here we present crystal structures of human JAK2 JH2, including both wild type and the most prevalent MPN mutant, V617F.  The structures reveal that JH2 adopts the fold of a prototypical protein kinase but binds Mg-ATP noncanonically.  The structural and biochem. data indicate that the V617F mutation rigidifies Î±-helix C in the N lobe of JH2, facilitating trans-phosphorylation of JH1.  The crystal structures of JH2 afford new opportunities for the design of novel JAK2 therapeutics targeting MPNs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGj9DoN3fj37Vg90H21EOLACvtfcHk0lhzXX52lbC3Pw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVKntLbM&md5=da64398430cd3279e131b2569cdc7391</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2348%26sid%3Dliteratum%253Aachs%26aulast%3DBandaranayake%26aufirst%3DR.%2BM.%26aulast%3DUngureanu%26aufirst%3DD.%26aulast%3DShan%26aufirst%3DY.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26atitle%3DCrystal%2520Structures%2520of%2520the%2520JAK2%2520Pseudokinase%2520Domain%2520and%2520the%2520Pathogenic%2520Mutant%2520V617F%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2012%26volume%3D19%26spage%3D754%26epage%3D759%26doi%3D10.1038%2Fnsmb.2348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Staerk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demoulin, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vainchenker, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantinescu, S. N.</span></span> <span> </span><span class="NLM_article-title">JAK1 and Tyk2 Activation by the Homologous Polycythemia Vera JAK2 V617F Mutation: Cross-talk with IGF1 Receptor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">41893</span>â <span class="NLM_lpage">41899</span>, <span class="refDoi">Â DOI: 10.1074/jbc.C500358200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1074%2Fjbc.C500358200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=16239216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlajsrjL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=41893-41899&author=J.+Staerkauthor=A.+Kallinauthor=J.+B.+Demoulinauthor=W.+Vainchenkerauthor=S.+N.+Constantinescu&title=JAK1+and+Tyk2+Activation+by+the+Homologous+Polycythemia+Vera+JAK2+V617F+Mutation%3A+Cross-talk+with+IGF1+Receptor&doi=10.1074%2Fjbc.C500358200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">JAK1 and Tyk2 Activation by the Homologous Polycythemia Vera JAK2 V617F Mutation: Cross-talk with IGF1 receptor</span></div><div class="casAuthors">Staerk, Judith; Kallin, Anders; Demoulin, Jean-Baptiste; Vainchenker, William; Constantinescu, Stefan N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">41893-41899</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The majority of polycythemia vera (PV) patients harbor a unique somatic mutation (V617F) in the pseudokinase domain of JAK2, which leads to constitutive signaling.  Here we show that the homologous mutations in JAK1 (V658F) and in Tyk2 (V678F) lead to constitutive activation of these kinases.  Their expression induces autonomous growth of cytokine-dependent cells and constitutive activation of STAT5, STAT3, mitogen-activated protein kinase, and Akt signaling in Ba/F3 cells.  The mutant JAKs exhibit constitutive signaling also when expressed in fibrosarcoma cells deficient in JAK proteins.  Expression of the JAK2 V617F mutant renders Ba/F3 cells hypersensitive to insulin-like growth factor 1 (IGF1), which is a hallmark of PV erythroid progenitors.  Upon selection of Ba/F3 cells for autonomous growth induced by the JAK2 V617F mutant, cells respond to IGF1 by activating STAT5, STAT3, Erk1/2, and Akt on top of the constitutive activation characteristic of autonomous cells.  The synergic effect on proliferation and STAT activation appears specific to the JAK2 V617F mutant.  Our results show that the homologous V617F mutation induces activation of JAK1 and Tyk2, suggesting a common mechanism of activation for the JAK1, JAK2, and Tyk2 mutants.  JAK3 is not activated by the homologous mutation M592F, despite the presence of the conserved GVC preceding sequence.  We suggest that mutations in the JAK1 and Tyk2 genes may be identified as initial mol. defects in human cancers and autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom-sdvNQ5aOLVg90H21EOLACvtfcHk0lhzXX52lbC3Pw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlajsrjL&md5=b3566dcbfb8de848f32b881526eae2fb</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1074%2Fjbc.C500358200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.C500358200%26sid%3Dliteratum%253Aachs%26aulast%3DStaerk%26aufirst%3DJ.%26aulast%3DKallin%26aufirst%3DA.%26aulast%3DDemoulin%26aufirst%3DJ.%2BB.%26aulast%3DVainchenker%26aufirst%3DW.%26aulast%3DConstantinescu%26aufirst%3DS.%2BN.%26atitle%3DJAK1%2520and%2520Tyk2%2520Activation%2520by%2520the%2520Homologous%2520Polycythemia%2520Vera%2520JAK2%2520V617F%2520Mutation%253A%2520Cross-talk%2520with%2520IGF1%2520Receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D41893%26epage%3D41899%26doi%3D10.1074%2Fjbc.C500358200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foulkes, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyers, P. A.</span></span> <span> </span><span class="NLM_article-title">Pseudokinases: Update on their Functions and Evaluation as New Drug Targets</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">245</span>â <span class="NLM_lpage">265</span>, <span class="refDoi">Â DOI: 10.4155/fmc-2016-0207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.4155%2Ffmc-2016-0207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=28097887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslWnurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=245-265&author=D.+P.+Byrneauthor=D.+M.+Foulkesauthor=P.+A.+Eyers&title=Pseudokinases%3A+Update+on+their+Functions+and+Evaluation+as+New+Drug+Targets&doi=10.4155%2Ffmc-2016-0207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Pseudokinases: update on their functions and evaluation as new drug targets</span></div><div class="casAuthors">Byrne, Dominic P.; Foulkes, Daniel M.; Eyers, Patrick A.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">245-265</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The pseudokinase complement of the human kinase superfamily consists of approx. 60 signaling proteins, which lacks one or more of the amino acids typically required to correctly align ATP and metal ions, and phosphorylate protein substrates.  Recent studies in the pseudokinase field have begun to expose the biol. relevance of pseudokinases, which are now thought to perform a diverse range of physiol. roles and are connected to a multitude of human diseases, including cancer.  In this review, we discuss how and why members of the 'pseudokinome' represent important new targets for drug discovery, and describe how knowledge of protein structure and function provides informative clues to help guide the rational chem. design or repurposing of inhibitors to target pseudokinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqInUA03dIObVg90H21EOLACvtfcHk0litKKeOPOtvxQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslWnurg%253D&md5=290fd229e4f7e5fefc308b2fae35881d</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2016-0207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2016-0207%26sid%3Dliteratum%253Aachs%26aulast%3DByrne%26aufirst%3DD.%2BP.%26aulast%3DFoulkes%26aufirst%3DD.%2BM.%26aulast%3DEyers%26aufirst%3DP.%2BA.%26atitle%3DPseudokinases%253A%2520Update%2520on%2520their%2520Functions%2520and%2520Evaluation%2520as%2520New%2520Drug%2520Targets%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2017%26volume%3D9%26spage%3D245%26epage%3D265%26doi%3D10.4155%2Ffmc-2016-0207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tredup, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zupa-Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elzinga, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dâarienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aranibar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span> <span> </span><span class="NLM_article-title">Identification of Imidazo[1,2-b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">383</span>â <span class="NLM_lpage">388</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.9b00035</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00035" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjsV2qu7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=383-388&author=C.+Liuauthor=J.+Linauthor=R.+Moslinauthor=J.+S.+Tokarskiauthor=J.+Muckelbauerauthor=C.+Changauthor=J.+Tredupauthor=D.+Xieauthor=H.+Parkauthor=P.+Liauthor=D.-R.+Wuauthor=J.+Strnadauthor=A.+Zupa-Fernandezauthor=L.+Chengauthor=C.+Chaudhryauthor=J.+Chenauthor=C.+Chenauthor=H.+Sunauthor=P.+Elzingaauthor=C.+D%E2%80%99arienzoauthor=K.+Gilloolyauthor=T.+L.+Taylorauthor=K.+W.+McIntyreauthor=L.+Salter-Cidauthor=L.+J.+Lombardoauthor=P.+H.+Carterauthor=N.+Aranibarauthor=J.+R.+Burkeauthor=D.+S.+Weinstein&title=Identification+of+Imidazo%5B1%2C2-b%5Dpyridazine+Derivatives+as+Potent%2C+Selective%2C+and+Orally+Active+Tyk2+JH2+Inhibitors&doi=10.1021%2Facsmedchemlett.9b00035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Imidazo[1,2-b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors</span></div><div class="casAuthors">Liu, Chunjian; Lin, James; Moslin, Ryan; Tokarski, John S.; Muckelbauer, Jodi; Chang, ChiehYing; Tredup, Jeffrey; Xie, Dianlin; Park, Hyunsoo; Li, Peng; Wu, Dauh-Rurng; Strnad, Joann; Zupa-Fernandez, Adriana; Cheng, Lihong; Chaudhry, Charu; Chen, Jing; Chen, Cliff; Sun, Huadong; Elzinga, Paul; Darienzo, Celia; Gillooly, Kathleen; Taylor, Tracy L.; McIntyre, Kim W.; Salter-Cid, Luisa; Lombardo, Louis J.; Carter, Percy H.; Aranibar, Nelly; Burke, James R.; Weinstein, David S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">383-388</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In sharp contrast to a previously reported series of 6-anilino imidazopyridazine based Tyk2 JH2 ligands, 6-((2-oxo-N1-substituted-1,2-dihydropyridin-3-yl)amino)imidazo[1,2-b]pyridazine analogs were found to display dramatically improved metabolic stability.  The N1-substituent on 2-oxo-1,2-dihydropyridine ring can be a variety of alkyl, aryl, and heteroaryl groups, but among them, 2-pyridyl provided much enhanced Caco-2 permeability, attributed to its ability to form intramol. hydrogen bonds.  Further structure-activity relationship studies at the C3 position led to the identification of highly potent and selective Tyk2 JH2 inhibitor 6, which proved to be highly effective in inhibiting IFNÎ³ prodn. in a rat pharmacodynamics model and fully efficacious in a rat adjuvant arthritis model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKahxaaZZWtbVg90H21EOLACvtfcHk0litKKeOPOtvxQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjsV2qu7w%253D&md5=65c8d8dccfcc2cf73175aef902df9fa2</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00035%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DMoslin%26aufirst%3DR.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DMuckelbauer%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DD.-R.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DZupa-Fernandez%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DElzinga%26aufirst%3DP.%26aulast%3DD%25E2%2580%2599arienzo%26aufirst%3DC.%26aulast%3DGillooly%26aufirst%3DK.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DAranibar%26aufirst%3DN.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26atitle%3DIdentification%2520of%2520Imidazo%255B1%252C2-b%255Dpyridazine%2520Derivatives%2520as%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Active%2520Tyk2%2520JH2%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D383%26epage%3D388%26doi%3D10.1021%2Facsmedchemlett.9b00035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wrobleski, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spergel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zupa-Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuster, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tredup, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulligan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâArienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aranibar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimalakonda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitts, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span> <span> </span><span class="NLM_article-title">Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8973</span>â <span class="NLM_lpage">8995</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b00444</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00444" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlyht7%252FP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8973-8995&author=S.+T.+Wrobleskiauthor=R.+Moslinauthor=S.+Linauthor=Y.+Zhangauthor=S.+Spergelauthor=J.+Kempsonauthor=J.+S.+Tokarskiauthor=J.+Strnadauthor=A.+Zupa-Fernandezauthor=L.+Chengauthor=D.+Shusterauthor=K.+Gilloolyauthor=X.+Yangauthor=E.+Heimrichauthor=K.+W.+McIntyreauthor=C.+Chaudhryauthor=J.+Khanauthor=M.+Ruzanovauthor=J.+Tredupauthor=D.+Mulliganauthor=D.+Xieauthor=H.+Sunauthor=C.+Huangauthor=C.+D%E2%80%99Arienzoauthor=N.+Aranibarauthor=M.+Chineyauthor=A.+Chimalakondaauthor=W.+J.+Pittsauthor=L.+Lombardoauthor=P.+H.+Carterauthor=J.+R.+Burkeauthor=D.+S.+Weinstein&title=Highly+Selective+Inhibition+of+Tyrosine+Kinase+2+%28TYK2%29+for+the+Treatment+of+Autoimmune+Diseases%3A+Discovery+of+the+Allosteric+Inhibitor+BMS-986165&doi=10.1021%2Facs.jmedchem.9b00444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165</span></div><div class="casAuthors">Wrobleski, Stephen T.; Moslin, Ryan; Lin, Shuqun; Zhang, Yanlei; Spergel, Steven; Kempson, James; Tokarski, John S.; Strnad, Joann; Zupa-Fernandez, Adriana; Cheng, Lihong; Shuster, David; Gillooly, Kathleen; Yang, Xiaoxia; Heimrich, Elizabeth; McIntyre, Kim W.; Chaudhry, Charu; Khan, Javed; Ruzanov, Max; Tredup, Jeffrey; Mulligan, Dawn; Xie, Dianlin; Sun, Huadong; Huang, Christine; D'Arienzo, Celia; Aranibar, Nelly; Chiney, Manoj; Chimalakonda, Anjaneya; Pitts, William J.; Lombardo, Louis; Carter, Percy H.; Burke, James R.; Weinstein, David S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8973-8995</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small mol. JAK inhibitors have emerged as a major therapeutic advancement in treating autoimmune diseases.  The discovery of isoform selective JAK inhibitors that traditionally target the catalytically active site of this kinase family has been a formidable challenge.  Our strategy to achieve high selectivity for TYK2 relies on targeting the TYK2 pseudokinase (JH2) domain.  Herein we report the late stage optimization efforts including a structure-guided design and water displacement strategy that led to the discovery of BMS-986165 (11, I) as a high affinity JH2 ligand and potent allosteric inhibitor of TYK2.  In addn. to unprecedented JAK isoform and kinome selectivity, I shows excellent pharmacokinetic properties with minimal profiling liabilities and is efficacious in several murine models of autoimmune disease.  On the basis of these findings, I appears differentiated from all other reported JAK inhibitors and has been advanced as the first pseudokinase-directed therapeutic in clin. development as an oral treatment for autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmA75TJmytlrVg90H21EOLACvtfcHk0lgZVR3g3dnE-g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlyht7%252FP&md5=ca161c470df002b0bdd2bf6b19920ada</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00444%26sid%3Dliteratum%253Aachs%26aulast%3DWrobleski%26aufirst%3DS.%2BT.%26aulast%3DMoslin%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSpergel%26aufirst%3DS.%26aulast%3DKempson%26aufirst%3DJ.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DZupa-Fernandez%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DShuster%26aufirst%3DD.%26aulast%3DGillooly%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DKhan%26aufirst%3DJ.%26aulast%3DRuzanov%26aufirst%3DM.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DMulligan%26aufirst%3DD.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DAranibar%26aufirst%3DN.%26aulast%3DChiney%26aufirst%3DM.%26aulast%3DChimalakonda%26aufirst%3DA.%26aulast%3DPitts%26aufirst%3DW.%2BJ.%26aulast%3DLombardo%26aufirst%3DL.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26atitle%3DHighly%2520Selective%2520Inhibition%2520of%2520Tyrosine%2520Kinase%25202%2520%2528TYK2%2529%2520for%2520the%2520Treatment%2520of%2520Autoimmune%2520Diseases%253A%2520Discovery%2520of%2520the%2520Allosteric%2520Inhibitor%2520BMS-986165%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8973%26epage%3D8995%26doi%3D10.1021%2Facs.jmedchem.9b00444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zupa-Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catlett, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâArienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimalakonda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrobleski, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L. M.</span></span> <span> </span><span class="NLM_article-title">Autoimmune Pathways in Mice and Humans are Blocked by Pharmacological Stabilization of the TYK2 Pseudokinase Domain</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">eaaw1736</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.aaw1736</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1126%2Fscitranslmed.aaw1736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=31341059" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=eaaw1736&author=J.+R.+Burkeauthor=L.+Chengauthor=K.+M.+Gilloolyauthor=J.+Strnadauthor=A.+Zupa-Fernandezauthor=I.+M.+Catlettauthor=Y.+Zhangauthor=E.+M.+Heimrichauthor=K.+W.+McIntyreauthor=M.+D.+Cunninghamauthor=J.+A.+Carmanauthor=X.+Zhouauthor=D.+Banasauthor=C.+Chaudhryauthor=S.+Liauthor=C.+D%E2%80%99Arienzoauthor=A.+Chimalakondaauthor=X.+Yangauthor=J.+H.+Xieauthor=J.+Pangauthor=Q.+Zhaoauthor=S.+M.+Roseauthor=J.+Huangauthor=R.+M.+Moslinauthor=S.+T.+Wrobleskiauthor=D.+S.+Weinsteinauthor=L.+M.+Salter-Cid&title=Autoimmune+Pathways+in+Mice+and+Humans+are+Blocked+by+Pharmacological+Stabilization+of+the+TYK2+Pseudokinase+Domain&doi=10.1126%2Fscitranslmed.aaw1736"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aaw1736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aaw1736%26sid%3Dliteratum%253Aachs%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DZupa-Fernandez%26aufirst%3DA.%26aulast%3DCatlett%26aufirst%3DI.%2BM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHeimrich%26aufirst%3DE.%2BM.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DCunningham%26aufirst%3DM.%2BD.%26aulast%3DCarman%26aufirst%3DJ.%2BA.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DBanas%26aufirst%3DD.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DChimalakonda%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DXie%26aufirst%3DJ.%2BH.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DRose%26aufirst%3DS.%2BM.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DMoslin%26aufirst%3DR.%2BM.%26aulast%3DWrobleski%26aufirst%3DS.%2BT.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26aulast%3DSalter-Cid%26aufirst%3DL.%2BM.%26atitle%3DAutoimmune%2520Pathways%2520in%2520Mice%2520and%2520Humans%2520are%2520Blocked%2520by%2520Pharmacological%2520Stabilization%2520of%2520the%2520TYK2%2520Pseudokinase%2520Domain%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2019%26volume%3D11%26spage%3Deaaw1736%26doi%3D10.1126%2Fscitranslmed.aaw1736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papp, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ThaÃ§i, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gooderham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girgis, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span> <span> </span><span class="NLM_article-title">Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>379</i></span>,  <span class="NLM_fpage">1313</span>â <span class="NLM_lpage">1321</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1806382</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1056%2FNEJMoa1806382" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=30205746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFWlsrbE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2018&pages=1313-1321&author=K.+Pappauthor=K.+Gordonauthor=D.+Tha%C3%A7iauthor=A.+Moritaauthor=M.+Gooderhamauthor=P.+Foleyauthor=I.+G.+Girgisauthor=S.+Kunduauthor=S.+Banerjee&title=Phase+2+Trial+of+Selective+Tyrosine+Kinase+2+Inhibition+in+Psoriasis&doi=10.1056%2FNEJMoa1806382"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis</span></div><div class="casAuthors">Papp, Kim; Gordon, Kenneth; Thaci, Diamant; Morita, Akimichi; Gooderham, Melinda; Foley, Peter; Girgis, Ihab G.; Kundu, Sudeep; Banerjee, Subhashis</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1313-1321</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Tyrosine kinase 2 (TYK2) signaling pathways, which mediate cytokine signaling, are implicated in the pathophysiol. of psoriasis.  Selective inhibitors of TYK2 may be effective in treating psoriasis. methods We conducted a phase 2, double-blind trial of a TYK2 inhibitor, BMS-986165, in adults with moderate-to-severe psoriasis, excluding patients with a previous lack of response to agents targeting cytokine signaling through the same tyrosine kinase pathway.  Patients were randomly assigned to receive the drug orally at a dose of 3 mg every other day, 3 mg daily, 3 mg twice daily, 6 mg twice daily, or 12 mg daily or to receive placebo.  The primary end point was a 75% or greater redn. from baseline in the Psoriasis Area and Severity Index (PASI) score at week 12 (higher scores indicate greater severity of psoriasis). results A total of 267 patients received at least one dose in an intervention group of the trial.  At week 12, the percentage of patients with a 75% or greater redn. in the PASI score was 7% (3 of 45 patients) with placebo, 9% (4 of 44 patients) with 3 mg of BMS-986165 every other day (P = 0.49 vs. placebo), 39% (17 of 44 patients) with 3 mg daily (P<0.001 vs. placebo), 69% (31 of 45 patients) with 3 mg twice daily (P<0.001 vs. placebo), 67% (30 of 45 patients) with 6 mg twice daily (P<0.001 vs. placebo), and 75% (33 of 44 patients) with 12 mg daily (P<0.001 vs. placebo).  There were three serious adverse events in patients receiving the active drug, as well as one case of malignant melanoma 96 days after the start of treatment. conclusions Selective inhibition of TYK2 with the oral agent BMS-986165 at doses of 3 mg daily and higher resulted in greater clearing of psoriasis than did placebo over a period of 12 wk.  Larger and longer-duration trials of this drug are required to det. its safety and durability of effect in patients with psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhqWANKhDdt7Vg90H21EOLACvtfcHk0lgdLzFXH7LRsw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFWlsrbE&md5=ededd5d925dd557cceacc472839a966a</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1806382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1806382%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DK.%26aulast%3DGordon%26aufirst%3DK.%26aulast%3DTha%25C3%25A7i%26aufirst%3DD.%26aulast%3DMorita%26aufirst%3DA.%26aulast%3DGooderham%26aufirst%3DM.%26aulast%3DFoley%26aufirst%3DP.%26aulast%3DGirgis%26aufirst%3DI.%2BG.%26aulast%3DKundu%26aufirst%3DS.%26aulast%3DBanerjee%26aufirst%3DS.%26atitle%3DPhase%25202%2520Trial%2520of%2520Selective%2520Tyrosine%2520Kinase%25202%2520Inhibition%2520in%2520Psoriasis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D379%26spage%3D1313%26epage%3D1321%26doi%3D10.1056%2FNEJMoa1806382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrobleski, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertzman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spergel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zupa-Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâArienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tredup, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulligan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aranibar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span> <span> </span><span class="NLM_article-title">Identification of N-Methyl Nicotinamide and N-Methyl Pyridazine-3-carboxamide Pseudokinase Domain Ligands as Highly Selective Inhibitors of Tyrosine Kinase 2 (TYK2)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8953</span>â <span class="NLM_lpage">8972</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b00443</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00443" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlOltbrO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8953-8972&author=R.+Moslinauthor=Y.+Zhangauthor=S.+T.+Wrobleskiauthor=S.+Linauthor=M.+Mertzmanauthor=S.+Spergelauthor=J.+S.+Tokarskiauthor=J.+Strnadauthor=K.+Gilloolyauthor=K.+W.+McIntyreauthor=A.+Zupa-Fernandezauthor=L.+Chengauthor=H.+Sunauthor=C.+Chaudhryauthor=C.+Huangauthor=C.+D%E2%80%99Arienzoauthor=E.+Heimrichauthor=X.+Yangauthor=J.+K.+Muckelbauerauthor=C.+Changauthor=J.+Tredupauthor=D.+Mulliganauthor=D.+Xieauthor=N.+Aranibarauthor=M.+Chineyauthor=J.+R.+Burkeauthor=L.+Lombardoauthor=P.+H.+Carterauthor=D.+S.+Weinstein&title=Identification+of+N-Methyl+Nicotinamide+and+N-Methyl+Pyridazine-3-carboxamide+Pseudokinase+Domain+Ligands+as+Highly+Selective+Inhibitors+of+Tyrosine+Kinase+2+%28TYK2%29&doi=10.1021%2Facs.jmedchem.9b00443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of N-Methyl Nicotinamide and N-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2)</span></div><div class="casAuthors">Moslin, Ryan; Zhang, Yanlei; Wrobleski, Stephen T.; Lin, Shuqun; Mertzman, Michael; Spergel, Steven; Tokarski, John S.; Strnad, Joann; Gillooly, Kathleen; McIntyre, Kim W.; Zupa-Fernandez, Adriana; Cheng, Lihong; Sun, Huadong; Chaudhry, Charu; Huang, Christine; D'Arienzo, Celia; Heimrich, Elizabeth; Yang, Xiaoxia; Muckelbauer, Jodi K.; Chang, ChiehYing; Tredup, Jeffrey; Mulligan, Dawn; Xie, Dianlin; Aranibar, Nelly; Chiney, Manoj; Burke, James R.; Lombardo, Louis; Carter, Percy H.; Weinstein, David S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8953-8972</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">As a member of the Janus (JAK) family of nonreceptor tyrosine kinases, TYK2 plays an important role in mediating the signaling of pro-inflammatory cytokines including IL-12, IL-23, and type 1 interferons.  The nicotinamide 4, identified by a SPA-based high-throughput screen targeting the TYK2 pseudokinase domain, potently inhibits IL-23 and IFNÎ± signaling in cellular assays.  The described work details the optimization of this poorly selective hit (4) to potent and selective mols. such as 47 and 48.  The discoveries described herein were crit. to the eventual identification of the clin. TYK2 JH2 inhibitor (see following report in this issue).  Compd. 48 provided robust inhibition in a mouse IL-12-induced IFNÎ³ pharmacodynamic model as well as efficacy in an IL-23 and IL-12-dependent mouse colitis model.  These results demonstrate the ability of TYK2 JH2 domain binders to provide a highly selective alternative to conventional TYK2 orthosteric inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAL6gc1mkX4bVg90H21EOLACvtfcHk0lgdLzFXH7LRsw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlOltbrO&md5=869bfe303f0743867b8c9eb8201707c3</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00443%26sid%3Dliteratum%253Aachs%26aulast%3DMoslin%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWrobleski%26aufirst%3DS.%2BT.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DMertzman%26aufirst%3DM.%26aulast%3DSpergel%26aufirst%3DS.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DGillooly%26aufirst%3DK.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DZupa-Fernandez%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DMulligan%26aufirst%3DD.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DAranibar%26aufirst%3DN.%26aulast%3DChiney%26aufirst%3DM.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DLombardo%26aufirst%3DL.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26atitle%3DIdentification%2520of%2520N-Methyl%2520Nicotinamide%2520and%2520N-Methyl%2520Pyridazine-3-carboxamide%2520Pseudokinase%2520Domain%2520Ligands%2520as%2520Highly%2520Selective%2520Inhibitors%2520of%2520Tyrosine%2520Kinase%25202%2520%2528TYK2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8953%26epage%3D8972%26doi%3D10.1021%2Facs.jmedchem.9b00443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="note"><p class="first last">PDB ID: 7K7O</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="note"><p class="first last">PDB ID: 7K7Q</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Theofilopoulos, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, F. J.</span></span> <span> </span><span class="NLM_article-title">Murine Models of Systemic Lupus Erythematosus</span>. <i>Adv. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">269</span>â <span class="NLM_lpage">390</span>, <span class="refDoi">Â DOI: 10.1016/S0065-2776(08)60342-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1016%2FS0065-2776%2808%2960342-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=3890479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADyaL2MXks12gtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1985&pages=269-390&author=A.+N.+Theofilopoulosauthor=F.+J.+Dixon&title=Murine+Models+of+Systemic+Lupus+Erythematosus&doi=10.1016%2FS0065-2776%2808%2960342-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Murine models of systemic lupus erythematosus</span></div><div class="casAuthors">Theofilopoulos, Argyrios N.; Dixon, Frank J.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Immunology</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">269-390</span>CODEN:
                <span class="NLM_cas:coden">ADIMAV</span>;
        ISSN:<span class="NLM_cas:issn">0065-2776</span>.
    </div><div class="casAbstract">A review with 597 refs.  Natural history and pathol. of lupus mice, T and B cellular abnormalities, genetics of murine systemic lupus erythematosus, and the influence of sex and sex hormones in the pathogenesis of murine SLE are among the topics considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvCtrCe7AgqbVg90H21EOLACvtfcHk0ljD7xM-ld-Rhw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXks12gtL4%253D&md5=e1c695a7396c705c8fde71a8dc62e06e</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2FS0065-2776%2808%2960342-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-2776%252808%252960342-9%26sid%3Dliteratum%253Aachs%26aulast%3DTheofilopoulos%26aufirst%3DA.%2BN.%26aulast%3DDixon%26aufirst%3DF.%2BJ.%26atitle%3DMurine%2520Models%2520of%2520Systemic%2520Lupus%2520Erythematosus%26jtitle%3DAdv.%2520Immunol.%26date%3D1985%26volume%3D37%26spage%3D269%26epage%3D390%26doi%3D10.1016%2FS0065-2776%2808%2960342-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span>; <span class="NLM_string-name">Lin, J.</span>; <span class="NLM_string-name">Moslin, R. M.</span>; <span class="NLM_string-name">Weinstein, D. S.</span>; <span class="NLM_string-name">Tokarski, J. S.</span></span> <span> </span><span class="NLM_article-title">Imidazopyridazine Compounds Useful as Modulators of IL-12, IL-23 and/or IFN-alpha Responses</span>. U.S. Patent <span class="NLM_patent">10,273,237</span>, April 30, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=C.+Liu&author=J.+Lin&author=R.+M.+Moslin&author=D.+S.+Weinstein&author=J.+S.+Tokarski&title=Imidazopyridazine+Compounds+Useful+as+Modulators+of+IL-12%2C+IL-23+and%2For+IFN-alpha+Responses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%26atitle%3DImidazopyridazine%2520Compounds%2520Useful%2520as%2520Modulators%2520of%2520IL-12%252C%2520IL-23%2520and%252For%2520IFN-alpha%2520Responses%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':[],'ref55':[],'ref56':['cit56'],'ref57':['cit57']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0022.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01698&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Literature Tyk2 JH1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01698&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Tyk2 JH2 ligands as Tyk2 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01698&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray co-crystal structure of <b>12</b> bound to Tyk2 JH2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K7O">7K7O</a>). (a) Binding interaction highlights. (b) Surface representation of the Tyk2 JH2 protein showing a pocket available at the top of the pyrimidine ring.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01698&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray co-crystal structure of <b>29</b> bound to Tyk2 JH2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K7Q">7K7Q</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01698&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Inhibitor <b>7</b> in a mouse PD model of IL-12/IL-18-induced IFNÎ³ production (vehicle: 5:5:90 EtOH:TPGS:PEG300).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01698&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Inhibitor <b>7</b> in a mouse model of IL-23-driven acanthosis (QD dosing; vehicle: 5:5:90 TPGS:EtOH:PEG300).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01698&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Inhibitor <b>7</b> in the SCID mouse model of anti-CD40-induced colitis (QD dosing; vehicle: aqueous suspension containing 0.5% Methocel and 0.1% Tween-80).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01698&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Inhibitor <b>7</b> in a spontaneous lupus model in NZB/W mice (QD dosing; vehicle: 5:5:90 EtOH:TPGS:PEG300).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01698&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>8â20</b>, <b>24â27</b>, and <b>29</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01698&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4,4,4â²,4â²,5,5,5â²,5â²-octamethyl-2,2â²-bi(1,3,2-dioxaborolane), PdCl<sub>2</sub>(dppf)-CH<sub>2</sub>Cl<sub>2</sub>, KOAc, 1,4-dioxane, 110 Â°C, 20 h, 60%; (b) ArCl, PdCl<sub>2</sub>(dppf)-CH<sub>2</sub>Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, 110 Â°C, 31â82%; (c) <b>37</b>, LiN(SiMe<sub>3</sub>)<sub>2</sub>, THF, rt, 7â92%; (d) cyclopropanecarboxamide, Pd<sub>2</sub>(dba)<sub>3,</sub> XantPhos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 145 Â°C, 6â56%.</p></p></figure><figure data-id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>21</b> and <b>23</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01698&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) ethyl 2-chloropyrimidine-5-carboxylate, PdCl<sub>2</sub>(dppf)-CH<sub>2</sub>Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, 75 Â°C, 74%; (b) 4,4,4â²,4â²,5,5,5â²,5â²-octamethyl-2,2â²-bi(1,3,2-dioxaborolane), PdCl<sub>2</sub>(dppf)-CH<sub>2</sub>Cl<sub>2</sub>, K<sub>2</sub>OAc, 1,4-dioxane, 105 Â°C, 61%; (c) ethyl 2-chloropyrimidine-5-carboxylate, PdCl<sub>2</sub>(dppf)-CH<sub>2</sub>Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, 75 Â°C, 79%; (d) <b>37</b>, LiN(SiMe<sub>3</sub>)<sub>2</sub>, THF, rt, 32% and 43% for <b>42a</b> and <b>42b</b>, respectively; (e) cyclopropanecarboxamide, Pd<sub>2</sub>(dba)<sub>3,</sub> XantPhos, Cs<sub>2</sub>CO<sub>3,</sub> 1,4-dioxane, 150 Â°C, microwave, 72% and 50% for <b>43a</b> and <b>43b</b>, respectively; (f) i. LiOHÂ·H<sub>2</sub>O, MeOH/THF, rt; ii. Et<sub>2</sub>NH or Me<sub>2</sub>NH, BOP, (<i>i</i>-Pr)<sub>2</sub>NEt, THF, 50 Â°C, 12% and 42% over two steps for <b>21</b> and <b>23</b>, respectively.</p></p></figure><figure data-id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <b>22</b> and <b>28</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01698&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 2,5-dibromopyrimidine, PdCl<sub>2</sub>(dppf)-CH<sub>2</sub>Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, 90 Â°C, 43%; (b) tributyl(1-ethoxyvinyl)stannane, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N, DMF, 100 Â°C, 75%; (c) 3-chloro-6-(1-ethoxyvinyl)pyridazine, PdCl<sub>2</sub>(dppf)-CH<sub>2</sub>Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, 105 Â°C, 1,4-dioxane, 100%; (d) <b>37</b>, LiN(SiMe<sub>3</sub>)<sub>2</sub>, THF, rt, 75% and 52 for <b>46a</b> and <b>46b</b>, respectively; (e) cyclopropanecarboxamide, Pd<sub>2</sub>(dba)<sub>3,</sub> XantPhos, Cs<sub>2</sub>CO<sub>3,</sub> 1,4-dioxane, 150 Â°C, microwave, 71% for <b>47a</b>; (f) 1 N HCl, THF, rt, 76% for <b>48a</b> and 52% (over 2 steps) for <b>48b</b>; (g) MeMgBr, THF, 0 Â°C, 29% and 38% for <b>22</b> and <b>28</b>, respectively.</p></p></figure><figure data-id="sch4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/medium/jm0c01698_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of <b>7</b> and <b>30â33</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01698/20210107/images/large/jm0c01698_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01698&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) ArCl, PdCl<sub>2</sub>(dppf)-CH<sub>2</sub>Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, 110 Â°C, 29â81%; (b) <b>49</b>, LiN(SiMe<sub>3</sub>)<sub>2</sub>, THF, rt, 63â77%; (c) cyclopropanecarboxamide, Pd<sub>2</sub>(dba)<sub>3,</sub> XantPhos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 145 Â°C, 45â65%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i121">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77444" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77444" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 57 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Villarino, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâShea, J. J.</span></span> <span> </span><span class="NLM_article-title">Mechanisms and Consequences of Jak-STAT Signaling in the Immune System</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">374</span>â <span class="NLM_lpage">384</span>, <span class="refDoi">Â DOI: 10.1038/ni.3691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1038%2Fni.3691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=28323260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvFagu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=374-384&author=A.+V.+Villarinoauthor=Y.+Kannoauthor=J.+J.+O%E2%80%99Shea&title=Mechanisms+and+Consequences+of+Jak-STAT+Signaling+in+the+Immune+System&doi=10.1038%2Fni.3691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms and consequences of Jak-STAT signaling in the immune system</span></div><div class="casAuthors">Villarino, Alejandro V.; Kanno, Yuka; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">374-384</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinases of the Jak ('Janus kinase') family and transcription factors (TFs) of the STAT ('signal transducer and activator of transcription') family constitute a rapid membrane-to-nucleus signaling module that affects every aspect of the mammalian immune system.  Research on this paradigmatic pathway has experienced breakneck growth in the quarter century since its discovery and has yielded a stream of basic and clin. insights that have profoundly influenced modern understanding of human health and disease, exemplified by the bench-to-bedside success of Jak inhibitors ('jakinibs') and pathway-targeting drugs.  Here we review recent advances in Jak-STAT biol., focusing on immune cell function, disease etiol. and therapeutic intervention, as well as broader principles of gene regulation and signal-dependent TFs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrUlP3emd5BrVg90H21EOLACvtfcHk0ljJi_UXoTeD3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvFagu7c%253D&md5=b50a88aee2b64fcb85c9a64d4ec1724e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fni.3691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.3691%26sid%3Dliteratum%253Aachs%26aulast%3DVillarino%26aufirst%3DA.%2BV.%26aulast%3DKanno%26aufirst%3DY.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DMechanisms%2520and%2520Consequences%2520of%2520Jak-STAT%2520Signaling%2520in%2520the%2520Immune%2520System%26jtitle%3DNat.%2520Immunol.%26date%3D2017%26volume%3D18%26spage%3D374%26epage%3D384%26doi%3D10.1038%2Fni.3691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sohn, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbema, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macleod, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulagowski, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewin-Koh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dengler, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L. C.</span></span> <span> </span><span class="NLM_article-title">A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective Inhibitors</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">2205</span>â <span class="NLM_lpage">2216</span>, <span class="refDoi">Â DOI: 10.4049/jimmunol.1202859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.4049%2Fjimmunol.1202859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=23894201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSgtL%252FP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=2205-2216&author=S.+J.+Sohnauthor=K.+Barrettauthor=A.+V.+Abbemaauthor=C.+Changauthor=P.+B.+Kohliauthor=H.+Kandaauthor=J.+Smithauthor=Y.+Laiauthor=A.+Zhouauthor=B.+Zhangauthor=W.+Yangauthor=K.+Williamsauthor=C.+Macleodauthor=C.+A.+Hurleyauthor=J.+J.+Kulagowskiauthor=N.+Lewin-Kohauthor=H.+S.+Denglerauthor=A.+R.+Johnsonauthor=N.+Ghilardiauthor=M.+Zakauthor=J.+Liangauthor=W.+S.+Blairauthor=S.+Magnusonauthor=L.+C.+Wu&title=A+Restricted+Role+for+TYK2+Catalytic+Activity+in+Human+Cytokine+Responses+Revealed+by+Novel+TYK2-Selective+Inhibitors&doi=10.4049%2Fjimmunol.1202859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective Inhibitors</span></div><div class="casAuthors">Sohn, Sue J.; Barrett, Kathy; Van Abbema, Anne; Chang, Christine; Kohli, Pawan Bir; Kanda, Hidenobu; Smith, Janice; Lai, Yingjie; Zhou, Aihe; Zhang, Birong; Yang, Wenqian; Williams, Karen; MacLeod, Calum; Hurley, Christopher A.; Kulagowski, Janusz J.; Lewin-Koh, Nicholas; Dengler, Hart S.; Johnson, Adam R.; Ghilardi, Nico; Zak, Mark; Liang, Jun; Blair, Wade S.; Magnuson, Steven; Wu, Lawren C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2205-2216</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">TYK2 is a JAK family protein tyrosine kinase activated in response to multiple cytokines, including type I IFNs, IL-6, IL-10, IL-12, and IL-23.  Extensive studies of mice that lack TYK2 expression indicate that the IFN-Î±, IL-12, and IL-23 pathways, but not the IL-6 or IL-10 pathways, are compromised.  In contrast, there have been few studies of the role of TYK2 in primary human cells.  A genetic mutation at the tyk2 locus that results in a lack of TYK2 protein in a single human patient has been linked to defects in the IFN-Î±, IL-6, IL-10, IL-12, and IL-23 pathways, suggesting a broad role for TYK2 protein in human cytokine responses.  In this article, we have used a panel of novel potent TYK2 small-mol. inhibitors with varying degrees of selectivity against other JAK kinases to address the requirement for TYK2 catalytic activity in cytokine pathways in primary human cells.  Our results indicate that the biol. processes that require TYK2 catalytic function in humans are restricted to the IL-12 and IL-23 pathways, and suggest that inhibition of TYK2 catalytic activity may be an efficacious approach for the treatment of select autoimmune diseases without broad immunosuppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgACYZYW8b07Vg90H21EOLACvtfcHk0ljJi_UXoTeD3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSgtL%252FP&md5=527289e055e91fe2dfb15d3de7faa894</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1202859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1202859%26sid%3Dliteratum%253Aachs%26aulast%3DSohn%26aufirst%3DS.%2BJ.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DAbbema%26aufirst%3DA.%2BV.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DKanda%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DWilliams%26aufirst%3DK.%26aulast%3DMacleod%26aufirst%3DC.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26aulast%3DLewin-Koh%26aufirst%3DN.%26aulast%3DDengler%26aufirst%3DH.%2BS.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DZak%26aufirst%3DM.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DMagnuson%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DL.%2BC.%26atitle%3DA%2520Restricted%2520Role%2520for%2520TYK2%2520Catalytic%2520Activity%2520in%2520Human%2520Cytokine%2520Responses%2520Revealed%2520by%2520Novel%2520TYK2-Selective%2520Inhibitors%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26spage%3D2205%26epage%3D2216%26doi%3D10.4049%2Fjimmunol.1202859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghoreschi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâShea, J. J.</span></span> <span> </span><span class="NLM_article-title">Janus Kinases in Immune Cell Signaling</span>. <i>Immunol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>228</i></span>,  <span class="NLM_fpage">273</span>â <span class="NLM_lpage">287</span>, <span class="refDoi">Â DOI: 10.1111/j.1600-065X.2008.00754.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1111%2Fj.1600-065X.2008.00754.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=19290934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=273-287&author=K.+Ghoreschiauthor=A.+Laurenceauthor=J.+J.+O%E2%80%99Shea&title=Janus+Kinases+in+Immune+Cell+Signaling&doi=10.1111%2Fj.1600-065X.2008.00754.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinases in immune cell signaling</span></div><div class="casAuthors">Ghoreschi, Kamran; Laurence, Arian; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">273-287</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The Janus family kinases (Jaks), Jak1, Jak2, Jak3, and Tyk2, form one subgroup of the non-receptor protein tyrosine kinases.  They are involved in cell growth, survival, development, and differentiation of a variety of cells but are critically important for immune cells and hematopoietic cells.  Data from exptl. mice and clin. observations have unraveled multiple signaling events mediated by Jaks in innate and adaptive immunity.  Deficiency of Jak3 or Tyk2 results in defined clin. disorders, which are also evident in mouse models.  A striking phenotype assocd. with inactivating Jak3 mutations is severe combined immunodeficiency syndrome, whereas mutation of Tyk2 results in another primary immunodeficiency termed autosomal recessive hyperimmunoglobulin E syndrome.  By contrast, complete deletion of Jak1 or Jak2 in the mouse are not compatible with life and, unsurprisingly, do not have counterparts in human disease.  However, activating mutations of each of the Jaks are found in assocn. with malignant transformation, the most common being gain-of-function mutations of Jak2 in polycythemia vera and other myeloproliferative disorders.  Our existing knowledge on Jak signaling pathways and fundamental work on their biochem. structure and intracellular interactions allow us to develop new strategies for controlling autoimmune diseases or malignancies by developing selective Jak inhibitors, which are now coming into clin. use.  Despite the fact that Jaks were discovered only a little more than a decade ago, at the time of writing there are 20 clin. trials underway testing the safely and efficacy of Jak inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp23ncK0nYqpbVg90H21EOLACvtfcHk0lgAgKYA65aZXA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ&md5=adc282a9ad381ee18abe57a82c921f65</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00754.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00754.x%26sid%3Dliteratum%253Aachs%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJanus%2520Kinases%2520in%2520Immune%2520Cell%2520Signaling%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D273%26epage%3D287%26doi%3D10.1111%2Fj.1600-065X.2008.00754.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murray, P. J.</span></span> <span> </span><span class="NLM_article-title">The JAK-STAT Signaling Pathway: Input and Output Integration</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">2623</span>â <span class="NLM_lpage">2629</span>, <span class="refDoi">Â DOI: 10.4049/jimmunol.178.5.2623</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.4049%2Fjimmunol.178.5.2623" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=17312100" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvFSju78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2007&pages=2623-2629&author=P.+J.+Murray&title=The+JAK-STAT+Signaling+Pathway%3A+Input+and+Output+Integration&doi=10.4049%2Fjimmunol.178.5.2623"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The JAK-STAT Signaling Pathway: Input and Output Integration</span></div><div class="casAuthors">Murray, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2623-2629</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">A review.  Universal and essential to cytokine receptor signaling, the JAK-STAT pathway is one of the best understood signal transduction cascades.  Almost 40 cytokine receptors signal through combinations of four JAK and seven STAT family members, suggesting commonality across the JAK-STAT signaling system.  Despite intense study, there remain substantial gaps in understanding how the cascades are activated and regulated.  Using the examples of the IL-6 and IL-10 receptors, the author discusses how diverse outcomes in gene expression result from regulatory events that effect the JAK1-STAT3 pathway, common to both receptors.  I also consider receptor preferences by different STATs and interpretive problems in the use of STAT-deficient cells and mice.  Finally, the author considers how the suppressor of cytokine signaling (SOCS) proteins regulate the quality and quantity of STAT signals from cytokine receptors.  New data suggests that SOCS proteins introduce addnl. diversity into the JAK-STAT pathway by adjusting the output of activated STATs that alters downstream gene activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcUsn_Apl_EbVg90H21EOLACvtfcHk0lgAgKYA65aZXA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvFSju78%253D&md5=4f3eb8e58b729f4dab66ab7c1a2dcdab</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.178.5.2623&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.178.5.2623%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DP.%2BJ.%26atitle%3DThe%2520JAK-STAT%2520Signaling%2520Pathway%253A%2520Input%2520and%2520Output%2520Integration%26jtitle%3DJ.%2520Immunol.%26date%3D2007%26volume%3D178%26spage%3D2623%26epage%3D2629%26doi%3D10.4049%2Fjimmunol.178.5.2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, T.</span></span> <span> </span><span class="NLM_article-title">JAK-STAT Signaling: From Interferons to Cytokines</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>282</i></span>,  <span class="NLM_fpage">20059</span>â <span class="NLM_lpage">20063</span>, <span class="refDoi">Â DOI: 10.1074/jbc.R700016200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1074%2Fjbc.R700016200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=17502367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsFWntr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=20059-20063&author=C.+Schindlerauthor=D.+E.+Levyauthor=T.+Decker&title=JAK-STAT+Signaling%3A+From+Interferons+to+Cytokines&doi=10.1074%2Fjbc.R700016200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">JAK-STAT Signaling: From Interferons to Cytokines</span></div><div class="casAuthors">Schindler, Christian; Levy, David E.; Decker, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">20059-20063</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review.  The early availability of recombinant interferons (IFNs) afforded an opportunity to study how cytokines induce gene expression, culminating in the identification of JAK-STAT signaling paradigm.  Subsequent studies identified 7 STATs and 4 JAKs, providing an insight how IFNs and other members of the four-helix bundle cytokine family transduce their biol. responses.  Here, the authors briefly summarize this signaling paradigm and then focus on STAT-dependent transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx3j1nH6yBhbVg90H21EOLACvtfcHk0lj5Z3dXH5LDhA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsFWntr8%253D&md5=9bbfc21b9afc22cd65dbd9a8605f7a03</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1074%2Fjbc.R700016200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.R700016200%26sid%3Dliteratum%253Aachs%26aulast%3DSchindler%26aufirst%3DC.%26aulast%3DLevy%26aufirst%3DD.%2BE.%26aulast%3DDecker%26aufirst%3DT.%26atitle%3DJAK-STAT%2520Signaling%253A%2520From%2520Interferons%2520to%2520Cytokines%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D20059%26epage%3D20063%26doi%3D10.1074%2Fjbc.R700016200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, K.</span></span> <span> </span><span class="NLM_article-title">FDA Approves Tofacitinib for Rheumatoid Arthritis</span>. <i>Am. J. Health Syst. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">2120</span>, <span class="refDoi">Â DOI: 10.2146/news120088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.2146%2Fnews120088" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=2120&author=K.+Traynor&title=FDA+Approves+Tofacitinib+for+Rheumatoid+Arthritis&doi=10.2146%2Fnews120088"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2146%2Fnews120088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2146%252Fnews120088%26sid%3Dliteratum%253Aachs%26aulast%3DTraynor%26aufirst%3DK.%26atitle%3DFDA%2520Approves%2520Tofacitinib%2520for%2520Rheumatoid%2520Arthritis%26jtitle%3DAm.%2520J.%2520Health%2520Syst.%2520Pharm.%26date%3D2012%26volume%3D69%26spage%3D2120%26doi%3D10.2146%2Fnews120088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenkopf, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brissette, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang-Poa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudlacz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lillie, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strelevitz, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanyam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whipple, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Changelian, P. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">8468</span>â <span class="NLM_lpage">8484</span>, <span class="refDoi">Â DOI: 10.1021/jm1004286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=C.+Shang-Poaauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hinesauthor=C.+Kentauthor=E.+M.+Kudlaczauthor=B.+M.+Lillieauthor=K.+S.+Magnusonauthor=S.+P.+McCurdyauthor=M.+J.+Munchhofauthor=B.+D.+Perryauthor=P.+S.+Sawyerauthor=T.+J.+Strelevitzauthor=C.+Subramanyamauthor=J.+Sunauthor=D.+A.+Whippleauthor=P.+S.+Changelian&title=Discovery+of+CP-690%2C550%3A+A+Potent+and+Selective+Janus+Kinase+%28JAK%29+Inhibitor+for+the+Treatment+of+Autoimmune+Diseases+and+Organ+Transplant+Rejection&doi=10.1021%2Fjm1004286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0lj5Z3dXH5LDhA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DKent%26aufirst%3DC.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520CP-690%252C550%253A%2520A%2520Potent%2520and%2520Selective%2520Janus%2520Kinase%2520%2528JAK%2529%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Autoimmune%2520Diseases%2520and%2520Organ%2520Transplant%2520Rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8468%26epage%3D8484%26doi%3D10.1021%2Fjm1004286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span> <i>FDA
Approves Jakafi (ruxolitinib)
to Treat Myelofibrosis</i>. . Nov 16, <span class="NLM_year">2011</span>. <a href="https://www.drugs.com/newdrugs/fda-approves-jakafi-myelofibrosis-2949.html" class="extLink">https://www.drugs.com/newdrugs/fda-approves-jakafi-myelofibrosis-2949.html</a> (accessed Nov 8, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+FDA%0AApproves+Jakafi+%28ruxolitinib%29%0Ato+Treat+Myelofibrosis.+.+Nov+16%2C+2011.+https%3A%2F%2Fwww.drugs.com%2Fnewdrugs%2Ffda-approves-jakafi-myelofibrosis-2949.html+%28accessed+Nov+8%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26jtitle%3DFDA%250AApproves%2520Jakafi%2520%2528ruxolitinib%2529%250Ato%2520Treat%2520Myelofibrosis%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campas-Moya, C.</span></span> <span> </span><span class="NLM_article-title">Ruxolitinib: Tyrosine-protein Kinase JAK1/2 Inhibitor: Treatment of Myelofibrosis: Treatment of Myeloproliferative Neoplasms: Treatment of Psoriasis</span>. <i>Drug Future</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">457</span>â <span class="NLM_lpage">465</span>, <span class="refDoi">Â DOI: 10.1358/dof.2010.035.06.1509764</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1358%2Fdof.2010.035.06.1509764" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=457-465&author=C.+Campas-Moya&title=Ruxolitinib%3A+Tyrosine-protein+Kinase+JAK1%2F2+Inhibitor%3A+Treatment+of+Myelofibrosis%3A+Treatment+of+Myeloproliferative+Neoplasms%3A+Treatment+of+Psoriasis&doi=10.1358%2Fdof.2010.035.06.1509764"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1358%2Fdof.2010.035.06.1509764&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2010.035.06.1509764%26sid%3Dliteratum%253Aachs%26aulast%3DCampas-Moya%26aufirst%3DC.%26atitle%3DRuxolitinib%253A%2520Tyrosine-protein%2520Kinase%2520JAK1%252F2%2520Inhibitor%253A%2520Treatment%2520of%2520Myelofibrosis%253A%2520Treatment%2520of%2520Myeloproliferative%2520Neoplasms%253A%2520Treatment%2520of%2520Psoriasis%26jtitle%3DDrug%2520Future%26date%3D2010%26volume%3D35%26spage%3D457%26epage%3D465%26doi%3D10.1358%2Fdof.2010.035.06.1509764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mogul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corsi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAuliffe, L.</span></span> <span> </span><span class="NLM_article-title">Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis</span>. <i>Ann. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">947</span>â <span class="NLM_lpage">953</span>, <span class="refDoi">Â DOI: 10.1177/1060028019839650</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1177%2F1060028019839650" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=30907116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVajsLjF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2019&pages=947-953&author=A.+Mogulauthor=K.+Corsiauthor=L.+McAuliffe&title=Baricitinib%3A+The+Second+FDA-Approved+JAK+Inhibitor+for+the+Treatment+of+Rheumatoid+Arthritis&doi=10.1177%2F1060028019839650"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis</span></div><div class="casAuthors">Mogul, Amanda; Corsi, Katherine; McAuliffe, Laura</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Pharmacotherapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">947-953</span>CODEN:
                <span class="NLM_cas:coden">APHRER</span>;
        ISSN:<span class="NLM_cas:issn">1542-6270</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Objective: To review the pharmacol., pharmacokinetics, safety, and efficacy of baricitinib, a recently approved selective Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA), and explore its potential role in therapy.  Data Sources: Articles were identified using a PubMed search from inception through Jan. 2019 using the terms rheumatoid arthritis, Olumiant, baricitinib, and LY3009104, its mol. name.  Study Selection and Data Extn.: Articles relating to randomized clin. trials, pharmacol., pharmacokinetics, efficacy, and safety of baricitinib were evaluated.  Data Synthesis: Baricitinib exerts its effects by inhibiting JAK1 and JAK2 enzymes, targeting cytokine and growth factor receptor stimulation, thus reducing downstream immune cell function.  Four trials have demonstrated the efficacy of baricitinib with or without methotrexate in patients naive to disease-modifying antirheumatic drugs (DMARDs) and those who had an inadequate response to or intolerance to both conventional and biol. DMARDs.  Furthermore, baricitinib was assocd. with delayed radiog. progression.  Despite baricitinib 4 mg often demonstrating greater efficacy compared with the 2 mg dose, only the 2 mg dose is Food and Drug Administration approved because of safety concerns with the 4 mg dose, primarily thromboembolism.  Relevance to Patient Care and Clin. Practice: Baricitinib provides an oral treatment option for patients failing tumor necrosis factor inhibitors (TNFis).  Safety, cost, and comparative effectiveness to tofacitinib should be considered prior to prescribing baricitinib.  Conclusion: Baricitinib is the second medication in its class and has been proven efficacious for the treatment of RA.  Given concerns for adverse effects assocd. with baricitinib, it should be reserved for patients who have failed one or more TNFis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0MPlLYo12drVg90H21EOLACvtfcHk0lgYYUjMjydkJQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVajsLjF&md5=9f9a87369759bb6d5fd36356ebff3f27</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1177%2F1060028019839650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1060028019839650%26sid%3Dliteratum%253Aachs%26aulast%3DMogul%26aufirst%3DA.%26aulast%3DCorsi%26aufirst%3DK.%26aulast%3DMcAuliffe%26aufirst%3DL.%26atitle%3DBaricitinib%253A%2520The%2520Second%2520FDA-Approved%2520JAK%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Rheumatoid%2520Arthritis%26jtitle%3DAnn.%2520Pharmacother.%26date%3D2019%26volume%3D53%26spage%3D947%26epage%3D953%26doi%3D10.1177%2F1060028019839650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mayence, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eynde, J. J. V.</span></span> <span> </span><span class="NLM_article-title">Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases</span>. <i>Pharmaceuticals</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">37</span>, <span class="refDoi">Â DOI: 10.3390/ph12010037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.3390%2Fph12010037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFGlsrbJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=37&author=A.+Mayenceauthor=J.+J.+V.+Eynde&title=Baricitinib%3A+A+2018+Novel+FDA-Approved+Small+Molecule+Inhibiting+Janus+Kinases&doi=10.3390%2Fph12010037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Baricitinib: a 2018 novel FDA-approved small molecule inhibiting janus kinases</span></div><div class="casAuthors">Mayence, Annie; Vanden Eynde, Jean Jacques</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceuticals</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37</span>CODEN:
                <span class="NLM_cas:coden">PHARH2</span>;
        ISSN:<span class="NLM_cas:issn">1424-8247</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  In 2018, Baricitinib was approved by the Food and Drig Administration (FDA) for the treatment of rheumatoid arthritis.  Baricitinib exerts its action by targeting Janus kinases (JAK).  In this study, we describe the necessary steps for prepg. the drug using two alternative routes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW_aEEygkb07Vg90H21EOLACvtfcHk0lgYYUjMjydkJQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFGlsrbJ&md5=879d0609660dccfd5a0c145bab708807</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.3390%2Fph12010037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fph12010037%26sid%3Dliteratum%253Aachs%26aulast%3DMayence%26aufirst%3DA.%26aulast%3DEynde%26aufirst%3DJ.%2BJ.%2BV.%26atitle%3DBaricitinib%253A%2520A%25202018%2520Novel%2520FDA-Approved%2520Small%2520Molecule%2520Inhibiting%2520Janus%2520Kinases%26jtitle%3DPharmaceuticals%26date%3D2019%26volume%3D12%26spage%3D37%26doi%3D10.3390%2Fph12010037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, C.</span></span> <i>FDA Approves Upadacitinib for Rheumatoid Arthritis</i>. <i>Rheumatology News</i>. Aug 16, <span class="NLM_year">2019</span>. <a href="https://www.mdedge.com/rheumatology/article/206593/rheumatoid-arthritis/fda-approves-upadacitinib-rheumatoid-arthritis" class="extLink">https://www.mdedge.com/rheumatology/article/206593/rheumatoid-arthritis/fda-approves-upadacitinib-rheumatoid-arthritis</a> (accessed Nov 8, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=C.+Palmer&title=FDA+Approves+Upadacitinib+for+Rheumatoid+Arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DPalmer%26aufirst%3DC.%26jtitle%3DFDA%2520Approves%2520Upadacitinib%2520for%2520Rheumatoid%2520Arthritis%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parmentier, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argiriadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padley, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosebraugh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, A. J.</span></span> <span> </span><span class="NLM_article-title">In Vitro and In Vivo Characterization of the JAK1 Selectivity of Upadacitinib (ABT-494)</span>. <i>BMC Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">23</span>, <span class="refDoi">Â DOI: 10.1186/s41927-018-0031-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1186%2Fs41927-018-0031-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=30886973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A280%3ADC%252BB3cbls1ymuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2018&pages=23&author=J.+M.+Parmentierauthor=J.+Vossauthor=C.+Graffauthor=A.+Schwartzauthor=M.+Argiriadiauthor=M.+Friedmanauthor=H.+S.+Campauthor=R.+J.+Padleyauthor=J.+S.+Georgeauthor=D.+Hylandauthor=M.+Rosebraughauthor=N.+Wishartauthor=L.+Olsonauthor=A.+J.+Long&title=In+Vitro+and+In+Vivo+Characterization+of+the+JAK1+Selectivity+of+Upadacitinib+%28ABT-494%29&doi=10.1186%2Fs41927-018-0031-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)</span></div><div class="casAuthors">Parmentier Julie M; Voss Jeff; Graff Candace; Schwartz Annette; Argiriadi Maria; Friedman Michael; George Jonathan S; Hyland Deborah; Wishart Neil; Olson Lisa; Long Andrew J; Camp Heidi S; Padley Robert J; Rosebraugh Matthew</div><div class="citationInfo"><span class="NLM_cas:title">BMC rheumatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Anti-cytokine therapies such as adalimumab, tocilizumab, and the small molecule JAK inhibitor tofacitinib have proven that cytokines and their subsequent downstream signaling processes are important in the pathogenesis of rheumatoid arthritis.  Tofacitinib, a pan-JAK inhibitor, is the first approved JAK inhibitor for the treatment of RA and has been shown to be effective in managing disease.  However, in phase 2 dose-ranging studies tofacitinib was associated with dose-limiting tolerability and safety issues such as anemia.  Upadacitinib (ABT-494) is a selective JAK1 inhibitor that was engineered to address the hypothesis that greater JAK1 selectivity over other JAK family members will translate into a more favorable benefit:risk profile.  Upadacitinib selectively targets JAK1 dependent disease drivers such as IL-6 and IFNÎ³, while reducing effects on reticulocytes and natural killer (NK) cells, which potentially contributed to the tolerability issues of tofacitinib.  Methods:  Structure-based hypotheses were used to design the JAK1 selective inhibitor upadacitinib.  JAK family selectivity was defined with in vitro assays including biochemical assessments, engineered cell lines, and cytokine stimulation.  In vivo selectivity was defined by the efficacy of upadacitinib and tofacitinib in a rat adjuvant induced arthritis model, activity on reticulocyte deployment, and effect on circulating NK cells.  The translation of the preclinical JAK1 selectivity was assessed in healthy volunteers using ex vivo stimulation with JAK-dependent cytokines.  Results:  Here, we show the structural basis for the JAK1 selectivity of upadacitinib, along with the in vitro JAK family selectivity profile and subsequent in vivo physiological consequences.  Upadacitinib is ~ 60 fold selective for JAK1 over JAK2, and > 100 fold selective over JAK3 in cellular assays.  While both upadacitinib and tofacitinib demonstrated efficacy in a rat model of arthritis, the increased selectivity of upadacitinib for JAK1 resulted in a reduced effect on reticulocyte deployment and NK cell depletion relative to efficacy.  Ex vivo pharmacodynamic data obtained from Phase I healthy volunteers confirmed the JAK1 selectivity of upadactinib in a clinical setting.  Conclusions:  The data presented here highlight the JAK1 selectivity of upadacinitinib and supports its use as an effective therapy for the treatment of RA with the potential for an improved benefit:risk profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTVFFxllNWaxfKb6ELK8t0fW6udTcc2eahuzn7AibOs7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbls1ymuw%253D%253D&md5=5ca2dcb18a98362567d2193e858cc800</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1186%2Fs41927-018-0031-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs41927-018-0031-x%26sid%3Dliteratum%253Aachs%26aulast%3DParmentier%26aufirst%3DJ.%2BM.%26aulast%3DVoss%26aufirst%3DJ.%26aulast%3DGraff%26aufirst%3DC.%26aulast%3DSchwartz%26aufirst%3DA.%26aulast%3DArgiriadi%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DM.%26aulast%3DCamp%26aufirst%3DH.%2BS.%26aulast%3DPadley%26aufirst%3DR.%2BJ.%26aulast%3DGeorge%26aufirst%3DJ.%2BS.%26aulast%3DHyland%26aufirst%3DD.%26aulast%3DRosebraugh%26aufirst%3DM.%26aulast%3DWishart%26aufirst%3DN.%26aulast%3DOlson%26aufirst%3DL.%26aulast%3DLong%26aufirst%3DA.%2BJ.%26atitle%3DIn%2520Vitro%2520and%2520In%2520Vivo%2520Characterization%2520of%2520the%2520JAK1%2520Selectivity%2520of%2520Upadacitinib%2520%2528ABT-494%2529%26jtitle%3DBMC%2520Rheumatol.%26date%3D2018%26volume%3D2%26spage%3D23%26doi%3D10.1186%2Fs41927-018-0031-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talpaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiladjian, J.-J.</span></span> <span> </span><span class="NLM_article-title">Fedratinib, a Newly Approved Treatment for Patients with Myeloproliferative Neoplasm-associated Myelofibrosis</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">17</span>, <span class="refDoi">Â DOI: 10.1038/s41375-020-0954-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1038%2Fs41375-020-0954-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=31776467" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&pages=1-17&author=M.+Talpazauthor=J.-J.+Kiladjian&title=Fedratinib%2C+a+Newly+Approved+Treatment+for+Patients+with+Myeloproliferative+Neoplasm-associated+Myelofibrosis&doi=10.1038%2Fs41375-020-0954-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fs41375-020-0954-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-020-0954-2%26sid%3Dliteratum%253Aachs%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DKiladjian%26aufirst%3DJ.-J.%26atitle%3DFedratinib%252C%2520a%2520Newly%2520Approved%2520Treatment%2520for%2520Patients%2520with%2520Myeloproliferative%2520Neoplasm-associated%2520Myelofibrosis%26jtitle%3DLeukemia%26date%3D2020%26spage%3D1%26epage%3D17%26doi%3D10.1038%2Fs41375-020-0954-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pardanani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasho, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noronha, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soll, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span> <span> </span><span class="NLM_article-title">TG101209, a Small Molecule JAK2-selective Kinase Inhibitor Potently Inhibits Myeloproliferative Disorder-associated <i>JAK</i>2V617F and <i>MPL</i>W515L/K Mutations</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1658</span>â <span class="NLM_lpage">1668</span>, <span class="refDoi">Â DOI: 10.1038/sj.leu.2404750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1038%2Fsj.leu.2404750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=17541402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnvVeltLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=1658-1668&author=A.+Pardananiauthor=J.+Hoodauthor=T.+Lashoauthor=R.+L.+Levineauthor=M.+B.+Martinauthor=G.+Noronhaauthor=C.+Finkeauthor=C.+C.+Makauthor=R.+Mesaauthor=H.+Zhuauthor=R.+Sollauthor=D.+G.+Gillilandauthor=A.+Tefferi&title=TG101209%2C+a+Small+Molecule+JAK2-selective+Kinase+Inhibitor+Potently+Inhibits+Myeloproliferative+Disorder-associated+JAK2V617F+and+MPLW515L%2FK+Mutations&doi=10.1038%2Fsj.leu.2404750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations</span></div><div class="casAuthors">Pardanani, A.; Hood, J.; Lasho, T.; Levine, R. L.; Martin, M. B.; Noronha, G.; Finke, C.; Mak, C. C.; Mesa, R.; Zhu, H.; Soll, R.; Gilliland, D. G.; Tefferi, A.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1658-1668</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">JAK2V617F and MPLW515L/K represent recently identified mutations in myeloproliferative disorders (MPD) that cause dysregulated JAK-STAT signaling, which is implicated in MPD pathogenesis.  The authors developed TG101209, an orally bioavailable small mol. that potently inhibits JAK2 (IC50 = 6 nM), FLT3 (IC50 = 25 nM) and RET (IC50 = 17 nM) kinases, with significantly less activity against other tyrosine kinases including JAK3 (IC50 = 169 nM).  TG101209 inhibited growth of Ba/F3 cells expressing JAK2V617F or MPLW515L mutations with an IC50 of â¼200 nM.  In a human JAK2V617F-expressing acute myeloid leukemia cell line, TG101209-induced cell cycle arrest and apoptosis, and inhibited phosphorylation of JAK2V617F, STAT5 and STAT3.  Therapeutic efficacy of TG101209 was demonstrated in a nude mouse model.  Furthermore, TG101209 suppressed growth of hematopoietic colonies from primary progenitor cells harboring JAK2V617F or MPL515 mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZFcz0joQsNbVg90H21EOLACvtfcHk0lhfGaQbSJQA9A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnvVeltLo%253D&md5=784ff4ff7d65097052d9d864c90e8138</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2404750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2404750%26sid%3Dliteratum%253Aachs%26aulast%3DPardanani%26aufirst%3DA.%26aulast%3DHood%26aufirst%3DJ.%26aulast%3DLasho%26aufirst%3DT.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DMartin%26aufirst%3DM.%2BB.%26aulast%3DNoronha%26aufirst%3DG.%26aulast%3DFinke%26aufirst%3DC.%26aulast%3DMak%26aufirst%3DC.%2BC.%26aulast%3DMesa%26aufirst%3DR.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DSoll%26aufirst%3DR.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DTG101209%252C%2520a%2520Small%2520Molecule%2520JAK2-selective%2520Kinase%2520Inhibitor%2520Potently%2520Inhibits%2520Myeloproliferative%2520Disorder-associated%2520JAK2V617F%2520and%2520MPLW515L%252FK%2520Mutations%26jtitle%3DLeukemia%26date%3D2007%26volume%3D21%26spage%3D1658%26epage%3D1668%26doi%3D10.1038%2Fsj.leu.2404750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piskin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sylva-Steenland, R. M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bos, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teunissen, M. B. M.</span></span> <span> </span><span class="NLM_article-title">In vitro and in situ Expression of IL-23 by Keratinocytes in Healthy Skin and Psoriasis lesions: Enhanced Expression in Psoriatic Skin</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">1908</span>â <span class="NLM_lpage">1915</span>, <span class="refDoi">Â DOI: 10.4049/jimmunol.176.3.1908</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.4049%2Fjimmunol.176.3.1908" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=16424222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BD28XlsFyktA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2006&pages=1908-1915&author=G.+Piskinauthor=R.+M.+R.+Sylva-Steenlandauthor=J.+D.+Bosauthor=M.+B.+M.+Teunissen&title=In+vitro+and+in+situ+Expression+of+IL-23+by+Keratinocytes+in+Healthy+Skin+and+Psoriasis+lesions%3A+Enhanced+Expression+in+Psoriatic+Skin&doi=10.4049%2Fjimmunol.176.3.1908"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro and In Situ Expression of IL-23 by Keratinocytes in Healthy Skin and Psoriasis Lesions: Enhanced Expression in Psoriatic Skin</span></div><div class="casAuthors">Piskin, Gamze; Sylva-Steenland, Regien M. R.; Bos, Jan D.; Teunissen, Marcel B. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1908-1915</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Keratinocytes contribute to cutaneous immune responses through the expression of cytokines.  The authors investigated whether human keratinocytes can express IL-23, a newly defined IFN-Î³-inducing cytokine composed of a unique p19 subunit and a p40 subunit shared with IL-12.  Cultured keratinocytes from normal and lesional psoriatic skin were found to express constitutively mRNA for both subunits of IL-23.  Low but significant levels of the heterodimeric IL-23 protein could be detected in cell lysates and supernatants from stimulated keratinocytes by immunoblotting and ELISA.  Functional anal. showed that these low levels of keratinocyte-derived IL-23 were sufficient to enhance the IFN-Î³ prodn. by memory T cells.  Immunostaining of skin sections confirmed expression of both subunits of IL-23 by keratinocytes in situ and also revealed expression of this cytokine in the dermal compartment.  IL-23 expression was significantly higher in psoriatic lesional skin, compared with normal and psoriatic nonlesional skin.  The immunostained prepns. of cultured cells and IL-23 levels in culture supernatants did not show any difference between normal and psoriatic keratinocytes indicating no intrinsic aberration of IL-23 expression in keratinocytes from psoriatic skin.  Double staining of cytospin prepns. demonstrated that IL-23 p19 is also expressed by epidermal Langerhans cells, dermal dendritic cells, and macrophages.  Psoriasis is a chronic inflammatory skin disease mediated by IFN-Î³-expressing type 1 memory T cells.  As IL-23 is important to activate memory T cells to produce IFN-Î³, its augmented expression of IL-23 by keratinocytes and cutaneous APC may contribute to the perpetuation of the inflammation process in this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEfsct9xM39rVg90H21EOLACvtfcHk0lhfGaQbSJQA9A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlsFyktA%253D%253D&md5=40142be77afa79fd8dc2f8a474502a2a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.176.3.1908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.176.3.1908%26sid%3Dliteratum%253Aachs%26aulast%3DPiskin%26aufirst%3DG.%26aulast%3DSylva-Steenland%26aufirst%3DR.%2BM.%2BR.%26aulast%3DBos%26aufirst%3DJ.%2BD.%26aulast%3DTeunissen%26aufirst%3DM.%2BB.%2BM.%26atitle%3DIn%2520vitro%2520and%2520in%2520situ%2520Expression%2520of%2520IL-23%2520by%2520Keratinocytes%2520in%2520Healthy%2520Skin%2520and%2520Psoriasis%2520lesions%253A%2520Enhanced%2520Expression%2520in%2520Psoriatic%2520Skin%26jtitle%3DJ.%2520Immunol.%26date%3D2006%26volume%3D176%26spage%3D1908%26epage%3D1915%26doi%3D10.4049%2Fjimmunol.176.3.1908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trepicchio, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oestreicher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhodapkar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, J. G.</span></span> <span> </span><span class="NLM_article-title">Increased Expression of Interleukin 23p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgris</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>199</i></span>,  <span class="NLM_fpage">125</span>â <span class="NLM_lpage">130</span>, <span class="refDoi">Â DOI: 10.1084/jem.20030451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1084%2Fjem.20030451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=14707118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvFWktw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=199&publication_year=2004&pages=125-130&author=E.+Leeauthor=W.+L.+Trepicchioauthor=J.+Oestreicherauthor=D.+Pittmanauthor=F.+Wangauthor=F.+Chamianauthor=M.+Dhodapkarauthor=J.+G.+Krueger&title=Increased+Expression+of+Interleukin+23p19+and+p40+in+Lesional+Skin+of+Patients+with+Psoriasis+Vulgris&doi=10.1084%2Fjem.20030451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris</span></div><div class="casAuthors">Lee, Edmund; Trepicchio, William L.; Oestreicher, Judith L.; Pittman, Debra; Wang, Frank; Chamian, Francesca; Dhodapkar, Madhav; Krueger, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">199</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">125-130</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Psoriasis is a type I-deviated disease characterized by the presence of interferon (IFN)-Î³ and multiple IFN-related inflammatory genes in lesions.  Because interleukin (IL)-23 is now recognized to play a role in the recruitment of inflammatory cells in a T helper cell (Th)1-mediated disease, we examd. psoriasis skin lesions for prodn. of this newly described cytokine.  IL-23 is composed of two subunits: a unique p19 subunit and a p40 subunit shared with IL-12.  We found a reliable increase in p19 mRNA by quant. reverse transcription polymerase chain reaction in lesional skin compared with nonlesional skin (22.3-fold increase; P = 0.001).  The p40 subunit, shared by IL-12 and IL-23, increased by 11.6-fold compared with nonlesional skin (P = 0.003), but the IL-12 p35 subunit was not increased in lesional skin.  IL-23 was expressed mainly by dermal cells and increased p40 immunoreactivity was visualized in large dermal cells in the lesions.  Cell isolation expts. from psoriatic tissue showed strong expression of p19 mRNA in cells expressing monocyte (CD14+ CD11c+ CD83-) and mature dendritic cell (DC) markers (CD14- CD11c+ CD83+), whereas in culture, the mRNAs for p40 and p19 were strongly up-regulated in stimulated monocytes and monocyte-derived DCs, persisting in the latter for much longer periods than IL-12.  Our data suggest that IL-23 is playing a more dominant role than IL-12 in psoriasis, a Th1 type of human inflammatory disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorJcxLmOKG_bVg90H21EOLACvtfcHk0ljff5XnsB-ihQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvFWktw%253D%253D&md5=b474156a73f56b9562f8074c00e4c711</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1084%2Fjem.20030451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20030451%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DE.%26aulast%3DTrepicchio%26aufirst%3DW.%2BL.%26aulast%3DOestreicher%26aufirst%3DJ.%26aulast%3DPittman%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DChamian%26aufirst%3DF.%26aulast%3DDhodapkar%26aufirst%3DM.%26aulast%3DKrueger%26aufirst%3DJ.%2BG.%26atitle%3DIncreased%2520Expression%2520of%2520Interleukin%252023p19%2520and%2520p40%2520in%2520Lesional%2520Skin%2520of%2520Patients%2520with%2520Psoriasis%2520Vulgris%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2004%26volume%3D199%26spage%3D125%26epage%3D130%26doi%3D10.1084%2Fjem.20030451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yawalkar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brand, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braathen, L. R.</span></span> <span> </span><span class="NLM_article-title">Expression of Interleukin-12 is Increased in Psoriatic Skin</span>. <i>J. Invest. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">1053</span>â <span class="NLM_lpage">1057</span>, <span class="refDoi">Â DOI: 10.1046/j.1523-1747.1998.00446.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1046%2Fj.1523-1747.1998.00446.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=9856816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADyaK1cXnvFyit78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=1998&pages=1053-1057&author=N.+Yawalkarauthor=S.+Karlenauthor=R.+Hungerauthor=C.+U.+Brandauthor=L.+R.+Braathen&title=Expression+of+Interleukin-12+is+Increased+in+Psoriatic+Skin&doi=10.1046%2Fj.1523-1747.1998.00446.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of interleukin-12 is increased in psoriatic skin</span></div><div class="casAuthors">Yawalkar, Nikhil; Karlen, Stephan; Hunger, Robert; Brand, Christoph U.; Braathen, Lasse R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Dermatology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1053-1057</span>CODEN:
                <span class="NLM_cas:coden">JIDEAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-202X</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science, Inc.</span>)
        </div><div class="casAbstract">Although the precise underlying pathomechanisms of psoriasis have not been fully elucidated, previous reports suggest that T helper 1-type cytokines are critically involved in the pathogenesis of this disease.  Interleukin-12 (IL-12), a heterodimeric cytokine, has been suggested to play a major role in the development of T helper 1 cell responses.  Here, the presence of IL-12 mRNA and protein was investigated in normal human skin as well as non-lesional and lesional psoriatic skin.  MRNA levels were detd. in biopsy specimens by a std. and a nested reverse transcriptase-polymerase chain reaction method.  Addnl., IL-12 protein expression was analyzed in situ by immunohistochem. using an antibody recognizing IL-12 p70.  Whereas specific transcripts for IL-12 p35 were reproducibly detected without any differences in all samples, enhanced IL-12 p40 mRNA signals were only found in lesional psoriatic skin as compared with normal and non-lesional psoriatic skin.  Furthermore, immunoreactivity for IL-12 p70 was markedly increased in the psoriatic skin lesions and was predominantly expressed on mononuclear cells in the dermis.  Thus, the authors' data suggest a crit. role for IL-12 in promoting and maintaining T cell activation and inducing T helper 1-type cytokines such as interferon-Î³ in psoriasis.  The authors speculate that IL-12 might be a key cytokine in the pathogenesis of psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAAbjfKV9NJ7Vg90H21EOLACvtfcHk0ljff5XnsB-ihQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnvFyit78%253D&md5=75640681f49caedafea2153151cf99f1</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1046%2Fj.1523-1747.1998.00446.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1523-1747.1998.00446.x%26sid%3Dliteratum%253Aachs%26aulast%3DYawalkar%26aufirst%3DN.%26aulast%3DKarlen%26aufirst%3DS.%26aulast%3DHunger%26aufirst%3DR.%26aulast%3DBrand%26aufirst%3DC.%2BU.%26aulast%3DBraathen%26aufirst%3DL.%2BR.%26atitle%3DExpression%2520of%2520Interleukin-12%2520is%2520Increased%2520in%2520Psoriatic%2520Skin%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D1998%26volume%3D111%26spage%3D1053%26epage%3D1057%26doi%3D10.1046%2Fj.1523-1747.1998.00446.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asahina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takekoshi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishimoto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komine, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamaki, K.</span></span> <span> </span><span class="NLM_article-title">Interleukin 12 Production by Monocytes from Patients with Psoriasis and its Inhibition by Ciclosporin A</span>. <i>Br. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">1180</span>â <span class="NLM_lpage">1183</span>, <span class="refDoi">Â DOI: 10.1111/j.1365-2133.2006.07180.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1111%2Fj.1365-2133.2006.07180.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=16704652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvVKkur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2006&pages=1180-1183&author=Y.+Tadaauthor=A.+Asahinaauthor=T.+Takekoshiauthor=E.+Kishimotoauthor=H.+Mitsuiauthor=H.+Saekiauthor=M.+Komineauthor=K.+Tamaki&title=Interleukin+12+Production+by+Monocytes+from+Patients+with+Psoriasis+and+its+Inhibition+by+Ciclosporin+A&doi=10.1111%2Fj.1365-2133.2006.07180.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Interleukin 12 production by monocytes from patients with psoriasis and its inhibition by ciclosporin A</span></div><div class="casAuthors">Tada, Y.; Asahina, A.; Takekoshi, T.; Kishimoto, E.; Mitsui, H.; Saeki, H.; Komine, M.; Tamaki, K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1180-1183</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Background: Psoriasis is a T-helper (Th)1 cytokine-mediated chronic skin disease and interleukin (IL)-12 has been shown to play a major role in the development of Th1 responses.  Objectives: To elucidate the role of IL-12 in the pathogenesis of psoriasis and to study the effect of ciclosporin A (CsA) on Th1 deviation of this disease.  Patients/Methods: We investigated IL-12 prodn. by stimulated monocytes from patients with psoriasis who were treated with or without CsA.  Monocytes were stimulated with interferon-Î³ plus lipopolysaccharide (LPS) or Staphylococcus aureus Cowan strain I (SAC).  The amt. of IL-12 p70 produced by stimulated monocytes was evaluated by ELISA.  Results: Compared with those from normal controls, LPS- but not SAC-stimulated monocytes from patients with psoriasis produced significantly higher amts. of IL-12.  Interestingly, LPS-stimulated monocytes from patients with psoriasis treated with CsA produced significantly decreased amts. of IL-12 compared with those patients not treated with CsA.  Conclusions: Our results suggest that IL-12 prodn. by monocytes may have a crit. role in the pathogenesis of psoriasis, and that the therapeutic effect of CsA on psoriasis may be achieved by correcting the deviation of the Th1/Th2 balance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo83AaDnVThWrVg90H21EOLACvtfcHk0ljff5XnsB-ihQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvVKkur8%253D&md5=9438f6f5abd41f6047f936a1f19c25f6</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2133.2006.07180.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2133.2006.07180.x%26sid%3Dliteratum%253Aachs%26aulast%3DTada%26aufirst%3DY.%26aulast%3DAsahina%26aufirst%3DA.%26aulast%3DTakekoshi%26aufirst%3DT.%26aulast%3DKishimoto%26aufirst%3DE.%26aulast%3DMitsui%26aufirst%3DH.%26aulast%3DSaeki%26aufirst%3DH.%26aulast%3DKomine%26aufirst%3DM.%26aulast%3DTamaki%26aufirst%3DK.%26atitle%3DInterleukin%252012%2520Production%2520by%2520Monocytes%2520from%2520Patients%2520with%2520Psoriasis%2520and%2520its%2520Inhibition%2520by%2520Ciclosporin%2520A%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2006%26volume%3D154%26spage%3D1180%26epage%3D1183%26doi%3D10.1111%2Fj.1365-2133.2006.07180.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piskin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tursen, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sylva-Steenland, R. M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bos, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teunissen, M. B. M.</span></span> <span> </span><span class="NLM_article-title">Clinical Improvement in Chronic Plaque-type Psoriasis Lesions after Narrow-band UVB Therapy is Accompanied by a Decrease in the Expression of IFN-Î³ Inducers - IL-12, IL-18 and IL-23</span>. <i>Exp. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">764</span>â <span class="NLM_lpage">772</span>, <span class="refDoi">Â DOI: 10.1111/j.0906-6705.2004.00246.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1111%2Fj.0906-6705.2004.00246.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=15560760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjt1yqug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2004&pages=764-772&author=G.+Piskinauthor=U.+Tursenauthor=R.+M.+R.+Sylva-Steenlandauthor=J.+D.+Bosauthor=M.+B.+M.+Teunissen&title=Clinical+Improvement+in+Chronic+Plaque-type+Psoriasis+Lesions+after+Narrow-band+UVB+Therapy+is+Accompanied+by+a+Decrease+in+the+Expression+of+IFN-%CE%B3+Inducers+-+IL-12%2C+IL-18+and+IL-23&doi=10.1111%2Fj.0906-6705.2004.00246.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical improvement in chronic plaque-type psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN-Î³ inducers - IL-12, IL-18 and IL-23</span></div><div class="casAuthors">Piskin, G.; Tursen, U.; Sylva-Steenland, R. M. R.; Bos, J. D.; Tennissen, M. B. M.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Dermatology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">764-772</span>CODEN:
                <span class="NLM_cas:coden">EXDEEY</span>;
        ISSN:<span class="NLM_cas:issn">0906-6705</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Type-1 cytokine-producing T cells are important in the pathogenesis of psoriasis vulgaris, for which efficient therapy is provided by means of narrow-band UV-B (NB-UVB).  The expression of the type-1 cytokine interferon-Î³ (IFN-Î³) is regulated by interleukin-12 (IL-12), IL-15, IL-18 and IL-23; however, not much is known about the effect of this therapy on the levels of these cytokines in lesional psoriatic skin in situ.  In this study, we investigated the effects of NB-UVB therapy on the expression of IFN-Î³-inducing cytokines.  Ten patients with chronic plaque-type psoriasis selected to be treated with NB-UVB therapy were recruited for these expts. and the expression of cytokines IL-12, IL-15, IL-18, IL-23 and IFN-Î³ in lesional psoriatic skin before, during and after therapy was detd. with the help of immunohistochem.  Double staining was performed in order to det. the cell types expressing these cytokines.  The decrease in the psoriasis area and severity index was accompanied by a significant decrease in the expression of IFN-Î³, and concomitantly, significant redn. of IFN-Î³-inducers IL-12, IL-18 and IL-23.  Thus, we concluded that the decrease of IFN-Î³ expression in psoriasis lesions after NB-UVB therapy could be a result of diminished expression of IL-12, IL-18 and IL-23 in lesional skin.  Therapies targeting these three cytokines should, therefore, be considered in the treatment of psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaPDkoT64eYLVg90H21EOLACvtfcHk0lggCt7zAGb63g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjt1yqug%253D%253D&md5=4986e2e8d38599e548dde1732564ac09</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1111%2Fj.0906-6705.2004.00246.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.0906-6705.2004.00246.x%26sid%3Dliteratum%253Aachs%26aulast%3DPiskin%26aufirst%3DG.%26aulast%3DTursen%26aufirst%3DU.%26aulast%3DSylva-Steenland%26aufirst%3DR.%2BM.%2BR.%26aulast%3DBos%26aufirst%3DJ.%2BD.%26aulast%3DTeunissen%26aufirst%3DM.%2BB.%2BM.%26atitle%3DClinical%2520Improvement%2520in%2520Chronic%2520Plaque-type%2520Psoriasis%2520Lesions%2520after%2520Narrow-band%2520UVB%2520Therapy%2520is%2520Accompanied%2520by%2520a%2520Decrease%2520in%2520the%2520Expression%2520of%2520IFN-%25CE%25B3%2520Inducers%2520-%2520IL-12%252C%2520IL-18%2520and%2520IL-23%26jtitle%3DExp.%2520Dermatol.%26date%3D2004%26volume%3D13%26spage%3D764%26epage%3D772%26doi%3D10.1111%2Fj.0906-6705.2004.00246.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przepiera-BÄdzak, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawicki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walecka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brzosko, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brzosko, M.</span></span> <span> </span><span class="NLM_article-title">Serum Interleukin-23 in Polish Patients with Systemic Lupus Erythematosus: Association with Lupus Nephritis, Obesity, and Peripheral Vascular Disease</span>. <i>Mediators Inflammation</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_fpage">9401432</span>, <span class="refDoi">Â DOI: 10.1155/2017/9401432</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1155%2F2017%2F9401432" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=29430084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjsVOitbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=9401432&author=K.+Fischerauthor=H.+Przepiera-B%C4%99dzakauthor=M.+Sawickiauthor=A.+Waleckaauthor=I.+Brzoskoauthor=M.+Brzosko&title=Serum+Interleukin-23+in+Polish+Patients+with+Systemic+Lupus+Erythematosus%3A+Association+with+Lupus+Nephritis%2C+Obesity%2C+and+Peripheral+Vascular+Disease&doi=10.1155%2F2017%2F9401432"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Serum interleukin-23 in polish patients with systemic lupus erythematosus: association with lupus nephritis, obesity, and peripheral vascular disease</span></div><div class="casAuthors">Fischer, Katarzyna; Przepiera-Bedzak, Hanna; Sawicki, Marcin; Walecka, Anna; Brzosko, Iwona; Brzosko, Marek</div><div class="citationInfo"><span class="NLM_cas:title">Mediators of Inflammation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9401432/1-9401432/9</span>CODEN:
                <span class="NLM_cas:coden">MNFLEF</span>;
        ISSN:<span class="NLM_cas:issn">0962-9351</span>.
    
            (<span class="NLM_cas:orgname">Hindawi Publishing Corp.</span>)
        </div><div class="casAbstract">To analyze the correlation between the serum concn. of interleukin-(IL-) 23 and atherosclerotic changes, traditional atherosclerotic risk factors, the autoantibody profile, and involvement of selected organs in systemic lupus erythematosus (SLE) patients.  Patients and Methods.  We studied 94 SLE patients and 27 controls.  We analyzed the IL-23 serum concn., autoantibodies, carotid intima-media thickness and atherosclerotic plaque, the ankle-brachial index, atherosclerotic risk factors, and organ manifestations.  Concns. of IL-23 significantly differed between SLE patients and the controls (p = 0.0015).  On the basis of multivariate stepwise anal., we revealed that high levels of IL-23 were assocd. with atherosclerotic plaque in common femoral arteries (OR = 12.67; 95% CI: 1.41-113.84), lupus nephritis (OR = 3.69; 95% CI: 1.16-12.22), and obesity (OR = 4.21; 95% CI: 1.40-12.67).  Autoantibodies related to IL-23 were anti-phosphatidylethanolamine antibodies (OR = 11.06; 95% CI: 1.24-98.65) and anti-SS-B/La antibodies (OR = 15.43; 95% CI: 1.73-137.25).  IL-23 may be involved in lupus nephritis pathogenesis.  Through its assocn. with obesity and selected antiphospholipid antibodies, IL-23 might promote a hypercoagulable state contributing to atherothrombosis development in SLE patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsfvxe1P-17LVg90H21EOLACvtfcHk0lggCt7zAGb63g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjsVOitbk%253D&md5=6c3fb3ea15fdc8b0961b28290be39b35</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1155%2F2017%2F9401432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2017%252F9401432%26sid%3Dliteratum%253Aachs%26aulast%3DFischer%26aufirst%3DK.%26aulast%3DPrzepiera-B%25C4%2599dzak%26aufirst%3DH.%26aulast%3DSawicki%26aufirst%3DM.%26aulast%3DWalecka%26aufirst%3DA.%26aulast%3DBrzosko%26aufirst%3DI.%26aulast%3DBrzosko%26aufirst%3DM.%26atitle%3DSerum%2520Interleukin-23%2520in%2520Polish%2520Patients%2520with%2520Systemic%2520Lupus%2520Erythematosus%253A%2520Association%2520with%2520Lupus%2520Nephritis%252C%2520Obesity%252C%2520and%2520Peripheral%2520Vascular%2520Disease%26jtitle%3DMediators%2520Inflammation%26date%3D2017%26spage%3D9401432%26doi%3D10.1155%2F2017%2F9401432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niewold, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salloum, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poole, B. D.</span></span> <span> </span><span class="NLM_article-title">Interferon Alpha in Systemic Lupus Erythematosus</span>. <i>J. Biomed. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_fpage">948364</span>, <span class="refDoi">Â DOI: 10.1155/2010/948364</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1155%2F2010%2F948364" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=20652065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A280%3ADC%252BC3cnpsVyitA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&pages=948364&author=T.+B.+Niewoldauthor=D.+N.+Clarkauthor=R.+Salloumauthor=B.+D.+Poole&title=Interferon+Alpha+in+Systemic+Lupus+Erythematosus&doi=10.1155%2F2010%2F948364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Interferon alpha in systemic lupus erythematosus</span></div><div class="casAuthors">Niewold Timothy B; Clark Daniel N; Salloum Rafah; Poole Brian D</div><div class="citationInfo"><span class="NLM_cas:title">Journal of biomedicine & biotechnology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2010</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">948364</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The pleiotropic cytokine interferon alpha is involved in multiple aspects of lupus etiology and pathogenesis.  Interferon alpha is important under normal circumstances for antiviral responses and immune activation.  However, heightened levels of serum interferon alpha and expression of interferon response genes are common in lupus patients.  Lupus-associated autoantibodies can drive the production of interferon alpha and heightened levels of interferon interfere with immune regulation.  Several genes in the pathways leading to interferon production or signaling are associated with risk for lupus.  Clinical and cellular manifestations of excess interferon alpha in lupus combined with the genetic risk factors associated with interferon make this cytokine a rare bridge between genetic risk and phenotypic effects.  Interferon alpha influences the clinical picture of lupus and may represent a therapeutic target.  This paper provides an overview of the cellular, genetic, and clinical aspects of interferon alpha in lupus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSaY99d7aSGBINpW7w2tapOfW6udTcc2ea3_aZoJoUwBLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cnpsVyitA%253D%253D&md5=2d0709a0539150a9b8d666107a4bca20</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1155%2F2010%2F948364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2010%252F948364%26sid%3Dliteratum%253Aachs%26aulast%3DNiewold%26aufirst%3DT.%2BB.%26aulast%3DClark%26aufirst%3DD.%2BN.%26aulast%3DSalloum%26aufirst%3DR.%26aulast%3DPoole%26aufirst%3DB.%2BD.%26atitle%3DInterferon%2520Alpha%2520in%2520Systemic%2520Lupus%2520Erythematosus%26jtitle%3DJ.%2520Biomed.%2520Biotechnol.%26date%3D2010%26spage%3D948364%26doi%3D10.1155%2F2010%2F948364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tucci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dammacco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvestris, F.</span></span> <span> </span><span class="NLM_article-title">Overexpression of Interleukin-12 and T Helper 1 Predominance in Lupus Nephritis</span>. <i>Clin. Exp. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">247</span>â <span class="NLM_lpage">254</span>, <span class="refDoi">Â DOI: 10.1111/j.1365-2249.2008.03758.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1111%2Fj.1365-2249.2008.03758.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=18795942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVSiur7N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2008&pages=247-254&author=M.+Tucciauthor=L.+Lombardiauthor=H.+B.+Richardsauthor=F.+Dammaccoauthor=F.+Silvestris&title=Overexpression+of+Interleukin-12+and+T+Helper+1+Predominance+in+Lupus+Nephritis&doi=10.1111%2Fj.1365-2249.2008.03758.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis</span></div><div class="casAuthors">Tucci, M.; Lombardi, L.; Richards, H. B.; Dammacco, F.; Silvestris, F.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">247-254</span>CODEN:
                <span class="NLM_cas:coden">CEXIAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-9104</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Imbalance of cytokine homeostasis is a prominent feature of both exptl. and human systemic lupus erythematosus (SLE).  Because interleukin (IL)-12 promotes interferon (IFN)-Î³ prodn. leading to polarization of peripheral cells toward a T helper (Th) 1 phenotype, we investigated its role in lupus nephritis (LN).  Sol. Th1 and Th2 cytokines were measured by ELISA in sera and urines of SLE patients and controls.  Th1/Th2 peripheral lymphocyte polarization was detd. by flow cytometry.  Glomerular accumulation of IL-12 was evaluated by immunohistochem., whereas urinary IL-12 was evaluated by ELISA.  Higher serum IL-12 levels in SLE were assocd. with LN, whereas IL-4 was unrelated to the renal damage.  Peripheral cells from LN patients showed a Th1 phenotype with a high IFN-Î³ expression that paralleled the severity of renal damage.  IL-12 was present within glomerular mononuclear cells in classes IV and V LN, and its accumulation was correlated strongly with urinary levels.  IL-12 overexpression in SLE may contribute to the development of LN.  Both serum and urinary IL-12 elevation reflect its glomerular prodn. and parallel Th1 polarization of peripheral T cells and high IFN-Î³ prodn.  In SLE patients, IL-12 measurement may thus be predictive of the development of LN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrirh1cpY_8dLVg90H21EOLACvtfcHk0lhI691zH8Hvdw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVSiur7N&md5=4a7f9fe503be792275d4b4f3ee3b1330</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2249.2008.03758.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2249.2008.03758.x%26sid%3Dliteratum%253Aachs%26aulast%3DTucci%26aufirst%3DM.%26aulast%3DLombardi%26aufirst%3DL.%26aulast%3DRichards%26aufirst%3DH.%2BB.%26aulast%3DDammacco%26aufirst%3DF.%26aulast%3DSilvestris%26aufirst%3DF.%26atitle%3DOverexpression%2520of%2520Interleukin-12%2520and%2520T%2520Helper%25201%2520Predominance%2520in%2520Lupus%2520Nephritis%26jtitle%3DClin.%2520Exp.%2520Immunol.%26date%3D2008%26volume%3D154%26spage%3D247%26epage%3D254%26doi%3D10.1111%2Fj.1365-2249.2008.03758.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moschen, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raine, T.</span></span> <span> </span><span class="NLM_article-title">IL-12, IL-23 and IL-17 in IBD: Immunobiology and Therapeutic Targeting</span>. <i>Nat. Rev. Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">185</span>â <span class="NLM_lpage">196</span>, <span class="refDoi">Â DOI: 10.1038/s41575-018-0084-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1038%2Fs41575-018-0084-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=30478416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlWnu7%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2019&pages=185-196&author=A.+R.+Moschenauthor=H.+Tilgauthor=T.+Raine&title=IL-12%2C+IL-23+and+IL-17+in+IBD%3A+Immunobiology+and+Therapeutic+Targeting&doi=10.1038%2Fs41575-018-0084-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting</span></div><div class="casAuthors">Moschen, Alexander R.; Tilg, Herbert; Raine, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Gastroenterology & Hepatology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">185-196</span>CODEN:
                <span class="NLM_cas:coden">NRGHA9</span>;
        ISSN:<span class="NLM_cas:issn">1759-5045</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  IL-12 and IL-23 are closely related cytokines with important roles in the regulation of tissue inflammation.  Converging evidence from studies in mice, human observational studies and population genetics supports the importance of these cytokines in the regulation of mucosal inflammation in the gut in particular.  Ustekinumab, a therapeutic antibody targeting both cytokines is now widely licensed for the treatment of Crohn's disease, including in Europe, the USA, Canada and Japan, while agents targeting IL-23 specifically are in late-phase clin. trials.  We review the emerging understanding of the biol. of IL-12 and IL-23, as well as that of their major downstream cytokines, including IL-17.  In particular, we discuss how their biol. has influenced the development of clin. trials and therapeutic strategies in IBD, as well as how findings from clin. trials, at times surprising, have in turn refocused our understanding of the underlying biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOpNxAUthv_rVg90H21EOLACvtfcHk0lhI691zH8Hvdw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlWnu7%252FE&md5=b1f23bb392012256b005f303341d8cc1</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fs41575-018-0084-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41575-018-0084-8%26sid%3Dliteratum%253Aachs%26aulast%3DMoschen%26aufirst%3DA.%2BR.%26aulast%3DTilg%26aufirst%3DH.%26aulast%3DRaine%26aufirst%3DT.%26atitle%3DIL-12%252C%2520IL-23%2520and%2520IL-17%2520in%2520IBD%253A%2520Immunobiology%2520and%2520Therapeutic%2520Targeting%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2019%26volume%3D16%26spage%3D185%26epage%3D196%26doi%3D10.1038%2Fs41575-018-0084-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andreou, N.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legaki, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazouli, M.</span></span> <span> </span><span class="NLM_article-title">Inflammatory Bowel Disease Pathobiology: the Role of the Interferon Signature</span>. <i>Ann. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">9</span>, <span class="refDoi">Â DOI: 10.20524/aog.2020.0457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.20524%2Faog.2020.0457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=31892791" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2020&pages=1-9&author=N.-P.+Andreouauthor=E.+Legakiauthor=M.+Gazouli&title=Inflammatory+Bowel+Disease+Pathobiology%3A+the+Role+of+the+Interferon+Signature&doi=10.20524%2Faog.2020.0457"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.20524%2Faog.2020.0457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.20524%252Faog.2020.0457%26sid%3Dliteratum%253Aachs%26aulast%3DAndreou%26aufirst%3DN.-P.%26aulast%3DLegaki%26aufirst%3DE.%26aulast%3DGazouli%26aufirst%3DM.%26atitle%3DInflammatory%2520Bowel%2520Disease%2520Pathobiology%253A%2520the%2520Role%2520of%2520the%2520Interferon%2520Signature%26jtitle%3DAnn.%2520Gastroenterol.%26date%3D2020%26volume%3D33%26spage%3D1%26epage%3D9%26doi%3D10.20524%2Faog.2020.0457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span> <i>FDA Approves Stelara
(ustekinumab) to Treat Psoriasis</i>. . Sept 25, <span class="NLM_year">2009</span>. <a href="https://www.drugs.com/newdrugs/fda-approves-stelara-ustekinumab-psoriasis-1667.html" class="extLink">https://www.drugs.com/newdrugs/fda-approves-stelara-ustekinumab-psoriasis-1667.html</a> (accessed Nov 8, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+FDA+Approves+Stelara%0A%28ustekinumab%29+to+Treat+Psoriasis.+.+Sept+25%2C+2009.+https%3A%2F%2Fwww.drugs.com%2Fnewdrugs%2Ffda-approves-stelara-ustekinumab-psoriasis-1667.html+%28accessed+Nov+8%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26jtitle%3DFDA%2520Approves%2520Stelara%250A%2528ustekinumab%2529%2520to%2520Treat%2520Psoriasis%26date%3D2009%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span> <i>FDA Approves Stelara
(ustekinumab) for the Treatment of Adults with Moderately to Severely
Active Crohnâs Diseases</i>. . Sept 26, <span class="NLM_year">2016</span>. <a href="https://www.drugs.com/newdrugs/fda-approves-stelara-ustekinumab-adults-moderately-severely-active-crohn-s-4436.html" class="extLink">https://www.drugs.com/newdrugs/fda-approves-stelara-ustekinumab-adults-moderately-severely-active-crohn-s-4436.html</a> (accessed Nov 8, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+FDA+Approves+Stelara%0A%28ustekinumab%29+for+the+Treatment+of+Adults+with+Moderately+to+Severely%0AActive+Crohn%E2%80%99s+Diseases.+.+Sept+26%2C+2016.+https%3A%2F%2Fwww.drugs.com%2Fnewdrugs%2Ffda-approves-stelara-ustekinumab-adults-moderately-severely-active-crohn-s-4436.html+%28accessed+Nov+8%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26jtitle%3DFDA%2520Approves%2520Stelara%250A%2528ustekinumab%2529%2520for%2520the%2520Treatment%2520of%2520Adults%2520with%2520Moderately%2520to%2520Severely%250AActive%2520Crohn%25E2%2580%2599s%2520Diseases%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boxler, D.</span></span> <i>Ustekinumab Gains FDA Approval as Ulcerative Colitis Treatment</i>. Drug Topics. Oct 23, <span class="NLM_year">2019</span>. <a href="https://www.drugtopics.com/view/ustekinumab-gains-fda-approval-ulcerative-colitis-treatment" class="extLink">https://www.drugtopics.com/view/ustekinumab-gains-fda-approval-ulcerative-colitis-treatment</a> (accessed Nov 8, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=D.+Boxler&title=Ustekinumab+Gains+FDA+Approval+as+Ulcerative+Colitis+Treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DBoxler%26aufirst%3DD.%26jtitle%3DUstekinumab%2520Gains%2520FDA%2520Approval%2520as%2520Ulcerative%2520Colitis%2520Treatment%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morand, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furie, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Askanase, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brohawn, P. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pineda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berglind, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummala, R.</span></span> <span> </span><span class="NLM_article-title">Trial of Anifrolumab in Active Systemic Lupus Erythematosus</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>382</i></span>,  <span class="NLM_fpage">211</span>â <span class="NLM_lpage">221</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1912196</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1056%2FNEJMoa1912196" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=31851795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1WjurY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2020&pages=211-221&author=E.+F.+Morandauthor=R.+Furieauthor=Y.+Tanakaauthor=I.+N.+Bruceauthor=A.+D.+Askanaseauthor=C.+Richezauthor=S.+C.+Baeauthor=P.+Z.+Brohawnauthor=L.+Pinedaauthor=A.+Berglindauthor=R.+Tummala&title=Trial+of+Anifrolumab+in+Active+Systemic+Lupus+Erythematosus&doi=10.1056%2FNEJMoa1912196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Trial of anifrolumab in active systemic lupus erythematosus</span></div><div class="casAuthors">Morand, E. F.; Furie, R.; Tanaka, Y.; Bruce, I. N.; Askanase, A. D.; Richez, C.; Bae, S.-C.; Brohawn, P. Z.; Pineda, L.; Berglind, A.; Tummala, R.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">211-221</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Anifrolumab, a human monoclonal antibody to type I interferon receptor subunit 1 investigated for the treatment of systemic lupus erythematosus (SLE), did not have a significant effect on the primary end point in a previous phase 3 trial.  The current phase 3 trial used a secondary end point from that trial as the primary end point. methods We randomly assigned patients in a 1:1 ratio to receive i.v. anifrolumab (300 mg) or placebo every 4 wk for 48 wk.  The primary end point of this trial was a response at week 52 defined with the use of the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA).  A BICLA response requires redn. in any moderate-to-severe baseline disease activity and no worsening in any of nine organ systems in the BILAG index, no worsening on the Systemic Lupus Erythematosus Disease Activity Index, no increase of 0.3 points or more in the score on the Physician Global Assessment of disease activity (on a scale from 0 [no disease activity] to 3 [severe disease]), no discontinuation of the trial intervention, and no use of medications restricted by the protocol.  Secondary end points included a BICLA response in patients with a high interferon gene signature at baseline; redns. in the glucocorticoid dose, in the severity of skin disease, and in counts of swollen and tender joints; and the annualized flare rate. results A total of 362 patients received the randomized intervention: 180 received anifrolumab and 182 received placebo.  The percentage of patients who had a BICLA response was 47.8% in the anifrolumab group and 31.5% in the placebo group (difference, 16.3 percentage points; 95% confidence interval, 6.3 to 26.3; P = 0.001).  Among patients with a high interferon gene signature, the percentage with a response was 48.0% in the anifrolumab group and 30.7% in the placebo group; among patients with a low interferon gene signature, the percentage was 46.7% and 35.5%, resp.  Secondary end points with respect to the glucocorticoid dose and the severity of skin disease, but not counts of swollen and tender joints and the annualized flare rate, also showed a significant benefit with anifrolumab.  Herpes zoster and bronchitis occurred in 7.2% and 12.2% of the patients, resp., who received anifrolumab.  There was one death from pneumonia in the anifrolumab group. conclusions Monthly administration of anifrolumab resulted in a higher percentage of patients with a response (as defined by a composite end point) at week 52 than did placebo, in contrast to the findings of a similar phase 3 trial involving patients with SLE that had a different primary end point.  The frequency of herpes zoster was higher with anifrolumab than with placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHmbZKnapYbLVg90H21EOLACvtfcHk0lgtkzvegCmIWA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1WjurY%253D&md5=a2c3436c34d4da2a93687426c442a1fa</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1912196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1912196%26sid%3Dliteratum%253Aachs%26aulast%3DMorand%26aufirst%3DE.%2BF.%26aulast%3DFurie%26aufirst%3DR.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DBruce%26aufirst%3DI.%2BN.%26aulast%3DAskanase%26aufirst%3DA.%2BD.%26aulast%3DRichez%26aufirst%3DC.%26aulast%3DBae%26aufirst%3DS.%2BC.%26aulast%3DBrohawn%26aufirst%3DP.%2BZ.%26aulast%3DPineda%26aufirst%3DL.%26aulast%3DBerglind%26aufirst%3DA.%26aulast%3DTummala%26aufirst%3DR.%26atitle%3DTrial%2520of%2520Anifrolumab%2520in%2520Active%2520Systemic%2520Lupus%2520Erythematosus%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D382%26spage%3D211%26epage%3D221%26doi%3D10.1056%2FNEJMoa1912196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ortmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeltz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shevach, E. M.</span></span> <span> </span><span class="NLM_article-title">A Heritable Defect in IL-12 Signaling in B10.Q/J Mice. I. <i>In vitro</i> Analysis</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>166</i></span>,  <span class="NLM_fpage">5712</span>â <span class="NLM_lpage">5719</span>, <span class="refDoi">Â DOI: 10.4049/jimmunol.166.9.5712</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.4049%2Fjimmunol.166.9.5712" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=11313413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjtFyqsr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2001&pages=5712-5719&author=R.+Ortmannauthor=R.+Smeltzauthor=G.+Yapauthor=A.+Sherauthor=E.+M.+Shevach&title=A+Heritable+Defect+in+IL-12+Signaling+in+B10.Q%2FJ+Mice.+I.+In+vitro+Analysis&doi=10.4049%2Fjimmunol.166.9.5712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A heritable defect in IL-12 signaling in B10.Q/J mice. I. In vitro analysis</span></div><div class="casAuthors">Ortmann, Robert; Smeltz, Ronald; Yap, George; Sher, Alan; Shevach, Ethan M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5712-5719</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">B10.Q mice are normally susceptible to the induction of collagen-induced arthritis.  The authors noted that one subline of B10.Q mice, B10.Q/J, was completely resistant to disease induction when immunized with collagen in CFA.  B10.Q/J mice have a global defect in the generation of Th1 responses, and antigen-specific T cells derived from this strain failed to produce IFN-Î³.  Because T cells from these mice could produce normal amts. of IFN-Î³ when activated by IL-12/IL-18-independent stimuli, the defect appeared to be a failure to respond to IL-12.  This defect extended to NK cells, which also failed to produce IFN-Î³ when stimulated by IL-12.  The capacity of NK cells, but not activated T cells, to produce IFN-Î³ in response to IL-12 could be partially restored by IL-18.  The expression of the IL-12R Î²1- and Î²2-chains on T cells and NK cells from B10.Q/J mice was normal.  However, activated T cells from B10.Q/J mice did not signal normally through the IL-12R and manifested a defect in their capacity to phosphorylate Stat4.  This defect was partial in that it could be overcome by increasing both the concn. of IL-12 and the incubation times in the Stat4 phosphorylation assays.  Because Stat4 function is apparently intact in B10.Q/J mice, the defect in IL-12 signaling can be localized between the IL-12R complex and Stat4.  This subtle abnormality in IL-12 responsiveness results in a profound defect in the generation of Th1 cells and the development of autoimmune disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnzWn-o1wME7Vg90H21EOLACvtfcHk0lgtkzvegCmIWA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjtFyqsr4%253D&md5=bf724d444e9db709a3a40fc251b73d40</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.166.9.5712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.166.9.5712%26sid%3Dliteratum%253Aachs%26aulast%3DOrtmann%26aufirst%3DR.%26aulast%3DSmeltz%26aufirst%3DR.%26aulast%3DYap%26aufirst%3DG.%26aulast%3DSher%26aufirst%3DA.%26aulast%3DShevach%26aufirst%3DE.%2BM.%26atitle%3DA%2520Heritable%2520Defect%2520in%2520IL-12%2520Signaling%2520in%2520B10.Q%252FJ%2520Mice.%2520I.%2520In%2520vitro%2520Analysis%26jtitle%3DJ.%2520Immunol.%26date%3D2001%26volume%3D166%26spage%3D5712%26epage%3D5719%26doi%3D10.4049%2Fjimmunol.166.9.5712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oyamada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikebe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itsumi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiwai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimoda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwakura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshikai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, H.</span></span> <span> </span><span class="NLM_article-title">Tyrosine Kinase 2 Plays Critical Roles in the Pathogenic CD4 T Cell Responses for the Development of Experimental Autoimmune Encephalomyelitis</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>183</i></span>,  <span class="NLM_fpage">7539</span>â <span class="NLM_lpage">7546</span>, <span class="refDoi">Â DOI: 10.4049/jimmunol.0902740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.4049%2Fjimmunol.0902740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=19917699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVehtrrE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2009&pages=7539-7546&author=A.+Oyamadaauthor=H.+Ikebeauthor=M.+Itsumiauthor=H.+Saiwaiauthor=S.+Okadaauthor=K.+Shimodaauthor=Y.+Iwakuraauthor=K.+I.+Nakayamaauthor=Y.+Iwamotoauthor=Y.+Yoshikaiauthor=H.+Yamada&title=Tyrosine+Kinase+2+Plays+Critical+Roles+in+the+Pathogenic+CD4+T+Cell+Responses+for+the+Development+of+Experimental+Autoimmune+Encephalomyelitis&doi=10.4049%2Fjimmunol.0902740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine Kinase 2 Plays Critical Roles in the Pathogenic CD4 T Cell Responses for the Development of Experimental Autoimmune Encephalomyelitis</span></div><div class="casAuthors">Oyamada, Akiko; Ikebe, Hiori; Itsumi, Momoe; Saiwai, Hirokazu; Okada, Seiji; Shimoda, Kazuya; Iwakura, Yoichiro; Nakayama, Keiichi I.; Iwamoto, Yukihide; Yoshikai, Yasunobu; Yamada, Hisakata</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7539-7546</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Tyrosine kinase 2 (Tyk2), a member of the JAK family, is involved in IL-12- and IL-23-mediated signaling.  In the present study, we examd. the roles of Tyk2 in the development of myelin oligodendrocyte glycoprotein (MOG)-induced exptl. autoimmune encephalomyelitis (EAE) by using Tyk2 knockout (KO) mice.  In vitro differentiation of Th1 but not Th17 cells was severely impaired in Tyk2 KO CD4 T cells, although Tyk2 KO Th17 cells did not respond to IL-23.  Tyk2 KO mice showed complete resistance against EAE with no infiltration of CD4 T cells in the spinal cord.  Surprisingly, the no. of MOG-specific Th17 cells in the periphery was comparable between KO and wild-type (WT) mice, whereas Th1 cells were greatly reduced in Tyk2 KO mice.  Adoptive transfer of MOG-primed WT T cells induced EAE in Tyk2 KO recipients, indicating that Tyk2 in the environment was dispensable for the infiltration of effector T cells into the spinal cord.  A reduced but significant no. of Tyk2 KO T cells were detected in the spinal cord of mice with EAE, which had been reconstituted with bone marrow cells of WT and KO mice.  Furthermore, MOG-immunized Tyk2 KO mice developed EAE after adoptive transfer of MOG-primed WT Th1 cells, which might trigger local inflammation that recruits Th17 cells.  Taken together, these results indicate that Tyk2 is critically involved in the pathogenic CD4 T cell responses and thus could be a target mol. for the treatment of autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0gM6rPFuApLVg90H21EOLACvtfcHk0lgtkzvegCmIWA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVehtrrE&md5=05bba19010fbdffbb10b751a1dda16fb</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0902740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0902740%26sid%3Dliteratum%253Aachs%26aulast%3DOyamada%26aufirst%3DA.%26aulast%3DIkebe%26aufirst%3DH.%26aulast%3DItsumi%26aufirst%3DM.%26aulast%3DSaiwai%26aufirst%3DH.%26aulast%3DOkada%26aufirst%3DS.%26aulast%3DShimoda%26aufirst%3DK.%26aulast%3DIwakura%26aufirst%3DY.%26aulast%3DNakayama%26aufirst%3DK.%2BI.%26aulast%3DIwamoto%26aufirst%3DY.%26aulast%3DYoshikai%26aufirst%3DY.%26aulast%3DYamada%26aufirst%3DH.%26atitle%3DTyrosine%2520Kinase%25202%2520Plays%2520Critical%2520Roles%2520in%2520the%2520Pathogenic%2520CD4%2520T%2520Cell%2520Responses%2520for%2520the%2520Development%2520of%2520Experimental%2520Autoimmune%2520Encephalomyelitis%26jtitle%3DJ.%2520Immunol.%26date%3D2009%26volume%3D183%26spage%3D7539%26epage%3D7546%26doi%3D10.4049%2Fjimmunol.0902740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dendrou, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attfield, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jostins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barber, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuttikkatte, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faergeman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheeseman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neville, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawcer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compston, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McVean, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fugger, L.</span></span> <span> </span><span class="NLM_article-title">Resolving TYK2 Locus Genotype-to-phenotype Differences in Autoimmunity</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">363ra149</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.aag1974</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1126%2Fscitranslmed.aag1974" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=27807284" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=363ra149&author=C.+A.+Dendrouauthor=A.+Cortesauthor=L.+Shipmanauthor=H.+G.+Evansauthor=K.+E.+Attfieldauthor=L.+Jostinsauthor=T.+Barberauthor=G.+Kaurauthor=S.+B.+Kuttikkatteauthor=O.+A.+Leachauthor=C.+Deselauthor=S.+L.+Faergemanauthor=J.+Cheesemanauthor=M.+J.+Nevilleauthor=S.+Sawcerauthor=A.+Compstonauthor=A.+R.+Johnsonauthor=C.+Everettauthor=J.+I.+Bellauthor=F.+Karpeauthor=M.+Ultschauthor=C.+Eigenbrotauthor=G.+McVeanauthor=L.+Fugger&title=Resolving+TYK2+Locus+Genotype-to-phenotype+Differences+in+Autoimmunity&doi=10.1126%2Fscitranslmed.aag1974"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aag1974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aag1974%26sid%3Dliteratum%253Aachs%26aulast%3DDendrou%26aufirst%3DC.%2BA.%26aulast%3DCortes%26aufirst%3DA.%26aulast%3DShipman%26aufirst%3DL.%26aulast%3DEvans%26aufirst%3DH.%2BG.%26aulast%3DAttfield%26aufirst%3DK.%2BE.%26aulast%3DJostins%26aufirst%3DL.%26aulast%3DBarber%26aufirst%3DT.%26aulast%3DKaur%26aufirst%3DG.%26aulast%3DKuttikkatte%26aufirst%3DS.%2BB.%26aulast%3DLeach%26aufirst%3DO.%2BA.%26aulast%3DDesel%26aufirst%3DC.%26aulast%3DFaergeman%26aufirst%3DS.%2BL.%26aulast%3DCheeseman%26aufirst%3DJ.%26aulast%3DNeville%26aufirst%3DM.%2BJ.%26aulast%3DSawcer%26aufirst%3DS.%26aulast%3DCompston%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DEverett%26aufirst%3DC.%26aulast%3DBell%26aufirst%3DJ.%2BI.%26aulast%3DKarpe%26aufirst%3DF.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DMcVean%26aufirst%3DG.%26aulast%3DFugger%26aufirst%3DL.%26atitle%3DResolving%2520TYK2%2520Locus%2520Genotype-to-phenotype%2520Differences%2520in%2520Autoimmunity%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2016%26volume%3D8%26spage%3D363ra149%26doi%3D10.1126%2Fscitranslmed.aag1974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, H.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, D.-Q.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Potential of Tyrosine Kinase 2 in Autoimmunity</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">571</span>â <span class="NLM_lpage">580</span>, <span class="refDoi">Â DOI: 10.1517/14728222.2014.892925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1517%2F14728222.2014.892925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=24654603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtFWksbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2014&pages=571-580&author=Y.+Liangauthor=Y.+Zhuauthor=Y.+Xiaauthor=H.+Pengauthor=X.-K.+Yangauthor=Y.-Y.+Liuauthor=W.-D.+Xuauthor=H.-F.+Panauthor=D.-Q.+Ye&title=Therapeutic+Potential+of+Tyrosine+Kinase+2+in+Autoimmunity&doi=10.1517%2F14728222.2014.892925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of tyrosine kinase 2 in autoimmunity</span></div><div class="casAuthors">Liang, Yan; Zhu, Yan; Xia, Yi; Peng, Hui; Yang, Xiao-Ke; Liu, Yan-Yan; Xu, Wang-Dong; Pan, Hai-Feng; Ye, Dong-Qing</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">571-580</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Tyrosine kinase 2 (Tyk2) is a Janus kinase family member that is crucial for signaling transduction in response to a wide variety of cytokines, including type I IFNs, IL-6, IL-10, IL-12 and IL-23.  An appropriate expression of Tyk2-mediated signaling might be essential for maintaining normal immune responses.  Areas covered: This review summarizes that Tyk2 is essential for the differentiation and function of a wide variety of immune cells, including natural killer cells, B cells, as well as T helper cells.  In addn., Tyk2-mediated signaling promoted the prodn. of autoimmune-assocd. components, which is implicated in the pathogenesis of autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis.  Aberrant expression of Tyk2 was obsd. in many autoimmune conditions.  Expert opinion: Until recently, no patent filings had claimed selective inhibitors of Tyk2.  Both CP-690,500 and CMP6 failed to be used in clin. treatment due to the difficulties of finding suitable selective leads or due to detrimental toxicities.  Although the result of Cmpd1 is promising, it remains to be seen how specific the Tyk2 inhibitor is and how they are working.  Currently, structure-based drug design (SBDD) technol. has provided us with a quite useful window for SBDD of Tyk2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0GDNGqruPWbVg90H21EOLACvtfcHk0lg5rsyOzyt-ig"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtFWksbg%253D&md5=ed91081f06962424d5e2d1e62cc1a37f</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1517%2F14728222.2014.892925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.2014.892925%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DX.-K.%26aulast%3DLiu%26aufirst%3DY.-Y.%26aulast%3DXu%26aufirst%3DW.-D.%26aulast%3DPan%26aufirst%3DH.-F.%26aulast%3DYe%26aufirst%3DD.-Q.%26atitle%3DTherapeutic%2520Potential%2520of%2520Tyrosine%2520Kinase%25202%2520in%2520Autoimmunity%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2014%26volume%3D18%26spage%3D571%26epage%3D580%26doi%3D10.1517%2F14728222.2014.892925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, X.-Y.</span></span> <span> </span><span class="NLM_article-title">Selective Tyk2 Inhibitors as Potential Therapeutic Agents: a Patent Review (2015-2018)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">137</span>â <span class="NLM_lpage">149</span>, <span class="refDoi">Â DOI: 10.1080/13543776.2019.1567713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1080%2F13543776.2019.1567713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=30621465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsF2kuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=137-149&author=X.+Heauthor=X.+Chenauthor=H.+Zhangauthor=T.+Xieauthor=X.-Y.+Ye&title=Selective+Tyk2+Inhibitors+as+Potential+Therapeutic+Agents%3A+a+Patent+Review+%282015-2018%29&doi=10.1080%2F13543776.2019.1567713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018)</span></div><div class="casAuthors">He, Xingrui; Chen, Xiabin; Zhang, Hancheng; Xie, Tian; Ye, Xiang-Yang</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">137-149</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Tyrosine kinase 2 (Tyk2) is a non-receptor tyrosine-protein kinase, an enzyme that in humans is encoded by the TYK2 gene.  Tyk2, together with three other family subtypes, namely, Jak1, Jak2, and Jak3, belong to the JAK family.  Before 2014, far more publications and patents appeared in public domain attributing to the development of selective Jak2 and Jak3 inhibitors than those for selective Tyk2 and Jak1 inhibitors.  This review sought to give an overview of patents related to small mol. selective Tyk2 inhibitors published from 2015 to 2018.  The article also covers clin. activities of small mol. selective Tyk2 inhibitors in recent years.  As a key component of the JAK-STAT signaling pathway, Tyk2 regulates INFÎ±, IL12, and IL23.  Selective inhibition of Tyk2 can provide pharmacol. benefits in the treatment of many diseases such as psoriasis, systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), rheumatoid arthritis (RA), cancer, and diabetes.  The selectivity against other Jak family subtypes (such as Jak2) is crucial in order to minimize the potential side effects and to maximize the desired pharmacol. effects.  In this context, this review of recent selective Tyk2 inhibitor patents may prove valid, interesting, and promising within the therapeutic paradigm.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrer4xPnKRtvrVg90H21EOLACvtfcHk0lg5rsyOzyt-ig"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsF2kuro%253D&md5=cf7fa5e5f7a92eb951886f7951f7da4b</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1080%2F13543776.2019.1567713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2019.1567713%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DT.%26aulast%3DYe%26aufirst%3DX.-Y.%26atitle%3DSelective%2520Tyk2%2520Inhibitors%2520as%2520Potential%2520Therapeutic%2520Agents%253A%2520a%2520Patent%2520Review%2520%25282015-2018%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2019%26volume%3D29%26spage%3D137%26epage%3D149%26doi%3D10.1080%2F13543776.2019.1567713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R. M.</span></span> <span> </span><span class="NLM_article-title">Advances in the Discovery and Development of Selective Tyrosine Kinase 2 (TYK2) Inhibitors</span>. <i>Med. Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">177</span>â <span class="NLM_lpage">200</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntlyjsb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2018&pages=177-200&author=D.+W.+Weinsteinauthor=R.+M.+Moslin&title=Advances+in+the+Discovery+and+Development+of+Selective+Tyrosine+Kinase+2+%28TYK2%29+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the discovery and development of selective tyrosine kinase 2 (TYK2) inhibitors</span></div><div class="casAuthors">Weinstein, David S.; Moslin, Ryan M.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">177-200</span>CODEN:
                <span class="NLM_cas:coden">MCREGD</span>;
        ISSN:<span class="NLM_cas:issn">2575-9175</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society, Division of Medicinal Chemistry</span>)
        </div><div class="casAbstract">A review discussing the advances in the discovery and development of selective tyrosine kinase 2 (TYK2) inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm_EO5ig1UTrVg90H21EOLACvtfcHk0lhliccgW-uQOg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntlyjsb8%253D&md5=1ae794f8190d9c312e67fcdd2e06b793</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeinstein%26aufirst%3DD.%2BW.%26aulast%3DMoslin%26aufirst%3DR.%2BM.%26atitle%3DAdvances%2520in%2520the%2520Discovery%2520and%2520Development%2520of%2520Selective%2520Tyrosine%2520Kinase%25202%2520%2528TYK2%2529%2520Inhibitors%26jtitle%3DMed.%2520Chem.%2520Rev.%26date%3D2018%26volume%3D53%26spage%3D177%26epage%3D200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toms, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshpande, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNally, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruner, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marto, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattler, M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Structure of a Pseudokinase Domain Switch that Controls Oncogenic Activation of Jak Kinases</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1221</span>â <span class="NLM_lpage">1223</span>, <span class="refDoi">Â DOI: 10.1038/nsmb.2673</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1038%2Fnsmb.2673" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=1221-1223&author=A.+V.+Tomsauthor=A.+Deshpandeauthor=R.+McNallyauthor=Y.+Jeongauthor=J.+M.+Rogersauthor=C.+U.+Kimauthor=S.+M.+Grunerauthor=S.+B.+Ficarroauthor=J.+A.+Martoauthor=M.+Sattler&title=Structure+of+a+Pseudokinase+Domain+Switch+that+Controls+Oncogenic+Activation+of+Jak+Kinases&doi=10.1038%2Fnsmb.2673"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2673%26sid%3Dliteratum%253Aachs%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DDeshpande%26aufirst%3DA.%26aulast%3DMcNally%26aufirst%3DR.%26aulast%3DJeong%26aufirst%3DY.%26aulast%3DRogers%26aufirst%3DJ.%2BM.%26aulast%3DKim%26aufirst%3DC.%2BU.%26aulast%3DGruner%26aufirst%3DS.%2BM.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DMarto%26aufirst%3DJ.%2BA.%26aulast%3DSattler%26aufirst%3DM.%26atitle%3DStructure%2520of%2520a%2520Pseudokinase%2520Domain%2520Switch%2520that%2520Controls%2520Oncogenic%2520Activation%2520of%2520Jak%2520Kinases%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2014%26volume%3D20%26spage%3D1221%26epage%3D1223%26doi%3D10.1038%2Fnsmb.2673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Min, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ungureanu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maxwell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HammarÃ©n, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thibault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillert, E.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenfield, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eksterowicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2)</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">27261</span>â <span class="NLM_lpage">27270</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M115.672048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1074%2Fjbc.M115.672048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=26359499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyrtrnO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=27261-27270&author=X.+Minauthor=D.+Ungureanuauthor=S.+Maxwellauthor=H.+Hammar%C3%A9nauthor=S.+Thibaultauthor=E.-K.+Hillertauthor=M.+Ayresauthor=B.+Greenfieldauthor=J.+Eksterowiczauthor=C.+Gabelauthor=N.+Walkerauthor=O.+Silvennoinenauthor=Z.+Wang&title=Structural+and+Functional+Characterization+of+the+JH2+Pseudokinase+Domain+of+JAK+Family+Tyrosine+Kinase+2+%28TYK2%29&doi=10.1074%2Fjbc.M115.672048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2)</span></div><div class="casAuthors">Min, Xiaoshan; Ungureanu, Daniela; Maxwell, Sarah; Hammaren, Henrik; Thibault, Steve; Hillert, Ellin-Kristina; Ayres, Merrill; Greenfield, Brad; Eksterowicz, John; Gabel, Chris; Walker, Nigel; Silvennoinen, Olli; Wang, Zhulun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">27261-27270</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">JAK (Janus family of cytoplasmic tyrosine kinases) family tyrosine kinase 2 (TYK2) participates in signaling through cytokine receptors involved in immune responses and inflammation.  JAKs are characterized by dual kinase domain: a tyrosine kinase domain (JH1) that is preceded by a pseudokinase domain (JH2).  The majority of disease-assocd. mutations in JAKs map to JH2, demonstrating its central regulatory function.  JH2s were considered catalytically inactive, but JAK2 JH2 was found to have low autoregulatory catalytic activity.  Whether the other JAK JH2s share ATP binding and enzymic activity has been unclear.  Here we report the crystal structure of TYK2 JH2 in complex with adenosine 5'-O-(thiotriphosphate) (ATP-Î³S) and characterize its nucleotide binding by biochem. and biophys. methods.  TYK2 JH2 did not show phosphotransfer activity, but it binds ATP and the nucleotide binding stabilizes the protein without inducing major conformational changes.  Mutation of the JH2 ATP-binding pocket increased basal TYK2 phosphorylation and downstream signaling.  The overall structural characteristics of TYK2 JH2 resemble JAK2 JH2, but distinct stabilizing mol. interactions around helix Î±AL in the activation loop provide a structural basis for differences in substrate access and catalytic activities among JAK family JH2s.  The structural and biochem. data suggest that ATP binding is functionally important for both TYK2 and JAK2 JH2s, whereas the regulatory phosphorylation appears to be a unique property of JAK2.  Finally, the co-crystal structure of TYK2 JH2 complexed with a small mol. inhibitor demonstrates that JH2 is accessible to ATP-competitive compds., which offers novel approaches for targeting cytokine signaling as well as potential therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4ZJIkM0pXXbVg90H21EOLACvtfcHk0lhliccgW-uQOg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyrtrnO&md5=2933fa07a5bdbea19f3d434591613070</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.672048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.672048%26sid%3Dliteratum%253Aachs%26aulast%3DMin%26aufirst%3DX.%26aulast%3DUngureanu%26aufirst%3DD.%26aulast%3DMaxwell%26aufirst%3DS.%26aulast%3DHammar%25C3%25A9n%26aufirst%3DH.%26aulast%3DThibault%26aufirst%3DS.%26aulast%3DHillert%26aufirst%3DE.-K.%26aulast%3DAyres%26aufirst%3DM.%26aulast%3DGreenfield%26aufirst%3DB.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DGabel%26aufirst%3DC.%26aulast%3DWalker%26aufirst%3DN.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DStructural%2520and%2520Functional%2520Characterization%2520of%2520the%2520JH2%2520Pseudokinase%2520Domain%2520of%2520JAK%2520Family%2520Tyrosine%2520Kinase%25202%2520%2528TYK2%2529%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D27261%26epage%3D27270%26doi%3D10.1074%2Fjbc.M115.672048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Abbema, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berezhkovsky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delarosa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVoss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halladay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyssikatos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menghrajani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambrone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, B.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, S.</span></span> <span> </span><span class="NLM_article-title">Lead Optimization of a 4-Aminopyridine Benzamide Scaffold To Identify Potent, Selective, and Orally Bioavailable TYK2 Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4521</span>â <span class="NLM_lpage">4536</span>, <span class="refDoi">Â DOI: 10.1021/jm400266t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400266t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsFakuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4521-4536&author=J.+Liangauthor=A.+van+Abbemaauthor=M.+Balazsauthor=K.+Barrettauthor=L.+Berezhkovskyauthor=W.+Blairauthor=C.+Changauthor=D.+Delarosaauthor=J.+DeVossauthor=J.+Driscollauthor=C.+Eigenbrotauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=J.+Halladayauthor=A.+Johnsonauthor=P.+B.+Kohliauthor=Y.+Laiauthor=Y.+Liuauthor=J.+Lyssikatosauthor=P.+Mantikauthor=K.+Menghrajaniauthor=J.+Murrayauthor=I.+Pengauthor=A.+Sambroneauthor=S.+Shiaauthor=Y.+Shinauthor=J.+Smithauthor=S.+Sohnauthor=V.+Tsuiauthor=M.+Ultschauthor=L.+C.+Wuauthor=Y.+Xiaoauthor=W.+Yangauthor=J.+Youngauthor=B.+Zhangauthor=B.-y.+Zhuauthor=S.+Magnuson&title=Lead+Optimization+of+a+4-Aminopyridine+Benzamide+Scaffold+To+Identify+Potent%2C+Selective%2C+and+Orally+Bioavailable+TYK2+Inhibitors&doi=10.1021%2Fjm400266t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Lead Optimization of a 4-Aminopyridine Benzamide Scaffold To Identify Potent, Selective, and Orally Bioavailable TYK2 Inhibitors</span></div><div class="casAuthors">Liang, Jun; van Abbema, Anne; Balazs, Mercedesz; Barrett, Kathy; Berezhkovsky, Leo; Blair, Wade; Chang, Christine; Delarosa, Donnie; DeVoss, Jason; Driscoll, Jim; Eigenbrot, Charles; Ghilardi, Nico; Gibbons, Paul; Halladay, Jason; Johnson, Adam; Kohli, Pawan Bir; Lai, Yingjie; Liu, Yanzhou; Lyssikatos, Joseph; Mantik, Priscilla; Menghrajani, Kapil; Murray, Jeremy; Peng, Ivan; Sambrone, Amy; Shia, Steven; Shin, Young; Smith, Jan; Sohn, Sue; Tsui, Vickie; Ultsch, Mark; Wu, Lawren C.; Xiao, Yisong; Yang, Wenqian; Young, Judy; Zhang, Birong; Zhu, Bing-yan; Magnuson, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4521-4536</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein the authors report the authors' lead optimization effort to identify potent, selective, and orally bioavailable TYK2 inhibitors, starting with lead mol. 2,6-dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide.  The authors used structure-based design to discover 2,6-dichloro-4-cyanophenyl and (1R,2R)-2-fluorocyclopropylamide modifications, each of which exhibited improved TYK2 potency and JAK1 and JAK2 selectivity relative to 2,6-dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide.  Further optimization eventually led to 2-Chloro-4-cyano-6-fluoro-N-(2-((1R,2R)-2-fluorocyclopropanecarboxamido)pyridin-4-yl)benzamide that showed good TYK2 enzyme and interleukin-12 (IL-12) cell potency, as well as acceptable cellular JAK1 and JAK2 selectivity and excellent oral exposure in mice.  When tested in a mouse IL-12 PK/PD model, 2-Chloro-4-cyano-6-fluoro-N-(2-((1R,2R)-2-ffluorocyclopropanecarboxamido)pyridin-4-yl)benzamide showed statistically significant knockdown of cytokine interferon-Î³ (IFNÎ³), suggesting that selective inhibition of TYK2 kinase activity might be sufficient to block the IL-12 pathway in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCinZ75WrtObVg90H21EOLACvtfcHk0li170UZOJ8SFg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsFakuro%253D&md5=290ee5f1e3e093136ac5fbb418323421</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm400266t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400266t%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBerezhkovsky%26aufirst%3DL.%26aulast%3DBlair%26aufirst%3DW.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DDelarosa%26aufirst%3DD.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDriscoll%26aufirst%3DJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DHalladay%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLyssikatos%26aufirst%3DJ.%26aulast%3DMantik%26aufirst%3DP.%26aulast%3DMenghrajani%26aufirst%3DK.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DPeng%26aufirst%3DI.%26aulast%3DSambrone%26aufirst%3DA.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DSohn%26aufirst%3DS.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DL.%2BC.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DYoung%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DB.-y.%26aulast%3DMagnuson%26aufirst%3DS.%26atitle%3DLead%2520Optimization%2520of%2520a%25204-Aminopyridine%2520Benzamide%2520Scaffold%2520To%2520Identify%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Bioavailable%2520TYK2%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4521%26epage%3D4536%26doi%3D10.1021%2Fjm400266t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yogo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagamiya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih-Chung, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohba, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokunaga, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhim, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skene, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okabe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marui, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aso, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span> <span> </span><span class="NLM_article-title">Structure-based Design and Synthesis of 3-Amino-1,5-dihydro-4<i>H</i>-pyrazolopyridin-4-one Derivatives as Tyrosine Kinase 2 Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">733</span>â <span class="NLM_lpage">749</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01857</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01857" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVygsbrO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=733-749&author=T.+Yogoauthor=H.+Nagamiyaauthor=M.+Setoauthor=S.+Sasakiauthor=H.+Shih-Chungauthor=Y.+Ohbaauthor=N.+Tokunagaauthor=G.+N.+Leeauthor=C.+Y.+Rhimauthor=C.+H.+Yoonauthor=S.+Y.+Choauthor=R.+Skeneauthor=S.+Yamamotoauthor=Y.+Satouauthor=M.+Kunoauthor=T.+Miyazakiauthor=H.+Nakagawaauthor=A.+Okabeauthor=S.+Maruiauthor=K.+Asoauthor=M.+Yoshida&title=Structure-based+Design+and+Synthesis+of+3-Amino-1%2C5-dihydro-4H-pyrazolopyridin-4-one+Derivatives+as+Tyrosine+Kinase+2+Inhibitors&doi=10.1021%2Facs.jmedchem.5b01857"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design and Synthesis of 3-Amino-1,5-dihydro-4H-pyrazolopyridin-4-one Derivatives as Tyrosine Kinase 2 Inhibitors</span></div><div class="casAuthors">Yogo, Takatoshi; Nagamiya, Hiroyuki; Seto, Masaki; Sasaki, Satoshi; Shih-Chung, Huang; Ohba, Yusuke; Tokunaga, Norihito; Lee, Gil Nam; Rhim, Chul Yun; Yoon, Cheol Hwan; Cho, Suk Young; Skene, Robert; Yamamoto, Syunsuke; Satou, Yousuke; Kuno, Masako; Miyazaki, Takahiro; Nakagawa, Hideyuki; Okabe, Atsutoshi; Marui, Shogo; Aso, Kazuyoshi; Yoshida, Masato</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">733-749</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report herein the discovery and optimization of 3-amino-1,5-dihydro-4H-pyrazolopyridin-4-one TYK2 inhibitors.  High-throughput screening against TYK2 and JAK1-3 provided aminoindazole deriv. 1 (I) as a hit compd.  Scaffold hopping of the aminoindazole core led to the discovery of 3-amino-1,5-dihydro-4H-pyrazolopyridin-4-one deriv. 3 (III) as a novel chemotype of TYK2 inhibitors.  Interestingly, initial SAR study suggested that this scaffold could have a vertically flipped binding mode, which prompted us to introduce a substituent at the 7-position as a moiety directed toward the solvent-exposed region.  Introduction of a 1-methyl-3-pyrazolyl moiety at the 7-position resulted in a dramatic increase in TYK2 inhibitory activity, and further optimization led to the discovery of 20 (XX).  Compd. 20 inhibited IL-23-induced IL-22 prodn. in a rat PD assay, as well as inhibited IL-23 signaling in human PBMC.  Furthermore, 20 showed selectivity for IL-23 signaling inhibition against GM-CSF, demonstrating the unique cytokine selectivity of the novel TYK2 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFqjGKQbCdlbVg90H21EOLACvtfcHk0li170UZOJ8SFg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVygsbrO&md5=05067e56ba1f96b58855f60eddc1a973</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01857%26sid%3Dliteratum%253Aachs%26aulast%3DYogo%26aufirst%3DT.%26aulast%3DNagamiya%26aufirst%3DH.%26aulast%3DSeto%26aufirst%3DM.%26aulast%3DSasaki%26aufirst%3DS.%26aulast%3DShih-Chung%26aufirst%3DH.%26aulast%3DOhba%26aufirst%3DY.%26aulast%3DTokunaga%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DG.%2BN.%26aulast%3DRhim%26aufirst%3DC.%2BY.%26aulast%3DYoon%26aufirst%3DC.%2BH.%26aulast%3DCho%26aufirst%3DS.%2BY.%26aulast%3DSkene%26aufirst%3DR.%26aulast%3DYamamoto%26aufirst%3DS.%26aulast%3DSatou%26aufirst%3DY.%26aulast%3DKuno%26aufirst%3DM.%26aulast%3DMiyazaki%26aufirst%3DT.%26aulast%3DNakagawa%26aufirst%3DH.%26aulast%3DOkabe%26aufirst%3DA.%26aulast%3DMarui%26aufirst%3DS.%26aulast%3DAso%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DM.%26atitle%3DStructure-based%2520Design%2520and%2520Synthesis%2520of%25203-Amino-1%252C5-dihydro-4H-pyrazolopyridin-4-one%2520Derivatives%2520as%2520Tyrosine%2520Kinase%25202%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D733%26epage%3D749%26doi%3D10.1021%2Facs.jmedchem.5b01857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrencik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efremov, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstenberger, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalsamy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingshead, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knafels, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limburg, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trujillo, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajdos, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Z.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((<i>S</i>)-2,2-Difluorocyclopropyl)((1R,5<i>S</i>)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)-pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8597</span>â <span class="NLM_lpage">8612</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b00917</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00917" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFWgtLfI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8597-8612&author=A.+Fensomeauthor=C.+M.+Amblerauthor=E.+Arnoldauthor=M.+E.+Bankerauthor=M.+F.+Brownauthor=J.+Chrencikauthor=J.+D.+Clarkauthor=M.+E.+Dowtyauthor=I.+V.+Efremovauthor=A.+Flickauthor=B.+S.+Gerstenbergerauthor=A.+Gopalsamyauthor=M.+M.+Haywardauthor=M.+Hegenauthor=B.+D.+Hollingsheadauthor=J.+Jussifauthor=J.+D.+Knafelsauthor=D.+C.+Limburgauthor=D.+Linauthor=T.+H.+Linauthor=B.+S.+Pierceauthor=E.+Saiahauthor=R.+Sharmaauthor=P.+T.+Symanowiczauthor=J.-B.+Telliezauthor=J.+I.+Trujilloauthor=F.+F.+Vajdosauthor=F.+Vincentauthor=Z.-K.+Wanauthor=L.+Xingauthor=X.+Yangauthor=X.+Yangauthor=L.+Zhang&title=Dual+Inhibition+of+TYK2+and+JAK1+for+the+Treatment+of+Autoimmune+Diseases%3A+Discovery+of+%28%28S%29-2%2C2-Difluorocyclopropyl%29%28%281R%2C5S%29-3-%282-%28%281-methyl-1H-pyrazol-4-yl%29amino%29-pyrimidin-4-yl%29-3%2C8-diazabicyclo%5B3.2.1%5Doctan-8-yl%29methanone+%28PF-06700841%29&doi=10.1021%2Facs.jmedchem.8b00917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)</span></div><div class="casAuthors">Fensome, Andrew; Ambler, Catherine M.; Arnold, Eric; Banker, Mary Ellen; Brown, Matthew F.; Chrencik, Jill; Clark, James D.; Dowty, Martin E.; Efremov, Ivan V.; Flick, Andrew; Gerstenberger, Brian S.; Gopalsamy, Ariamala; Hayward, Matthew M.; Hegen, Martin; Hollingshead, Brett D.; Jussif, Jason; Knafels, John D.; Limburg, David C.; Lin, David; Lin, Tsung H.; Pierce, Betsy S.; Saiah, Eddine; Sharma, Raman; Symanowicz, Peter T.; Telliez, Jean-Baptiste; Trujillo, John I.; Vajdos, Felix F.; Vincent, Fabien; Wan, Zhao-Kui; Xing, Li; Yang, Xiaojing; Yang, Xin; Zhang, Liying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8597-8612</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cytokine signaling is an important characteristic of autoimmune diseases.  Many pro-inflammatory cytokines signal through the Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) pathway.  JAK1 is important for the Î³-common chain cytokines, interleukin (IL)-6 and type-I interferon (IFN) family, while TYK2 in addn. to type-I IFN signaling also plays a role in IL-23 and IL-12 signaling.  Intervention with monoclonal antibodies (mAbs) or JAK1 inhibitors has demonstrated efficacy in Phase III psoriasis, psoriatic arthritis, inflammatory bowel disease and rheumatoid arthritis studies, leading to multiple drug approvals.  It is hypothesized that a dual JAK1/TYK2 inhibitor will provide addnl. efficacy, while managing risk by optimizing selectivity against JAK2 driven hematopoietic changes.  Our program began with a conformationally constrained piperazinyl-pyrimidine Type 1 ATP site inhibitor, subsequent work led to the discovery of PF-06700841 (compd. 23), which is in Phase II clin. development (NCT02969018, NCT02958865, NCT03395184, and NCT02974868).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWNhVkNWDMq7Vg90H21EOLACvtfcHk0lgo9XlMmkFY_Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFWgtLfI&md5=c321512f524560cba445d070b9639e55</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00917%26sid%3Dliteratum%253Aachs%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DAmbler%26aufirst%3DC.%2BM.%26aulast%3DArnold%26aufirst%3DE.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DChrencik%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DEfremov%26aufirst%3DI.%2BV.%26aulast%3DFlick%26aufirst%3DA.%26aulast%3DGerstenberger%26aufirst%3DB.%2BS.%26aulast%3DGopalsamy%26aufirst%3DA.%26aulast%3DHayward%26aufirst%3DM.%2BM.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DHollingshead%26aufirst%3DB.%2BD.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DKnafels%26aufirst%3DJ.%2BD.%26aulast%3DLimburg%26aufirst%3DD.%2BC.%26aulast%3DLin%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DSaiah%26aufirst%3DE.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DTrujillo%26aufirst%3DJ.%2BI.%26aulast%3DVajdos%26aufirst%3DF.%2BF.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DWan%26aufirst%3DZ.-K.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DDual%2520Inhibition%2520of%2520TYK2%2520and%2520JAK1%2520for%2520the%2520Treatment%2520of%2520Autoimmune%2520Diseases%253A%2520Discovery%2520of%2520%2528%2528S%2529-2%252C2-Difluorocyclopropyl%2529%2528%25281R%252C5S%2529-3-%25282-%2528%25281-methyl-1H-pyrazol-4-yl%2529amino%2529-pyrimidin-4-yl%2529-3%252C8-diazabicyclo%255B3.2.1%255Doctan-8-yl%2529methanone%2520%2528PF-06700841%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D8597%26epage%3D8612%26doi%3D10.1021%2Facs.jmedchem.8b00917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banfield, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaramozza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieras, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goteti, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkle, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeva, E.</span></span> <span> </span><span class="NLM_article-title">The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients with Plaque Psoriasis</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">434</span>â <span class="NLM_lpage">447</span>, <span class="refDoi">Â DOI: 10.1002/jcph.1046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1002%2Fjcph.1046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=29266308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVKrurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2018&pages=434-447&author=C.+Banfieldauthor=M.+Scaramozzaauthor=W.+Zhangauthor=E.+Kierasauthor=K.+M.+Pageauthor=A.+Fensomeauthor=M.+Vincentauthor=M.+E.+Dowtyauthor=K.+Gotetiauthor=P.+J.+Winkleauthor=E.+Peeva&title=The+Safety%2C+Tolerability%2C+Pharmacokinetics%2C+and+Pharmacodynamics+of+a+TYK2%2FJAK1+Inhibitor+%28PF-06700841%29+in+Healthy+Subjects+and+Patients+with+Plaque+Psoriasis&doi=10.1002%2Fjcph.1046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis</span></div><div class="casAuthors">Banfield, Christopher; Scaramozza, Matthew; Zhang, Weidong; Kieras, Elizabeth; Page, Karen M.; Fensome, Andrew; Vincent, Michael; Dowty, Martin E.; Goteti, Kosalaram; Winkle, Peter J.; Peeva, Elena</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">434-447</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06700841 were assessed in a randomized, double-blind, placebo-controlled, single- and multiple-dose escalation, parallel-group study in healthy subjects and patients with plaque psoriasis.  The single ascending dose (1, 3, 10, 30, 100, or 200 mg) and multiple ascending dose (MAD; PF-06700841; up to 175 mg once daily or 50 mg twice daily for 10 days) periods included 54 healthy participants.  In addn., 30 patients with psoriasis received PF-06700841 30 or 100 mg or placebo once daily for 28 days.  Single PF-06700841 doses were rapidly absorbed, with peak plasma concns. â¤ 1 h, proportional exposure up to 100 mg, and mean half-life 3.8-7.5 h.  On day 10 of MAD, plasma concns. peaked at â¤1.5 h postdose (10-175 mg once daily).  Elimination half-life was 4.9-10.7 h; steady state was reached by day 8.  In psoriasis patients on day 28, peak plasma concns. occurred at 1-2 h.  Biomarkers IP-10 and high-sensitivity C-reactive protein were reduced and returned to near baseline levels after dosing.  Maximal mean percent change from baseline in the Psoriasis Area and Severity Index scores for PF-06700841 30 mg once daily and 100 mg once daily were -67.92% and -96.31%, resp., in week 4.  All adverse events were mild/moderate.  PF-06700841 was safe and well tolerated up to 200 mg once daily in healthy subjects and 100 mg once daily in patients with psoriasis, suggesting potential therapeutic utility in plaque psoriasis and other inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHMconrLwJf7Vg90H21EOLACvtfcHk0lgo9XlMmkFY_Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVKrurw%253D&md5=a907c91ff2d50db9cba930c2249ed37b</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2Fjcph.1046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.1046%26sid%3Dliteratum%253Aachs%26aulast%3DBanfield%26aufirst%3DC.%26aulast%3DScaramozza%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DKieras%26aufirst%3DE.%26aulast%3DPage%26aufirst%3DK.%2BM.%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DVincent%26aufirst%3DM.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DGoteti%26aufirst%3DK.%26aulast%3DWinkle%26aufirst%3DP.%2BJ.%26aulast%3DPeeva%26aufirst%3DE.%26atitle%3DThe%2520Safety%252C%2520Tolerability%252C%2520Pharmacokinetics%252C%2520and%2520Pharmacodynamics%2520of%2520a%2520TYK2%252FJAK1%2520Inhibitor%2520%2528PF-06700841%2529%2520in%2520Healthy%2520Subjects%2520and%2520Patients%2520with%2520Plaque%2520Psoriasis%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2018%26volume%3D58%26spage%3D434%26epage%3D447%26doi%3D10.1002%2Fjcph.1046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerstenberger, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dermenci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fish, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingshead, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knafels, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajdos, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, S. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_fpage">13561</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.0c00948</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00948" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFeksL%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&pages=13561&author=B.+S.+Gerstenbergerauthor=C.+Amblerauthor=E.+P.+Arnoldauthor=M.-E.+Bankerauthor=M.+F.+Brownauthor=J.+D.+Clarkauthor=A.+Dermenciauthor=M.+E.+Dowtyauthor=A.+Fensomeauthor=S.+Fishauthor=M.+M.+Haywardauthor=M.+Hegenauthor=B.+D.+Hollingsheadauthor=J.+D.+Knafelsauthor=D.+W.+Linauthor=T.+H.+Linauthor=D.+R.+Owenauthor=E.+Saiahauthor=R.+Sharmaauthor=F.+F.+Vajdosauthor=L.+Xingauthor=X.+Yangauthor=X.+Yangauthor=S.+W.+Wright&title=Discovery+of+Tyrosine+Kinase+2+%28TYK2%29+Inhibitor+%28PF-06826647%29+for+the+Treatment+of+Autoimmune+Diseases&doi=10.1021%2Facs.jmedchem.0c00948"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases</span></div><div class="casAuthors">Gerstenberger, Brian S.; Ambler, Catherine; Arnold, Eric P.; Banker, Mary-Ellen; Brown, Matthew F.; Clark, James D.; Dermenci, Alpay; Dowty, Martin E.; Fensome, Andrew; Fish, Susan; Hayward, Matthew M.; Hegen, Martin; Hollingshead, Brett D.; Knafels, John D.; Lin, David W.; Lin, Tsung H.; Owen, Dafydd R.; Saiah, Eddine; Sharma, Raman; Vajdos, Felix F.; Xing, Li; Yang, Xiaojing; Yang, Xin; Wright, Stephen W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">13561-13577</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tyrosine kinase 2 (TYK2) is a member of the JAK kinase family that regulates signal transduction downstream of receptors for the IL-23/IL-12 pathways and type I interferon family, where it pairs with JAK2 or JAK1, resp.  On the basis of human genetic and emerging clin. data, a selective TYK2 inhibitor provides an opportunity to treat autoimmune diseases delivering a potentially differentiated clin. profile compared to currently approved JAK inhibitors.  The discovery of an ATP-competitive pyrazolopyrazinyl series of TYK2 inhibitors was accomplished through computational and structurally enabled design starting from a known kinase hinge binding motif.  With understanding of PK/PD relationships, a target profile balancing TYK2 potency and selectivity over off-target JAK2 was established.  Lead optimization involved modulating potency, selectivity, and ADME properties which led to the identification of the clin. candidate PF-06826647 (22).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDqYsbCoP1k7Vg90H21EOLACvtfcHk0lgo9XlMmkFY_Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFeksL%252FE&md5=b096585420a37ce60c1be0b851570fb8</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00948%26sid%3Dliteratum%253Aachs%26aulast%3DGerstenberger%26aufirst%3DB.%2BS.%26aulast%3DAmbler%26aufirst%3DC.%26aulast%3DArnold%26aufirst%3DE.%2BP.%26aulast%3DBanker%26aufirst%3DM.-E.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DDermenci%26aufirst%3DA.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DFish%26aufirst%3DS.%26aulast%3DHayward%26aufirst%3DM.%2BM.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DHollingshead%26aufirst%3DB.%2BD.%26aulast%3DKnafels%26aufirst%3DJ.%2BD.%26aulast%3DLin%26aufirst%3DD.%2BW.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DOwen%26aufirst%3DD.%2BR.%26aulast%3DSaiah%26aufirst%3DE.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DVajdos%26aufirst%3DF.%2BF.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DWright%26aufirst%3DS.%2BW.%26atitle%3DDiscovery%2520of%2520Tyrosine%2520Kinase%25202%2520%2528TYK2%2529%2520Inhibitor%2520%2528PF-06826647%2529%2520for%2520the%2520Treatment%2520of%2520Autoimmune%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26spage%3D13561%26doi%3D10.1021%2Facs.jmedchem.0c00948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zupa-Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tredup, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedicord, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edavettal, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witmer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkin, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blat, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitts, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span> <span> </span><span class="NLM_article-title">Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes is Blocked by Pharmacological Stabilization of its Pseudokinase Domain</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">11061</span>â <span class="NLM_lpage">11074</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M114.619502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1074%2Fjbc.M114.619502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=25762719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFSqt70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=11061-11074&author=J.+S.+Tokarskiauthor=A.+Zupa-Fernandezauthor=J.+A.+Tredupauthor=K.+Pikeauthor=C.+Y.+Changauthor=D.+Xieauthor=L.+Chengauthor=D.+Pedicordauthor=J.+Muckelbauerauthor=S.+R.+Johnsonauthor=S.+Wuauthor=S.+C.+Edavettalauthor=Y.+Hongauthor=M.+R.+Witmerauthor=L.+L.+Elkinauthor=Y.+Blatauthor=W.+J.+Pittsauthor=D.+S.+Weinsteinauthor=J.+R.+Burke&title=Tyrosine+Kinase+2-mediated+Signal+Transduction+in+T+Lymphocytes+is+Blocked+by+Pharmacological+Stabilization+of+its+Pseudokinase+Domain&doi=10.1074%2Fjbc.M114.619502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase 2-mediated signal transduction in T lymphocytes is blocked by pharmacological stabilization of its pseudokinase domain</span></div><div class="casAuthors">Tokarski, John S.; Zupa-Fernandez, Adriana; Tredup, Jeffrey A.; Pike, Kristen; Chang, Chieh Ying; Xie, Dianlin; Cheng, Lihong; Pedicord, Donna; Muckelbauer, Jodi; Johnson, Stephen R.; Wu, Sophie; Edavettal, Suzanne C.; Hong, Yang; Witmer, Mark R.; Elkin, Lisa L.; Blat, Yuval; Pitts, William J.; Weinstein, David S.; Burke, James R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">11061-11074</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Inhibition of signal transduction downstream of the IL-23 receptor represents an intriguing approach to the treatment of autoimmunity.  Using a chemogenomics approach marrying kinome-wide inhibitory profiles of a compd. library with the cellular activity against an IL-23-stimulated transcriptional response in T lymphocytes, a class of inhibitors was identified that bind to and stabilize the pseudokinase domain of the Janus kinase tyrosine kinase 2 (Tyk2), resulting in blockade of receptor-mediated activation of the adjacent catalytic domain.  These Tyk2 pseudokinase domain stabilizers were also shown to inhibit Tyk2-dependent signaling through the Type I interferon receptor but not Tyk2-independent signaling and transcriptional cellular assays, including stimulation through the receptors for IL-2 (JAK1- and JAK3-dependent) and thrombopoietin (JAK2-dependent), demonstrating the high functional selectivity of this approach.  A crystal structure of the pseudokinase domain liganded with a representative example showed the compd. bound to a site analogous to the ATP-binding site in catalytic kinases with features consistent with high ligand selectivity.  The results support a model where the pseudokinase domain regulates activation of the catalytic domain by forming receptor-regulated inhibitory interactions.  Tyk2 pseudokinase stabilizers, therefore, represent a novel approach to the design of potent and selective agents for the treatment of autoimmunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwSl_Zer56d7Vg90H21EOLACvtfcHk0liJyp1J7UJ15Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFSqt70%253D&md5=49e10a7c3e430c8be198c119b26bb16b</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.619502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.619502%26sid%3Dliteratum%253Aachs%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DZupa-Fernandez%26aufirst%3DA.%26aulast%3DTredup%26aufirst%3DJ.%2BA.%26aulast%3DPike%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DPedicord%26aufirst%3DD.%26aulast%3DMuckelbauer%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DEdavettal%26aufirst%3DS.%2BC.%26aulast%3DHong%26aufirst%3DY.%26aulast%3DWitmer%26aufirst%3DM.%2BR.%26aulast%3DElkin%26aufirst%3DL.%2BL.%26aulast%3DBlat%26aufirst%3DY.%26aulast%3DPitts%26aufirst%3DW.%2BJ.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26atitle%3DTyrosine%2520Kinase%25202-mediated%2520Signal%2520Transduction%2520in%2520T%2520Lymphocytes%2520is%2520Blocked%2520by%2520Pharmacological%2520Stabilization%2520of%2520its%2520Pseudokinase%2520Domain%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D11061%26epage%3D11074%26doi%3D10.1074%2Fjbc.M114.619502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lupardus, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallweber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bir Kohli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span> <span> </span><span class="NLM_article-title">Structure of the Pseudokinase-Kinase Domains from Protein Kinase TYK2 Reveals a Mechanism for Janus Kinase (JAK) Autoinhibition</span>. <i>Proc. Natl. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">8025</span>â <span class="NLM_lpage">8030</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1401180111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1073%2Fpnas.1401180111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=24843152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A280%3ADC%252BC2cjktFyntg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=8025-8030&author=P.+J.+Lupardusauthor=M.+Ultschauthor=H.+Wallweberauthor=P.+Bir+Kohliauthor=A.+R.+Johnsonauthor=C.+Eigenbrot&title=Structure+of+the+Pseudokinase-Kinase+Domains+from+Protein+Kinase+TYK2+Reveals+a+Mechanism+for+Janus+Kinase+%28JAK%29+Autoinhibition&doi=10.1073%2Fpnas.1401180111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition</span></div><div class="casAuthors">Lupardus Patrick J; Ultsch Mark; Wallweber Heidi; Eigenbrot Charles; Bir Kohli Pawan; Johnson Adam R</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8025-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Janus kinases (JAKs) are receptor-associated multidomain tyrosine kinases that act downstream of many cytokines and interferons.  JAK kinase activity is regulated by the adjacent pseudokinase domain via an unknown mechanism.  Here, we report the 2.8-ÃA structure of the two-domain pseudokinase-kinase module from the JAK family member TYK2 in its autoinhibited form.  We find that the pseudokinase and kinase interact near the kinase active site and that most reported mutations in cancer-associated JAK alleles cluster in or near this interface.  Mutation of residues near the TYK2 interface that are analogous to those in cancer-associated JAK alleles, including the V617F and "exon 12" JAK2 mutations, results in increased kinase activity in vitro.  These data indicate that JAK pseudokinases are autoinhibitory domains that hold the kinase domain inactive until receptor dimerization stimulates transition to an active state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRsxgEXiV6j3TQLBVDQn4bCfW6udTcc2eb1YFCOzyd3Mbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjktFyntg%253D%253D&md5=47f1d528f736376c9e02add92839ac67</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1401180111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1401180111%26sid%3Dliteratum%253Aachs%26aulast%3DLupardus%26aufirst%3DP.%2BJ.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DWallweber%26aufirst%3DH.%26aulast%3DBir%2BKohli%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DEigenbrot%26aufirst%3DC.%26atitle%3DStructure%2520of%2520the%2520Pseudokinase-Kinase%2520Domains%2520from%2520Protein%2520Kinase%2520TYK2%2520Reveals%2520a%2520Mechanism%2520for%2520Janus%2520Kinase%2520%2528JAK%2529%2520Autoinhibition%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%26date%3D2014%26volume%3D111%26spage%3D8025%26epage%3D8030%26doi%3D10.1073%2Fpnas.1401180111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toms, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshpande, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNally, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruner, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marto, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Structure of a Pseudokinase Domain Switch that Controls Oncogenic Activation of Jak Kinases</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1221</span>â <span class="NLM_lpage">1223</span>, <span class="refDoi">Â DOI: 10.1038/nsmb.2673</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1038%2Fnsmb.2673" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=24013208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtl2ktrnO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1221-1223&author=A.+V.+Tomsauthor=A.+Deshpandeauthor=R.+McNallyauthor=Y.+Jeongauthor=J.+M.+Rogersauthor=C.+U.+Kimauthor=S.+M.+Grunerauthor=S.+B.+Ficarroauthor=J.+A.+Martoauthor=M.+Sattlerauthor=J.+D.+Griffinauthor=M.+J.+Eck&title=Structure+of+a+Pseudokinase+Domain+Switch+that+Controls+Oncogenic+Activation+of+Jak+Kinases&doi=10.1038%2Fnsmb.2673"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases</span></div><div class="casAuthors">Toms, Angela V.; Deshpande, Anagha; McNally, Randall; Jeong, Youngjee; Rogers, Julia M.; Kim, Chae Un; Gruner, Sol M.; Ficarro, Scott B.; Marto, Jarrod A.; Sattler, Martin; Griffin, James D.; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1221-1223</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The V617F mutation in the Jak2 pseudokinase domain causes myeloproliferative neoplasms, and the equiv. mutation in Jak1 (V658F) is found in T-cell leukemias.  Crystal structures of wild-type and V658F-mutant human Jak1 pseudokinase reveal a conformational switch that remodels a linker segment encoded by exon 12, which is also a site of mutations in Jak2.  This switch is required for V617F-mediated Jak2 activation and possibly for physiol. Jak activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH5DpUPWQk57Vg90H21EOLACvtfcHk0liJyp1J7UJ15Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtl2ktrnO&md5=e38a60cb1460c113ba8460319902c493</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2673%26sid%3Dliteratum%253Aachs%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DDeshpande%26aufirst%3DA.%26aulast%3DMcNally%26aufirst%3DR.%26aulast%3DJeong%26aufirst%3DY.%26aulast%3DRogers%26aufirst%3DJ.%2BM.%26aulast%3DKim%26aufirst%3DC.%2BU.%26aulast%3DGruner%26aufirst%3DS.%2BM.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DMarto%26aufirst%3DJ.%2BA.%26aulast%3DSattler%26aufirst%3DM.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructure%2520of%2520a%2520Pseudokinase%2520Domain%2520Switch%2520that%2520Controls%2520Oncogenic%2520Activation%2520of%2520Jak%2520Kinases%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D1221%26epage%3D1223%26doi%3D10.1038%2Fnsmb.2673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bandaranayake, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ungureanu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, S. R.</span></span> <span> </span><span class="NLM_article-title">Crystal Structures of the JAK2 Pseudokinase Domain and the Pathogenic Mutant V617F</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">754</span>â <span class="NLM_lpage">759</span>, <span class="refDoi">Â DOI: 10.1038/nsmb.2348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1038%2Fnsmb.2348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=22820988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVKntLbM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=754-759&author=R.+M.+Bandaranayakeauthor=D.+Ungureanuauthor=Y.+Shanauthor=D.+E.+Shawauthor=O.+Silvennoinenauthor=S.+R.+Hubbard&title=Crystal+Structures+of+the+JAK2+Pseudokinase+Domain+and+the+Pathogenic+Mutant+V617F&doi=10.1038%2Fnsmb.2348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F</span></div><div class="casAuthors">Bandaranayake, Rajintha M.; Ungureanu, Daniela; Shan, Yibing; Shaw, David E.; Silvennoinen, Olli; Hubbard, Stevan R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">754-759</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The protein tyrosine kinase JAK2 mediates signaling through numerous cytokine receptors.  JAK2 possesses a pseudokinase domain (JH2) and a tyrosine kinase domain (JH1).  Through unknown mechanisms, JH2 regulates the catalytic activity of JH1, and hyperactivating mutations in the JH2 region of human JAK2 cause myeloproliferative neoplasms (MPNs).  We showed previously that JAK2 JH2 is, in fact, catalytically active.  Here we present crystal structures of human JAK2 JH2, including both wild type and the most prevalent MPN mutant, V617F.  The structures reveal that JH2 adopts the fold of a prototypical protein kinase but binds Mg-ATP noncanonically.  The structural and biochem. data indicate that the V617F mutation rigidifies Î±-helix C in the N lobe of JH2, facilitating trans-phosphorylation of JH1.  The crystal structures of JH2 afford new opportunities for the design of novel JAK2 therapeutics targeting MPNs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGj9DoN3fj37Vg90H21EOLACvtfcHk0li5xoeW5P8tbQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVKntLbM&md5=da64398430cd3279e131b2569cdc7391</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2348%26sid%3Dliteratum%253Aachs%26aulast%3DBandaranayake%26aufirst%3DR.%2BM.%26aulast%3DUngureanu%26aufirst%3DD.%26aulast%3DShan%26aufirst%3DY.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26atitle%3DCrystal%2520Structures%2520of%2520the%2520JAK2%2520Pseudokinase%2520Domain%2520and%2520the%2520Pathogenic%2520Mutant%2520V617F%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2012%26volume%3D19%26spage%3D754%26epage%3D759%26doi%3D10.1038%2Fnsmb.2348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Staerk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demoulin, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vainchenker, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantinescu, S. N.</span></span> <span> </span><span class="NLM_article-title">JAK1 and Tyk2 Activation by the Homologous Polycythemia Vera JAK2 V617F Mutation: Cross-talk with IGF1 Receptor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">41893</span>â <span class="NLM_lpage">41899</span>, <span class="refDoi">Â DOI: 10.1074/jbc.C500358200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1074%2Fjbc.C500358200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=16239216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlajsrjL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=41893-41899&author=J.+Staerkauthor=A.+Kallinauthor=J.+B.+Demoulinauthor=W.+Vainchenkerauthor=S.+N.+Constantinescu&title=JAK1+and+Tyk2+Activation+by+the+Homologous+Polycythemia+Vera+JAK2+V617F+Mutation%3A+Cross-talk+with+IGF1+Receptor&doi=10.1074%2Fjbc.C500358200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">JAK1 and Tyk2 Activation by the Homologous Polycythemia Vera JAK2 V617F Mutation: Cross-talk with IGF1 receptor</span></div><div class="casAuthors">Staerk, Judith; Kallin, Anders; Demoulin, Jean-Baptiste; Vainchenker, William; Constantinescu, Stefan N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">41893-41899</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The majority of polycythemia vera (PV) patients harbor a unique somatic mutation (V617F) in the pseudokinase domain of JAK2, which leads to constitutive signaling.  Here we show that the homologous mutations in JAK1 (V658F) and in Tyk2 (V678F) lead to constitutive activation of these kinases.  Their expression induces autonomous growth of cytokine-dependent cells and constitutive activation of STAT5, STAT3, mitogen-activated protein kinase, and Akt signaling in Ba/F3 cells.  The mutant JAKs exhibit constitutive signaling also when expressed in fibrosarcoma cells deficient in JAK proteins.  Expression of the JAK2 V617F mutant renders Ba/F3 cells hypersensitive to insulin-like growth factor 1 (IGF1), which is a hallmark of PV erythroid progenitors.  Upon selection of Ba/F3 cells for autonomous growth induced by the JAK2 V617F mutant, cells respond to IGF1 by activating STAT5, STAT3, Erk1/2, and Akt on top of the constitutive activation characteristic of autonomous cells.  The synergic effect on proliferation and STAT activation appears specific to the JAK2 V617F mutant.  Our results show that the homologous V617F mutation induces activation of JAK1 and Tyk2, suggesting a common mechanism of activation for the JAK1, JAK2, and Tyk2 mutants.  JAK3 is not activated by the homologous mutation M592F, despite the presence of the conserved GVC preceding sequence.  We suggest that mutations in the JAK1 and Tyk2 genes may be identified as initial mol. defects in human cancers and autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom-sdvNQ5aOLVg90H21EOLACvtfcHk0li5xoeW5P8tbQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlajsrjL&md5=b3566dcbfb8de848f32b881526eae2fb</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1074%2Fjbc.C500358200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.C500358200%26sid%3Dliteratum%253Aachs%26aulast%3DStaerk%26aufirst%3DJ.%26aulast%3DKallin%26aufirst%3DA.%26aulast%3DDemoulin%26aufirst%3DJ.%2BB.%26aulast%3DVainchenker%26aufirst%3DW.%26aulast%3DConstantinescu%26aufirst%3DS.%2BN.%26atitle%3DJAK1%2520and%2520Tyk2%2520Activation%2520by%2520the%2520Homologous%2520Polycythemia%2520Vera%2520JAK2%2520V617F%2520Mutation%253A%2520Cross-talk%2520with%2520IGF1%2520Receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D41893%26epage%3D41899%26doi%3D10.1074%2Fjbc.C500358200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foulkes, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyers, P. A.</span></span> <span> </span><span class="NLM_article-title">Pseudokinases: Update on their Functions and Evaluation as New Drug Targets</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">245</span>â <span class="NLM_lpage">265</span>, <span class="refDoi">Â DOI: 10.4155/fmc-2016-0207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.4155%2Ffmc-2016-0207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=28097887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslWnurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=245-265&author=D.+P.+Byrneauthor=D.+M.+Foulkesauthor=P.+A.+Eyers&title=Pseudokinases%3A+Update+on+their+Functions+and+Evaluation+as+New+Drug+Targets&doi=10.4155%2Ffmc-2016-0207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Pseudokinases: update on their functions and evaluation as new drug targets</span></div><div class="casAuthors">Byrne, Dominic P.; Foulkes, Daniel M.; Eyers, Patrick A.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">245-265</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The pseudokinase complement of the human kinase superfamily consists of approx. 60 signaling proteins, which lacks one or more of the amino acids typically required to correctly align ATP and metal ions, and phosphorylate protein substrates.  Recent studies in the pseudokinase field have begun to expose the biol. relevance of pseudokinases, which are now thought to perform a diverse range of physiol. roles and are connected to a multitude of human diseases, including cancer.  In this review, we discuss how and why members of the 'pseudokinome' represent important new targets for drug discovery, and describe how knowledge of protein structure and function provides informative clues to help guide the rational chem. design or repurposing of inhibitors to target pseudokinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqInUA03dIObVg90H21EOLACvtfcHk0lha_QJQqVi9Zg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslWnurg%253D&md5=290fd229e4f7e5fefc308b2fae35881d</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2016-0207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2016-0207%26sid%3Dliteratum%253Aachs%26aulast%3DByrne%26aufirst%3DD.%2BP.%26aulast%3DFoulkes%26aufirst%3DD.%2BM.%26aulast%3DEyers%26aufirst%3DP.%2BA.%26atitle%3DPseudokinases%253A%2520Update%2520on%2520their%2520Functions%2520and%2520Evaluation%2520as%2520New%2520Drug%2520Targets%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2017%26volume%3D9%26spage%3D245%26epage%3D265%26doi%3D10.4155%2Ffmc-2016-0207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tredup, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zupa-Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elzinga, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dâarienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aranibar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span> <span> </span><span class="NLM_article-title">Identification of Imidazo[1,2-b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">383</span>â <span class="NLM_lpage">388</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.9b00035</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00035" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjsV2qu7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=383-388&author=C.+Liuauthor=J.+Linauthor=R.+Moslinauthor=J.+S.+Tokarskiauthor=J.+Muckelbauerauthor=C.+Changauthor=J.+Tredupauthor=D.+Xieauthor=H.+Parkauthor=P.+Liauthor=D.-R.+Wuauthor=J.+Strnadauthor=A.+Zupa-Fernandezauthor=L.+Chengauthor=C.+Chaudhryauthor=J.+Chenauthor=C.+Chenauthor=H.+Sunauthor=P.+Elzingaauthor=C.+D%E2%80%99arienzoauthor=K.+Gilloolyauthor=T.+L.+Taylorauthor=K.+W.+McIntyreauthor=L.+Salter-Cidauthor=L.+J.+Lombardoauthor=P.+H.+Carterauthor=N.+Aranibarauthor=J.+R.+Burkeauthor=D.+S.+Weinstein&title=Identification+of+Imidazo%5B1%2C2-b%5Dpyridazine+Derivatives+as+Potent%2C+Selective%2C+and+Orally+Active+Tyk2+JH2+Inhibitors&doi=10.1021%2Facsmedchemlett.9b00035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Imidazo[1,2-b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors</span></div><div class="casAuthors">Liu, Chunjian; Lin, James; Moslin, Ryan; Tokarski, John S.; Muckelbauer, Jodi; Chang, ChiehYing; Tredup, Jeffrey; Xie, Dianlin; Park, Hyunsoo; Li, Peng; Wu, Dauh-Rurng; Strnad, Joann; Zupa-Fernandez, Adriana; Cheng, Lihong; Chaudhry, Charu; Chen, Jing; Chen, Cliff; Sun, Huadong; Elzinga, Paul; Darienzo, Celia; Gillooly, Kathleen; Taylor, Tracy L.; McIntyre, Kim W.; Salter-Cid, Luisa; Lombardo, Louis J.; Carter, Percy H.; Aranibar, Nelly; Burke, James R.; Weinstein, David S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">383-388</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In sharp contrast to a previously reported series of 6-anilino imidazopyridazine based Tyk2 JH2 ligands, 6-((2-oxo-N1-substituted-1,2-dihydropyridin-3-yl)amino)imidazo[1,2-b]pyridazine analogs were found to display dramatically improved metabolic stability.  The N1-substituent on 2-oxo-1,2-dihydropyridine ring can be a variety of alkyl, aryl, and heteroaryl groups, but among them, 2-pyridyl provided much enhanced Caco-2 permeability, attributed to its ability to form intramol. hydrogen bonds.  Further structure-activity relationship studies at the C3 position led to the identification of highly potent and selective Tyk2 JH2 inhibitor 6, which proved to be highly effective in inhibiting IFNÎ³ prodn. in a rat pharmacodynamics model and fully efficacious in a rat adjuvant arthritis model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKahxaaZZWtbVg90H21EOLACvtfcHk0lha_QJQqVi9Zg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjsV2qu7w%253D&md5=65c8d8dccfcc2cf73175aef902df9fa2</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00035%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DMoslin%26aufirst%3DR.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DMuckelbauer%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DD.-R.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DZupa-Fernandez%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DElzinga%26aufirst%3DP.%26aulast%3DD%25E2%2580%2599arienzo%26aufirst%3DC.%26aulast%3DGillooly%26aufirst%3DK.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DAranibar%26aufirst%3DN.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26atitle%3DIdentification%2520of%2520Imidazo%255B1%252C2-b%255Dpyridazine%2520Derivatives%2520as%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Active%2520Tyk2%2520JH2%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D383%26epage%3D388%26doi%3D10.1021%2Facsmedchemlett.9b00035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wrobleski, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spergel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zupa-Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuster, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tredup, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulligan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâArienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aranibar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimalakonda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitts, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span> <span> </span><span class="NLM_article-title">Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8973</span>â <span class="NLM_lpage">8995</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b00444</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00444" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlyht7%252FP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8973-8995&author=S.+T.+Wrobleskiauthor=R.+Moslinauthor=S.+Linauthor=Y.+Zhangauthor=S.+Spergelauthor=J.+Kempsonauthor=J.+S.+Tokarskiauthor=J.+Strnadauthor=A.+Zupa-Fernandezauthor=L.+Chengauthor=D.+Shusterauthor=K.+Gilloolyauthor=X.+Yangauthor=E.+Heimrichauthor=K.+W.+McIntyreauthor=C.+Chaudhryauthor=J.+Khanauthor=M.+Ruzanovauthor=J.+Tredupauthor=D.+Mulliganauthor=D.+Xieauthor=H.+Sunauthor=C.+Huangauthor=C.+D%E2%80%99Arienzoauthor=N.+Aranibarauthor=M.+Chineyauthor=A.+Chimalakondaauthor=W.+J.+Pittsauthor=L.+Lombardoauthor=P.+H.+Carterauthor=J.+R.+Burkeauthor=D.+S.+Weinstein&title=Highly+Selective+Inhibition+of+Tyrosine+Kinase+2+%28TYK2%29+for+the+Treatment+of+Autoimmune+Diseases%3A+Discovery+of+the+Allosteric+Inhibitor+BMS-986165&doi=10.1021%2Facs.jmedchem.9b00444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165</span></div><div class="casAuthors">Wrobleski, Stephen T.; Moslin, Ryan; Lin, Shuqun; Zhang, Yanlei; Spergel, Steven; Kempson, James; Tokarski, John S.; Strnad, Joann; Zupa-Fernandez, Adriana; Cheng, Lihong; Shuster, David; Gillooly, Kathleen; Yang, Xiaoxia; Heimrich, Elizabeth; McIntyre, Kim W.; Chaudhry, Charu; Khan, Javed; Ruzanov, Max; Tredup, Jeffrey; Mulligan, Dawn; Xie, Dianlin; Sun, Huadong; Huang, Christine; D'Arienzo, Celia; Aranibar, Nelly; Chiney, Manoj; Chimalakonda, Anjaneya; Pitts, William J.; Lombardo, Louis; Carter, Percy H.; Burke, James R.; Weinstein, David S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8973-8995</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small mol. JAK inhibitors have emerged as a major therapeutic advancement in treating autoimmune diseases.  The discovery of isoform selective JAK inhibitors that traditionally target the catalytically active site of this kinase family has been a formidable challenge.  Our strategy to achieve high selectivity for TYK2 relies on targeting the TYK2 pseudokinase (JH2) domain.  Herein we report the late stage optimization efforts including a structure-guided design and water displacement strategy that led to the discovery of BMS-986165 (11, I) as a high affinity JH2 ligand and potent allosteric inhibitor of TYK2.  In addn. to unprecedented JAK isoform and kinome selectivity, I shows excellent pharmacokinetic properties with minimal profiling liabilities and is efficacious in several murine models of autoimmune disease.  On the basis of these findings, I appears differentiated from all other reported JAK inhibitors and has been advanced as the first pseudokinase-directed therapeutic in clin. development as an oral treatment for autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmA75TJmytlrVg90H21EOLACvtfcHk0lha_QJQqVi9Zg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlyht7%252FP&md5=ca161c470df002b0bdd2bf6b19920ada</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00444%26sid%3Dliteratum%253Aachs%26aulast%3DWrobleski%26aufirst%3DS.%2BT.%26aulast%3DMoslin%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSpergel%26aufirst%3DS.%26aulast%3DKempson%26aufirst%3DJ.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DZupa-Fernandez%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DShuster%26aufirst%3DD.%26aulast%3DGillooly%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DKhan%26aufirst%3DJ.%26aulast%3DRuzanov%26aufirst%3DM.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DMulligan%26aufirst%3DD.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DAranibar%26aufirst%3DN.%26aulast%3DChiney%26aufirst%3DM.%26aulast%3DChimalakonda%26aufirst%3DA.%26aulast%3DPitts%26aufirst%3DW.%2BJ.%26aulast%3DLombardo%26aufirst%3DL.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26atitle%3DHighly%2520Selective%2520Inhibition%2520of%2520Tyrosine%2520Kinase%25202%2520%2528TYK2%2529%2520for%2520the%2520Treatment%2520of%2520Autoimmune%2520Diseases%253A%2520Discovery%2520of%2520the%2520Allosteric%2520Inhibitor%2520BMS-986165%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8973%26epage%3D8995%26doi%3D10.1021%2Facs.jmedchem.9b00444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zupa-Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catlett, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâArienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimalakonda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrobleski, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L. M.</span></span> <span> </span><span class="NLM_article-title">Autoimmune Pathways in Mice and Humans are Blocked by Pharmacological Stabilization of the TYK2 Pseudokinase Domain</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">eaaw1736</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.aaw1736</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1126%2Fscitranslmed.aaw1736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=31341059" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=eaaw1736&author=J.+R.+Burkeauthor=L.+Chengauthor=K.+M.+Gilloolyauthor=J.+Strnadauthor=A.+Zupa-Fernandezauthor=I.+M.+Catlettauthor=Y.+Zhangauthor=E.+M.+Heimrichauthor=K.+W.+McIntyreauthor=M.+D.+Cunninghamauthor=J.+A.+Carmanauthor=X.+Zhouauthor=D.+Banasauthor=C.+Chaudhryauthor=S.+Liauthor=C.+D%E2%80%99Arienzoauthor=A.+Chimalakondaauthor=X.+Yangauthor=J.+H.+Xieauthor=J.+Pangauthor=Q.+Zhaoauthor=S.+M.+Roseauthor=J.+Huangauthor=R.+M.+Moslinauthor=S.+T.+Wrobleskiauthor=D.+S.+Weinsteinauthor=L.+M.+Salter-Cid&title=Autoimmune+Pathways+in+Mice+and+Humans+are+Blocked+by+Pharmacological+Stabilization+of+the+TYK2+Pseudokinase+Domain&doi=10.1126%2Fscitranslmed.aaw1736"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aaw1736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aaw1736%26sid%3Dliteratum%253Aachs%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DZupa-Fernandez%26aufirst%3DA.%26aulast%3DCatlett%26aufirst%3DI.%2BM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHeimrich%26aufirst%3DE.%2BM.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DCunningham%26aufirst%3DM.%2BD.%26aulast%3DCarman%26aufirst%3DJ.%2BA.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DBanas%26aufirst%3DD.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DChimalakonda%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DXie%26aufirst%3DJ.%2BH.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DRose%26aufirst%3DS.%2BM.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DMoslin%26aufirst%3DR.%2BM.%26aulast%3DWrobleski%26aufirst%3DS.%2BT.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26aulast%3DSalter-Cid%26aufirst%3DL.%2BM.%26atitle%3DAutoimmune%2520Pathways%2520in%2520Mice%2520and%2520Humans%2520are%2520Blocked%2520by%2520Pharmacological%2520Stabilization%2520of%2520the%2520TYK2%2520Pseudokinase%2520Domain%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2019%26volume%3D11%26spage%3Deaaw1736%26doi%3D10.1126%2Fscitranslmed.aaw1736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papp, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ThaÃ§i, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gooderham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girgis, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span> <span> </span><span class="NLM_article-title">Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>379</i></span>,  <span class="NLM_fpage">1313</span>â <span class="NLM_lpage">1321</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1806382</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1056%2FNEJMoa1806382" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=30205746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFWlsrbE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2018&pages=1313-1321&author=K.+Pappauthor=K.+Gordonauthor=D.+Tha%C3%A7iauthor=A.+Moritaauthor=M.+Gooderhamauthor=P.+Foleyauthor=I.+G.+Girgisauthor=S.+Kunduauthor=S.+Banerjee&title=Phase+2+Trial+of+Selective+Tyrosine+Kinase+2+Inhibition+in+Psoriasis&doi=10.1056%2FNEJMoa1806382"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis</span></div><div class="casAuthors">Papp, Kim; Gordon, Kenneth; Thaci, Diamant; Morita, Akimichi; Gooderham, Melinda; Foley, Peter; Girgis, Ihab G.; Kundu, Sudeep; Banerjee, Subhashis</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1313-1321</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Tyrosine kinase 2 (TYK2) signaling pathways, which mediate cytokine signaling, are implicated in the pathophysiol. of psoriasis.  Selective inhibitors of TYK2 may be effective in treating psoriasis. methods We conducted a phase 2, double-blind trial of a TYK2 inhibitor, BMS-986165, in adults with moderate-to-severe psoriasis, excluding patients with a previous lack of response to agents targeting cytokine signaling through the same tyrosine kinase pathway.  Patients were randomly assigned to receive the drug orally at a dose of 3 mg every other day, 3 mg daily, 3 mg twice daily, 6 mg twice daily, or 12 mg daily or to receive placebo.  The primary end point was a 75% or greater redn. from baseline in the Psoriasis Area and Severity Index (PASI) score at week 12 (higher scores indicate greater severity of psoriasis). results A total of 267 patients received at least one dose in an intervention group of the trial.  At week 12, the percentage of patients with a 75% or greater redn. in the PASI score was 7% (3 of 45 patients) with placebo, 9% (4 of 44 patients) with 3 mg of BMS-986165 every other day (P = 0.49 vs. placebo), 39% (17 of 44 patients) with 3 mg daily (P<0.001 vs. placebo), 69% (31 of 45 patients) with 3 mg twice daily (P<0.001 vs. placebo), 67% (30 of 45 patients) with 6 mg twice daily (P<0.001 vs. placebo), and 75% (33 of 44 patients) with 12 mg daily (P<0.001 vs. placebo).  There were three serious adverse events in patients receiving the active drug, as well as one case of malignant melanoma 96 days after the start of treatment. conclusions Selective inhibition of TYK2 with the oral agent BMS-986165 at doses of 3 mg daily and higher resulted in greater clearing of psoriasis than did placebo over a period of 12 wk.  Larger and longer-duration trials of this drug are required to det. its safety and durability of effect in patients with psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhqWANKhDdt7Vg90H21EOLACvtfcHk0lg6IuwBsg4zNg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFWlsrbE&md5=ededd5d925dd557cceacc472839a966a</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1806382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1806382%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DK.%26aulast%3DGordon%26aufirst%3DK.%26aulast%3DTha%25C3%25A7i%26aufirst%3DD.%26aulast%3DMorita%26aufirst%3DA.%26aulast%3DGooderham%26aufirst%3DM.%26aulast%3DFoley%26aufirst%3DP.%26aulast%3DGirgis%26aufirst%3DI.%2BG.%26aulast%3DKundu%26aufirst%3DS.%26aulast%3DBanerjee%26aufirst%3DS.%26atitle%3DPhase%25202%2520Trial%2520of%2520Selective%2520Tyrosine%2520Kinase%25202%2520Inhibition%2520in%2520Psoriasis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D379%26spage%3D1313%26epage%3D1321%26doi%3D10.1056%2FNEJMoa1806382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrobleski, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertzman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spergel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zupa-Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâArienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tredup, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulligan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aranibar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span> <span> </span><span class="NLM_article-title">Identification of N-Methyl Nicotinamide and N-Methyl Pyridazine-3-carboxamide Pseudokinase Domain Ligands as Highly Selective Inhibitors of Tyrosine Kinase 2 (TYK2)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8953</span>â <span class="NLM_lpage">8972</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b00443</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00443" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlOltbrO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8953-8972&author=R.+Moslinauthor=Y.+Zhangauthor=S.+T.+Wrobleskiauthor=S.+Linauthor=M.+Mertzmanauthor=S.+Spergelauthor=J.+S.+Tokarskiauthor=J.+Strnadauthor=K.+Gilloolyauthor=K.+W.+McIntyreauthor=A.+Zupa-Fernandezauthor=L.+Chengauthor=H.+Sunauthor=C.+Chaudhryauthor=C.+Huangauthor=C.+D%E2%80%99Arienzoauthor=E.+Heimrichauthor=X.+Yangauthor=J.+K.+Muckelbauerauthor=C.+Changauthor=J.+Tredupauthor=D.+Mulliganauthor=D.+Xieauthor=N.+Aranibarauthor=M.+Chineyauthor=J.+R.+Burkeauthor=L.+Lombardoauthor=P.+H.+Carterauthor=D.+S.+Weinstein&title=Identification+of+N-Methyl+Nicotinamide+and+N-Methyl+Pyridazine-3-carboxamide+Pseudokinase+Domain+Ligands+as+Highly+Selective+Inhibitors+of+Tyrosine+Kinase+2+%28TYK2%29&doi=10.1021%2Facs.jmedchem.9b00443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of N-Methyl Nicotinamide and N-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2)</span></div><div class="casAuthors">Moslin, Ryan; Zhang, Yanlei; Wrobleski, Stephen T.; Lin, Shuqun; Mertzman, Michael; Spergel, Steven; Tokarski, John S.; Strnad, Joann; Gillooly, Kathleen; McIntyre, Kim W.; Zupa-Fernandez, Adriana; Cheng, Lihong; Sun, Huadong; Chaudhry, Charu; Huang, Christine; D'Arienzo, Celia; Heimrich, Elizabeth; Yang, Xiaoxia; Muckelbauer, Jodi K.; Chang, ChiehYing; Tredup, Jeffrey; Mulligan, Dawn; Xie, Dianlin; Aranibar, Nelly; Chiney, Manoj; Burke, James R.; Lombardo, Louis; Carter, Percy H.; Weinstein, David S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8953-8972</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">As a member of the Janus (JAK) family of nonreceptor tyrosine kinases, TYK2 plays an important role in mediating the signaling of pro-inflammatory cytokines including IL-12, IL-23, and type 1 interferons.  The nicotinamide 4, identified by a SPA-based high-throughput screen targeting the TYK2 pseudokinase domain, potently inhibits IL-23 and IFNÎ± signaling in cellular assays.  The described work details the optimization of this poorly selective hit (4) to potent and selective mols. such as 47 and 48.  The discoveries described herein were crit. to the eventual identification of the clin. TYK2 JH2 inhibitor (see following report in this issue).  Compd. 48 provided robust inhibition in a mouse IL-12-induced IFNÎ³ pharmacodynamic model as well as efficacy in an IL-23 and IL-12-dependent mouse colitis model.  These results demonstrate the ability of TYK2 JH2 domain binders to provide a highly selective alternative to conventional TYK2 orthosteric inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAL6gc1mkX4bVg90H21EOLACvtfcHk0lg6IuwBsg4zNg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlOltbrO&md5=869bfe303f0743867b8c9eb8201707c3</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00443%26sid%3Dliteratum%253Aachs%26aulast%3DMoslin%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWrobleski%26aufirst%3DS.%2BT.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DMertzman%26aufirst%3DM.%26aulast%3DSpergel%26aufirst%3DS.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DGillooly%26aufirst%3DK.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DZupa-Fernandez%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DMulligan%26aufirst%3DD.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DAranibar%26aufirst%3DN.%26aulast%3DChiney%26aufirst%3DM.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DLombardo%26aufirst%3DL.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26atitle%3DIdentification%2520of%2520N-Methyl%2520Nicotinamide%2520and%2520N-Methyl%2520Pyridazine-3-carboxamide%2520Pseudokinase%2520Domain%2520Ligands%2520as%2520Highly%2520Selective%2520Inhibitors%2520of%2520Tyrosine%2520Kinase%25202%2520%2528TYK2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8953%26epage%3D8972%26doi%3D10.1021%2Facs.jmedchem.9b00443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="note"><p class="first last">PDB ID: 7K7O</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="note"><p class="first last">PDB ID: 7K7Q</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Theofilopoulos, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, F. J.</span></span> <span> </span><span class="NLM_article-title">Murine Models of Systemic Lupus Erythematosus</span>. <i>Adv. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">269</span>â <span class="NLM_lpage">390</span>, <span class="refDoi">Â DOI: 10.1016/S0065-2776(08)60342-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=10.1016%2FS0065-2776%2808%2960342-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=3890479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;key=1%3ACAS%3A528%3ADyaL2MXks12gtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1985&pages=269-390&author=A.+N.+Theofilopoulosauthor=F.+J.+Dixon&title=Murine+Models+of+Systemic+Lupus+Erythematosus&doi=10.1016%2FS0065-2776%2808%2960342-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Murine models of systemic lupus erythematosus</span></div><div class="casAuthors">Theofilopoulos, Argyrios N.; Dixon, Frank J.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Immunology</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">269-390</span>CODEN:
                <span class="NLM_cas:coden">ADIMAV</span>;
        ISSN:<span class="NLM_cas:issn">0065-2776</span>.
    </div><div class="casAbstract">A review with 597 refs.  Natural history and pathol. of lupus mice, T and B cellular abnormalities, genetics of murine systemic lupus erythematosus, and the influence of sex and sex hormones in the pathogenesis of murine SLE are among the topics considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvCtrCe7AgqbVg90H21EOLACvtfcHk0lglIdGju9_e4A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXks12gtL4%253D&md5=e1c695a7396c705c8fde71a8dc62e06e</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2FS0065-2776%2808%2960342-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-2776%252808%252960342-9%26sid%3Dliteratum%253Aachs%26aulast%3DTheofilopoulos%26aufirst%3DA.%2BN.%26aulast%3DDixon%26aufirst%3DF.%2BJ.%26atitle%3DMurine%2520Models%2520of%2520Systemic%2520Lupus%2520Erythematosus%26jtitle%3DAdv.%2520Immunol.%26date%3D1985%26volume%3D37%26spage%3D269%26epage%3D390%26doi%3D10.1016%2FS0065-2776%2808%2960342-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span>; <span class="NLM_string-name">Lin, J.</span>; <span class="NLM_string-name">Moslin, R. M.</span>; <span class="NLM_string-name">Weinstein, D. S.</span>; <span class="NLM_string-name">Tokarski, J. S.</span></span> <span> </span><span class="NLM_article-title">Imidazopyridazine Compounds Useful as Modulators of IL-12, IL-23 and/or IFN-alpha Responses</span>. U.S. Patent <span class="NLM_patent">10,273,237</span>, April 30, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=C.+Liu&author=J.+Lin&author=R.+M.+Moslin&author=D.+S.+Weinstein&author=J.+S.+Tokarski&title=Imidazopyridazine+Compounds+Useful+as+Modulators+of+IL-12%2C+IL-23+and%2For+IFN-alpha+Responses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%26atitle%3DImidazopyridazine%2520Compounds%2520Useful%2520as%2520Modulators%2520of%2520IL-12%252C%2520IL-23%2520and%252For%2520IFN-alpha%2520Responses%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K7O" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K7O','PDB','7K7O'); return false;">PDB: 7K7O</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K7Q" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K7Q','PDB','7K7Q'); return false;">PDB: 7K7Q</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i117"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01698">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_05752"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01698?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01698</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">The Molecular formula strings list (CSV) is available free of charge on the ACS Publications website at DOI:</p><p class="last">Molecular formula strings list (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01698/suppl_file/jm0c01698_si_001.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01698/suppl_file/jm0c01698_si_001.csv">jm0c01698_si_001.csv (2.64 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates for the X-ray structures of compound <b>12</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K7O">7K7O</a>) and <b>29</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K7Q">7K7Q</a>) bound to TYK2 JH2 are available from the RCSB Protein Data Bank (<a href="http://www.rscb.org" class="extLink">www.rscb.org</a>). Authors will release the atomic coordinates upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01698&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-1%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01698%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01698" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6679800c6dd22410","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
